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Abstract 
Nonalcoholic steatohepatitis (NASH) is a major complication in patients with obesity and 
type 2 diabetes, and can progress to cirrhosis, liver failure and death.  No effective 
treatments exist. NASH is characterized by steatosis and increased numbers of 
inflammatory myeloid cells in the liver, and depletion of myeloid cells with toxic-liposomes 
reduces disease. Liposomes therefore offer a means to selectively target myeloid cells with 
compounds that inhibit inflammatory pathways.  
In this thesis I investigate whether anti-inflammatory compounds, encapsulated into 100 nm 
liposomes can target inflammatory myeloid cells, inhibit inflammatory pathways in myeloid 
cells and the outcome of this on liver disease. Two rodent NASH models were examined: 
an acute model where mice were fed methionine and choline deficient (MCD) diet for 3 
weeks and a chronic model where mice were fed a high-fat high-sugar (HFHS) diet for 14 
weeks.  
In the acute MCD model, mice developed severe steatohepatitis, with increased proportions 
of inflammatory myeloid cells. Intravenously injected curcumin liposomes targeted hepatic 
inflammatory myeloid cells including inflammatory DCs, macrophages and monocytes. RNA 
sequencing of mRNA from DCs that had taken up liposomes indicated that curcumin down 
regulated mRNA in the JNK-MAPK-pathway, upregulated mRNA associated with alternative 
macrophage activation, oxidative phosphorylation and retinoic acid production. Mice treated 
with curcumin liposomes had reduced liver damage, inflammation and steatosis compared 
with untreated mice. 
In the chronic model, mice fed HFHS diet developed insulin resistance and NASH 
associated with hepatic inflammation and liver fibrosis. Intravenous injection of curcumin 
and vitamin D3 liposomes, but not empty liposomes, reduced liver histological scores and 
liver fibrosis in mice fed HFHS diet. RNA sequencing of mRNA from livers of mice fed a 
HFHS diet identified upregulation of mRNA encoding proteins associated with extracellular 
matrix deposition, regulation of apoptosis and leukocyte recruitment and activation. Similar 
analysis of livers from mice treated with curcumin or vitamin D3 liposomes identified 
downregulation of mRNAs encoding proteins within these pathways. 
Finally, the role of regulatory T cells in NASH was investigated. Mice fed a MCD-diet for 3 
weeks had increased proportions of regulatory T cells in the liver. Depletion of regulatory T 
cells exacerbated MCD-diet induced liver damage, steatosis and necroinflammation. 
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Injection of ovalbumin and curcumin in a single liposome formulation induced proliferation 
of adoptively transferred ovalbumin specific CD4+ T cells in the liver and spleen. 
Furthermore, mice injected intravenously with ovalbumin/curcumin liposomes together with 
adoptively transferred ovalbumin specific regulatory T cells had reduced MCD-diet induced 
hepatocyte damage. 
Together these data indicate that anti-inflammatory drugs including curcumin and vitamin 
D3, encapsulated in liposomes, target hepatic inflammatory DCs, induce 
alternative/tolerogenic phenotype and prevent steatohepatitis progression to liver fibrosis. 
Curcumin liposomes coupled with ovalbumin, co-injected with ovalbumin-specific regulatory 
T cells has an additional therapeutic effect. These findings demonstrate the importance of 
both innate and adaptive immune cells in progression of liver disease and the feasibility of 
delivering anti-inflammatory drugs and antigen to these cells to treat NASH.  
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1.1 Nonalcoholic fatty liver disease: An overview 
Over consumption of food rich in fat and carbohydrates causes excess fat accumulation in 
adipose tissue and the liver, which leads to obesity and its complications, including insulin 
resistance and nonalcoholic fatty liver disease (NAFLD) (1) (2). NAFLD can be described 
as a syndrome, beginning with peripheral insulin resistance and fat deposition in the 
hepatocytes (fatty liver), which leads to hepatocyte ballooning and lobular inflammation, a 
condition known as nonalcoholic steatohepatitis (NASH). Untreated, NASH can progress to 
cirrhosis and hepatocellular carcinoma (HCC) through fibrosis (3). Among many liver 
diseases, NASH is the second major reason for liver transplantation in the United States (4). 
Diagnosis of NAFLD mostly depends on screening for elevated aminotransferases such as 
alanine transaminase (ALT) and aspartate transaminase in serum, and detection of 
hepatomegaly, fatigue, malaise and vague right upper quadrant pain on physical 
examination. However, it has been shown that ALT values are not strongly correlated with 
severity of steatosis and fibrosis in NAFLD (5). Thus histological observations of liver 
biopsies are considered the gold standard method to determine the severity of 
steatohepatitis and fibrosis in NAFLD patients, though there are some limitations (6). Due 
to the many stages and complications, to date no drug has been approved to treat patients 
with NAFLD. Although anti-diabetic drugs and life style modifications reduce insulin 
resistance and body weight respectively, they alone are insufficient to prevent inflammation 
mediated progression of NASH to cirrhosis (7). Therefore new therapeutics that target 
inflammation are required to treat NAFLD, together with noninvasive biomarkers to test their 
efficacy in clinical trials.  
1.2 Epidemiology of NAFLD: 
1.2.1 Prevalence of NAFLD in general population: 
Data on the incidence of NAFLD in the general population is limited as many patients are 
asymptomatic. Studies of liver biopsies, ultrasound and magnetic resonance screening have 
demonstrated that on average 20% and 2.7%-12.2% of the general population worldwide is 
affected by NAFLD and NASH respectively (8). Steatohepatitis can advance to cirrhosis and 
HCC in more than one third of NASH patients. About 20% of NASH patients develop 
cirrhosis, and 30%-40% will develop liver related death(9). In the United States, NASH is 
considered the second most common reason for liver transplantations and is projected to 
become the primary cause by 2025 (4) (10). Magnetic resonance spectroscopic 
measurements estimated that 32% of the United States general population is affected by 
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NAFLD. In Australia, the prevalence of NAFLD in the general population is between 10 to 
30% (11).  Interestingly, ethnicity also plays a role in NAFLD incidence, as Hispanics (45%) 
are more prone to the disease compared to Caucasian (33%) and African Americans (24%), 
according to The Dallas Heart Study (12).  
1.2.2 Prevalence of NAFLD in high-risk population: 
Obesity, type 2 diabetes (T2DM) and metabolic syndrome are considered as major risk 
factors for developing NAFLD. The global epidemic of obesity and T2DM has rapidly 
increased over the past three decades with Australia being among one of the developed 
nations dealing with the health burden of obesity and its associated problems in all 
socioeconomic groups. In 2011-12, 63% of Australian adults were considered either 
overweight or obese (13). Besides adults, children and adolescents aged 2-18 years are 
also reported to be either overweight (17%) or obese (6%).  
Autopsy studies revealed that obese subjects (72%) are more prone to NASH than lean 
subjects (36%) (14). Studies on bariatric surgery patients show that 90% of morbidly obese 
populations have steatohepatitis (15). Autopsy studies in USA have shown 9.6% and 13% 
of NAFLD prevalence in children and adolescents respectively(16). Moreover, abnormal 
ALT levels were reported in 6% of overweight and 10% of obese adolescents in the Third 
National Health and Nutrition Examination Survey data(17). Obese children with NAFLD 
have a 13.8-fold higher risk of dying or requiring liver transplantations compared to adult 
population (18).  
T2DM is characterised by insulin resistance and chronic inflammation. In Australia 1.7 
million people are diabetic and 3.5 million people are expected to suffer from diabetes by 
2033(19). Patients with T2DM are more prone to get NAFLD and vice versa, with 60-76% 
and 22% of NAFLD and NASH prevalence in diabetic patients respectively (20). Patients 
with T2DM have a 75 times greater chance to progress from NAFLD to NASH and fibrosis 
(21). Moreover studies have reported a 9.9% incidence of NAFLD in T2DM patients 
compared to 3.7% in non-NAFLD group (22). In Australia, it is estimated that more than 50% 
of T2DM patients have NAFLD/NASH.  
Metabolic syndrome is defined as the presence of 3 of 5 risk factors, including increased 
waist circumference, elevated levels of triglycerides, decreased levels of high-density 
lipoproteins, ≥ 130 mm Hg systolic blood pressure or ≥ 85 mm Hg diastolic pressure and 
increased fasting plasma glucose levels (23). It was reported that over 25% of USA 
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population and over 30% of Australian population is affected by metabolic syndrome (24). 
Individuals with metabolic syndrome are more likely to develop NAFLD (25). 
1.3 Molecular mechanisms implicated in NAFLD development and progression: 
NAFLD, as the name implies is a disease of liver with excess hepatic fat accumulation 
associated with nonalcoholic behaviors including over-nutrition and a sedentary lifestyle. 
NAFLD is a hepatic manifestation of metabolic syndrome, in which peripheral insulin 
resistance, dyslipidemia and systemic inflammation cause excess triglyceride deposition 
inside the hepatocytes. Lipid-induced apoptosis of hepatocytes leads to the release of 
damage associated molecular patterns (DAMPs) that activate liver resident macrophages 
(Kuppffer cells). Hepatocyte injury, combined with inflammation, exacerbates disease 
progression and promotes liver failure. Here below I have described the current 
understanding of cellular and molecular basis of NAFLD pathogenesis. 
1.3.1. Hepatic steatosis is the result of triglyceride accumulation in the liver: 
In obesity and T2DM, both dietary fats and insulin resistance induce hyperglycemia and 
hyperinsulinemia that promote de novo lipogenesis in the liver, thus increasing triglyceride 
levels (26, 27). Glucose and Insulin increase lipogenesis by activating the transcription 
factors carbohydrate response element binding protein (ChREBP) and sterol regulatory 
element–binding protein-1c (SREBP-1c) respectively (28) (29).  Mice deficient for either 
ChREBP or SREBP-1c have reduced hepatic lipid deposits due to diminished lipogenesis 
(30) (31).  
Over-nutrition induced fat deposition in the adipose tissue results in a chronic low-grade 
inflammatory state characterised by elevated levels of inflammatory mediators including 
adipokines and cytokines, such as leptin, adiponectin, resistin, plasminogen activator 
inhibitor, C-reactive protein, tumor necrosis factor α (TNF-α), interleukin (IL)-1β and IL-6 (32-
34). Early induction of cytokines activates catabolism to limit weight gain via inflammation 
and lipolysis, however chronic inflammation mediated lipolysis in expanded adipose tissue 
leads to continuous release of free fatty acids (FFA), which are transferred to the liver via 
portal vein. In the liver, FFA transported via CD36 is converted to triglyceride (35). Donnelly 
et al., has shown that in NAFLD patients FFA contribute to 59% of hepatic fat whereas DNL 
and diet contribute to 26% and 15% respectively (36). Increased triglyceride synthesis and 
storage as lipid droplets in hepatocytes leads to a condition known as fatty liver with simple 
steatosis (37). Although excess triglyceride storage in the liver is a hallmark of fatty liver, it 
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has been shown that inhibiting triglyceride synthesis reduces hepatic steatosis but worsens 
liver damage, indicating that increased triglyceride synthesis is a mechanism by which the 
liver may avoid FFA toxicity (38) (39). Nevertheless, elevated serum FFA levels were 
correlated with NAFLD parameters such as body mass index, fasting plasma glucose, high 
sensitivity C-reactive protein and serum levels of hepatocellular damage (40). Circulating 
FFA, especially saturated fatty acids, in contrast to unsaturated, are highly cytotoxic to 
hepatocytes(36). Saturated FFA such as palmitate can trigger toll-like receptor (TLR)-4 and 
TLR-2 signaling on hepatocytes, inducing nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) and activator protein-1 (AP-1) transcription factors leading to 
proinflammatory activation of hepatocytes (41). Palmitic acid can induce secretion of 
neutrophil chemoattractant, interleukin (IL)-8, when added to HepG2 cultured hepatocyte 
cells (42).  
Similar to FFA, free cholesterol accumulation in the liver is positively associated with NAFLD 
progression (43) (44). Treatment with 25-hydroxycholesterol, a derivative of cholesterol, 
promoted TNFα induced NF-κB activation in hepatocytes and the release of IL-8 from 
macrophages (45). Hepatic Expression of SREBP-2, a key nuclear transcription factor of 
cholesterol homeostasis, both cholesterol synthesis and cellular uptake, is enhanced in 
NASH patients (46). Increased free cholesterol to phospholipid ratio in cell membranes leads 
to impaired membrane organization by increasing rigidity and fluidity loss (47). Excess 
cellular free cholesterol increases ROS generation and lipid peroxidation in mitochondria 
and induces unfolded protein responses in the endoplasmic reticulum (ER) (48) (49). 
Moreover, scavenger receptor mediated uptake of oxidized low-density lipoproteins (LDL) 
increases free cholesterol in Kupffer cells and hepatic stellate cells (HSCs) and causes 
proinflammatory activation by increasing TLR4 expression and cytokine production (50) 
(51).  
Overall, in the setting of energy excess and obesity, adipose tissue lipolysis derived FFA 
together with dietary fats promote lipogenesis and accumulation of triglyceride and free 
cholesterol in hepatocytes, macrophages and HSCs. Hyperinsulinemia and hyperglycemia 
further aggravate hepatic lipogenesis to induce hepatic steatosis. Excess lipid storage 
induces oxidative and ER stress mediated hepatocyte apoptosis and secretion of 
proinflammatory mediators, which recruit inflammatory cells into the liver driving hepatic 
steatosis to steatohepatitis. The mechanisms underlying this changeover are discussed in 
the following section.  
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1.3.2 Progression from steatosis to steatohepatitis: 
The “two-hit” hypothesis proposed by Day and James (1998) has been considered as the 
possible mechanism for progression of simple steatosis to NASH (52). However, based on 
two decades of understanding of the inflammatory interplay between adipose tissue, gut and 
liver, Herbert and Alexander modified the "two-hit" hypothesis to the "multiple parallel hits" 
hypothesis (53). In this model the 'first hit' for NASH is FFA deposition as triglycerides in 
hepatocytes mediated by inflammation induced adipose tissue lipolysis. FFA in the liver are 
oxidized via gluconeogenesis, boosting blood glucose levels, which increase insulin 
synthesis and secretion by pancreatic β cells, and leads to hyperinsulinemia (54). Over time, 
when hyperinsulinemia fails to regulate hyperglycemia, this leads to the condition termed 
glucose intolerance or pre-diabetes. Hyperglycemia also stimulates lipogenesis by 
activating transcription factor ChREBP, which switches on several lipogenic genes (55). 
Furthermore, hyperinsulinemia also induces lipogenesis by activating SREBP-1c, thereby 
leading to the development of hepatic steatosis (31). Hepatic steatosis has been shown to 
cause hepatic insulin resistance (56). Augmented levels of FFA trigger liver inflammation 
through TNFα and reactive oxygen species (ROS), which reduce insulin signaling by 
inhibiting insulin-signaling pathways directly through NF-κB activation (57). Although simple 
steatosis is benign and non-progressive, the liver becomes susceptible to several hits 
mediated by multiple pathological factors including ER stress, oxidative stress and persistent 
inflammation.  
Excess FFA metabolized through β-oxidation in the mitochondria enhances ROS 
production, inducing oxidative and ER stress mediated apoptosis of hepatocytes 
(lipoapoptosis) (58). Impaired mitochondrial function has been reported in NASH patients 
and mouse models (59). In addition, human liver biopsies from NASH patients display 
increased lipid peroxidation by-products indicating the presence of oxidative stress (60). 
Increased lipid deposition in the hepatocyte cytoplasm results in a ballooned phenotype, a 
characteristic feature of NASH. Ballooned hepatocytes are more susceptible to 
lipoapoptosis. Apoptosis is programmed cell death, which is a key pathological feature of 
NASH. Apoptosis scores are strongly correlated with liver injury, inflammatory stages of 
NASH and fibrosis in humans and mice (61). Interestingly, serological estimation of 
cytokeratin 18 fragments (a marker of epithelial apoptosis) clearly distinguished NASH 
patients from simple steatosis (62). Hepatocytes isolated from mice fed a high fat diet (HFD) 
showed increased expression of the death receptor Fas, and are more susceptible to FasL-
mediated apoptosis. Increased FFA induces apoptosis in hepatocytes through induction of 
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pro-apoptotic BCL-2 proteins (Bim, Bid, Bad, Bmf, Hrk, Noxa and Puma) and lysosomal 
permeabilisation (63) (64). Lysosomal permeabilisation increases hepatic TNFα through 
activation of NF-κB (37). Lipotoxicity and TNFα induce ER stress and the unfolded protein 
response (65). Prolonged ER stress promotes apoptotic pathways and hepatocyte death. 
ER stress activates NF-κB, p38 mitogen-activated protein kinases (MAPK) and C-jun N-
terminal kinase (JNK) pathways in liver, leading to reduced insulin receptor substrate-1 
signalling and insulin resistance (66). Furthermore, suppression of hepatic TNFα by 
treatment with anti-TNF antibody and metformin (an anti-inflammatory drug) reduces hepatic 
steatosis in ob/ob mice (67, 68).  
In summary, inflammatory signalling pathways are activated in hepatocytes with excess lipid 
deposits. Lipid accumulation cause hepatic insulin resistance and sensitivity to inflammation 
induced apoptosis. Damage associated molecular patterns (DAMPs) released by dead 
hepatocytes activate liver resident immune cells and also promote recruitment of circulatory 
immune cells. Thus ballooned and apoptotic hepatocytes, surrounded by inflammatory cells 
(necroinflammation), are a characteristic features of NASH. Immune cell composition in the 
inflammatory foci of NASH determines the fate of NASH progression. The following 
subsection discusses the role of innate and adaptive immune cells in NASH. 
A. Immune cells implicated in NAFLD/NASH: 
The liver functions as a major metabolic organ to process the nutrients that are absorbed by 
the gut, which enter the liver through portal vein. One third of the blood that enter the liver 
flows from the gut, carrying both nutrients and microbial and food derived antigens. This 
continuous flow of pathogen associated molecular patterns (PAMPs), with the capability of 
inducing inflammatory activation of KCs that line the sinusoidal lumen, harbours major 
threats to liver. In order to reduce the inflammatory activation of hepatic immune cells, the 
liver maintains its immunomodulatory environment through factors secreted by liver 
sinusoidal endothelial cells, hepatocytes and hepatic stellate cells. However during NASH 
this immunomodulatory function is impaired and PAMPs and DAMPs activate both liver 
resident and recruited immune cells. The liver is abundant in innate immune cells including 
Kupffer cells (20%), natural Killer (NK) (10%) and natural killer T cells (NKT) (30%) and 
activation of these liver resident immune cells in NASH promotes the recruitment of blood-
derived monocytes and neutrophils to the site, which enhance the inflammation triggered by 
adipose tissue derived FFA and cytokines.  
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a. Innate immune cells implicated in NASH progression and regression: 
Kupffer cells (liver macrophages):  
Kupffer cells (KCs) account for majority of total tissue macrophages in the body. Food and 
microbial derived antigens that enter the liver through the portal vein are cleared effectively 
by KCs and this prevents their systemic dissemination. Due to their immunomodulatory 
nature, KCs prevent inflammatory responses and maintain homeostasis to exposed 
antigens. Liver inflammation impairs this immunological tolerance induced by KCs and 
exacerbates liver and peripheral inflammation (69). KC activation plays an essential role in 
the transition of steatosis to steatohepatitis. Circulating FFA and pro-inflammatory cytokines, 
and gut derived LPS, bind to receptors on KC and causes proinflammatory activation leading 
to secretion of cytokines such as TNFα (70) (71) (72) (Figure1-1). TNF receptor 1 and 2 
knockout mice fed methionine and choline deficient (MCD)-diet have attenuated NASH (73). 
KC derived TNFα has also been implicated in NASH development by recruiting inflammatory 
monocytes into liver, indicating the role of KC derived proinflammatory cytokines in driving 
simple steatosis to NASH (70).  
LPS and TNFα signal through MYD88 dependent and independent pathways to activate NF-
κB in KCs. Interestingly, myeloid but not hepatocyte specific ablation of IκB kinase beta 
(IKK)-β, an essential kinase regulating the nuclear translocation of NF-κB (p65/RelA), 
prevents hepatic inflammation and whole body insulin resistance in response to high fat diet 
(HFD) (74). Similar improvements have been shown following treatment of mice and 
humans with sodium salicylate, an inhibitor of IKK-β (75),(76). In addition to NF-κB, Nod-like 
receptor protein 3 activation by TLR2 ligand and palmitic acid specifically in KCs, but not in 
stellate cells, is implicated in the development of NASH (77). Both NF-κB and NLRP3 
activation induce classical activation or M1 phenotype in KCs. M1 KCs produce increased 
levels of proinflammatory cytokines including TNFα, IL-12 and IL-6, leading to the 
recruitment of blood-derived cells and activation of hepatic stellate cells. Alternatively 
activated KCs with M2 phenotype produce the anti-inflammatory cytokine IL-10 and 
selectively induce M1 KCs apoptosis (78). Patients with minimal liver disease have an 
increased M2 gene signature in the liver compared to patients with severe NASH (78). The 
M1 phenotype is associated with alterations in macrophage metabolism with increased 
glycolysis, reduced beta-oxidation and increased nitric oxide production (79). Associated 
mitochondrial dysfunction and increased ROS production by KCs leads to increased 
hepatocyte apoptosis. Upon liver injury large numbers of KCs are recruited and activated in 
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the liver (80). Selective depletion of KCs with gadolinium chloride prevents thioacetamide 
(TAA), carbon tetrachloride (CCL4) and ethanol-induced liver disease (81), (82), (83). 
Furthermore, depletion of KCs with clodronate liposomes attenuates methionine and choline 
deficient (MCD) diet-induced NASH (70). These depletion studies highlight the importance 
of M1 activation of KCs in transition of simple steatosis to NASH. 
In addition to KCs, monocyte-derived inflammatory macrophages promote NASH 
progression. Both dead hepatocytes and activated KCs release C-C chemokine ligand 
(CCL)-2 or monocyte chemotactic protein (MCP)-1, that recruits bone marrow derived Ly6C-
high expressing monocytes to the injured area in the liver, where they differentiate into 
inflammatory macrophages (84). Mice deficient in C-C chemokine receptor type 2 (CCR2), 
the receptor for CCL2, fed HFD have fewer adipose tissue and liver macrophages and 
consequently reduced insulin sensitivity and reduced steatosis (85-87). Moreover, anti 
CCL2 therapy reduced monocyte recruitment and reduced MCD diet induced steatohepatitis 
and liver fibrosis (88, 89). A study by Nio et al., using lipoatrophic diabetic A-ZIP transgenic 
mice found that CCL2 deficiency increased M2 macrophages in the liver and was associated 
with reduced insulin resistance and steatosis (90). Using CD11b-DTR model system, it has 
been shown that macrophage cell depletion reduced liver fibrosis progression, but impaired 
regression from fibrosis (91). This suggests that factors released by parenchymal cells 
govern the fate of macrophage activation. Pro inflammatory factors present during early 
disease skew monocytes and macrophages towards an M1 phenotype, while anti-
inflammatory mediators such as TGFβ and retinoic acid induce M2 phenotype during 
fibrosis. Together these studies underscore the pathogenic role of proinflammatory activated 
liver resident KCs and CCL2 dependent monocyte derived macrophages in NASH 
development and progression to liver fibrosis (Figure1-1). Therefore therapeutic strategies 
that reduce KCs activation and monocyte recruitment, and favour M2 KCs are necessary to 
reduce insulin resistance and steatohepatitis in NAFLD patients. 
Dendritic cells: 
Similar to other non-lymphoid organs, the liver has resident classical and plasmacytoid 
dendritic cells (DCs), as well as monocyte derived DCs (moDCs). In normal liver, DCs are 
tolerogenic like their counterparts, KCs, however during NASH, persistent inflammation 
alters DC’s phenotype. DCs from NASH livers have impaired antigen processing while 
secreting higher levels of inflammatory cytokines (92). CCR2+ monocytes recruited to NASH 
livers differentiate into moDCs with a proinflammatory phenotype. Similar to inflamed 
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adipose tissue, NASH livers from ob/ob mice are enriched in DCs producing TNFα and iNOS 
(Tip-DCs) (Figure1-1). Previous studies demonstrate that Tip-DCs are required for clearing 
infections in the liver and increase in number in response to obesity (93) (94). Mice fed an 
MCD diet have an increased proportion of mature DCs expressing high CD11c and major 
histocompatibility complex (MHC) class-II, in the liver compared with healthy mice (95). 
Interestingly, depletion of CD11c+ cells using the CD11c-DTR system during liver fibrosis 
exacerbated scarring and increased fibrosis, and conversely expansion of liver DCs with 
FLT3L reduced fibrosis resolution (95) (96). These studies indicate that myeloid cells 
expressing CD11c are important modulators of steatohepatitis progression.  
An elegant study by Miller’s group identified two subsets of DCs in NASH livers based on 
their lipid storage (97). Liver DCs with high-lipid content are highly immunogenic whereas 
low-lipid DCs are tolerogenic (Figure1-1). Numbers of high-lipid DCs increase in NASH, or 
treatment with LPS, indicating that both inflammatory activation of DCs and steatosis may 
increase DCs capacity for lipid uptake and synthesis. Recently Everts B et al, have shown 
that the proinflammatory phenotype of LPS stimulated DCs is dependent on metabolic 
reprogramming, with increased glycolysis but decreased oxidative phosphorylation 
(OXPHOS) (a Warburg metabolism), which could have resulted in increased fatty acid 
synthesis and thus higher lipid content in hepatic DCs of NASH liver (98) (79). This aerobic 
glycolysis sharply raises cellular ATP levels, which is required for inflammatory protein 
secretion, migration and cell-cell interactions. Functionally, decreased mitochondrial 
respiration is attributed to nitrosylation of proteins of electron transport chain (mainly 
complex I, II and IV) by nitric oxide synthesized by inducible nitric oxide synthase (iNOS), 
which is increased upon LPS stimulation in DCs (98). Similar to inflammatory DCs, M1 
macrophages are also found to have higher intracellular lipid levels, while on the other hand 
M2 macrophages contain reduced intracellular lipid deposits due to increased lipolysis 
mediated by lysosomal acid lipase (LAL), and inhibition of LAL activity with Orlistat, a lipase 
inhibitor, diminished expression of IL-4 induced M2 activation markers such as CD301, 
CD206, PD-L2 and RELMα (99). Using metabolomics and transcriptomic approaches Jha K 
et al., identified key metabolic intermediates that are enriched during M1 or M2 macrophage 
polarization. Consistent with increased lipid deposits, M1 macrophages have a fragmented 
Kreb’s cycle, which besides increasing citrate levels, which is required for fatty acid 
synthesis and production of an anti-microbial compound, itaconic acid, also increases nitric 
oxide levels. On the other hand M2 macrophages have increased glutamine metabolism to 
produce UDP-N-acetyl-alpha-D-glucosamine metabolite, which is required for N-
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glycosylation of M2 markers such as CD206 and CD301 (100). Whether similar mechanisms 
exist in hepatic DCs during NASH development needed further investigation. 
 
Figure 1-1: A schematic representation illustrating myeloid cell activation in NAFLD 
pathogenesis. Circulating free fatty acids, damage/danger-associated molecular patterns 
(DAMPs) from stressed hepatocytes, and gut derived LPS, activates yolk sac derived liver 
resident KCs  to secrete proinflammatory cytokines and chemokines, which induces 
recruitment of blood derived monocytes into liver (blue line). Proinflammatory environment 
in NASH livers, skew the recruited monocytes to Ly6Chigh M1 macrophages, moDCs, Tip-
DCs and high-lipid DCs, which exacerbate hepatic inflammation leading to hepatic stellate 
cell activation and liver fibrosis development. In contrast, Ly6Clow M2 macrophages and low-
lipid DCs are restorative or tolerogenic and inhibit hepatic inflammation and reduce liver 
fibrosis development. 
Natural killer (NK) and NKT cells: 
In addition to KCs and DCs, NK and NKT cells are predominantly found in the liver, and 
obesity is associated with increased NK cells and reduced numbers of hepatic NKT 
cells(79). In the early disease stage NK cell enrichment might cause necrosis of steatotic 
hepatocytes and promote liver damage, but at later stages NK cells can preferentially kill 
activated hepatic stellate cells and limit liver fibrosis (101). Mice depleted of NK cells are 
protected from LPS induced liver damage (102). Studies performed by Guebre-Xabier et al., 
and others, have shown that livers in obese mice have reduced NKT cell population. 
Adoptive transfer of NKT cells to obese mice reduced hepatic fat and reduced steatosis 
(103). Glycolipid signalling of NKT cells induces IL-4 production, which can promote Th2 
polarisation of T cells and suppress inflammatory cytokine production by myeloid cells. 
17 
 
Therefore the selective depletion of NKT in the context of obesity may explain the inability 
of myeloid cells to suppress inflammation. The reduction in NKT cell numbers is a 
consequence of NKT cell apoptosis induced by hepatic inflammatory myeloid cells 
expressing nitric oxide, or through IL-12 induced NKT cell-mediated death (85, 104). NKT 
cells, though lower in steatotic livers, increase in the fibrosis stage. Mice fed an MCD diet 
for 8 weeks have fibrotic livers with increased hedgehog and osteopontin signaling which is 
arrested in mice deficient in NKT cells. NKT cell-derived hedgehog and osteopontin 
differentiate stellate cells to myofibroblasts and serum levels of osteopontin are positively 
correlated with fibrosis (105). 
b. Adaptive immune cells implicated in NASH progression and regression: 
T and B-lymphocytes: 
T and B cells promote insulin resistance in the context of obesity and are increased in 
number in metabolic tissues. Both CD4 and CD8 T cells accumulate in the liver in obesity 
and produce Th1 cytokines, including IFN-γ, which expands inflammatory macrophages 
(106), (107). Spectrotyping TCR diversity of T cells isolated from abdominal adipose tissue 
from obese mice reveals that T cells have a substantial TCR Vα bias. These studies indicate 
that infiltrating T cells may recognise specific antigens derived from dying or necrotic cells 
present within stressed metabolic tissue, similar to observations made in autoimmune type 
1 diabetes, where T cells and antibodies are prevalent against autoantigens such as insulin 
and GAD. In this regard, autoantibodies have been detected in humans with T2D, including 
anti-glial fibrillary protein (GFAP), which is upregulated during activation of hepatic stellate 
cells and development of fibrosis in the liver (108). The presence of autoantibodies against 
GFAP argues for a direct involvement of CD4 T cells to induce B cells with GFAP antibody-
producing capacity. NASH livers are abundant in Th1 cytokines that are known to promote 
inflammation by activating KCs. CD4 and CD8 T cells are enriched in the liver of mice fed 
an MCD diet (109). CCL4 treated mice deficient for B cells have reduced collagen deposition 
and greater clearance of necrotic bodies compared to T cell deficient and control mice (110). 
Antibodies against lipid peroxidation products such as malondialdehyde (MDA) are 
associated with NAFLD progression and immunization with MDA exacerbated MCD diet 
induced NASH in mice (98) (109). B cells have been shown to promote insulin resistance 
through antibody production and associated antibody-mediated myeloid inflammation (108). 
Sources of auto antigen may also include hypertrophied dying adipocytes or hepatocytes or 
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unknown infectious agents mimicking self-antigens or which promiscuously infect metabolic 
tissue (111).  
Regulatory T lymphocytes: 
Regulatory T cells (Tregs) are a subset of T-lymphocytes expressing transcription factor 
forkhead box transcription factor-3 (Foxp3) with suppressive ability. Tregs generated in the 
thymus are distinguished from peripherally induced Tregs by their expression of markers 
such as helios and neurophilin-1 (112) (113). Tregs suppress activation of effector T-cells, 
DCs and macrophages through cell contact dependent and independent mechanisms. 
Tregs mediate contact suppression via signalling through MHC-antigen and lymphocyte 
function-associated antigen 1 and cytotoxic T lymphocyte- associated antigen and 
programmed death-1 (114) (115). Tregs produce suppressive factors including IL-10, IL-35, 
and TGFβ that directly down modulate APC function. Tregs also inhibit effector T cell 
function by competing for MHC-antigen occupancy, IL-2 and ATP (116).  
Mice fed a HFD have decreased numbers of adipose tissue Tregs compared with healthy 
mice. Increasing CD4+FoxP3+ Tregs with oral anti-CD3 or adoptive transfer is protective in 
obesity-induced insulin resistance and depletion of Tregs promotes insulin resistance (107) 
(117). The role of Tregs in NAFLD and NASH is ill defined. Feeding mice a HFD reduces 
hepatic Treg numbers and treating mice with an antioxidant prevents hepatic Treg death 
and protects from LPS induced liver inflammation (118). Adoptive transfer of polyclonal 
Tregs likewise protects the liver from LPS-induced liver inflammation (118). Consistent with 
the requirement of DC for homeostatic maintenance of Tregs, mice fed HFD either depleted 
of CD11c cells or deficient in B7 co-stimulation have reduced hepatic Tregs. This reduction 
in Tregs may explain why CD11c-depletion during MCD diet induced liver disease increases 
fibrosis and liver scarring (95). In humans, a recent study demonstrated that both Tregs and 
macrophage numbers were increased in NASH (119). These data argue that Tregs may 
limit inflammation in liver disease and that increasing their numbers and or function may 
provide a therapeutic opportunity to treat insulin resistance and NASH. 
B. Gut inflammation and microbiota in NAFLD/NASH: 
The gut harbours diverse bacterial communities, together defined as the gut microbiome, 
that regulate the gut homeostasis by maintaining the architecture and immune system 
maturation. Intestinal microbiota is a major determinant in the development of obesity and 
its complications, as germ free mice are resistant to diet induced obesity, insulin resistance 
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and NAFLD(120). These mice can develop obesity when the microbiome is repopulated with 
the obese, but not lean, microbiome. The obese microbiome is more efficient in harvesting 
energy from the diet, which contributes to fat absorption in the gut and accumulation 
ectopically (121). Obese microbiota also has the ability to deprive the host of 
phosphatidylcholine through increased conversion of dietary choline to methylamines, 
mimicking the effects of depriving choline in animal models to induce NASH (122). The 
increased potential of bacteria to metabolise dietary components can result in bacterial 
overgrowth - indeed 50% of NASH patients are diagnosed with small intestinal bacterial 
overgrowth (123). Since this outgrowth is regulated by intestinal immunity, this implies that 
bacteria may evade intestinal immune cells in the context of obesity. In addition, the immune 
system may be more activated in obesity, which has been shown in the jejunum from obese 
patients with increased numbers of CD8+ T cells, mature macrophages and DCs (124). Gut 
inflammation leads to increased epithelial permeability, and the potential for bacterial 
translocation to liver. In normal mice, bacteria are detectable only in mesenteric lymph nodes 
(mLN), however, in NASH bacteria can be detected in the liver, indicating that the mLN 
‘firewall’ is breached. Bacterial ‘leakage’ to the liver is likely to promote liver inflammation 
and can be considered an ongoing ‘multiple hit’ to accelerate liver disease (125).  In support 
of this idea, mice deficient in TLR-4 or CD14 are resistant to HFD induced liver fibrosis (126), 
(127). Important questions remained unanswered, such as whether a change in the 
microbiota is contributing to gut inflammation or vice versa. Recent studies in mice indicate 
that HFD feeding alters the microbiota in as little as 10 days, which was associated with 
reduced IL-17 producing T cells, important regulators of gut microbiota diversity (128). 
Interestingly gut specific antiiflammatory drugs and probiotics could prevent HFD induced 
gut inflammation and dysbiosis (128) (129). 
Overall, current understanding about the gut to liver axis in NASH indicate that diet rich in 
fat and simple sugars induces gut dysbiosis. Altered microbiota result in chronic low-grade 
inflammation locally in the gut, increasing gut permeability, leading to leakage of gut derived 
bacteria and/or bacterial products into the liver and acceleration of NASH to cirrhosis and 
liver failure. 
In summary, simple steatosis progression to NASH and cirrhosis is mediated by multiple 
factors including FFA, insulin resistance, hepatocyte apoptosis, oxidative stress, 
mitochondrial dysfunction, pro-fibrogenic cytokines and bacteria or bacterial endotoxins 
leading to liver injury (Figure 1-2). Both resident and recruited pro-inflammatory immune 
cells further enhance this liver injury (Figure 1-2). Thus treatments that reduce the 
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aforementioned pathological pathway activation need to be considered to treat NAFLD and 
NASH patients, some of which I will discuss in the following sub section. 
 
Figure 1-2: A schematic representation of NAFLD pathogenesis. Dysregulation in 
hepatic β-oxidation increases fat accumulation in hepatocytes (steatosis) and induces ER 
and oxidative-stress mediated hepatocyte death. Damage/danger-associated molecular 
patterns (DAMPs) from stressed hepatocytes and gut-derived LPS from impaired intestinal 
permeability induces activation of liver resident and recruited macrophages, DCs, NK cells, 
neutrophils and T cells promoting hepatic inflammation (steatohepatitis). Pro inflammatory 
liver environment activates hepatic stellate cells, key producers of extracellular matrix 
proteins such as αSMA and collagen, accelerating progression to liver fibrosis and liver 
failure. 
1.4 Current therapeutic options to treat NAFLD: 
To date, no specific therapeutic compound has been approved to treat any stage of the 
NAFLD spectrum. Among the NAFLD stages, NASH, being highly progressive under the 
metabolic and immune stress conditions, is the major therapeutic target to reduce liver 
related morbidity and mortality. Since NASH is associated with multiple risk factors including 
overweight, T2DM, insulin resistance, oxidative stress, lipogenesis and pro-inflammation, 
several studies have examined physical, surgical and pharmacological inhibition of any of 
these factors to treat NASH patients. 
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1.4.1 Diet and lifestyle modification: 
Prior to industrialization, food intake and energy consumption were maintained in most 
individuals through good food habits and lifestyles, which slowly began to change with 
technological advancement, causing a sedentary life style that leads to obesity. In general, 
less total intake of fibers, vegetables and fruits, and higher consumption of refined foods 
with excess fat and added sugar are among the major causes of obesity and associated 
liver disease. Therefore, weight loss management programs with increased physical activity 
and proper diet are considered the most effective NAFLD treatments (130), (131). Lifestyle 
intervention in biopsy-proven NASH patients for 52 weeks reduced steatohepatitis (25%), 
NAFLD activity score (NAS) (47%) and liver fibrosis (19%). Patients with ≥10% weight 
reduction had a 90% reversal of NASH. Although beneficial, rapid weight loss may result in 
increased portal inflammation and fibrosis in severely obese patients (132). Furthermore, 
regular physical activity is difficult to maintain in many unmotivated patients.   
1.4.2 Bariatric surgical intervention: 
In the majority of severely obese patients with co morbidities like T2DM and NASH, bariatric 
surgery (a surgical reduction of the stomach size) is a potential therapeutic option (133). 
Interestingly, studies on histological evaluations of post-bariatric liver biopsies revealed that 
this surgical intervention reduced steatosis and ballooning but not fibrosis compared to 
baseline (134), (135). In a recent study 85% of patients who underwent bariatric surgery had 
complete disappearance of NASH phenotypes in a year (136). The positive effect of bariatric 
surgery on liver histology is possibly due to the amelioration of NASH risk factors including 
obesity, T2DM and metabolic syndrome by altering gut microbiota, as germ free mice 
receiving fecal material from patients who underwent bypass or gastroplasty had reduced 
fat mass and respiratory quotient (137). A major limitation of bariatric surgery is that it is 
applicable only to morbidly obese patients.  
1.4.3 Pharmacological interventions:  
Several randomized and placebo controlled studies have evaluated the pharmacological 
efficacy of various drugs that can inhibit NAFLD risk factors including insulin resistance, 
oxidative stress, dislipidemia and inflammation. Unfortunately, none of the studies have 
recommended any drug to treat NAFLD spectrum due to either lack of effect or side effects. 
Anti-obese drugs sibutramine and orlistat did not reduce liver damage irrespective of their 
effect on weight loss (138), (139). Though slightly hepatotoxic, statin treatment for 10.3 to 
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16.3 years significantly reduced steatosis and halted fibrosis in NAFLD patients through 
inhibiting cholesterol production (140). Since hepatic apoptosis is the driving factor for NASH 
development and progression, cytoprotective ursodeoxycholic acid was evaluated (141). 
Although well tolerated, no improvements in NASH were observed. Oxidative stress is 
another mediator of hepatic injury. Vitamin E with its anti-oxidant properties had shown to 
significantly reduce the hepatocyte ballooning and hepatic injury in two large randomized 
trials (142). However, its use for NASH treatment is not recommended as doses of ≥ 
400IU/day is associated with mortality (143).  
Insulin resistance as an important mediator of NASH pathology is also targeted through 
insulin sensitizers, including rosiglitazone, pioglitazone, metformin and losartan (144-146). 
Although these drugs either individually or combined reduce steatosis, insulin resistance, 
ballooning degeneration, inflammation and ﬁbrosis, long-term therapy is required to maintain 
the effects and they have unwanted side effects preventing long term use (147). Hepatic 
glucose and lipid metabolism is regulated by bile acid signalling of the nuclear bile acid 
receptor farnesoid X receptor (148). In two human clinical trials, obeticholic acid (6-
ethylchenodeoxycholic acid), a synthetic farnesoid X receptor agonist treatment significantly 
reduced insulin sensitivity and histological features of NASH (149) (150). Although promising 
therapeutically, side effects such as pruritus and high circulatory LDL levels cautions against 
long term use of farnesoid X receptor agonists in NAFLD. A variety of other drugs can assist 
in management of NAFLD, including anti-inflammatory agents such as the TNFα inhibitor 
pentoxifylline and NF-kB inhibitor sodium salicylate, however systemic immune suppression 
precludes prolonged clinical use (151) (75). Hence there is a need to identify new 
approaches to treating NAFLD, which is major aim of this thesis. Below I will discuss two 
potential nutraceuticals drug candidates that I have used in the current thesis to treat NASH 
in diet induced mouse models. 
A. Curcumin as a potential therapeutic agent for NAFLD treatment:  
Since ancient times, turmeric extracts were in medicinal use (mostly through oral 
administration and/or topical application) to treat several diseases in humans (152). Recent 
emphasis by the scientific community to identify potential compounds of turmeric extracts 
revealed that one of its active compounds, curcumin, has a wide range of health beneficial 
properties, including anti-inflammatory, anti-apoptotic, anti-oxidant, anti-fibrotic and 
immunomodulatory, and with these pleiotropic properties curcumin has been reported to 
regulate the majority of factors implicated in NASH and fibrosis. Several randomized, double 
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blind, placebo-controlled human trials have been conducted either with active curcumin or 
curcuminoids (turmeric extract), given orally, to study their effect on various diseases. No 
dose-limiting toxicities were observed in healthy human volunteers consuming a single dose 
of curcumin ranging from 500 to 12000 mg/day (153). Anti-hyperglycaemic effects of dietary 
curcumin have been observed in T2DM and obese patients similar to the observations made 
in animal models (154) (155). Clinical trials in inflammatory diseases including psoriasis, 
pancreatitis, vitiligo, ulcerative colitis, inflammatory bowel disease and postoperative 
inflammation have shown that curcumin can dampen inflammation and reduces the 
inflammatory profile in different patient groups (156-161). 
In the context of NASH progression, dietary curcumin reduces hepatic lipid accumulation 
through increased fatty acid β-oxidation and decreased activity of fatty acid synthase and 
acyl CoA cholesterol acyltransferase (162).  This hypolipemic effect of curcumin leads to 
reduced hepatic tissue levels of FFA, cholesterol and triglyceride in LDL receptor deficient 
mice (163). Studies by Kaur et al., and Cerny et al., using endotoxin and LPS/d-
galactosamine liver injury models demonstrated an anti-oxidant effect of curcumin with 
decreased hepatic and serum levels of glutathione, superoxide dismutases, thiobarbituric 
acid reactive substances and heme oxygenase-1 (164) (165). Also, curcumin reduced 
hepatic NO synthase-2 expression, and reduced mitochondrial dysfunction, antioxidant 
production and increased peroxisome proliferator-activated receptor-γ (PPAR-γ) levels 
(166) (167, 168) (169) (170). Dietary curcumin supplementation induced hepato-protective 
effects through regulating NF-κB signaling with decreased hepatic NF-κB and TNFα levels 
in obese and diabetic mouse models (171) (172) (155). Moreover, studies in mouse models 
of chronic liver diseases indicated that curcumin treatment reduced liver fibrosis 
development by negatively regulating transcription and/or function of several important 
pathways implicated in the activation of hepatic stellate cells, key mediators of collagen 
production during liver fibrosis (173). Treatment with curcumin diminished leptin and 
transforming growth factor (TGF)-β induced HSC activation (174-176). HSC isolated from 
curcumin treated chronic liver injury models were identified to have increased expression of 
matrix metalloproteinases (MMP), collagen degrading enzymes, and decreased expression 
of tissue inhibitors of metalloproteinases (TIMPs) (177), (178). Trans-differentiation of 
quiescent HSC to myofibroblastic cells is associated with decreased intracellular lipid 
content and PPAR-γ expression (179). Curcumin, with its ability to inhibit NF-κB and 
oxidative stress increases PPAR-γ expression and AMP-activated protein kinase (AMPK) 
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activity, which reduced intracellular lipid deposits thereby reducing HSC fibrotic activation 
(180), (181).  
Inflammatory activation of macrophages and myeloid cells is primarily regulated by NF-κB, 
and pre-clinical studies have shown that curcumin downregulated NF-κB in metabolic tissue 
leading to reduced TNF, IL-6, resistin and leptin, and increased anti-inflammatory adipokine 
adiponectin (182). Similarly, a pilot human intervention trial found that oral administration of 
capsules containing 150 mg curcumin (30%) inhibited TNF-induced NF-κB DNA binding 
activity in lymphocytes of 11 healthy adults (183). In another study, the effects of dietary 
curcumin on postprandial plasma glucose and insulin levels was investigated (184). 
Although no significant differences in pre or post-prandial glucose were demonstrated, 
serum insulin levels were increased 30 and 60 min after the oral glucose challenge in 
curcumin-treated subjects. These studies suggest that dietary curcumin inhibits NF-κB 
systemically which in turn influences glucose uptake and insulin release. In addition to NF-
κB, curcumin regulates transcription and/or function of several important pathways including 
wnt, hedgehog, autophagy and beta-oxidation (173).  
Poor bioavailability limits curcumin use for treatment in NASH patients: 
Although human studies provide evidence that oral curcumin reduces inflammation, the 
mechanism by which curcumin reduces insulin resistance in human and animal models of 
obesity are poorly defined.  Curcumin can modulate adipocyte, hepatocyte, hepatic stellate 
cell, pancreatic cell and immune cell function directly, with the caveat that these effects are 
observed ex vivo and often in cell lines (185-188). In addition, it is likely that dietary curcumin 
influences intestinal nutrient intake and/or altered intestinal microbiota, which can 
themselves regulate systemic inflammation and disease progression. Also, poor 
bioavailability of dietary curcumin limits its use in treating inflammatory diseases in human 
(189). Studies on uptake and biodistribution of dietary curcumin in rodents indicate that after 
ingestion of oral curcumin, peak serum levels of curcumin are low, with the highest dose of 
2 g/kg resulting in 1.35 ug/mL peak serum levels (190) (191). In humans, a 4–8 g dose 
resulted in peak serum levels of 0.4–3.6 uM after 1 hour, and a 12 g dose resulted in a peak 
serum level of 51 ng/mL after 1 hour (153, 192). The bioavailability of dietary curcumin can 
be increased by inhibiting enzymatic reduction (glucuronidation) of curcumin or by 
complexing curcumin with nanocarriers including lipids (193).  Bypassing the digestive 
system by intra-peritoneal injection results in tenfold higher levels of curcumin in the plasma 
and detectable curcumin levels in the spleen, liver, kidney, lungs, muscle and brain (190). 
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This is due to curcuminoids bypassing the liver and digestive system where they are 
converted to glucuronides/sulfates of curcumin. The effect of combining piperine, a known 
inhibitor of hepatic and intestinal glucuronidation, was evaluated on the bioavailability of 
curcumin in rats and healthy human volunteers. Curcumin given at a dose of 2 g/kg to rats 
with piperine (20 mg/kg) increased the bioavailability by 154%. Similarly in humans, a dose 
of 2 g curcumin with piperine (20 mg) increased the bioavailability of curcumin by 2000%. 
Thus piperine enhances the serum concentration, extent of absorption and bioavailability of 
curcumin in both rats and humans with no adverse effects (194).  
B. Vitamin D3 as a potential therapeutic agent for NAFLD treatment:  
Vitamin D3 in nonalcoholic fatty liver disease: 
Another nutraceutical is vitamin D3 (also known as calcitriol or cholecalciferol or 1,25 
dihydroxy-vitamin D), an active compound of vitamin D. The source of Vitamin D is mainly 
from cholesterol following ultraviolet B sun exposure, but it can also be derived from diet or 
oral supplementation. In the liver and kidney vitamin D is hydroxylated to Vitamin D3 
(1,25(OH)2D) which is the active form that binds and signals to the vitamin D receptor (VDR) 
(195). VDR when bound to vitamin D3, heterodimerizes with retinoid x receptor (RXR) and 
regulates expression of several genes involved in immunity, metabolism, calcium and 
phosphorous uptake (collectively known as vitamin D response elements). Immune cells 
including macrophages, DCs and T cells also express critical enzymes for vitamin D 
hydroxylation and secrete vitamin D3 locally to modulate immune responses (196). Both 
myeloid and lymphoid cells express VDR, and vitamin D3 signaling is required for their 
development (195), (197). Defects in either VDR expression or vitamin D3 levels are 
associated with several autoimmune diseases (198).  
Chronic inflammatory diseases such as obesity co-associate with low serum vitamin D3 
levels. Obese children with biopsy-proven NASH have decreased levels of circulatory 
vitamin D3 (199). Similarly, studies in obese and NAFLD patients from different ethnicities 
indicate that vitamin D3 deficiency is common in NAFLD (200). This association has been 
attributed to: 1) sedentary life style limiting sun exposure, 2) sequestration of fat soluble 
vitamin D3 in adipose tissue, 3) reduced hydroxylation in the liver because of liver 
dysfunction. Experimentally, vitamin D deficiency transitions steatosis to steatohepatitis in 
rats fed a HFD diet, by increasing TLR activation mediated hepatic inflammation and 
oxidative stress (201). In NASH patients, liver fibrosis negatively correlates with serum 
vitamin D3 levels and VDR protein expression in liver (202). Vitamin D3 reduces TGFβ 
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mediated fibrotic activation of human HSCs ex vivo and reduces extra cellular protein 
production and proliferation of rat HSCs. Supplementation of mice with Vitamin D3 reduces 
TAA-induced liver fibrosis (203). Remarkably, exposure to artificial sunlight increased 
Vitamin D3 levels, which was sufficient to prevent progression of NAFLD in Zucker fa/fa rats 
and rats fed a choline-deficient and iron-supplemented l-amino acid-defined diet (204). 
These studies indicate that either vitamin D supplementation or UV-B light exposure (natural 
or artificial) may aid in the treatment of NAFLD with the following limitations: vitamin D 
supplementation at high levels can cause hypercalcemia mediated bone fractures and 
excessive sun light exposure can be oncogenic to squamous and basal skin cells.  
Immunomodulatory function of Vitamin D3: 
VDR is expressed on both parenchymal and non-parenchymal cells of the liver and can elicit 
wide functions on liver damage and regeneration. VDR is expressed as membrane bound 
and intracellular protein to sense extracellular and cell intrinsic vitamin D3 respectively (205). 
In normal liver VDR is highly expressed in cholangiocytes and lower levels were found in 
hepatocytes and hepatic immune cells, which reduce in NASH livers. Interestingly VDR 
expression on liver inflammatory cells is inversely correlated with portal inflammation in 
NASH patients (206). VDR knockout mice are highly sensitive to LPS induced septic shock 
and macrophages isolated from these mice are proinflammatory (207). Moreover, myeloid 
specific VDR deletion in LDL receptor (Ldlr) knockout mice fed HFD promotes insulin 
resistance and hepatic inflammation (208). One of the major targets of vitamin D3 is the 
transcription factor NF-κB. VDR signaling inhibits both the canonical (p65) and non-
canonical (RelB) NF-κB pathway via inhibition of IKKβ, and prevent IKK activity, which is 
required for release of functional NF-κB proteins for DNA binding and activation of 
proinflammatory cytokine expression (209). RelB expression in monocytes regulates 
maturation to dendritic cells and differentiation of human monocyte DCs in the presence of 
Vitamin D3 promotes tolerogenic DCs with reduced expression of MHC class-II and co-
stimulatory molecules such as CD40, CD80 and CD86 (210), (211). Culture of Vitamin D3-
DCs with allogenic T cells promotes Th2 and Treg phenotype while reducing Th17 cell 
differentiation (212), (213). This tolerogenic phenotype is dependent on inhibition of RelB 
and activation of metabolic reprograming. In DCs, Vitamin D3 treatment causes direct 
binding of VDR/RXRα heterodimers to the RelB promoter, which suppresses RelB 
expression, and the absence of VDR abolished RelB inhibitory effect of Vitamin D3 (210), 
(214). Recent studies have shown that a tolerogenic phenotype in DCs and macrophages 
is associated with reduced intracellular lipid deposits due to decreased fatty acid synthesis, 
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and increased OXPHOS and lipolysis (79), (99). Interestingly, Vitamin D3 treatment of 
human monocyte derived DCs also induced upregulation of genes involved in glycolysis, 
Kreb’s cycle and oxidative phosphorylation (215). Vitamin D3, besides effecting antigen-
presenting cells also regulates T cell activation and differentiation directly with active VDR 
inhibiting transcription of IL-2 and IFNγ, while increasing IL-4 and IL-10 transcription (216) 
(217) (218) (219). Moreover, vitamin D3 has been shown to inhibit B cell proliferation and 
differentiation thereby decreasing immunoglobulin secretion (220), (221).  
Due to its ability to modulate both innate and adaptive immune cells, vitamin D3 is 
considered a promising immune modulatory drug to treat diseases such as autoimmunity, 
graft versus host disease, obesity and cancer. However, adverse side effects including 
hypercalcemia, renal calcification and bone resorption preclude vitamin D3 and its analogs 
when administered for extended use in humans. 
In summary, both curcumin and vitamin D3 have a potential to be prospective drug 
candidates to treat obesity complications such as T2DM and NAFLD, either poor 
bioavailability or adverse off target effects limit their clinical translation. In the following 
section I will give an overview on how nanoparticle drug delivery can improve these 
limitations to treat inflammatory diseases.  
C. Enhancing curcumin and vitamin D3 bioavailability and improved cell 
targeting: 
Nanoparticles for drug targeting: 
Technological advancement has made several discoveries translatable from bench to 
bedside to treat or diagnose chronic diseases like atherosclerosis and cancer. Among them 
is nanotechnology, where nanometer sized (1 to 1000nm) particles (nanoparticles), loaded 
with drugs, target cancer and treat disease. Nanoparticles of several types have been used 
in the past three decades for drug delivery and these include nanopolymers (ex: polymer 
conjugates, polymer micelles and nanogel), metal nanoparticles (ex: gold, silver, silica, iron 
and carbon) and lipid vesicles such as micelles and liposomes (222). Among these, 
liposome nanoparticles are widely used as they offer the advantage of being cheap to 
manufacture, of low toxicity, adjustable in size and lipid composition, amenable to 
conjugation with cell specific targeting molecules and flexible delivery systems for 
entrapment of other aqueous drugs or antigens. Interaction of liposomes with targeted cells 
is determined by their physicochemical properties. Liposomes ranging from 15nm to 100nm 
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diameter are efficiently taken up by the macrophage phagocytic system (223). Chemical 
composition defines the surface charge of nanoparticles. Positively charged particles are 
effective at immune activation rather than immune modulation, which can be achieved 
through negatively charged nanoparticles (224), (225). Release of drugs loaded in the 
liposomes within targeted cells is mediated through phospholipid transfer to apolipoproteins 
and membrane leakage via the activation of complement system (226) (227). 
D.  Targeting myeloid cells with curcumin and vitamin D3 liposomes: 
Liver injury is characterised by infiltrating monocytes; inflammatory macrophages and DCs. 
Liposomes are efficient at targeting these myeloid cells due to their intrinsic properties to 
interact with scavenger receptors expressed on myeloid cells (224). Furthermore 
engineering liposomes with ligands or antibodies that interact with receptors expressed on 
myeloid cells increases their potential to target specific myeloid cell type (228). Unligated 
liposomes loaded with anti-inflammatory drugs like dexamethasone or siRNA targeting 
inflammatory genes reduce myeloid cell activation and reduce inflammation in mice with 
chronic liver disease and atherosclerosis (229), (230), (231). 
Curcumin loaded liposome nanoparticles increases its bioavailability and cell targeting: 
Less than 100 nm sized nanoparticles of curcumin complexed with poly(butylcyanocylate, 
poly(lactide-co-glycolide), chitosan, albumin or acrylamide polymers have all been shown to 
enhance bioavailabity and peak serum levels of curcumin, compared with free 
curcumin(232, 233). As it is highly lipophilic, curcumin bioavailability is also increased when 
complexed with liposomes, micelles and phospholipids (234). Curcumin liposomes have 
been shown to be beneficial in treating mice with insulin resistance (94). Curcumin 
liposomes delivered intraperitoneally to obese mice had reduced systemic insulin resistance 
as measured by homeostasis model assessment-estimated insulin resistance (HOMA-IR). 
Curcumin liposomes reduced NF-κB and associated inflammatory cytokine production in 
TNF/iNOS liver dendritic cells and adipose tissue inflammatory macrophages (94).  
Curcumin–phosphatidylcholine complex (Meriva) increases bioavailability of oral curcumin 
and has been shown in humans to reduce markers of serum inflammation. Fifty patients with 
osteoarthritis were treated for 3 months with Meriva daily (235). C-reactive protein levels 
decreased from 168±18 to 11.3±4.1 mg/L in the subpopulation with high C-reactive protein, 
while the control group experienced only a modest improvement in these parameters 
(175±12.3 to 112±22.2 mg/L). In another study Meriva was administered at the dosage of 2 
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tablets/day (1g Meriva/day) to 25 diabetic patients for 4 weeks (236). Microcirculatory and 
clinical evaluations indicated a decrease in skin flux at the surface of the foot, a finding 
diagnostic of an improvement in microangiopathy. In addition, a significant decrease in the 
edema score and a corresponding improvement in the venoarteriolar response were 
observed. These findings were present in all subjects using Meriva but not in the control 
group. Meriva has been shown to be safe for human use and these preliminary findings 
suggest the usefulness of this and other curcumin formulations for the management of 
inflammatory disorders such as diabetes, obesity, and NAFLD. Future studies treating 
patients with diabetes or prediabetes with Meriva will determine if curcumin/lipid complexes 
have increased efficacy over oral curcumin alone. 
In summary, dietary curcumin is an antioxidant and NF-κB inhibitor that relieves stress in 
metabolic tissue, leading to improvements in obesity and associated disease complications 
in humans and rodent models. These effects are likely due to systemic anti-inflammatory 
effects of curcumin on innate immune pathways that influence metabolic disease. Curcumin 
packaged with carriers such as liposomes directly target cells of the immune system, 
including inflammatory macrophages and antigen presenting cells, specifically reducing 
inflammation in these cells and improving bioavailability of curcumin.  
Vitamin D3 loaded nanoparticles increases its bioavailability and cell targeting: 
Though systemic administration of vitamin D3 is associated with off-target effects like 
hypercalcemia and hypercalciuria, cell specific targeting approaches are not well 
characterised. Vitamin D3 or its analogs have been encapsulated into either polymer 
nanoparticles or liposome formulation and tested in vitro for the delivery of calcipotriol, a 
vitamin D3 analog, into the skin, and also to inhibit keratinocyte proliferation (237) (238). 
Vitamin D3 is lipophilic and incorporates into the lipid phase of liposomes, protecting it from 
oxidation. PEGylated (poly ethylene glycol) liposomes loaded with calcipotriol have been 
developed (238).  Liposomal entrapment enhanced calcipotriol stability and when these 
liposomes were conjugated with RKKH-peptide to target integrin α2β1 receptor on 
keratinocytes, calcipotriol was delivered to keratinocytes and induced the antimicrobial 
peptide cathelicidin, a VDRE downstream gene (239). Compared to free vitamin D3, 
liposomal vitamin D3 significantly inhibited proliferation of myeloid leukaemic cells from 
acute myeloid leukaemia patients, and myelomonocytic cell line HL60, but not T-cell lines 
(240). These studies indicate that vitamin D3 can be incorporated into liposomes similar to 
curcumin and deliver active drug to target cells. 
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Taken together, encapsulation of nutraceutical drugs, curcumin and vitamin D3 into 
liposomes would increase their bioavailability by protecting them from metabolism and 
oxidation. In addition, liposomes of 100 nm are taken up from the circulation by phagocytic 
cells, including liver Kupffer cells. By delivering anti-inflammatory compounds to these cells, 
liposomes may reduce inflammation in diseases such as NASH where myeloid cells play a 
pivotal role in disease progression.  
I have developed diet-induced pre-clinical mouse models of NASH to test the potential of 
liposomes loaded either with curcumin or vitamin D3 to treat disease. I will discuss these 
mouse models of NASH in the next section. 
1.5 Diet induced mouse models of NAFLD/NASH: 
For decades animal models were used to understand the pathophysiology of human fatty 
liver disease. Though none of the animal models developed so far has completely covered 
the full spectrum of human NAFLD progression, they are beneficial to understand the 
pathological factors associated with the human disease and to test potential therapeutics 
that target these factors for disease amelioration.  Based on the mode of disease induction 
in rodents, models can be broadly classified into diet induced, genetic and hepato-toxin 
induced. NAFLD, being a metabolic disorder, is strongly associated with over nutrition, 
therefore diet induced fatty liver disease animal models accurately recapitulate human 
NAFLD. 
1.5.1. Methionine and choline deficient diet: 
Methionine and choline are essential for glutathione and phophatidylcholine synthesis, 
hepatic β-oxidation and production and secretion of very low-density lipoprotein (241). Mice 
fed a diet deficient in methionine and choline with high sucrose (40%) and fat (10%) develop 
features of NAFLD. Excess sucrose and fat accelerate hepatic lipogenesis, and methionine 
and choline deprivation increase fatty acid uptake by liver and reduces hepatic triglyceride 
secretion. This leads to accumulation of triglycerides in the liver and steatosis (242). Mice 
fed an MCD diet develop steatosis as early as day 10, fibrosis by 3-4 weeks and fibrotic 
scaring at 8-10 weeks (243) (244). In addition to hepatic triglyceride accumulation, feeding 
mice an MCD diet induces lipotoxicity and hepatocellular injury through FFA and acylglycerol 
intermediates. This can be detected in the serum as elevation in ALT, a biomarker for 
hepatocyte damage. Oxidative stress is important in disease progression as mice lacking 
nuclear factor E2-related factor-2, a master antioxidant defence regulator, or 
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pharmacological inhibition of oxidative stress reduces MCD-induced hepatic inflammation 
and fibrosis (176), (245), (246).  
Together with steatosis, mice fed an MCD diet have activated Kupffer cells, recruited 
monocytes and reduced numbers of hepatic NKT cells (104), (247). This correlates with 
increased NF-ĸB in both parenchymal and non-parenchymal cells and increased IL-6, IL-1β 
TNFα and TGF-β (248). Mice fed an MCD diet also have increased hepatic expression of 
TLR-4, TLR-7 and TLR-9 and engagement of these receptors induces TNFα and IL-1β-
induced hepatocyte apoptosis (249), (250). 
Although the MCD model recapitulates many of the key features of NAFLD, mice do not 
exhibit peripheral obesity. Feeding mice an MCD diet leads to significant weight loss over 
four weeks (approx. 40%) and mice are insulin sensitive, with low serum glucose, insulin 
and leptin levels, and unchanged adiponectin levels (251). Nevertheless, mice fed an MCD 
diet for 4 weeks develop hepatic insulin resistance (252).  
1.5.2.  High fat and high sugar diet: 
Lieber et al., developed an NAFLD animal model by feeding rodents fat (71%), 
carbohydrates (11%) and proteins (18%) (HFD) (253). Severity of liver damage induced by 
this HFD is comparatively less and more variable compared with mice fed an MCD diet. Rats 
fed a HFD display a similar metabolic profile and histopathology seen in human NAFLD and 
have hyperglycaemia, hyperinsulinemia, hyperleptinemia, hypoadiponectinemia, insulin 
resistance, glucose intolerance, oxidative stress and hepatic lipid deposition along with 
hepatic activation of JNK and NF-ĸB (254), (255). Feeding mice a HFD induces ER stress, 
leading to hepatocellular damage through increased hepatic lipogenesis and secretion of 
pro-inflammatory proteins such as serum amyloid P and C-reactive protein (65). Blocking 
ER stress through over expression of glucose-regulated protein 78, ER protein chaperon, 
reduces hepatic lipid deposition in mice fed a HFD (256). 
Whereas mice fed an MCD diet for 10 days develop steatosis, mice need to be fed a HFD 
for 4 - 6 months to induce hepatic steatosis, and is a major disadvantage of this NAFLD 
model. Several studies in humans have implicated a role of fructose in NAFLD pathogenesis 
(257). Fructose may provide a secondary hit for NAFLD as combined with HFD it induces 
increased steatosis, inflammation and fibrosis (258). Excess fructose consumption 
promotes NAFLD progression through hepatic insulin resistance, hyperglycemia, 
dyslipidemia, oxidative stress and endotoxinemia (259). Feeding mice for 16 weeks with 
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excess trans-fat diet and fructose syrup together with reduced physical activity lead to 
extensive hepatic steatosis with necro-inflammation (260). In another study, rats fed a diet 
of 70% fructose for five weeks had increased microvesicular steatosis and lobular 
inflammation. In addition a high fructose diet induced hepatic production of pro-inflammatory 
cytokines including TNFα and IL-6 (261). Interestingly, mice fed a high fructose diet (30%) 
for 8 weeks had increased levels of endotoxin in the portal blood, which promoted hepatic 
inflammation by activating Kupffer cells (262). Although these studies indicate that fructose 
alone can mediate liver damage, the most consistent induction of NASH is observed when 
high fructose supplements MCD or HFD models. In this regard, mice fed a HFD and water 
containing 55% and 45% of fructose and sucrose respectively developed complete NASH 
phenotype by 16 weeks (263). Thus feeding mice with a diet rich in saturated fatty acids and 
simple sugars can offer a highly relevant model to understand NASH pathophysiology and 
also to test potential therapeutics in the preclinical setting. 
1.6 Knowledge gaps and aims of this thesis:  
Several years of basic research in understanding pathological aspects of metabolic diseases 
like NAFLD established that, while disease is induced through poor dietary and sedentary 
habits chronic progression is dependent on hepatic inflammation. Recruitment of circulatory 
monocytes and conversion to inflammatory macrophages and dendritic cells within 
damaged liver fuel the inflammation (89), (90). Mouse studies using conditional knockout of 
key proinflammatory signaling cascades such as NF-κB, JNK, TNFα in myeloid cells indicate 
that pharmacological inhibition of these pathways in myeloid cells may ameliorate diet-
induced insulin resistance and steatohepatitis in human, however translational research in 
this regard is limited (76) (249) (266). 
Our group previously demonstrated that liposomes loaded with anti-inflammatory drug, 
curcumin, target inflammatory DCs inhibit NF-κB and reduce insulin resistance in leptin 
deficient mice (95). Though curcumin inhibits NF-κB, whether it is the direct target of 
curcumin or modulated through other pathways is unclear. Molecular characterization of 
curcumin targeted DCs would help to delineate these pathways. Moreover, obesity is 
associated with steatohepatitis including fibrosis, but leptin deficient mice develop steatosis 
in the absence of fibrosis. Thus the ability of curcumin liposome therapy to treat inflammatory 
liver diseases (NASH) needed to be validated. This was performed in 2 mouse models, mice 
fed MCD diet that develop acute NASH (chapter 3) and HFHS fed mice that develop NASH 
together with hyperglycaemia and insulin resistance (chapter 4).  
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Further to innate immune activation, impaired adaptive immune regulation also been 
reported in obesity. Diet induced obesity is associated with decreased ratio of Treg to T 
helper type 1 and 17 cells in visceral adipose tissue and Treg expansion or adoptive transfer 
therapy with polyclonal Tregs reduces insulin resistance and LPS induced liver damage in 
mice fed HFD (117) (106) (118). Antigen-specific Treg therapy has been shown to reduce 
liver inflammation in autoimmune hepatitis and liver transplantation (264). Whether antigen-
specific Treg therapy reduces acute liver damage and inflammation in the context of NASH 
is unknown. In chapter 5, I have tested the hypothesis that, liposomes with ability to target 
liver myeloid cells may deliver entrapped antigen along with drug, which can facilitate 
cognate antigen recognition in the liver by adoptively transferred Tregs to enhance antigen-
specific Treg immunotherapy to treat NASH.  
Findings described in this thesis demonstrate the potential of liposome nanoparticles to 
deliver immunomodulatory drugs to hepatic myeloid cells to induce alternative or tolerogenic 
activation. The results also show that liposomes effectively deliver antigen to hepatic 
myeloid cells, which facilitates cognate antigen recognition by antigen-specific Tregs and 
reduce hepatic inflammation and prevent NASH progression in obesity.  
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2. Materials and Research Methods 
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The second chapter is divided into two parts, the first part will describe the reagent 
preparations, and then the second part covers the research methods that I have used to 
conduct the experiments in this thesis work. 
2.1. Materials: 
Deionized water was collected from a MilliQ system (Merck Millipore) for reagent 
preparation. Nalgene vacuum filtration system (pore size 0.2 μm) was used to filter-sterilize 
the reagents where mentioned. pH of the solutions was adjusted to 7.2 to 7.4 using 1M HCl 
and 1M NaOH. 
2.1.1 O.5M NaOH: 
NaOH (19.99g) (molecular weight = 39.997g/mol) was dissolved in 500 mL of deionized 
water and adjusted to 1 L to make 0.5M NaOH, which was stored in a plastic bottle.  
Table 2-1: Chemicals or reagents used to prepare 0.5M NaOH solution 
Chemical/Reagent Catalogue number Company 
NaOH S8045 Sigma-Aldrich 
 
2.1.2 Phosphate buffer saline (PBS):  
10x PBS was prepared by dissolving NaCl (80g), KCl (2g), Na2HPO4x2H2O (11.5g), KH2PO4 
(2g) in 500mL of deionized water using a magnetic stirrer at room temperature (RT) and 
adjusted to 1 litre. 10x PBS was diluted 1:10 with deionized water to prepare the working 
solution (1x PBS), and pH was adjusted to 7.2 to 7.4. 10x and 1x PBS were autoclaved and 
stored at room temperature (RT). 50mL of heat-inactivated (56oC for 30min) fetal bovine 
serum (FBS) was added to 450mL of 1x PBS under sterile conditions to prepare 10%-FBS 
PBS. 
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Table 2-2: Chemicals or reagents used to prepare 10x PBS solution 
Chemical/Reagent Catalogue number Company 
NaCl S9625 Sigma-Aldrich 
KCl V016080 Vetec (Sigma-Aldrich) 
Na2HPO4x2H2O V019160 Vetec (Sigma-Aldrich) 
KH2PO4 V016150 Vetec (Sigma-Aldrich) 
 
2.1.3 ACK red blood cell lysis buffer:  
10x ACK (Ammonium-Chloride-Potassium) lysis buffer was prepared by dissolving NH4Cl 
(82.9g), KHCO3 (10g), EDTA (372mg) in 500mL of deionized water and adjusted to 1 L. 
Working solution (1x ACK) was prepared by diluting 10x ACK 1:10 in deionized water, pH 
was adjusted to 7.2 to 7.4. Both stock and working solution was filter sterilized and stored 
at 4oC. 
Table 2-3: Chemicals or reagents used to prepare 10x ACK solution 
Chemical/Reagent Catalogue number Company 
NH4Cl A0171 Sigma-Aldrich 
KHCO3 237205 Sigma-Aldrich 
EDTA ED4S Sigma-Aldrich 
 
2.1.4 FACS washing solution:  
10x FACS wash solution was prepared by dissolving BSA (10g), 0.5M EDTA (40mL), in 
500mL of deionized water and adjusted to 1 L, sterilized, pH was adjusted to 7.2 to 7.4. Filter 
sterilized 10x stock solution was stored as 50mL aliquots at -30oC.  Working solution (1x 
FACS wash) was prepared by diluting 10x FACS wash 1:10 in sterile PBS and stored at 
4oC. 
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Table 2-4: Chemicals or reagents used to prepare 10x FACS wash solution 
Chemical/Reagent Catalogue number Company 
BSA BSAM 0.1 Bovogen Biologicals 
EDTA ED4S Sigma-Aldrich 
 
2.1.5 Complete cell culture medium:  
Complete cell culture medium was prepared by mixing RPMI-1640 (440mL) with 50mL of 
heat-inactivated FBS, 5mL of penicillin-streptomycin-glutamine (100x), 5mL of sodium 
pyruvate (100mM) under sterile conditions and stored at 4oC until use. 
Table 2-5: Chemicals or reagents used to prepare complete cell culture medium 
Chemical/Reagent Catalogue number Company 
RPMI-1640 21870-076 Gibco 
Fetal bovine serum (FBS) SFBS-F Bovogen Biologicals 
Penicillin-Streptomycin-Glutamine (100x) 10378-016 Gibco 
Sodium pyruvate (100mM) 11360-070 Gibco 
 
2.1.6 High sugar water:  
42g of sugar (23.1g of fructose (55%) and 18.9g of sucrose (45%)) was dissolved in 500mL 
of autoclaved water at RT and adjusted to 1 L, filter-sterilized and stored at RT. High sugar 
water was provided to mice in a 250mL bottle with a nozzle.  
Table 2-6: Chemicals or reagents used to prepare high sugar water 
Chemical/Reagent Catalogue number Company 
Fructose 0226 Amresco 
Sucrose 0335 Amresco 
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2.1.7 Antibodies:  
Anti-mouse monoclonal antibodies derived from rat and/or mouse and/or Armenian hamster 
were used for staining cells (refer to section 2.2.10) and frozen liver sections (refer to section 
2.2.13). Details of these antibodies are provided in the table-2.6. Antibodies for surface and 
intracellular staining were diluted (1:100) in 1x FACS wash buffer and 1x permeabilisation 
buffer (eBioscience) respectively. 
Table 2-7: Antibodies used for flow cytometry and immunofluorescence staining 
Antigen 
specificity 
Fluorochrome(s)  Clone Isotype(s) 
Catalogue 
number 
Company 
Aqua - - - L34957 Invitrogen 
CD3 PE/Cy7 17A2 Rat IgG2b, κ 100220 Biolegend 
CD4 APC/Cy7 OKT4 Mouse IgG2b, κ 317418 Biolegend 
CD8α PE/Texas Red 53-6.7 IgG2a ab25294 abcam 
CD11b APC M1/70 Rat IgG2b, κ 101212 Biolegend 
CD11c Alexa Fluor 488 N418 
Armenian 
Hamster IgG 
117311 Biolegend 
CD19 
PerCP/Cy5.5 & 
APC 
6D5 Rat IgG2a, κ 115534 Biolegend 
CD45.1 FITC A20 Mouse IgG2a, κ 110706 Biolegend 
CD45.2 Alexa Fluor 700 104 Mouse IgG2a, κ 109822 Biolegend 
CD80 FITC 16-10A1 
Armenian 
Hamster IgG 
104706 Biolegend 
CD86 PerCP/Cy5.5 GL-1 Rat IgG2a, κ 105028 Biolegend 
CD206 PE/Cy7 C068C2 Rat IgG2a, κ 141720 Biolegend 
F4/80 
PE/Cy7 & 
APC/cy7 
BM8 Rat IgG2a k 
123114 & 
123118 
Biolegend 
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Foxp3 
(ICS*) 
Alexa Fluor 488 FJK-16s Rat IgG2a k 
53-5773-
82 
eBioscien
ce 
Helios 
(ICS*) 
Pacific Blue 22F6 
Armenian 
Hamster IgG 
137220 Biolegend 
IA/IE Pacific Blue 
M5/114.15.
2 
Rat IgG2b, κ 107620 Biolegend 
NK 1.1 Alexa Fluor 700 PK136 Mouse IgG2a, κ 108730 Biolegend 
IFNγ 
(ICS*) 
PerCP/Cy5.5 XMG1.2 Rat IgG2b, κ 505822 Biolegend 
TNFα 
(ICS*) 
APC MP6-XT22 Rat IgG1, κ 506308 Biolegend 
IL-1β 
(ICS*) 
FITC NJTEN3 Rat IgG1, κ 
11-7114-
82 
eBioscien
ce 
IL-4 (ICS*) APC & PE 11B11 Rat IgG1, κ 
554436 & 
504104 
BD 
Pharming
en & 
Biolegend 
IL-10 
(ICS*) 
APC JES3-9D7 Rat IgG2b, κ 501410 Biolegend 
IL-17 
(ICS*) 
Alexa Fluor 488 
TC11-
18H10.1 
Rat IgG1, κ 506910 Biolegend 
* Intra cellular staining (ICS) 
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2.2 Research methods: 
2.2.1 Animals: 
Six-week-old female C57BL/6J mice, supplied by the Animal Research Centre (Murdoch, 
Australia) were housed in specific pathogen-free conditions. The ovalbumin (OVA)-specific 
TCR-transgenic, OT-2 mice (CD45.2) and SJL mice (CD45.1) on the C57BL/6 background 
were bred at the University of Queensland. Ad libitum normal water was provided to all mice, 
unless otherwise indicated. The University of Queensland animal ethics committee 
approved all procedures and experiments. 
2.2.2 Models of NASH: 
A. MCD diet induced NASH model: NASH was induced by feeding six week old C57BL/6J 
(CD45.2) mice a methionine and choline deficient diet (supplied by Speciality Feeds, 
Australia) for 3 weeks. Control group mice were age-matched and fed a standard chow 
diet for the same period.  
B. High-fat high-sugar (HFHS) diet induced NASH model: NASH was induced by feeding 
six week old C57BL/6J (CD45.2) mice with a 60% fat diet (supplied by Speciality Feeds, 
WA, and Australia) and high-sugar water (fructose - 55% and sucrose - 45%) (refer to 
section 2.1.6) for 14 weeks. Control mice were age-matched and fed standard chow diet 
for the same period of time.  
2.2.3 Liposome-drug formulation: 
Egg phosphatidylcholine (140mg) and cholesterol (60mg) were combined in a round bottom 
(RB) flask, 9:1 ratio of chloroform and ethanol was added to dissolve lipid. To this dissolved 
lipid, curcumin (3.5mg) or calcitriol (6 µg in ethanol) was added. Using a rotary evaporator 
(at 40oC) a thin film of lipid/drug was made in RB flask. Rehydrated solution was subjected 
to 3 cycles of freeze-thaw and the prepared liposomal solution passed through high-
pressure homogenizer (Emulsiflex-C3, Avestin) at 12000 psi for 15 cycles (9.6 
sec/cycle/8ml) and free drug was separated using diafiltration. For some experiments 
ovalbumin (OVA) protein (Sigma-Aldrich) (40mg) loaded liposomes were prepared by 
adding OVA solution to the pre-formed lipid/drug. The liposome particle size was measured 
on Malvern Zetasizer Nano ZS (Malvern, Worcestershire, UK) and the prepared liposomes 
were stored at 4oC. For liposome uptake studies, liposomes were fluorescently labelled with 
the ethanolic stock of lipophilic fluorescent marker DiI (1,1'-Dioctadecyl-3,3,3',3'-
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Tetramethylindocarbocyanine Perchlorate) or DiR (1,1'-Dioctadecyl-3,3,3',3'-
Tetramethylindotricarbocyanine Iodide) (Invitrogen Molecular Probes).  
2.2.4 In vivo imaging: 
Mice were injected intravenously with DiR-labelled liposomes (DiR has excitation and 
emission maxima in the near infrared region, at which auto fluorescence of many tissues is 
undetectable). Dorsal and ventral regions of mice were shaved and anaesthetised mice 
were positioned as supine and right lateral recumbent to image liver and spleen respectively. 
In vivo imaging system (IVIS) (IVIS Imaging Systems) was used to image live mice or 
excised organs. Images were processed on Living Image Software (IVIS Imaging Systems) 
to calculate total radiant efficiency of DiR fluorescence.  
2.2.5 Serum collection: 
Blood from eye bleed or cardiac puncture was collected into a 2 mL microfuge tube, 
incubated at 37oC for 10 minutes and then spun at 10000 rotations per minute (rpm) for 10 
minutes at RT. Collected serum was used to measure alanine transaminase (section 2.2.6) 
and insulin (section 2.2.7). 
2.2.6 Alanine transaminase (ALT) assay: 
MaxDiscoveryTM Alanine Transaminase Color Endpoint Kit (Biooscientific, catalog, # 3460-
08) was used to measure ALT (U/L) activity in serum according to the manufacturer's 
instructions. In brief, 10ul of serum was added (in duplicate) to flat bottom 96 well plate. 
50μL of ALT reagent mix was added to the serum, after incubation at 37oC for 30 minutes 
50μL of DNPH colour solution was added and incubated for further 10 minutes at 37oC. 
Finally 200μL of 0.5M NaOH was added and absorbance of wells read at 510nm using 
SkanIt software (version 3.2) on Multiskan™ GO microplate spectrophotometer (Thermo 
Scientific). In MCD diet induced NASH model serum ALT levels are highly variable between 
mice during disease progression. Hence the disease progression in individual mice is 
represented as change in ALT levels from before treatment to 1 week post treatment. 
2.2.7 Fasting blood glucose and insulin measurement: 
Mice were fasted for 5-6 hours, blood was collected by tail bleed and glucose levels were 
measured using strip test kit (FreeStyle Optium-Abbott). Fasting insulin was measured in 
serum (section 2.2.5) using ultra-sensitive mouse insulin assay kit (Crystal Chem) according 
to manufacturer’s instructions. In brief, 5µl of serum or insulin standard was dispensed into 
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wells of anti-insulin (mouse) antibody pre coated microplate and incubated for 2 hours at 
4oC. Plate was washed 5 times with wash buffer and then incubated for 30 minutes with 
anti-insulin enzyme conjugate (100µl). After a further 5 washes 100µl of substrate was 
added to each well and plates incubated for 40 minutes at RT. Stop solution was added to 
each well and absorbance at A450 and A630 measured using SkanIt software (version 3.2) on 
Multiskan™ GO microplate spectrophotometer (Thermo Scientific). Insulin concentrations 
were calculated based on the standard curve.  
2.2.8 Single cell isolation from tissues: 
A. Hepatic immune cell isolation: Liver was excised from mice and lobes dissected with a 
scalpel. The caudate lobe of liver was fixed in 10% formalin (Sigma-Aldrich) and in optimal 
cutting temperature (OCT) (Tissue-Tek) snap frozen in liquid nitrogen. Remaining liver was 
used for hepatic immune cell isolation. Livers were minced with the back end of a plunger 
and digested with 1mg/mL collagenase type VIII (Worthington) in RPMI (Gibco) for 30 
minutes at 37oC, 5% CO2. Cells were then filtered through 70μm cell strainers (BD Falcon) 
and washed twice with 10% PBS.  The single cell suspension was mixed in a 50mL tube 
with 10mL of 37.5% Percoll (GE Healthcare Life Sciences) prepared in 1x PBS and 
centrifuged (Eppendorf centrifuge 5810 R) with no brake at 2200 rpm for 30 minutes at 20oC. 
The supernatant was discarded and the cell pellet was washed twice with 50 mL of 10% 
PBS. Red blood cells were lysed with 1x ACK lysis buffer for 1-2 minutes at RT and cells 
were washed with 10 mL of 10% PBS. Isolated non-parenchymal cell fraction was 
resuspended in 5mL cold complete RPMI medium and stored at 4oC until further procedure.  
B. Splenic immune cell isolation: Spleens were disaggregated and digested as described 
for liver in section 2.2.8A, RBC lysed, single cell suspension was resuspended in 5mL cold 
complete RPMI and stored on ice till further process. 
C. Lymph node (LN) and adipose tissue cell isolation: Lymph nodes or adipose tissues were 
disrupted through a 70µm filter and single cell suspension collected, washed cells were 
resuspended in 5mL cold complete RPMI and stored at 4oC. 
2.2.9 Cell transfer experiments: 
CD4 single positive cells were enriched using automated Magnetic Associated Cell Sorting 
system (AutoMACS- Miltenyi Biotec) from total immune cells isolated from spleens and LNs 
of OT-2 mice. CD4+CD25high (purity >90%, and Foxp3+ cells were >80%), CD4+CD25- 
(purity >98%, and >98% were Foxp3-) were sorted using MoFlo® Astrios™ (Beckman 
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Coulter). Trypan blue (Bibco) stained cells were counted using haemocytometer 
(Hirschmann 0.0025mm2) and Olympus CKX41 microscope. CellTrace™CFSE Cell 
Proliferation Kit (Invitrogen) was used to label the cells according to the manufacturer’s 
guidelines. CFSE labelled cells were resuspended in 100-200µL sterile PBS and injected 
intravenously into mice through tail vail. 
2.2.10 Flow cytometry staining and analysis: 
Fluorochrome conjugated anti-mouse mAbs (section 2.1.7) were used to stain immune cells 
obtained as mentioned in section 2.2.8. Centrifugation of live cells was performed at 1500 
rpm, 4oC for 5 minutes and fixed cells at 2000 rpm, 4oC for 3 minutes. First, leukocytes were 
stained with amine-binding live/dead discriminator Aqua (1:1000 in RO water) for 10 minutes 
and washed with FACS wash buffer. Cells were surface stained with mAb for 30 minutes at 
4oC, CD16/32 antibody added to block surface Fc receptors, and unbound antibodies were 
washed away with FACS wash buffer. After washing, cells were fixed for 20 minutes at 4oC, 
using eBioscience fixation/permibilzation kit according to manufacturer’s instructions. 
Fixative was washed with 1x permibilization buffer and intracellular staining was performed 
for 30 minutes at 4oC. Stained samples were acquired using Gallios (Beckman Coulter) and 
analysed using Kaluza software (Beckman Coulter). Singlets were gated based on side and 
forward scatter properties and Aqua negative cells were considered as live cells. CD45+ 
cells were gated from live cell gate and used for further analysis. Flow-Count Fluorospheres 
(Beckman Coulter) were added to samples just before acquisition and used to calculate 
number of cells per whole liver.  
A. Hepatic myeloid and lymphoid cells FACS gating strategy:  
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Figure 2-1: A schematic representation of hepatic myeloid and lymphoid cells FACS 
gating strategy. Singlets were gated based on their side and forward scatter properties and 
aqua negative cells were considered as live cells. CD45.2+ cells were gated from live cell 
gate and further gated to identify myeloid or lymphoid subsets based on their surface and 
intracellular expression various markers. Colour coding demonstrates relative expression of 
other markers and side and forward scatter properties of gated populations. 
2.2.11 In vitro cytokine stimulation assay:  
Immune cells isolated from livers and spleens were resuspended in complete RPMI medium, 
trypan blue (Bibco) stained cells were applied onto a haemocytometer (Hirschmann 
0.0025mm2) and counted using Olympus CKX41 microscope. 5x105 cells were cultured in 
a 96 well U-bottom plate (Greiner Bio-one) in 250µl of medium and stimulated with a final 
concentration of 50ng/mL phorbol-12-myristate-13-actetate (PMA; Calbiochem), 1μg/ml 
ionomycin (Sigma-Aldrich) and 5μg/ml brefeldin-A (Sigma-Aldrich) for 4 hours at 37°C, 5% 
CO2. After incubation, cells were harvested, stained for surface marker antibodies diluted in 
FACS wash containing 5μg/ml brefeldin-A, fixed and stained for intracellular cytokines as 
described in section 2.2.10. Unstimulated cells were used as controls and isotype controls 
were used to avoid background staining. 
2.2.12 Histochemical staining and scoring of liver and adipose tissue:  
A. Haematoxylin & Eosin (H&E) staining: Livers and gonadal adipose tissues (GAT) were 
fixed in 10% formalin were embedded in paraffin blocks and 4μm sections prepared on 
microscope slides. H&E staining was performed using conventional haematoxylin and eosin 
reagents.  
B. Masson Trichrome (MT) staining: MT for collagen was carried out on paraffin tissue 
sections using Sigma Accustain Trichrome Stain Kit (Catalog #HT15). Briefly, deparaffinised 
sections were stained with working Weigert's Iron Hematoxylin Solution for 5 minutes, then 
Biebrich Scarlet-Acid Fuchsin solution for 5 minutes followed by collagen staining using 
Aniline Blue for 5 minutes. After dehydration, slides were mounted in xylene based 
peramount medium.  
C. Oil Red-O (ORO) staining: ORO staining was performed using the protocol described by 
Falkevall A et al., (265). In brief, 10µm sections from frozen livers were prepared on 
superfrost slides (Menzel-Glaser) using cryostat-microtome (Leica) and stained using ~1ml 
of working ORO (Sigma-Aldrich) solution for 5 minutes. After washing under tap water for 
approximately 30 minutes, slides were mounted in water-soluble mounting medium, cover 
slipped and edges were closed using nail polish.  
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D. Liver scoring: Blind scorings for NAFLD assessing score and fibrosis were performed by 
a hepatologist using H&E and MT stained slides respectively according to Kleiner’s scoring 
system (266). ORO stained slides were scanned using Olympus Automatic Virtual Slide 
Scanning System (VS120) and scanned images were analysed using ImageJ software to 
quantitate oil deposition in liver. 
E. Adipocyte size measurement: H&E stained slides of GAT were scanned using Olympus 
Automatic Virtual Slide Scanning System (VS120) and scanned images were analysed 
using ImageJ software to quantitate adipocyte size. 
2.2.13 Immunofluorescence staining of liver sections:  
10µm sections of OCT embedded frozen livers were used for immunofluorescence staining. 
Slides with sections, air-dried for 10 minutes, boundaries marked (DAKO pen) and 150µL of 
4% paraformaldehyde (ProSciTech) was added and tissue fixed for 15 minutes. After 
incubation, tissue was washed twice with 1x PBS, with a rest in 1x PBS for 5 minutes each 
cycle. 150µL of blocking buffer was added to tissue, incubated in the dark for 1 hour,   
washed twice in 1x PBS for 5 minutes each cycle, then incubated for 1 hour in the dark with 
200µL of anti-mouse primary mAb (1:100 in blocking buffer). After washing twice, 
fluorochrome conjugated secondary mAb (1:100 in blocking buffer) was applied and 
incubated for a further 30 minutes in the dark. Finally, nuclei were stained with DAPI (1:1000 
in blocking buffer) (Invitrogen) for 2 minutes in the dark, washed, cover slipped and images 
acquired using confocal microscopy (Zeiss). Images were analysed using AxioVision 4.6 
software (Zeiss). 
2.2.14 RNA extraction and cDNA synthesis for RNA sequencing: 
RNA was extracted from FACS sorted cells and snap-frozen liver tissue using RNeasy micro 
kit (Qiagen) and RNeasy mini kit (Qiagen) respectively, according to guidelines provided in 
the manuals. In short, sample (cells or tissue) was collected in buffer RLT and homogenized, 
mixed with an equal volume of ethanol and transferred to RNeasy spin columns. After 
spinning for 30 seconds at ≥8000g, on column DNase digestion using DNase-I was 
conducted. RNA was washed and eluted into a new 1.5mL tube (Eppendorf).  Quality and 
quantity of RNA was estimated either using Nanodrop (Thermo Scientific) or Bioanalyzer 
(Agilent Technologies).  
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RNA collected from FACS sorted cells was used to prepare and amplify cDNA for RNA 
sequencing using SMARTer Ultra Low Input RNA Kit for Sequencing - v3 (Clontech 
Laboratories) according to procedure described in the manual. 
2.2.15 RNA sequencing and data analysis: 
RNA sequencing on amplified cDNA from FACS sorted cells (approximately 45M reads per 
sample) and the whole liver RNA (approximately 20M reads per sample) was performed by 
the University of Queensland Centre for Clinical Genomics (UQCCG) and the Australian 
Genome Research Facility (AGRF) personnel respectively.  
Sequencing data analysis: Reads were aligned to the reference mouse genome GRCm38 
with STAR (267) (version 2.4.0d). Gene read counts were quantified against the GENCODE 
gene model (version M6). Analysis and differential expression testing was performed with 
the DESeq2 (268) (version 1.8.1) Bioconductor package. R package (version 3.2.1) was 
used to further analysis. Functional annotation analysis for  was performed using DAVID 
Bioinformatics Resources 6.7 (269). Heatmaps of differentially expressed genes were 
prepared by GENE-E (http://www.broadinstitute.org/cancer/software/GENE-E/index.html) 
and Venn diagrams were plotted through GeneVenn (270). Protein-protein interaction 
network analysis was conducted with online portal, Networkanalyst (271). 
2.2.16 Statistical analysis:  
Graph Pad Prism 6 software was used to prepare graphs and statistical analysis. Two 
groups were compared by means of unpaired two-tailed analysis (Mann Whitney-U test) and 
for comparison of multiple groups One-way ANOVA analysis with Bonferroni post hoc 
multiple comparison test was used. All error bars represent standard error mean (SEM). 
Significance was indicated as *P=<0.05, **P=<0.01, ***P=<0.001, and ****P=<0.0001.  
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3. Targeting liver myeloid cells with curcumin liposomes induce alternative 
activation of inflammatory dendritic cells and reduce MCD diet induced NASH in mice 
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3.1 Abstract: 
Nonalcoholic steatohepatitis is associated with fat accumulation in the liver and 
characterised by an increase in the number of hepatic myeloid cells with a pro-inflammatory 
phenotype. Myeloid specific genetic ablation of NF-κB reduces insulin resistance in obese 
mice, nevertheless accomplishing this with pharmaceutical agents is challenging (74). We 
recently showed that this could be achieved through liposome nanoparticles entrapped with 
anti-inflammatory drug curcumin (curcumin liposomes) (94). Curcumin liposomes 
significantly reduced NF-κB nuclear translocation in targeted DCs. However, whether this is 
due to direct inhibition or through modulating NF-κB inducing pathways is unknown. To 
elucidate the mechanisms I have studied curcumin liposomes targeted hepatic DCs from 
mice with MCD diet induced steatohepatitis. The results summarized in this chapter provide 
evidence that curcumin liposomes were taken up by F4/80+ DCs and macrophages. Gene 
expression analysis of curcumin targeted liver DCs indicates that curcumin reduces 
activation of signals upstream to NF-κB such as JNK and MAPK, and induce alternative 
phenotype as indicated by higher expression of IL-10 receptor β (IL-10rb), mannose receptor 
C type-1 (MRC-1) and peroxisome proliferator–activated receptor-γ (PPARγ). Curcumin 
also inhibits autophagy and promotes oxidative phosphorylation. The outcome of targeting 
hepatic phagocytic cells with curcumin liposomes was diminished myeloid cell activation 
which reduced MCD diet induced liver damage as measured by serum ALT and NAFLD 
assessing score of H&E stained liver sections.  
3.2 Introduction: 
NASH is a major co-morbidity in obesity, type-2 diabetes and metabolic syndrome patients. 
NASH is associated with fat accumulation and chronic inflammation in the liver. Due to lack 
of specific treatments, NASH may progress to liver cirrhosis and hepatocellular carcinoma, 
thereby increasing liver related deaths worldwide, secondly only to viral and alcoholic liver 
diseases (272). 
Although lipotoxicity mediated hepatocyte death underlies the NASH pathology, the fate of 
disease progression is dependent on myeloid cell mediated inflammation. Blocking 
monocyte recruitment to the liver or depletion of hepatic macrophages reduces 
steatohepatitis in several liver injury animal models, emphasizing the role of hepatic 
macrophages in NASH pathogenesis (70) (81) (82) (88) (250) (273).  Interestingly, 
alternatively activated (M2) macrophages induce apoptosis of pro-inflammatory (M1) 
macrophages and reduce HFD induced NASH, implying the protective role of M2 
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macrophages in preventing NASH progression (78). Hepatic DCs with high lipid deposits 
are immunogenic while low-lipid DCs are tolerogenic (97). These findings suggest that 
therapeutics that alter inflammatory activation, intracellular metabolism and promote 
alternative signature in liver myeloid cells may prevent NASH progression.   
Pro- and anti- inflammatory phenotypes of liver myeloid cells are dependent on activation of 
NF-κB, as myeloid specific ablation of IKK-β or sodium salicylate (an inhibitor of IKK-β) 
treatment prevents NF-κB activation and reduces inflammation and insulin resistance in 
response to HFD(74) (76). Curcumin, a natural NF-κB inhibitor when supplemented orally 
or intraperitoneally reduces MCD- and HFD-diet induced steatohepatitis by inhibiting NF-κB 
and its downstream genes including TNFα, ICAM-1, COX-2 and MCP-1 (172) (171) (169), 
(176). Though clinically beneficial, poor bioavailability of curcumin limits use in treating 
human NASH. Being highly lipophilic, curcumin bioavailability is increased when complexed 
with liposomes, micelles and phospholipids (190). Our group has shown that curcumin 
liposomes delivered intraperitoneally to obese mice reduced systemic insulin resistance as 
measured by HOMA-IR (94). Curcumin liposomes reduced NF-κB and associated 
inflammatory cytokine production in TNFα/iNOS producing (Tip)-DCs (Tip-DCs) and adipose 
tissue inflammatory macrophages. Thus liposomal formulations enhance the delivery and 
therapeutic potential of NF-κB inhibitors such as curcumin to treat metabolic inflammatory 
diseases. 
3.3 Rationale and aim:  
Curcumin with its pleotropic properties regulate several pro-inflammatory pathways (185). 
Although curcumin may be delivered to the liver by intestinal absorption following dietary 
consumption or gavage, it is poorly absorbed by the intestine and processed to metabolites 
via host glucuronidation and metabolised by flavonoid utilising bacteria. Hence, it is difficult 
to assess both delivery of curcumin to liver and direct curcumin effects as opposed to 
secondary, microbiota effects. Therefore, the experiments in this first results chapter aims 
to characterise the effect of liposomally delivered curcumin on gene expression within 
targeted liver DCs and the influence of this immunomodulation on DC phenotype and NASH 
progression. To this aim I have used a well-characterised acute NASH model where female 
C57BL/6J mice are fed an MCD diet for 3 weeks.  
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3.4 Results: 
3.4.1 C57BL/6J mice fed MCD diet develop both serological and histological features 
of human NASH: 
Since the MCD model had never been used by our group, my first aim was to characterise 
disease progression in C57BL/6J mice. Mice were fed a chow diet or an MCD diet for 4 
weeks and groups of mice sacrificed weekly to assess severity of disease by histological 
evaluation of livers (NAS score), liver damage (serum ALT) and fibrosis (Masson Trichrome 
stain). Histological evaluation of tissue sections shows that MCD diet feeding induced simple 
steatosis in 2 weeks with progression to steatohepatitis by 3 weeks (Figure 3-1, A & B). 
MCD diet supplementation significantly increased hepatic lipid accumulation by two weeks, 
compared to control, as measured by Oil red-O staining for lipid deposition on frozen liver 
tissue sections (Figure 3-1, A & C). Next, the effect of MCD diet on the liver fibrosis was 
assessed using Masson Trichrome staining for collagen. Compared to control diet, mice fed 
an MCD diet for 3 weeks had increased collagen in the liver (Figure 3-1, A & D). Mice fed 
an MCD diet for 3-4 weeks had significant hepatocyte damage, as measured by elevated 
serum ALT (Figure 3-1, E). Moreover, hepatocyte damage positively correlated with NAFLD 
assessing score (NAS score) (Figure 3-1, F). In summary, these data indicate that mice fed 
an MCD diet for 3 weeks develop NASH with both serological and histological features of 
human nonalcoholic steatohepatitis. 
3.4.2 Livers from mice fed MCD diet are enriched in inflammatory myeloid cells: 
Initial experiments sought to determine whether MCD diet induced immune cells within the 
liver with altered expression of pro- and anti- inflammatory cytokines. Hepatic immune cells 
isolated from mice fed a control diet or an MCD diet were stimulated ex vivo with phorbol 
myristate acetate (PMA) and ionomycin in presence of brefeldin-A for 4 hours. Cells were 
analysed by flow cytometry for intracellular expression of cytokines. Kupffer cells (F4/80+ 
CD11blo) (red colour gate in Figure 2-1) from mice fed an MCD diet for 3 weeks had 
significantly increased pro-inflammatory cytokines including IFNγ, IL-1β and IL-17 (Figure 
3-2, A). Having identified an inflammatory signature, a detailed characterisation of hepatic 
immune cells within control and MCD fed mice was undertaken. 
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Figure 3-1: Mice fed MCD diet develop serological and histological features of human 
NASH. A-D: Liver tissue from mice fed MCD were stained with hematoxylin and eosin (H&E) 
to determine NAFLD assessing (NAS) score (A and B), Oil red-O for oil deposition (A and 
C) or Masson Trichrome stain for collagen (A and D). n=5/group excluding C n=2/group) E: 
Serum alanine transaminase (ALT) levels in mice fed MCD diet or control diet. n=10/group. 
F:  Spearman correlation of NAS score and serum ALT (U/L) levels. Data are mean ±SEM. 
Representative of two separate experiments analysing individual mice. Arrows indicate 
inflammatory foci. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by one-way ANOVA with 
Bonferroni post hoc test. 
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Notably, mice fed an MCD diet had increased proportions of hepatic CD11b+ myeloid cells 
compared with mice fed a normal diet (Figure 3-2, B). Within the myeloid cells, DC (MHCII+, 
CD11c+), monocyte derived DC (moDC) (CD11bhi CD11c+), Kupffer cell (F4/80+ CD11blo) 
monocytes (CD11bhi, F4/80int) and neutrophil (Ly6G+) proportions were increased (Figure 
3-2, B). These populations could be further classified as follows: In DC, both F4/80+ and 
F4/80- DC proportions were increased following feeding the MCD diet (Figure 3-2, C). Of 
importance, increased numbers of F4/80+ DC are present in the liver in response to HFD 
and parasitic liver infection and are pro-inflammatory expressing both TNFα and iNOS (Tip-
DCs) (93). Within monocyte subsets, Ly6Chigh monocytes, which are recruited to the liver in 
response to liver damage (including NASH), were increased (Figure 3-2, C). Next, 
expression of MHC-II was evaluated on myeloid subsets by flow cytometry. Both F4/80+ 
and F4/80- DC subsets and MoDCs from livers of mice fed an MCD diet for 3 weeks had 
increased expression of MHC-II compared with DCs from mice on a normal diet (Figure 3-
2, D). In contrast, Kupffer cells and B cells had decreased expression of MHC-II. Next, the 
proportion of hepatic lymphoid cells from mice fed an MCD diet for 3 weeks was compared 
with mice fed a normal diet. Liver damage was associated with increased CD3+CD4-CD8- 
T-cells (mostly γδ-T cells), CD4+ Foxp3+ Treg and natural killer (NK) cells, while NKT and 
B cells were decreased (Figure 3-2, E). 
In summary, this data indicate that feeding mice an MCD diet for 3 weeks increases hepatic 
myeloid cell proportions, including blood derived DC subsets (MoDC) and inflammatory 
monocytes with increased MHC-II. Lymphoid cells, including Treg and NK cells were 
increased whereas B-cell proportions were reduced. 
3.4.3 Curcumin liposomes target hepatic inflammatory myeloid cells, present in mice 
with MCD diet-induced liver disease: 
Previous studies from our group have shown that Intraperitoneally (IP) injected curcumin 
liposomes target hepatic Tip-DCs and adipose tissue macrophages, and reduced 
inflammation and insulin resistance in obese (ob/ob) mice (18). To determine the 
biodistribution of curcumin liposomes, in vivo imaging (IVIS system) of live mice, fed an MCD 
diet for 2 weeks, was carried out following intravenous injection of curcumin liposomes 
labelled with DiR. Imaging of anaesthetised mice at 24 hours, 7 days and 14 days post 
treatment indicated that DiR was found in the liver and spleen at all-time points (Figure 3-3, 
A). At 14 days post treatment mice were sacrificed and blood, liver, spleen and mLN were 
removed and imaged. While no signal was detected in blood and mLN, the spleen had 
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minimal fluorescence and the liver displayed the brightest signal (Figure 3-3, B). These 
experiments indicated that the liver was the primary organ targeted following intravenous 
injection of curcumin liposomes and indicated long persistence of DiI within the liver up to 2 
weeks post treatment. 
Next experiments examined which cells were targeted by curcumin liposomes within the 
liver of mice with MCD diet induced liver disease. The approach taken was to label curcumin 
liposomes with DiI and inject these intravenously into mice fed an MCD diet for two weeks. 
Livers were harvested 24 hours post treatment, immune cells were isolated and stained for 
leukocyte markers and analysed for DiI positive cells by flow cytometry. DC, moDC, Kuppfer 
cells and to a lesser extent inflammatory monocytes were DiI positive (Figure 3-3, C). When 
enumerated, about 87±4%, 64±5% and 43±9% of F4/80+ DCs, moDC and Kupffer cells 
respectively were targeted by curcumin liposomes (Figure 3-3, D). From the flow cytometry 
analysis it was apparent that F4/80+ DCs were the main DC population DiI positive at 24 
hours post treatment (Figure 3-3, C and D). Interestingly, although DiI positive cells were 
reduced 7 days post treatment, hepatic F4/80+DCs were the predominant cell DiI positive 
(~40%) (Figure 3-3, D).  Immunofluorescence staining of frozen liver sections confirmed that 
F4/80+DCs surrounding ballooned hepatocytes were DiI positive (Figure 3-3, E), and no DiI 
was detected in parenchymal cells. Next experiments examined if intraperitoneal injection 
of curcumin liposomes reduced uptake by hepatic myeloid cells. Comparison of 
intraperitoneal and intravenous injected liposomes indicated that the intravenous route 
resulted in 2-fold higher uptake by hepatic myeloid cells (Figure 3-3, F) and this injection 
route was used for subsequent experiments. 
In summary, F4/80+DCs, MoDC and Kupffer cells are found to retain DiI derived from 
curcumin liposomes. We hypothesise that these cells have taken up the liposomes and 
curcumin is released into the cytosol and would have inhibitory effects on inflammatory 
pathways. Whether curcumin liposomes modulate myeloid cell phenotype is addressed in 
the next section. 
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Figure 3-2: Inflammatory myeloid cells increase in the liver of mice fed MCD diet. A: 
Cytokine production from PMA/ionomcyin stimulated Kupffer cells isolated from livers of 
mice fed normal diet or MCD diet for 3 weeks. B-E: Representative FACS plots showing 
myeloid cells in livers isolated from mice fed normal diet or MCD diet for 3 weeks and 
quantitation of the proportion of myeloid cell subsets (C) their median fluorescence intensity 
(MFI) of MHC class-II (D), and proportion of lymphoid cell subsets (E). Data are mean ±SEM. 
Representative of two separate experiments analysing individual mice. n=5/group. *p<0.05, 
**p<0.01, ***p<0.001 by Mann Whitney t- test. 
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Figure 3-3: Curcumin liposomes target hepatic inflammatory myeloid cells. A&B: Mice 
fed MCD diet for 2 weeks were intravenously injected with 100µl of DiR-labelled curcumin 
liposomes and in vivo imaged with IVIS system 1, 7 and 14 days later (A). Total radiant 
efficiency for DiR fluorescence was determined for liver and spleen (B). Data are mean 
±SEM of one experiment analysing individual mice. C: Representative FACS plots (C) and 
quantitation (D) of DiI uptake in myeloid cells 1 and 7 days post injection of DiI-labelled 
curcumin liposomes. E: Immunofluorescence staining of liver sections with Alexa-655 F4/80, 
Alexa-488 CD11c imaged by confocal microscopy. F: Proportion of DiR+ cells in liver of 
mice fed MCD diet treated intraperitoneally  (IP) or intravenously (IV) with DiI+ curcumin 
liposomes. Data are mean ±SEM. Representative of two separate experiments analysing 
individual mice. n=5/group. **p<0.01, ***p<0.001, ****p<0.0001 by Mann Whitney t- test. 
 
3.4.4 Curcumin inhibits JNK-MAPK-NF-κB activation and induces a tolerogenic 
phenotype in targeted hepatic DCs: 
The next experiments examined whether gene transcription in DiI positive DCs was different 
following intravenous injection of liposomes with or without curcumin. Mice fed an MCD diet 
for 2 weeks were injected intravenously with DiI labelled empty or curcumin liposomes, and 
24 hours later DiI positive and negative hepatic DCs (CD11c+ MHC class-II+) were sort 
purified by FACS. 3650 to 12290 hepatic DCs were recovered from NASH livers of DiI 
liposome treated mice. RNA was extracted, reverse-transcribed to double-stranded cDNA 
(ds-cDNA), amplified and sequenced (Appendix table 3.1). The groups amplified and 
sequenced included: 1) empty liposome DiI positive DC (ELPDC); 2) curcumin liposome DiI 
positive DC (CLPDC); 3) empty liposome DiI negative DC (ELNDC); and 4) curcumin 
liposome DiI negative DC (CLNDC).  
To determine if curcumin modulated gene transcription in DCs, a list of mRNAs that were 
significantly upregulated between ELNDC and ELPDC was generated (Appendix table 3.2). 
A Similar mRNA list was prepared for CLNDC and CLPDC (Appendix table 3.3). Overlaps 
of these lists identified common mRNAs upregulated and are candidate liposome-induced 
genes (Orange, 308 mRNAs, Figure, 3-4, A). The mRNA unique to ELPDC represents 
mRNA inhibited by curcumin (Red, 234 mRNAs, Figure, 3-4, A), whereas mRNA unique to 
CLPDC represents mRNA upregulated by curcumin (Yellow, 302 mRNAs, Figure 3-4, A). 
Curcumin inhibited mRNAs in the p38 mitogen-activated protein kinases (MAPK) pathway 
including C-jun N-terminal kinase-1 (JNK-1/MAPK8) and JNK-binding protein-1 (JNKbp-
1/MAPKBP1), an activator of JNK pathway; and in the NF-κB pathway; NF-kB activators 
TNF receptor superfamily, member 13B and Nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent-3 (NFATC3). Curcumin up-regulated mRNAs co-ordinating 
alternative activation including mannose receptor C type-1 (MRC-1), peroxisome 
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proliferator-activated receptor-γ (PPARγ), IL-10 receptor-β (IL-10rb) and matrix 
metalloproteinases (MMP)-13 and mRNA regulating retinoic acid including vitamin A 
synthesizing genes alcohol dehydrogenase (Adh)-1 and retinaldehyde dehydrogenase 1 
family, member A1 (RALDH1/Aldh1a1). Curcumin, is a potent antioxidant and induced 
glutathione peroxidase-3 and catalase mRNA, key antioxidant enzymes protecting against 
oxidative stress.  
Unbiased gene ontology analysis of differentially expressed mRNA between ELPDC and 
CLPDC using DAVID bioinformatics resources 6.7, a well curated functional annotation tool, 
identified pathways in mitochondrial β-oxidation and autophagy (Figure 3-4, B). Metabolic 
reprogramming towards oxidative phosphorylation (OXPHOS) is required for alternative 
activation of macrophages and DCs (274). Additional mRNA that were downregulated by 
curcumin, included, inhibitor of NF-κB kinase beta (Ikbkb), and MAPK1, MPAK11, MAP3k7, 
JunD, janus kinase-3 (JAK-3), suppressor of cytokine signaling-1 and harvey rat sarcoma 
viral oncogene homolog (p<0.05) (Appendix table 3.4 and Figure 3-4, C). Together these 
results suggest that curcumin reduced inflammatory activation of liver DCs by inhibiting pro-
inflammatory pathways and autophagy while increasing oxidative phosphorylation, and thus 
promoted an alternative/tolerogenic phenotype. 
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Figure 3-4: Curcumin liposomes targeted hepatic DC have reduced expression of 
JNK-MAPK-NF-κB mRNA and increased expression of mRNA encoding genes 
promoting a tolerogenic phenotype. A-C: Mice fed MCD diet for 2 weeks were treated IV 
with DiI-labelled empty or curcumin liposomes and hepatic immune cells isolated 24 hours 
later. DiI+ and DiI- hepatic DCs were purified by flow cytometry sorting and mRNA extracted 
and sequenced. Data of one experiment. n=3/group. A: Venn diagram showing mRNA 
upregulated in ELPDC and CLPDC compared to ELNDC and CLNDC respectively. B:  
Differentially expressed mRNAs encoding proteins of autophagy and mitochondrial function 
in CLPDC. C: Heat map of mRNA differentially expressed between ELPDC and CLPDC. 
 
A F4/80+ liver DCs are pro-inflammatory and express the liposome uptake 
marker CD36. 
Principle component analysis (PCA) on normalized gene expression showed significant 
separation between DiI positive and negative DCs (Figure 3-5, A) indicating that they may 
represent distinct DC populations with differing capacity for liposome uptake. 542 mRNAs 
were upregulated in ELPDC when compared to ELNDC of which 308 were commonly 
upregulated in CLPDC when compared to CLNDC (Figure 3-4, A). Of the 308 mRNAs, which 
we associate with capacity for liposome uptake, significant gene ontology enrichment of 
innate and adaptive immune response mRNAs encoding complement activating proteins 
and leukocyte activating proteins was observed (Appendix table 3.5). Likewise DCs with 
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capacity for liposome uptake had increased mRNA for IL-12a and JNK encoding signalling 
proteins mediating TLR signalling. DCs with capacity for liposome uptake had increased 
mRNA for C-C chemokine receptor (CCR)-7, MHC-II, CD1D1, CD86, and CD38, all markers 
of DC activation. 
Additional pathways with significant gene ontology enrichment in DCs with capacity for 
liposome uptake include lipid synthesis (SCD1, PTGS1, DEGS2), lipid catabolism (LPL, 
PLD3, PLA2G4A, PAFAH1B3) and lipid transport (APOE, APOC1, ABCG1) (Figure 3-5, B). 
Moreover, mRNA of CD36, which has been implicated in liposome/lipid uptake, was 
increased in DCs with liposome uptake capacity. In section 3.6, DCs that were DiI positive 
expressed F4/80, a feature of inflammatory DCs (Figure 3-5, C). Comparison of DCs with 
liposome uptake capacity confirmed that Adgre-1 (F4/80 or Emr-1 encoding gene) mRNA 
was increased (Figure 3-5, D). 
In summary F4/80+ DCs have the capacity for liposome uptake and have an inflammatory 
activated phenotype. Curcumin, when added to liposomes, can be delivered to F4/80+ DCs 
and reduce mRNAs associated with inflammation and promote pathways promoting 
alternative activation.  
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Figure 3-5: Comparison of mRNA expression in DC with or without liposome uptake 
capacity. A: Principle component analysis plot of differential mRNA expression between 
DiI+DC and DiI-DC.  n=3/group. B: Heat map of differentially expressed of mRNA encoding 
proteins of lipid synthesis, lipid catabolism and lipid transport in DiI+DC and DiI-DC. 
n=6/group. C: F4/80 MFI of DiI+ and DiI- hepatic DC determined by flow cytometry. D: 
Normalized Adgre-1 (F4/80) mRNA expression in DiI+ and DiI- hepatic DC. Data are mean 
±SEM of one experiment analysing individual mice. n=6/group. **p<0.01 by Mann Whitney 
t- test. 
 
3.4.5 Curcumin liposomes treatment reduced MCD diet induced NASH: 
Having shown that curcumin liposomes target inflammatory myeloid cells in the liver of MCD 
diet fed mice, and that curcumin induces alternative activation and dampening of pro-
inflammatory activation, I next examined whether curcumin liposomes modulates MCD diet 
induced liver disease. Female C57BL/6 mice were fed an MCD diet for 2 weeks and then 
randomised into groups with similar serum ALT variance. Groups of mice were then treated 
intravenously with empty liposomes or curcumin liposomes. After 7 days, mice were 
sacrificed, blood and livers harvested and analysed for parameters associated with liver 
disease, including hepatocyte damage (serum ALT) and histological NAS score. Compared 
with empty liposomes or untreated mice, mice treated with curcumin liposomes had reduced 
change in serum ALT levels (Figure 3-5, A) and reduced NAS score (Figure 3-5, B).  
Consistent with reduced serum ALT levels, mice treated with curcumin liposomes had 
reduced hepatic inflammation as assessed by antibody-cell staining and flow cytometry. 
Compared to non-treated mice, mice treated with curcumin liposomes had reduced 
expression of MHC class-II expression on hepatic DCs, MoDC and macrophages (Figure 3-
62 
 
5, C). While proportions of total macrophages and DCs were unchanged (Figure 3-5, D) 
proportions of hepatic F4/80+DCs and moDCs were reduced (Figure 3-5, D). Changes in 
lymphoid cells was also observed with an increased proportion of B cells and reduced 
proportions of hepatic CD3+ T-cells and CD4 CD8 double negative T cells (Figure 3-5, E). 
Interestingly, DCs from the curcumin liposomes treated mice produced increased levels of 
anti-inflammatory cytokines IL-10 and IL-4 when stimulated ex vivo with PMA and 
ionomycin, which supports curcumin’s ability to induce tolerogenic phenotype in targeted 
DCs (Figure 3-5, F). This data indicate that curcumin liposomes reduce histological, serum 
and cellular parameters associated with MCD diet induced liver disease and may represent 
a stand-alone or adjunct therapy for NASH.  
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Figure 3-6: Treatment of mice with MCD diet induced NASH with curcumin liposomes 
reduces disease. Mice fed MCD diet for 2 weeks were injected intravenously with empty or 
curcumin liposomes and 7 days later serum and liver cells isolated. A: Change in serum 
ALT (U/L) levels after treatment. Data are mean ±SEM. n=25 (untreated), n=12 (empty 
liposomes), n=20 (curcumin liposomes). B: Representative H&E stained paraffin embedded 
liver sections from treated and untreated mice and combined histological scoring presented 
as a NAS score. n=5/group. C-E: Immune cells from livers were stained for surface markers 
against leukocyte subsets and analysed by flow cytometry to determine median 
fluorescence intensity (MFI) of MHC class-II on myeloid cells (C) and proportion of myeloid 
cells (D) and lymphoid cells (E). n=5/group. F: Hepatic immune cells isolated from mice fed 
MCD diet treated with or without curcumin liposomes were stimulated with PMA-Ionomycin-
Brefeldin A for 4 hours and stained for IL-10 and IL-4 intracellularly. n=5/group. Data are 
mean ±SEM. Representative of two separate experiments analysing individual mice. 
*p<0.05, **p<0.01 by Mann Whitney t- test.  
3.5 Discussion:  
NASH is a rapidly progressing liver disease with no effective treatment currently available. 
NASH is characterised by hepatocellular injury and inflammation, and if untreated it may 
progress to liver cirrhosis and cancer, thus increasing the burden of liver transplantations 
and liver related deaths worldwide. Under obese conditions, free fatty acids and adipokines 
like leptin and TNFα released from adipose tissue recirculate into the liver through the portal 
vein and cause hepatic steatosis (23). Hepatic β-oxidation is required for lipid synthesis and 
fatty acid release as low/very-low/high-density lipoproteins for peripheral fat storage. 
Impaired hepatic β-oxidation is implicated in steatosis exacerbation and hepatocellular injury 
through lipotoxicity (275). Similarly, with a diet deficient in methionine and choline, the lack 
of essential nutrients required for hepatic β-oxidation causes severe steatohepatitis. 
Increased plasma concentrations of MCP-1, found in NASH patients and in mice fed HFD, 
promotes recruitment of monocytes into liver and adipose tissue and promote inflammation, 
insulin resistance and steatohepatitis (28) (29) (4) (30). NASH can be reversed in mice 
lacking MCP-1, treated either with MCP-1 antagonist and depleted of myeloid cells through 
liposomes containing clodronate (29) (3). Thus myeloid cell mediated inflammation is 
required for disease aggravation. 
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Although an accepted model of liver disease, the MCD model had previously not been used 
or developed within our research group. Since animal house, microbiome and MCD diet 
sourcing can effect severity of the model, I had to characterize as many parameters 
associated with liver disease in this model within our facility before proceeding with 
therapeutic intervention. Akin to previous reports, feeding C57Bl/6J mice with MCD diet for 
3 weeks induced complete features of human NASH, making it a valuable model to 
understand NASH pathogenesis and pre-clinical drug testing. I identified a significant 
increase in F4/80+DC in the liver of mice fed the MCD diet. These cells have been shown 
to be recruited to the liver upon bacterial or parasitic infections and in obesity, and express 
TNFα and iNOS, and have been called Tip-DCs (31) (18). In the liver, F4/80 expressing Tip-
DCs has been shown to differentiate in an IFNγ and MyD88 dependent manner from CCR2+ 
monocytes recruited upon parasitic infection.  
In addition to DCs, Kupffer cells and monocyte derived CD11bhigh DC (moDC) increased 4- 
and 10-fold following MCD diet induced liver disease. Studies indicate that obese mice 
exhibit increased susceptibility to free fatty acid and endotoxin mediated liver injury through 
hepatic NF-κB mediated production of pro-inflammatory cytokines (27) (35) (36). I identified 
increased proportions of IFNγ and IL-17 positive Kupffer cells in the liver of mice with MCD 
diet induced liver disease. IFNγ, together with LPS, promote a pro-inflammatory phenotype 
in macrophages (M1 macrophage) (32). Moreover obesity is associated with increased IFNγ 
and IL-17A production in humans and increased IL-17 producing cells characterize portal 
infiltrates in human NASH livers (33) (34). In summary, hepatic inflammation is a common 
feature of NASH and reducing it by therapeutic interventions may reduce NASH progression. 
NASH is a complex phenotype with insulin resistance, fat accumulation and inflammation 
within the liver and other metabolic organs. Therapeutic strategies such as metformin or 
statins have been used to treat insulin resistance and improve lipid profile respectively. 
However no drugs are currently available to treat NASH and co-morbidities. Several elegant 
studies using preclinical animal models highlighted the role of organ specific myeloid cell 
infiltration in augmenting insulin resistance and NASH. Myeloid cell specific but not 
hepatocyte specific deletion of IKKβ has been shown to reduce HFD induced glucose 
intolerance in mice (74). In addition, monocyte chemoattractant MCP-1 deficient mice were 
found to have diminished NASH development and progression (88) (90) (276). Interestingly, 
clodronate liposomes mediated depletion of myeloid cells reduced NASH (29), indicating 
liposome formulations could be used to target hepatic myeloid cells with anti-inflammatory 
drugs instead of cytotoxic agents to treat disease. Among the many nanoparticles 
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investigated, liposomes have successfully been used to treat diseases in human and they 
offer a flexible delivery systems for entrapment of lipophilic and aqueous drugs and can be 
engineered to target specific cells in vivo (277).  
In my study, the uptake of liposomes was undertaken in the context of liver disease, where 
increased numbers of inflammatory myeloid cells are found in the target organ.  By labelling 
liposomes with a fluorescent dye, I was able to follow uptake in organs of live animals and 
assess biodistribution of liposomes following intravenous injection. As expected the liver 
was the main organ targeted 24 hours post injection, but surprisingly, DiI was still detected 
in the liver at 14 days post injection. This indicates that targeted cells are long lived, a feature 
of macrophages, or that the DiI is taken up by newly recruited phagocytic cells. 
Immunofluorescent staining of liver sections confirmed that DiI was present in myeloid cells 
(CD11c+, F4/80+) surrounding lipid-loaded hepatocytes but not parenchymal cells. Using 
DiI as a marker of liposome uptake, I was able to demonstrate that DC, Kupffer cells and 
monocytes retained DiI for 24 hours post injection and F4/80+ DC for 7 days post injection. 
Specific targeting of myeloid cells by liposomes relates to liposome size (100µm) as ≥100nm 
liposomes, in contrast to <100nm sized, is cleared by mononuclear phagocytes. I also 
confirmed that myeloid cell targeting was greater following intravenous rather than 
intraperitoneal injection. Hence these observations indicate that liver myeloid cells increased 
in number in mice with liver disease and these can be efficiently targeted with liposomes. 
In obese mice, F4/80+ DCs have previously been characterised to have a pro-inflammatory 
phenotype (94). However, molecular pathways initiating and propagating inflammation in 
different DC subsets remain poorly understood. I found that liposomes were taken up by 
DCs, and by using DiI as a marker of liposome uptake I was able to sort DCs with liposome 
uptake capacity. mRNA sequencing analysis of liposome targeted and non-targeted DCs 
revealed a number of mRNA transcripts encoding proteins for liposome uptake and 
inflammatory activation. F4/80+ DCs express a suite of mRNAs encoding proteins for 
binding lipid and fatty acid metabolism and lipid biogenesis, catabolic process and transport. 
Increased expression of mRNA encoding CD36 (fatty acid translocase), a member of 
scavenger receptor class B which has been implicated in oxidized LDL and apoptotic cell 
uptake may have facilitated liposome uptake (278) (279). In general, liposomes injected into 
the circulation interact with serum proteins such as opsonins and complement factors (280). 
This interaction further facilitates liposome uptake by the macrophage phagocytic system 
through phagocytosis and/or endocytosis. Inflammation in the liver is known to increase 
opsonins and complement factors. Indeed DiI positive DCs have increased mRNAs 
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encoding complement activation proteins. With the ability to endocytose exogenous lipid 
and synthesize fatty acid, F4/80+ DCs may deposit excess lipid compared to F4/80- DCs. 
In this regard, recently Ibrahim J et al., found that hepatic DCs with high-lipid content are 
enriched in NASH liver, and they are highly immunogenic and can activate CD4+ T cells, 
NK and NKT cells (97). Like high-lipid DCs, F4/80+ DCs can migrate to lymph nodes by 
sensing chemokine ligands CCL19 and CCL21 through CCR7 and activate T and NKT cells 
through MHC class-II, CD86, CD38 and CD1D1. Indeed, MHC class-II protein expression is 
increased on hepatic F4/80+DCs, moDCs and macrophages isolated from mice fed MCD 
diet compared to control-diet.   
DCs that had taken up liposomes (DiI+) had increased mRNAs encoding JNK-1, p38-MAPK 
and IL-12 compared to DiI- DC. Multiple signalling pathways including NF-κB control pro-
inflammatory activation of myeloid cells. Nuclear translocated NF-κB homo/hetero dimers 
activate inflammatory gene transcription. Nuclear translocation of NF-κB is dependent on 
activation of IKKβ that degrades the NF-κB/inhibitor kappa B (IκB) complex in cytosol to 
liberate NF-κB. Activation of IKKβ is induced by various stimuli such as LPS, TNFα, ER-
stress, and oxidative stress through numerous pathways including JNK, MAPK, AP-1 and 
JAK-STAT. Pharmaceutical inhibitors that target NF-κB upstream pathways or NF-κB itself 
may reduce inflammatory activation and reduce disease. Curcumin and its analogues are 
broad-spectrum inhibitors that reduce inflammatory activation by inhibiting NF-κB and JNK 
and decrease obesity induced inflammation and insulin resistance (281) (282) (172) (283). 
In humans, oral supplementation with curcumin reduced type-2 diabetes (284) (285). 
Curcumin supplemented in the diet ameliorated MCD diet induced NASH and reduced NF-
κB activation (171). Moreover intraperitoneal administration of 25ug curcumin limited MCD 
diet induced fibrosis by reducing macrophage and extracellular matrix gene expression 
(176). These studies indicate the therapeutic potential of curcumin to target NF-κB and its 
upstream cascades in inflammatory myeloid cells to reduce NASH progression. However, 
poor bioavailability of curcumin due to low absorption and rapid metabolism by 
glucuronidation in liver limits the translation into clinical setting (286).  
Curcumin, with its lipophilic nature, can be entrapped into the lipid bilayer of liposome 
nanoparticles (bilayer phospholipid vesicles) improving its bioavailability (287). In leptin 
deficient (ob/ob) obese mice, curcumin liposomes have been shown to be taken up by Tip-
DCs and adipose tissue macrophages, and inhibit NF-κB (RelA and p50) translocation to 
the nucleus and pro-inflammatory cytokine production, improving insulin signaling (18). 
However this study failed to show direct targets of curcumin and signalling pathways 
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modulated by curcumin. To address this knowledge gap, RNA sequencing was carried out 
on liver DCs isolated 24 hours post injection of curcumin liposomes. Curcumin targeted DCs 
had reduced mRNA encoding JNK-MAPK-NF-κB proteins and oxidative stress proteins 
compared to empty liposome targeted DCs. Importantly, in addition to inhibiting pro-
inflammatory activation, curcumin induced mRNA encoding proteins promoting tolerogenic 
phenotype with ability to sense PPARγ agonists, IL-10 and produce retinoic acid. This 
tolerogenic phenotype was associated with increased mRNA encoding OXPHOS which has 
been implicated in M2 macrophage formation, suggesting that curcumin induces a metabolic 
reprogramming in targeted F4/80+ DCs (274).  
Impaired β-oxidation has been reported in liver, muscle and fat of T2DM patients (288, 289). 
PPARy agonists such as thiazolidinediones induce OXPHOS in metabolic organs and 
reduce IR in T2DM patients and mice (290) (291). Augmentation of the glycolytic pathway 
and diminishing β-oxidation is a hallmark of pro-inflammatory activation of macrophages and 
DCs (274). Curcumin is a known inducer of tolerogenic DCs and alternatively activated 
macrophages through PPARγ and IL-4 (188) (292) (293), (294). M2 macrophage derived 
IL-4 has also been shown to reduce β-oxidation through STAT6 mediated induction of 
PPARγ co-activator-1β, which promotes oxidative metabolism (295). Tolerogenic DCs have 
increased therapeutic potential by inducing Treg and type-1 regulatory T cells (Tr1 cells) 
while dampening Th-1 and CD8 T cell driven inflammation during autoimmunity, 
transplantation, obesity, cancer and infection (296), (297). It would be interesting in future 
studies to see whether curcumin targeted DCs induce Treg/Tr1 cells in NASH liver.  
Consistent with reduced mRNA encoding JNK and NF-κB proteins in curcumin liposome 
targeted DCs, significantly decreased expression of MHC class-II protein on DCs and 
macrophages was detected in mice treated with curcumin liposomes. Treatment also 
reduced proportions of inflammatory F4/80+ DCs and moDCs either through curcumin-
induced alternative activation of F4/80+ myeloid cells and/or reduced conversion of Ly6Chigh 
monocytes to moDCs. Inhibition of JNK-MAPK-NF-κB axis in precursors of inflammatory 
DCs, may reduce DC conversion to F4/80+ DC. In the study where curcumin liposomes 
were used to treat obese leptin deficient mice, CD11c+F4/80+ DC produced a 3-fold 
increase in IL-4 (94) (298). Similarly DCs from curcumin liposomes treated mice produced 
elevated levels of anti-inflammatory cytokine such as IL-10 and IL-4, are known to reduce 
MCP-1 secretion and associated monocyte recruitment of precursors for moDC and F4/80+ 
DC development. In addition to reduced inflammatory myeloid cells, curcumin liposome 
treatment lowered CD4-CD8- T-cell proportions in livers of mice fed an MCD diet, which are 
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positively associated with moderate to severe steatosis in human liver biopsies compared 
to those without steatosis (299). 
3.6 Future directions:  
My results corroborate studies indicating myeloid cells predominantly drive inflammation and 
cellular damage in NASH. Importantly I demonstrate that significant proportions of myeloid 
cells within the liver are DiI positive, indicative of liposome targeting. Classical DCs (CD11c+ 
MHC class-II+) expressing F4/80 are the main myeloid cells to take up liposomes and RNA 
sequencing of mRNA from these DCs indicate a selective advantage of F4/80+ DCs in lipid 
metabolism and antigen presentation, suggesting their inflammatory and phagocytic 
potential. Liposome clearance in vivo is associated with both aforementioned processes. 
Scavenger receptor CD36, which has been implicated in clearance of apoptotic bodies that 
resemble lipid vesicles, is highly expressed by F4/80+ DCs and this indicates a possible role 
of CD36 mediated endocytosis of liposomes. However, CD36 is also expressed on 
hepatocytes, which were not seen to take up liposomes in my study. Therefore future studies 
could investigate the mechanism of liposome uptake and the role of CD36 and/or accessory 
proteins in this process.  
In MCD-induced liver disease and in patients with NASH, Miller’s group found 2 types of 
hepatic DCs that are different in their lipid deposits using bodipy staining for lipid (97). DCs 
with high-lipid content were immunogenic while those with low-lipid content were 
immunoregulatory. Surface markers differentiating these DC types have not been described. 
Like bodipy, the liposome targeting approach identified 2 subsets of hepatic DCs. F4/80+ 
DCs with increased expression of mRNA encoding proteins involved in lipid metabolism with 
a high-lipid phenotype with excessive intracellular lipid deposits in contrast to F4/80- DCs, 
which have low-lipid phenotype. The pro-inflammatory profile of F4/80+ DCs correlated with 
the high-lipid phenotype described. Hence F4/80 or other surface expressed proteins 
described in this chapter (Appendix table 3.2 and 3.3) could be useful markers in 
distinguishing DCs with high and low lipid content. Future studies could look for DC surface 
markers and their correlation with intracellular lipid in F4/80+ and F4/80- DCs, thus 
identifying surface markers discriminating immunogenic and regulatory hepatic DCs 
associated with NASH.  
My data demonstrate that curcumin liposomes passively targeted to a specific subset of 
hepatic myeloid cells, which can be efficiently sort purified to delineate curcumin induced 
alterations at molecular level, suggesting that this approach can now be used in future 
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studies to investigate the molecular targets of several drugs in targeted hepatic myeloid cells 
and outcome on NASH and other diseases.   
Treatment with curcumin liposomes may also induce immunomodulation of other targeted 
myeloid subsets associated with NASH. Recent studies underscore the importance of 
OXPHOS activation in macrophage alternative phenotype. Curcumin promoted β-oxidation, 
thereby OXPHOS activation and it remains to be investigated whether stimulating OXPHOS 
is the major mechanism by which curcumin mediates its antioxidant and anti-inflammatory 
effects. 
Although data presented in Figure 3-4 (A-C) and Figure 3-6 (A) show that curcumin 
liposomes but not empty liposomes decreased inflammatory activation of DCs and NASH 
progression. Histological severity of NASH and cell phenotype was not measured in empty 
liposome treated mice. Therefore, future experiments could include a group treated with 
empty liposomes. 
3.7 Limitations of the study described in the chapter 3:  
Although the MCD model represents the complete pathology of human NASH, the model 
comes with a major limitation of not being replicative of obesity induced NASH as the mice 
lose significant weight due to impaired hepatic secretion of triglycerides and reduced calorie 
intake (300, 301) and thus do not develop insulin resistance (251). Being a diet induced 
model, mice develop variable degrees of NASH and serum ALT levels fluctuate from time 
to time, which could be due to differences in diet intake that cannot be equalized between 
mice, hence large numbers of mice are required for each group per experiment.  
3.8 Transition to next chapter: 
Even though feeding mice with an MCD diet causes severe NASH, obesity induced liver 
disease in general is chronic in nature. Feeding mice with obesogenic diets rich in both fat 
and simple sugars known to cause obesity and chronic low-grade inflammation in liver, 
resembling human NASH. My results described in this chapter demonstrate that curcumin 
when targeted to myeloid cells inhibits NF-κB and activates cell metabolism to induce 
tolerogenic/alternative DCs and macrophages in the liver and treat MCD diet induced acute 
NASH. In the next chapter, efficacy of curcumin liposomes to treat chronic NASH induced 
by high fat and high sugar diet is investigated and compared with another lipophilic 
nutraceutical drug, vitamin D3, which is known to inhibit NF-κB and alter DC metabolism to 
induce tolerogenic phenotype (209, 210) (215).  
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4. Targeting liver myeloid cells with curcumin liposomes or vitamin D3 
liposomes reduces HFHS diet induced chronic NASH in mice 
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4.1 Abstract: 
Obesity causes chronic low-grade inflammation and insulin resistance in the liver. Curcumin 
liposomes targeted to liver inflammatory myeloid cells, reduces inflammation and damage 
associated with the MCD diet induced NASH. Whether liposomal curcumin or other 
antiinflammatory drugs can be used to treat obesity induced chronic NASH is unknown. 
Feeding wild type mice with high-fat and high-sugar (HFHS) diet for 14 weeks induced 
obesity, insulin resistance and NASH with liver fibrosis. Intravenously injected DiR labelled 
liposomes targeted hepatic inflammatory myeloid cells including CD103+ DCs and Kupffer 
cells in obese mice. Treatment of mice with curcumin liposomes reduced liver disease as 
measured by NAS score and liver fibrosis. Similar finding were observed with vitamin-D3 
liposomes but not empty liposomes. Improvement in liver disease was associated with 
reduction in expression of mRNAs regulating myeloid cell activation, leukocyte recruitment, 
and collagen deposition assessed by mRNA sequencing of liver tissue.  
4.2 Introduction: 
Obesity is a pandemic, affecting both developed and developing countries. In humans, 
excess accumulation of fat in adipose tissue (AT) leads to obesity. Obesity is caused either 
due to genetic abnormalities that dysregulate food intake, energy utilization and storage or 
through over consumption of high calorie diets (302). Dietary fatty acids and carbohydrates 
are processed by the liver to triglycerides, and stored in adipose tissue. Inflammation 
dependent lipolysis of fatty acids in AT enhances circulatory FFA, which are utilized for 
lipogenesis and gluconeogenesis in the liver. Increased gluconeogenesis in the liver or 
decreased insulin mediated glucose uptake (known as insulin resistance) elevates blood 
glucose levels (hyperglycemia). In addition to fat, carbohydrate fructose intake is 
significantly associated with NAFLD severity (259), (303). High fructose intake enhances 
hepatic denovo lipogenesis, worsening hepatic steatosis and liver damage through oxidative 
stress and lipid peroxidation (304). High fructose intake may alter gut microbiota and 
increase gut permeability, increasing translocation of bacteria or its components to the liver, 
where they activate hepatocytes and Kupffer cells (305). Fructose intake has been shown 
to correlate with circulatory LPS levels and LPS treatment of leptin deficient mice and diet 
induced obese (DIO) mice exacerbates hepatic inflammation (262) (306). In contrast to DIO 
mice, leptin deficient mice do not exhibit severe NASH as leptin is required for CD14 
expression on Kupffer cells, which is required for LPS induced macrophage activation (126). 
Rodent models fed a high fat diet alone develop obesity and insulin resistance within 2-4 
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weeks, but take about 9-14 months to develop severe steatohepatitis (307). In contrast, 
combining high fat diet with high sugar (HFHS) (42g/1L (55% fructose and 45% sucrose)) 
causes obesity and NASH with fibrosis in just 4 months (263), making it a reliable chronic 
model to perform preclinical studies.  
Similar to the MCD model, inflammation in the HFHS diet is also attributed to CCL2-
dependent monocyte recruitment and conversion to M1 macrophage in AT and the liver. 
Mice deficient in proinflammatory signaling cascades such as NF-κB, JNK, and MYD88 are 
resistant to HFD induced obesity (74, 308, 309), implicating their role in disease 
development.  In addition to inflammation, mitochondrial dysfunction plays a key role in 
hepatic fat accumulation mediated oxidative and ER stress (310). Hence, drugs such as 
curcumin and vitamin E, which exhibit both anti-inflammatory and antioxidant properties 
have shown beneficial effects, improving IR and NASH in obese and T2DM patients. 
Interestingly none of the curcumin treated pre-diabetics progressed to diabetes and vitamin 
E supplementation significantly reduced metabolic syndrome and NASH in obese patients 
(284) (311).   
Treatment with Vitamin D3, another natural anti-inflammatory agent reduced insulin 
resistance in pre-diabetics and HFD fed mice (312) (313). Biopsy proven NASH patients 
had reduced levels of serum vitamin D3 and hepatic vitamin D3 receptor (VDR) expression 
(314) (206). HFD fed Ldlr knockout mice with myeloid cell specific VDR deficiency develop 
hepatic inflammation and insulin resistance (208). Vitamin D3 is an immunomodulator that 
induces a tolerogenic phenotype in monocyte derived DCs by inhibiting RelB and activating 
glycolysis, tricarboxylic acid cycle and oxidative phosphorylation (OXPHOS) (315) (215). 
Thus, vitamin D3, similar to curcumin, elicits its immunomodulatory function by inhibiting NF-
κB and inducing metabolic reprogramming to maintain tolerogenic phenotype in DCs, which 
could have contributed its beneficial effects in limiting hepatic inflammation.   
4.3 Rationale and aim:  
Obesity is associated with hyperglycaemia, systemic IR and inflammation in the liver, AT 
and muscle. Tissue inflammation is characterised by infiltration of monocytes and 
differentiation towards proinflammatory macrophages and DCs. Curcumin liposomes have 
previously been shown to target inflammatory DCs, reduce inflammatory activation and 
reduce glucose intolerance in leptin deficient obese mice (94). I have found that curcumin 
liposomes therapy induces alternative activation in targeted hepatic DCs and reduces acute 
NASH progression in MCD diet model. Therefore it is interesting to know whether curcumin 
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liposomes also reduce liver inflammation and chronic NASH in DIO models, as they 
represent human obesity in full spectrum. Moreover, vitamin D3, being lipophilic and being 
known for glucose lowering properties, could also reduce obesity induced insulin resistance 
and NASH. Hence, this chapter is aimed at testing curcumin and vitamin D3 liposomes ability 
to reduce insulin resistance and NASH in the DIO model. To this aim, I have fed mice a 
HFHS diet and treated them with either empty or curcumin or vitamin D3 liposomes and 
investigated treatment outcomes on liver disease and insulin resistance. 
4.4  Results:  
4.4.1 C57BL/6J mice fed high-fat high-sugar diet develop obesity, insulin resistance 
and steatohepatitis with liver fibrosis: 
Initial experiments were performed to characterize the DIO model in female C57BL/6J mice. 
Mice were fed a HFHS diet for 14 weeks and compared with female age matched mice fed 
a chow diet. Weight of the mice was measured at baseline and every week following diet 
intervention for up to 14 weeks. Compared to mice fed a chow diet, mice on HFHS diet had 
increased weight at 5 weeks, which increased up until 14 weeks (Figure 4-1, A). At the end 
of 14 weeks mice were fasted for 5-6 hours and groups of mice were sacrificed, blood and 
tissues were collected to assess disease severity. Fasting blood glucose and insulin levels 
were measured and homeostasis model assessment-estimated insulin resistance (HOMA-
IR) was calculated. HFHS diet fed mice had significantly higher blood glucose levels (Figure 
4-1, B) and HOMA-IR (Figure 4-1, C) compared to mice fed normal diet. Thus feeding mice 
with HFHS diet induced obesity, hyperglycaemia and insulin resistance. 
Next I determined parameters associated with NASH. HFHS diet supplementation increased 
hepatocyte damage, as measured by increased serum ALT (Figure 4-1, D). Histological 
evaluation of H&E stained liver sections revealed that feeding mice with HFHS diet induced 
steatosis, ballooning of hepatocytes and necroinflammation resulting in increased NAS 
scores (Figure 4-1, E and F). HFHS diet increased fat accumulation in the liver as detected 
by Oil red-O staining on frozen liver sections (Figure 4-1, E and G). Since scaring of liver is 
a phenotype of NASH, next I measured collagen deposition using Masson Trichrome 
staining on liver sections. Compared to control diet, mice fed HFHS diet for 14 weeks 
developed perisinusoidal and portal/periportal liver fibrosis (Figure 4-1, E and H).  
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In summary, mice fed a HFHS diet for 14 weeks developed obesity and its complications 
including, hyperglycaemia, insulin resistance, fat accumulation in liver and steatohepatitis. 
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Figure 4-1: Mice fed high-fat high-sugarHFHS) diet develop obesity, insulin resistance 
and steatohepatitis with liver fibrosis. A: Body weight of the mice fed chow diet (black 
line) and HFHS diet (red line) were measured from week 0 to week 14. (Note that due to 
fighting, chow diet fed mice had a drop in body weight at 8 week time point). B & C: Mice 
were fasted for 5-6 hours and fasting blood glucose (B) and HOMA-IR (C) measured. D: 
Serum alanine transaminase (ALT) levels in mice fed control diet or HFHS diet for 14 weeks. 
E-H: Livers from mice fed control diet or HFHS diet were fixed in paraffin, sectioned and 
stained with hematoxylin and eosin (H&E) and NAFLD assessing score (NAS) score 
determined (E and F). Frozen liver sections were stained with Oil red-O and scored for oil 
deposition (E and G), and paraffin liver sections were stained with Masson Trichrome stain 
and area of collagen determined. Data are mean ±SEM. Representative of three separate 
experiments analysing individual mice. n=5/group. Arrows indicate inflammatory foci. 
*p<0.05, **p<0.01 by Mann Whitney t- test. 
 
4.4.2 HFHS diet induced NASH associated with increased inflammation, collagen 
deposition and liver failure.  
To determine the composition of immune cells within the liver, non-parenchymal cells were 
isolated from livers of mice fed a HFHS diet for 14 weeks and stained for leukocyte markers 
and analysed by flow cytometry. Compared with mice fed a control diet, and consistent with 
increased inflammatory scores on H&E stained liver sections, mice fed HFHS diet had an 
increased numbers of CD11b+F4/80+ inflammatory monocytes. No significant differences 
in DCs, T cells and NK cell numbers was observed (Figure 4-2, A), indicating that 
inflammation is primarily monocyte derived.  
Feeding mice a HFHS diet induced severe NASH with steatosis, inflammation and fibrosis, 
indicating activation of multiple signaling cascades involved in these processes. To 
characterise pathophysiology of NASH in an obese setting, total RNA from livers of non-
obese and obese mice was extracted; mRNA sequenced and analysed to identify 
differentially expressed mRNAs. 2691 genes were differentially expressed in liver with 
NASH compared to normal liver, of which 1610 and 1081 mRNAs upregulated and 
downregulated respectively (Figure 4-2, B and Appendix table 4.1).  
Differentially expressed mRNAs indicates alteration of several biological processes 
associated with NASH phenotype. To identify these biological processes, gene ontology 
enrichment analysis of differentially expressed mRNAs was performed using DAVID 
functional annotation tool. First mRNAs upregulated in NASH livers were analysed. 162 
gene ontology terms were significantly enriched (Appendix table 4.2), the majority 
associated with cell adhesion or extracellular matrix deposition, consistent with increased 
liver fibrosis observed by Masson Trichrome staining on liver sections. Consistent with 
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increased steatosis score in HFHS diet fed mice, mRNAs co-ordinating lipid uptake and 
metabolism (CD36, lipoprotein lipase (lpl), stearoyl-CoA desaturase (SCD)), and lipid vesicle 
enlargement (Fat-specific protein-27 or Cell death-inducing DFFA-like effector C (CIDEC)) 
were upregulated in NASH liver compared to normal liver. Moreover, livers of obese mice 
were enriched for mRNAs encoding proteins regulating cell division, programmed cell death, 
antigen presentation, chemotaxis of leukocytes and cytokine production. Activation of these 
biological processes is indicative of liver damage mediated recruitment of immune cells, and 
associated with progression of NASH to fibrosis. Gene ontology enrichment analysis of 
downregulated genes identified enrichment for 83 gene ontology terms (Appendix table 4.3). 
Among these, the most significantly enriched biological process is oxidation-reduction. 86 
mRNA coding proteins involved in mitochondrial function were downregulated in HFHS diet 
fed mice compared to chow-diet fed mice. Mitochondrial dysfunction has been identified in 
both NASH patients and mouse models of NASH (316, 317). Remaining GO terms 
downregulated encoded mRNA for proteins regulating major metabolic pathways within the 
liver including coagulation factor synthesis, steroid metabolism, lipid homeostasis, urea 
cycle, macromolecule biosynthesis and catabolism.  
To identify principle pathways associated with hepatic inflammation, I next analysed protein-
protein interaction (PPI) networks by Networkanalyst online module, which uses well curated 
experimentally validated interactions for genes in innate immune response via InnateDB 
database. Zero-order network analysis for direct interactions of upregulated and 
downregulated mRNAs contained 396 nodes and 502 edges (Figure 4-2, C). Based on 
network measures of degree centrality and betweenness centrality, which corresponds to 
the number of direct or indirect interactions that a gene share with other genes, 16 major 
hubs were identified (Figure 4-2, C and Appendix table 4.4). The majority of the hubs were 
formed by upregulated mRNAs (13 hubs) and among these, interferon regulatory factor 
(IRF)-8 is the main hub mRNA with highest network measures (Figure 4-2, D). IRF8 
regulates DC development and inactivation of IRF8 in mice leads to absence of DCs 
expressing CD103 and CD8 within the liver. Thus identification of increased IRF8 may be 
indicative of increased CD103+ CD8+ dendritic cells associated with liver inflammation in 
mice fed a HFHS diet. In support of this, expression of mRNA integrin, alpha E (ITGAE), 
which codes for CD103 gene, was increased in livers with NASH. Furthermore, network-
based analysis identified upregulation of mRNAs encoding proteins associated with 
leukocyte activation and recruitment including Jun, FBJ murine osteosarcoma viral 
oncogene homolog (Fos), NF-κB1, CXCL9 and CCL2. Of the 3 hubs formed by 
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downregulated mRNA, sirtuin 1 (Sirt1) and CCAAT/enhancer binding protein (C/EBP) alpha 
(C/EBPα) were the most prominent hubs with highest degree centrality. C/EBPα regulates 
cell proliferation, gluconeogenesis and lipogenesis and its downregulation supports 
dysregulation in cell division and lipid homeostasis identified with gene ontology enrichment 
analysis. Together, this data indicates mitochondrial dysfunction, hepatocyte death, 
recruitment and activation of leukocytes, increased inflammation and fibrosis in the HFHS 
diet model of NASH.  
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Figure 4-2: Analysis of immune cells and mRNA expression in liver isolated from mice 
fed HFHS diet for 14 weeks. A: Immune cells isolated from livers of mice fed control diet 
or HFHS diet were stained for surface markers against leukocyte subsets and analysed by 
flow cytometry. Representative of three separate experiments analysing individual mice. 
n=5/group. *p<0.05 by Mann Whitney t- test. B: Heat map of differentially expressed mRNA 
isolated from livers of mice fed control diet or HFHS diet. n=3/group. C: Zero order 
interaction analysis to identify key protein-protein interaction (PPI) networks using 
Networkanalyst. Nodes and edges with red and green colors represent upregulated and 
downregulated hepatic mRNA from mice fed HFHS diet respectively. D:  PPI networks 
showing IRF8 interaction with other genes in the dataset.  
 
4.4.3 Curcumin liposomes target hepatic inflammatory myeloid cells in HFHS NASH: 
In the previous chapter, I demonstrated that F4/80+ DCs in the liver of mice fed an MCD 
diet were able to take up liposomes injected intravenously, and if coupled with curcumin, 
deliver curcumin to the cell and regulate DCs. To assess liposome targeting to the liver in 
the DIO model, mice were fed HFHS diet for 12 weeks and injected intravenously with DiR-
labelled liposomes. 24 hours and 7 days later, mice were imaged using IVIS system to 
determine organ biodistribution of liposomes. Imaging of mice identified DiR signal in the 
79 
 
liver and spleen at both time points (Figure 4-3, A and B). Next experiments determined 
which hepatic immune cells were targeted by curcumin liposomes in HFHS diet induced 
NASH. Livers were harvested 7 days post treatment with DiR labelled liposomes, immune 
cells were isolated and stained for myeloid cell markers and analysed for liposome uptake 
by flow cytometry. Hepatic myeloid cells including DCs, Kupffer cells and monocytes were 
DiR positive, indicative of liposome uptake (Figure 4-3, C). Hepatic DCs have been classified 
as tissue specific DCs and migratory DCs based on their CD103 and CD11b expression 
(318).  Interestingly, 7 days post liposome treatment, 60% and 15% of tissue specific DCs 
(CD103+CD11b-) and migratory DCs (CD103-CD11b+) were DiR+ respectively (Figure 4-
3, D), indicating that CD103+DCs are the principle DC type with liposome phagocytic 
capacity. In the previous chapter, I identified F4/80 as a marker on hepatic DCs associated 
with liposome uptake capacity. In the DIO model of NASH, F4/80 was also expressed at 
higher levels on CD103+CD11b- DCs compared to CD103-CD11b+ DCs (Figure 4-3, E), 
confirming observations in MCD diet fed mice that F4/80+ DCs are the main DC type 
increased during NASH, and are the main target of liposomes.  
4.4.4 Curcumin liposome or vitamin D3 liposome treatment reduces HFHS diet 
induced steatohepatitis, liver fibrosis and liver dysfunction: 
A. Treatment of mice with HFHS-induced NASH with curcumin or vitamin D3 
liposomes reduces disease. 
Having found that liposomes target hepatic F4/80+ myeloid cells in DIO, I next sought to 
determine the therapeutic efficacy of curcumin liposomes to treat HFHS diet induced NASH. 
As a comparison we also prepared liposomes containing vitamin D3, a compound which 
inhibits NF-κB and activates OXPHOS in DCs, and induces a tolerogenic phenotype in 
human or mouse DCs when added in vitro during their development (215, 319). 
Mice were fed a HFHS diet for 12 weeks and fasting blood glucose and insulin levels were 
measured. Mice were randomised into groups with similar mean ALT values and continued 
on HFHS diet. Groups of mice were treated with curcumin or vitamin D3 or empty liposomes 
at week 12 and then week 13. At 14 weeks mice were fasted and sacrificed, and blood and 
liver were collected and processed to analyse parameters associated with NASH, including 
insulin resistance (fasting glucose and insulin), hepatocyte damage (ALT), liver injury (NAS 
scores) and liver fibrosis. Treatment with curcumin liposomes and vitamin D3 liposomes but 
not empty liposomes reduced HFHS diet induced liver disease as measured by NAS scores 
(Figure, 4-4, A and B). In addition, reduced collagen staining was observed in liver sections 
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from mice treated with curcumin and vitamin D3 liposomes (Fig. 4A and 4C). Staining for 
neutral lipid stores on frozen liver sections indicated lower fat deposition in mice treated with 
vitamin D3 liposomes (Figure 4-4, A and D). No significant differences in serum levels of 
ALT, a hepatocyte death marker was observed following treatment (Figure 4-4, E).  
B. Treatment of mice with HFHS-induced NASH with curcumin or vitamin D3 
liposomes decreases hepatic mRNA inflammatory signature. 
I next determined mRNA expression levels in the liver of mice treated with curcumin or 
vitamin D3 liposomes by mRNA sequencing analysis. PCA analysis on normalized gene 
expression indicated that HFHS diet fed mice treated with curcumin or vitamin D3 liposomes 
significantly separated from untreated HFHS diet fed mice and clustered with control diet 
fed mice (Figure 4-5, A), indicating that both treatments normalised HFHS diet induced 
mRNA expression. Using differentially expressed mRNAs, a Venn diagram was created to 
determine mRNA downregulated in livers of curcumin and vitamin D3 liposomes treated 
obese mice versus mRNA upregulated in untreated obese mice, and compared to normal 
liver. Of the 1610 mRNAs that were upregulated in HFHS diet fed mice, 351 mRNAs were 
downregulated by both curcumin and vitamin D3 liposomes, whereas 213 and 172 mRNAs 
were downregulated independently by curcumin and vitamin D3 liposomes respectively 
(Figure 4-5, B).  
Next, commonly downregulated mRNAs were assessed for gene ontology enrichment 
analysis and were identified to be involved in extracellular matrix deposition, antigen 
processing and presentation, and the cell cycle (Appendix table 4.5). Importantly, treatment 
of mice with curcumin or vitamin D3 liposomes inhibited expression of mRNA encoding 
chemokine ligands including CX3CL1, CXCL10, CCL5 (RANTES), CCL22, and receptors 
CCR2 and CX3CR1, involved in recruitment of monocyte, dendritic cells and T cells. 
Consistent with reduced antigen presentation and chemokine expression, CD8+ T cell 
mRNA encoding CD8A and CD8B1 were downregulated following treatment. Thus both 
curcumin and vitamin D3 liposomes downregulate a core set of mRNAs associated with 
hepatic inflammation and associated immune cell recruitment.  
Interestingly, curcumin and vitamin D3 independently downregulated hepatic mRNA 
associated with HFHS diet. Curcumin reduced chemotaxis mRNA (CCL3/MIP1α, 
CCL4/MIP1β, CXCL16, CMTM7, CMTM3, SLIT2), whereas vitamin D3 reduced collagen 
deposition and mRNAs involved in the cell cycle. Vitamin D3, in addition to reducing 
monocyte chemokine receptor CCR2, also reduced its corresponding ligand CCL2, which 
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correlated with lower Ly6C2 expression. Ly6C+ monocyte recruitment into steatotic liver 
occurs in both human and mouse models of NASH (88, 273, 320).  
Zero-order network meta-analysis of differentially expressed mRNA revealed that curcumin 
liposome treatment modulated major inflammatory networks induced with HFHS diet, 
including IRF8, Jun, BCL2, TCF4, C/EPBα, WIPF1 (Figure 4-5, C), whereas vitamin D3 
liposome treatment modified SIRT1 and CCL2 (Figure 4-5, D). Additionally, while treatment 
with curcumin liposomes dampened type I interferon signalling by reducing the Retinoic 
Acid-Inducible Gene 1 network, treatment with vitamin D3 liposomes increased mRNA of 
C/EBPβ and STAT3, which regulates liver regeneration. This data indicate that treatment 
with curcumin or vitamin D3 liposomes reduces activation of the innate and adaptive immune 
response, cell cycle and reduced collagen deposition, indicative of diminished tissue 
remodelling in accordance with lower NAS and fibrosis scores. 
C.  Treatment of mice with HFHS-induced NASH with curcumin or vitamin D3 
liposomes decreases liver dysfunction signature mRNAs: 
To determine if liver metabolic dysfunction was reduced in treated mice, hepatic mRNA 
upregulated in liposome treated obese mice was compared with mRNA downregulated in 
untreated obese mice. Feeding mice with HFHS diet reduced 1081 mRNAs in liver and 
treatment with curcumin or vitamin D3 liposomes increased 200 and 162 mRNAs 
respectively, with 75 mRNAs common to both (Figure 4-5, E). Gene ontology enrichment 
analysis indicated that treatment with either curcumin or vitamin D3 increased mRNAs 
encoding proteins associated with mitochondria, endoplasmic reticulum and microsomes 
(Appendix table 4.6). Consistent with the known antioxidant properties of curcumin, mRNA 
encoding proteins in oxidation-reduction and mitochondrial pathways were increased 
following curcumin liposome treatment. Vitamin D3 increased mRNAs encoding proteins 
regulating complement activation and coagulation, may hence activated innate immune 
response to promote wound healing.  
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Figure 4-3: Curcumin liposomes target hepatic inflammatory myeloid cells in mice fed 
a HFHS diet. A&B: Mice fed HFHS diet for 12 weeks were intravenously injected with 100µl 
of fluorescent dye, DiR, labelled curcumin liposomes and in vivo imaged with IVIS system 1 
and 7 days later (A). Total radiant efficiency was determined for liver and spleen (B). n=2 
(untreated), n=8 (DiR+liposomes treated) C&D: Representative FACS plots (C) and 
quantitation (D) of DiR uptake in myeloid cells 7 days post injection of DiR-labelled curcumin 
liposomes. n=10/group. E: Median fluorescence intensity (MFI) of F4/80 on hepatic CD103- 
DC and CD103+ DC. Data are mean ±SEM. Representative of three separate experiments 
analysing individual mice. n=10/group. ****p<0.0001 by Mann Whitney t-test. 
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Figure 4-4: Treatment of mice with HFHS diet induced NASH with curcumin liposomes 
or vitamin-D3 liposomes reduces disease. A-D: Mice fed HFHS diet for 14 weeks were 
treated with 2 doses of empty, curcumin or vitamin D3 liposomes at weeks 12 and 13. Livers 
were harvested at week 14, fixed, paraffin embedded, sectioned and stained with H&E. 
Representative images of H&E stained sections, with arrows indicating inflammatory foci, 
are shown in A together with NAS scores (B). Paraffin liver sections were stained with 
Masson Trichrome stain and scored for collagen with representative images shown in A and 
quantitation in C. Livers embedded in OCT were sectioned and stained with Oil red-O and 
scored for oil deposition with representative images shown in A and quantitation in D. E: 
Serum ALT (U/L) levels in HFHS diet fed mice treated with different liposomes. Data are 
mean ±SEM. Representative of three separate experiments analysing individual mice. 
n=5/group. *p<0.05 by one-way ANOVA followed by Bonferroni post hoc test. 
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Figure 4-5: Expression analysis of hepatic mRNA from mice with HFHS diet induced 
NASH treated with curcumin liposomes or vitamin-D3 liposomes. A: Principle 
component analysis showing the distribution of hepatic mRNA expression of control-diet fed 
mice (black), 14 week HFHS diet fed mice untreated (blue) or treated with 2 doses of 
curcumin liposomes (red) or vitamin D3 liposomes at week 12 and 13 (green). Data of one 
experiment. n=3/group. B: Venn diagram showing mRNA upregulated in livers of HFHS diet 
fed mice (red) and mRNA downregulated in HFHS diet fed mice treated with curcumin 
liposomes (yellow) and vitamin D3 liposomes (green). C: Shown is the protein-protein 
interaction network of upregulated (red) and downregulated (green) hepatic mRNA following 
treatment of mice fed HFHS diet with curcumin liposomes. D: Shown is the protein-protein 
interaction network of upregulated (red) ad downregulated (green) hepatic mRNA following 
treatment of mice fed HFHS diet with vitaminD3 liposomes. E: Venn diagram showing 
mRNA downregulated in livers of HFHS diet fed mice (red) and mRNA upregulated in HFHS 
diet fed mice treated with curcumin liposomes (yellow) and vitamin D3 liposomes (green). 
 
4.4.5  Treatment of mice with HFHS-induced NASH with curcumin or vitamin D3 
liposomes reduces adipocyte size and normalises hyperglycaemia and insulin 
resistance. 
Next, I examined the gonadal adipose tissue harvested from mice fed either normal chow 
diet or HFHS diet for 14 weeks. Consistent with an increased body weight of mice fed a 
HFHS diet (Figure 4-1, A), H&E staining of adipose tissue sections demonstrated increased 
adipocyte size (Figure 4-6, A) and crown like structures known to contain immune cells 
(Figure 4-6, B). To characterise changes in immune cell populations following HFHS diet, 
cells were isolated from the gonadal adipose tissue of HFHS-fed or chow-fed mice, stained 
for leukocyte markers and analysed by flow cytometry. Adipose tissue from obese mice had 
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increased proportions of inflammatory myeloid cells including DCs, F4/80+ DCs and 
CD11b+F4/80+ inflammatory monocytes (Figure 4-6, C).  
The next experiments determined the effects of liposome treatment on adiposity (adipocyte 
size), hyperglycaemia (fasting blood glucose) and insulin resistance (HOMA-IR). Mice fed a 
HFHS diet were treated with curcumin or vitamin D3 or empty liposomes at week 12 and 
then week 13. At 14 weeks mice were fasted and sacrificed and blood and adipose tissue 
harvested. Treatment with vitamin D3 liposomes but not curcumin or empty liposomes 
reduced the size of adipocytes (Figure 4-6, D) and reduced fasting blood glucose levels 
(Figure 4-6, E) and HOMA-IR (Figure 4-6, F). No changes in the proportion of immune cells 
within the adipose tissue were observed indicating that liposomes did not deplete cells.  
In summary, feeding mice with HFHS diet for 14 weeks had increased adipocyte size and 
proportions of immune cells. Treatment of mice with vitamin D3 liposomes reduced 
adipocyte size and reduced hyperglycaemia and insulin resistance. 
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Figure 4-6: Treatment of mice with HFHS diet induced NASH with vitamin D3 
liposomes reduces HFHS diet induced fat accumulation in adipose tissue, 
hyperglycaemia and insulin resistance. A&B: Gonadal adipose tissue (GAT) was 
harvested from mice fed either chow diet or HFHS diet for 14 weeks, fixed, paraffin 
embedded, sectioned and stained with H&E. Representative image of adipose tissue shown 
in A (arrows identify crown like structures known to contain immune cell infiltrate) and 
quantitation of adipocyte size shown in (B). n=10/group. C: Immune cells within GAT were 
identified by staining with myeloid cell antibodies and flow cytometry analysis. n=10/group. 
D: Quantitation of adipocytes size in GAT of HFHS diet fed mice treated with empty, 
curcumin or vitamin D3 liposomes. n=10/group.  E&F: Fasting blood glucose (E) and HOMA-
IR (F) of HFHS diet fed mice treated with empty, curcumin or vitamin D3 liposomes. 
n=10/group (E). n=5/group (F).  Data are mean ±SEM. Representative of three separate 
experiments analysing individual mice. *p<0.05, **p<0.01, ****p<0.0001 by one-way ANOVA 
followed by Bonferroni post hoc test (D, E and F) and *p<0.05, ****p<0.0001 by Mann 
Whitney t-test (B and C). 
 
4.5 Discussion: 
Over consumption of a diet rich in fat and simple sugars elevates circulatory levels of 
triglycerides, which are stored in adipocytes. Triglyceride levels in the body are determined 
by the amount of fat absorbed in the gut and synthesized in the liver. Excess accumulation 
of triglycerides in adipose tissue increases fat mass thereby increasing body weight, a 
hallmark of obesity. Indeed, I observed increased body weight in mice fed high-fat high-
sugar diet for 14 weeks compared to mice fed chow diet. Excess intracellular levels of fat in 
adipocytes cause hypertrophy that leads to secretion of proinflammatory mediators. These, 
in synergy with other inflammatory cytokines secreted by innate immune cells, augment 
adipose tissue inflammation, leading to chronic lipolysis in adipocytes and release of free 
fatty acids (FFA) into the circulation (321). The liver, being a major metabolic organ, 
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continuously synthesizes and secretes triglycerides from circulatory FFA and gut absorbed 
fatty acids and carbohydrates. Metabolic stress on the liver to bring homeostasis in body 
lipid levels leads to impairment in liver function to secrete lipid due to decreased hepatic β-
oxidation. Consequently, fat is stored in the liver leading to hepatic steatosis. Frozen liver 
sections stained with Oil-red O stain, which stain for neutral lipids, showed higher hepatic 
lipid content in obese mice compared to non-obese mice, indicating impaired hepatic β-
oxidation in DIO. Prolonged feeding of an obesogenic diet to mice increased fasting blood 
glucose levels and insulin resistance, which are associated with hepatic steatosis in humans 
(322).  
In contrast to a high-fat diet, where the only source of calories is fat, the DIO model described 
in this chapter uses a 60% fat diet combined with excess sugar in water (55% fructose and 
45% sucrose). In female C57BL/6J mice, 14 weeks of feeding with fat and fructose induces 
stage-3 liver fibrosis, which generally takes up to 14 months if mice are fed only a fat rich 
diet (307). The combination of both fat and sugar may be more relevant for human NAFLD, 
where fructose, a major source of sweetness in sugary beverages, is strongly associated 
with steatohepatitis and liver fibrosis in obese and type 2 diabetes patients (303). NAFLD 
patients were found to consume 5 fold higher carbohydrates from sugary drinks than healthy 
individuals (323). Epidemiological studies have found a positive correlation between extent 
of biopsy proven liver fibrosis in obese patients and intake of sugary drinks, but not soda 
(259). Ingested fructose is absorbed in the gut through glucose transporter-5 and used to 
synthesize glucose or triglycerides in the liver thus contributing to hyperglycaemia and 
hepatic steatosis. Moreover, fructose can alter microbial composition in the gut which may 
increase gut permeability, and release endotoxin into the portal circulation which can 
progress steatohepatitis to liver fibrosis (324). In support of this, mice deficient in LPS 
signaling proteins, such as TLR-4 or MYD88 are resistant to developing liver fibrosis (127).  
In this study, feeding mice with HFHS diet induced complete features of human NASH within 
14 weeks. Using this model, I have performed sequencing on mRNA extracted from livers 
of mice fed control chow diet or HFHS diet. I identified increased expression of mRNA 
encoding proteins SCD2, LPL and CD36 that regulate fatty acid uptake and synthesis in the 
liver. The major sources of lipids in hepatocytes are triglycerides converted from circulating 
FFA and fat synthesized through de novo lipogenesis. FFA enter the liver through the portal 
vein and are recognized by CD36 on hepatocytes and used for triglyceride synthesis (325). 
Excess lipid droplet formation in hepatocytes activates pro-apoptotic signalling pathways 
leading to cell death. CIDEC, which binds lipid droplets and favours their enlargement, is 
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highly expressed in humans with alcoholic steatohepatitis, and expression levels correlated 
with hepatic steatosis, liver damage and mortality (326). CIDEC is also known to increase 
susceptibility of steatotic hepatocytes and fat loaded adipocytes to stress induced apoptosis 
(327). CIDEC mRNA was highly upregulated in livers of mice fed a HFHS diet along with 
other positive regulators of programmed cell death including caspase-2, Apoptotic protease 
activating factor 1 (APAF1) and lymphotoxin-β. 
Similar to stressed adipocytes, which secrete adipokines to recruit CCR2+ monocytes into 
adipose tissue, steatotic hepatocytes release cytokines and chemokines to promote 
chemotaxis of blood derived monocytes and Kupffer cells. Kupffer cells, being resident in 
the liver, are the primary sensors of stressed steatotic hepatocytes. Kupffer cells have been 
shown to trigger monocyte recruitment to steatotic liver and secrete the proinflammatory 
cytokine TNFα, which promote steatohepatitis development (70). Depletion of Kupffer cells 
using clodronate liposomes prior to inducing liver disease by feeding mice an MCD diet, 
prevented development of steatosis and hepatic inflammation (273). Similarly, blockade of 
monocyte (CD11b+F4/80+) recruitment to the injured liver reduces inflammation and 
disease (273). In my study, mice fed a HFHS diet had increased number of CD11b+ F4/80+ 
monocytes in the liver compared with mice fed a normal diet. Higher expression of CCR2 
and CCL2 mRNA was also detected in the liver.  
In contrast to monocytes and Kupffer cell depletion, depletion of liver DCs in mice fed an 
MCD diet increased inflammation and fibrosis (95). The protective function of liver DCs is 
mostly attributed to their ability to clear apoptotic bodies from damaged liver and to limit 
inflammatory activation of Kupffer cells, monocytes and neutrophils. Using the NASH 
recovery model, where mice with NASH transition to feed on normal chow diet, it has been 
shown that liver DCs are essential only in the initial stages of recovery, whereas CCR2+ 
monocytes are indispensable. CCR2 knockout mice, which could not recruit Ly6Chigh 
monocytes, are depleted of restorative macrophages as Ly6Chigh expressing monocytes 
recruited to NASH livers are converted to Ly6Clow restorative macrophages, reducing scaring 
of liver and promoting recovery (328). Liver DCs (CD11c+ MHC class-II+) are generally 
classified as CD11b+ and CD11b-. Notably, CD11b- DCs express CD8, a phenotype of 
crosspresenting DCs, and their development is dependent on precursors expressing 
transcription factors interferon regulatory factor 8 (IRF-8) and Basic Leucine Zipper 
Transcription Factor, ATF-Like 3 (BATF3) as IRF-8 and BATF3 knockout mice have reduced 
numbers of CD11b- DCs but not CD11b+ DCs. While CD11b- DCs express CD103, a tissue 
specific marker, CD11b+ DCs are CD103-. Therefore IRF8 regulates development of liver 
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resident DCs (318). Using network meta-analysis for innate immune responses I found that 
the HFHS diet upregulated 72 mRNAs interacting with IRF8, making IRF8 a key hub gene. 
Although IRF8 is highly expressed in myeloid cells, it is also been shown to be expressed 
at lower levels in non-hematopoietic cells (329), (330). Therefore, it would be interesting to 
determine the role of IRF8 in NASH development and progression in future studies.  
Increased expression of IRF8 may indicate expansion of CD103+ DCs. In the MCD diet 
model I identified 2 types of DCs based on F4/80 expression, F4/80+ DCs are 
proinflammatory with higher activation of JNK-MAPK signalling cascades, compared with 
F4/80- DCs. Interestingly F4/80 expression is higher in CD103+ DCs relative to CD103- DCs 
in the HFHS model, indicating that IRF8 dependent CD103+ DCs are indeed 
proinflammatory hepatic F4/80+ DCs. In addition, in the MCD model, F4/80 expression on 
hepatic DCs distinguish liposome uptake capacity. Liposomes were taken up by F4/80+ 
DCs, which also express CD36 and other phagocytic markers. Previously, studies have 
shown that injection of curcumin liposomes inhibited hepatic NF-κB and reduced hepatic 
insulin resistance in obese leptin deficient mice (94), however the effects on liver disease 
could not be assessed in this model as leptin regulates fibrosis. Intravenous injection of 
curcumin liposomes targeted F4/80+ CD103+ liver DCs and on average 60% of the 
liposome targeted CD103+ DCs were detected in the liver 7 days post treatment. Although 
it is possible that F4/80+ cells outside the liver captured injected liposomes and migrated 
into liver during NASH, liver DCs with liposome uptake capacity express integrin protein 
CD103, a marker of tissue residency and CD103+ DCs express significantly higher F4/80 
compared CD103- DCs, indicating that F4/80+DCs are likely to be liver resident cells. 
Biodistribution analysis of fluorescently labelled liposomes confirmed the presence of 
targeted cells in the liver and this is in parallel with observation I made in MCD model, which 
could be attributed to long lived phenotypes of DCs and macrophages.  
In the previous chapter I determined that curcumin liposomes reduced mRNA levels of JNK-
MAPK and induced mRNA promoting alternative activation, OXPHOS and retinoic acid 
production, which resulted in increased secretion of IL-4 and IL10  (chapter 3, section 3.7.2). 
In a previous study, curcumin liposomes injected intraperitioneally decreased NF-κB DNA 
binding in hepatic DCs leading to reduced hepatic and systemic insulin resistance in leptin 
deficient mice (94). In the previous chapter curcumin liposomes injected intravenously 
reduced MCD diet induced hepatocyte damage. Likewise, in mice fed a HFHS diet, 
treatment with curcumin liposomes reduced liver disease as assessed by reduced NAS 
scores and reduced liver fibrosis. Improvement in necroinflammation correlated with 
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reduced expression of mRNAs encoding chemokines that recruit leukocytes into injured 
liver. Importantly, treatment of mice with curcumin liposomes prevented progression of 
steatohepatitis to liver fibrosis, which is major cause of liver failure in NAFLD patients. Liver 
mRNAs regulating extracellular matrix deposition, including 16 collagen genes, 4 MMP and 
2 inhibitors of MMPs (TIMP1 and TIMP2) were downregulated with curcumin liposomes 
therapy.  
Vitamin D3 is an active component of vitamin D and functions through binding to VDR. 
Besides being a key regulator of bone homeostasis, vitamin D3 is an important 
immunomodulator, regulating development and maturation of immune cells including 
macrophages, DCs and T cells. Vitamin D3 deficiency positively correlates with several 
infectious, autoimmune and metabolic diseases (331). Vitamin D3 has specific effects on 
DCs, promoting a tolerogenic phenotype with capacity to induce antigen specific Tregs 
(319). Monocyte derived DCs cultured in vitro with vitamin D3 have lower expression of MHC 
class-II and costimulatory molecules (CD80 and CD86) and secrete immunoregulatory 
cytokine IL-10. Functionally, vitamin D3 activated VDR negatively regulates both canonical 
(p65) and non-canonical (RelB) pathways of NF-κB (210). RelB expression is upregulated 
during monocyte maturation to DCs, and DCs from RelB knockout mice are immature and 
have increased capacity to induce antigen specific tolerance through IL-10 and treat 
autoimmune arthritis (332). Maturation of DCs is associated with increased glycolysis and 
reduced OXPHOS (Warburg effect) to meet the increased energy demand and RelB 
knockout DCs have reduced metabolic activation (333). Recently, in vitro treatment of DCs 
with vitamin D3 was shown to induce metabolic reprogramming to produce energy through 
glycolysis, TCA and OXPHOS (215). Thus curcumin and vitamin D3 share common 
molecular functions to induce tolerogenic phenotype in DCs. Similar to curcumin, vitamin D3 
is also lipophilic, facilitating entrapment into the lipid bilayer of liposomes. Treatment of mice 
fed a HFHS diet with vitamin D3 liposomes reduced liver disease as assessed by NAS 
scores, liver fibrosis and steatosis. Analysis of liver mRNA after treatment revealed that 
vitamin D3 liposomes, like curcumin liposomes, reduced mRNA levels of proteins mediating 
cell death, chemotaxis of immune cells and collagen deposition. Interestingly, regression 
from diet induced steatohepatitis with curcumin and vitamin D3 liposomes reduced liver 
dysfunction by increasing hepatic-β oxidation, and complement and coagulation protein 
production. Therefore, my findings indicate that inducing alternative/tolerogenic activation in 
hepatic DCs by targeting with curcumin and vitamin D3 liposomes is a promising therapeutic 
strategy to prevent NASH development even in the presence of continuous metabolic stress.  
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Adipose tissue is one of the primary targets of metabolic inflammation. Excess accumulation 
of triglycerides leads to adipocyte stress that activates resident NK cells to secrete IFNγ, 
promoting differentiation of recruited monocytes to proinflammatory macrophages and DCs 
(334). Adipose tissue from obese mice have increased proportions of TNFα and iNOS 
producing DCs (335). Like hepatic CD103+ DCs, Tip-DCs in adipose tissue also express 
F4/80 and take-up intraperitonially injected liposomes. Targeting Tip-DCs with curcumin 
liposomes inhibited NF-κB DNA binding and reduced insulin resistance in leptin deficient 
mice (94). In HFHS diet induced obese mice, although I was unable to detect liposome 
uptake in adipose tissue derived F4/80+ DCs and macrophages 7 days post intravenous 
injection, I found that treatment with vitamin D3 liposomes reduced fasting glucose and 
insulin resistance. In contrast to a previous published study, curcumin liposomes did not 
reduce either fasting glucose or HOMA-IR. This discrepancy could be attributed to 1) 
differences in animal models, as the previous study was conducted in leptin deficient ob/ob 
obese mice in contrast to HFHS diet induced obese mice used in my study, 2) route of 
delivery and dosage of curcumin liposomes, since the published study used 1 intraperitoneal 
injection of 40ug/mouse curcumin containing liposomes, compared to 2 consecutive 
intravenous injections of 20ug/mouse curcumin liposomes. The additional effect of vitamin 
D3 liposomes over curcumin liposomes on improving metabolic syndrome could be due to 
its ability to inhibit alternative NF-κB, RelB, whose expression is required for LPS and 
lymphotoxin mediated inflammatory activation of DCs and macrophages. These 
observations shed light on the role of myeloid specific activation of RelB in obesity induced 
inflammation and targeting alternative NF-κB pathway in myeloid cells may offer a preferred 
therapeutic strategy to treat metabolic syndrome and NASH in obese humans.  
Taken together, feeding mice with obesogenic diet rich in fat and fructose causes NASH 
with liver fibrosis, mimicking NASH in obese humans. Targeting myeloid cells, including 
DCs, macrophages and inflammatory monocytes with immunomodulatory drug loaded 
liposomes reduce inflammation and diet induced exacerbation of steatosis to liver fibrosis, 
ultimately improving the liver function. The therapeutic potential of curcumin and vitamin D3 
liposomes to prevent NASH progression is fascinating in the light of the current growing 
epidemic of obesity induced liver failures and the higher demand for liver transplantations 
(336).  
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4.6 Future directions: 
The obese model presented in this chapter is a relatively short term model compared to high 
fat diet induced models described elsewhere (337) and replicated the majority of the features 
of obesity and its complications, including hyperglycaemia, insulin resistance and severe 
NASH with fibrosis. Sequencing mRNA from normal and NASH livers revealed several novel 
genes and pathways modulated in livers with NASH. According to my knowledge, majority 
of the genes described in this study have not been fully characterised for their role in NASH 
development and progression. Hence, future studies could investigate the pathogenic role 
played by these genes in NASH.  
One of the mRNA’s that formed the major protein-protein interaction network hub is IRF8, 
which has been shown to be important for liver resident CD103+ DCs development (318) 
and is increased in NASH livers. Moreover, mRNA for CD103 coding gene, ITGAE was 
upregulated in NASH livers. Based on these findings, it is possible that IRF8 dependent DCs 
play a key role in either progression or regression of NASH. Considering that DC depletion 
worsens the fibrosis and inflammation, and impaired regression from disease in acute NASH 
model (95), future studies could investigate the role of IRF8 dependent DCs in diet induced 
NASH development.  
Immunomodulatory liposomes selectively targeted the F4/80 expressing hepatic CD103+ 
DCs of obese mice and F4/80 expressing hepatic DCs in mice fed an MCD diet. Moreover, 
F4/80 is highly upregulated at the mRNA and protein level in DCs with the ability to take up 
liposomes.  Future studies could investigate specific surface receptors such as CD36, C-
type lectins (CLEC4A1, CLE4A3, CLEC4B1, CLEC4D, CELC4E and CLEC4N) that may 
contribute to selective liposome uptake in tissue DCs, to develop improved drug targeting of 
liver DCs.  
Liposomally delivered curcumin and vitamin D3 elicited immunomodulatory effects on 
targeted myeloid cells and reduced metabolic inflammation induced by obesogenic diet in 
mice. Practically, these liposomes delivered curcumin and vitamin D3 into the cell, where 
they interact with proteins and alter gene and protein expression. I have found that curcumin 
induced tolerogenic gene expression in targeted hepatic DCs.  While treating human moDCs 
with vitamin D3 in in vitro has been shown to induce tolerogenic phenotype by inducing a 
similar gene signature that favour alternative/tolerogenic phenotype, whether targeting the 
DCs with vitamin D3 liposomes also mimics this signature will require further investigation.  
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Flow cytometry studies conducted in chapter 3 and 4 only assessed the uptake of liposomes 
by hepatic immune cells separated from hepatic parenchymal cells. Although hepatic 
myeloid cells are the main cell type taking up injected liposomes, minimal uptake by 
parenchymal cells including hepatocytes, liver sinusoidal endothelial cells and stellate cells 
may have occurred. Future studies could investigate the liposome uptake by these 
parenchymal cells in normal and NASH livers. 
In my experiments, the effect of co-delivery of both curcumin and vitamin D3 was not 
investigated. Curcumin and vitamin D3 being potent anti-inflammatory drugs may cause 
cytotoxicity induced depletion of targeted myeloid cells, which could lead to decreased 
NASH progression as shown with clodronate liposome treatment in several NASH models. 
Future studies could examine dose kinetics of curcumin or vitamin D3 in liposomes alone or 
in combination and therapeutic effects. 
4.7 Limitations of the study described in the chapter 4: 
The major limitation of the present study is that neither glucose tolerance test (GTT) nor 
insulin tolerance test (ITT) were measured, which are standard tests to measure the insulin 
resistance and beta cell function respectively. Measuring GTT and ITT at different time 
points post treatment with curcumin and vitamin D3 liposomes would provide a more precise 
understanding of duration and efficacy of the treatment.  
4.8 Transition to next chapter: 
My findings indicate that targeting hepatic myeloid cells with immunomodulatory liposomes 
induce alternative/tolerogenic phenotype and prevent diet induced steatohepatitis 
progression in both acute and chronic NASH models. Regulatory T cells are natural 
immunomodulatory cells in the body, which confer protection from inflammatory liver 
diseases by secreting immunoregulatory cytokines IL-10 and IL-35 (264). Since curcumin 
liposome therapy induced immunomodulation in DCs to moderate NASH, whether the 
disease outcome is dependent or independent of Tregs is investigated in the next chapter. 
Furthermore, the therapeutic potential of adoptively transferred Tregs together with 
curcumin liposomes to prevent NASH progression is evaluated.  
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5. Targeting hepatic myeloid cells with curcumin and antigen-specific regulatory 
T cells reduces MCD diet induced NASH 
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5.1 Abstract: 
Nonalcoholic steatohepatitis (NASH) is associated with activation of both innate and 
adaptive immune responses in the liver. Regulatory T cells can suppress immune responses 
and reduce tissue inflammation. In the previous chapter, curcumin liposomes reduced 
inflammation and reduced MCD diet induced NASH. However the role of Tregs in this 
improvement was not determined. Mice with MCD diet induced NASH have increased 
proportions of Tregs in the liver. Depletion of Tregs in DEREG mice fed an MCD diet 
untreated or treated with curcumin liposomes induced neutrophil recruitment and hepatocyte 
damage as assessed by increased serum ALT. Curcumin liposome treatment prevented 
Treg-depletion induced neutrophilia and reduced liver damage as assessed by NAS score. 
Increasing hepatic Tregs in mice fed an MCD diet, by injecting curcumin-ovalbumin (OVA) 
antigen entrapped liposomes and adoptively transferring OVA-specific Tregs, reduced 
neutrophilia and hepatocyte damage. Targeting curcumin and antigen to hepatic myeloid 
cells together with adoptive transfer of Tregs is a novel approach to prevent NASH 
progression 
5.2 Introduction: 
Nonalcoholic steatohepatitis (NASH) is a chronic inflammatory metabolic disease. 
Alterations in liver metabolism to synthesize and secrete lipid causes oxidative stress and 
hepatic steatosis, which in turn induces hepatocyte apoptosis. Consequently, immune cells, 
especially myeloid cells, are recruited to damaged liver to remove dead hepatocytes. The 
presence of damage associated molecular patterns (DAMPs) leads to increased production 
of chemokines and pro-inflammatory cytokines within the liver. This facilitates the infiltration 
and activation of adaptive immune cells including, CD4+ T cells, CD8+ T cells and B cells. 
Portal infiltrates in liver biopsies of NAFLD patients are characterised by increased T and B 
cells (338). T and B cells have been shown to promote insulin resistance and adipose tissue 
inflammation in obese mice (106) (107). Mice depleted of CD4+ T cells and B cells have 
attenuated liver disease (98), (110).  Adaptive immune responses to oxidative stress 
induced lipid peroxidation products significantly correlated with hepatic inflammation and 
progression to liver fibrosis in NASH patients (98). Mice with MCD diet induced NASH have 
higher titres of antibodies-to-protein adducts, with lipid peroxidation products and increased 
proportions of CD4+ T cells and B cells in the liver (109). Similarly, autoantibodies to glial 
fibrillary protein (GFAP), a marker of hepatic stellate cell activation, were detected in humans 
with type 2 diabetes (108), (339). The presence of autoantibodies to liver antigens in 
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metabolic diseases indicates the development of antigen specific CD4+ T cells to induce B 
cells with autoantibody producing capacity. CD4+ T cells in the liver and visceral adipose 
tissue have a T-helper 1 (Th1) phenotype and produce increased levels of interferon-γ 
(IFNγ), which in turn promotes classical activation of recruited macrophages, and depletion 
of CD4+ T cells has been shown to reduce nitric oxide synthase, a marker of classical 
activation of macrophages (109). In addition to IFNγ, CD4 T cells producing interleukin (IL)-
17 are enriched in livers of high fat diet fed mice, and obese mice treated with anti-IL-17 are 
protected from endotoxin induced liver inflammation and injury (340).  
In general, the liver maintains the highest tolerance to tissue injury compared to other 
organs, through several mechanisms (341). Non-parenchymal cells, including liver 
sinusoidal endothelial cells, hepatic stellate cells, Kupffer cells and dendritic cells (DCs) play 
a key role in liver immune tolerance by secreting various immunomodulatory factors 
including IL-10, transforming growth factor (TGF)-β and retinoic acid. In addition to antigen 
presenting cells (APC), regulatory T-cells (Tregs) expressing transcription factor forkhead 
box P3 (Foxp3) maintain liver tolerance and depletion of Tregs has been shown to reduce 
concanavalin A induced tolerance in liver by diminishing hepatic IL-10 levels (342). Mice fed 
a high fat diet have reduced numbers of Tregs in liver and adipose tissue (107) (118). 
Reduction in hepatic Tregs during NASH is attributed to oxidative stress induced cell death, 
and treatment with antioxidant protected Tregs from apoptosis, and reduces hepatic 
inflammation (118). Depletion of Tregs enhances fasting blood glucose levels and insulin 
resistance in leptin deficient mice, and promotes atherosclerosis in Ldlr knockout mice (343) 
(344). In contrast, adoptively transferred Tregs conferred protection against impaired insulin 
sensitivity and atherosclerosis.  
The role of Tregs in NASH development is ill defined. Recent studies provided indirect clues 
to Treg ability to dampen hepatic inflammation in NASH. Using mice deficient in B7 
costimulatory molecules, which lack Tregs due to a proapoptotic environment, 
Chatzigeorgiou et al., have shown that high fat diet feeding induced severe obesity with 
steatohepatitis and insulin resistance (345). Moreover, deletion of DCs in MCD diet fed 
CD11c-DTR bone marrow chimeric mice exacerbated inflammation and promoted 
development of liver fibrosis (95). Depletion of CD11c cells in this system was associated 
with decreased hepatic Tregs. In contrast to these findings, humans with NAFLD and other 
chronic liver diseases exhibit increased hepatic Foxp3 mRNA expression, which correlated 
with apoptosis mediators Fas and FasL, indicating expansion of Tregs in NASH livers as a 
99 
 
response to limit inflammation and injury (346). Therefore strategies that enhance either 
hepatic Treg numbers or function may have therapeutic potential to treat NASH. 
5.3 Rationale and aim: 
Tregs are a subset of leukocytes with immunomodulatory activity. Defects in Treg numbers 
or function are associated with metabolic inflammatory diseases such as type 2 diabetes 
and NASH. Increasing Treg numbers through adoptive transfer or immunotherapy has been 
shown to reduce metabolic dysfunction in obese mice (107) (345). I found that inducing 
immunomodulation in hepatic myeloid cells, including DCs, with curcumin liposomes 
reduces NASH in mice. Since DCs regulate Treg numbers and function, I hypothesised that 
curcumin liposome mediated improvements in liver disease may be dependent on Tregs. 
To this aim, I have depleted Tregs in Foxp3-DTR (DEREG) mice fed an MCD diet, treated 
with or without curcumin liposomes, and analysed disease parameters. Furthermore, 
expanding Tregs in the liver could enhance therapeutic potential of immunomodulatory 
liposomes, as adoptively transferred Tregs reduce hepatic inflammation in obese mice 
(118). To test this hypothesis, C57BL/6J mice were fed an MCD diet, treated with ovalbumin 
(OVA) antigen loaded curcumin liposomes, co-injected with OVA-specific Tregs, and liver 
disease assessed. 
5.4 Results: 
5.4.1: IL-17 T cells and regulatory T-cells are increased in NASH livers. 
Initial experiments were performed to determine if hepatic T lymphocyte percentages were 
altered in mice with NASH compared to age and gender matched normal mice. Female 
C57BL/6J mice were fed an MCD diet for 3 weeks, immune cells were isolated from livers, 
stained for T cell markers and analysed by flow cytometry. Compared to normal livers, NASH 
livers have significantly increased proportions of CD3+ T cells with greater mean 
fluorescence intensity for CD3 (Figure 5-1, A), indicating hyper activation of T cells in NASH. 
Moreover, NASH livers have increased CD8 to CD4 ratio (Figure 5-1, B) and CD4 CD8 
double negative (DN) T cells compared to normal livers. Proinflammatory cytokine IL-17 
producing T cells have previously been shown to aggravate liver injury in obese mice (340), 
(347). To evaluate the phenotype of T cells in NASH livers, hepatic immune cells were 
isolated from livers of mice fed either control chow diet or MCD diet for 3 weeks, stimulated 
ex vivo with phorbol myristate acetate (PMA) and ionomycin in presence of brefeldin-A for 
4 hours, and cells were stained for T cell surface markers and intracellular IL-17A. CD3+ T 
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cells from NASH livers had increased expression of IL-17 compared to control livers (Figure 
5-1, C). Among the T cell subsets, CD4+ Foxp3- and CD8+ T cells expressed higher IL-17A, 
whereas DN T cells, although key produces of IL-17A in liver, tended to be higher and no 
IL-17A+ Tregs (CD4+FoxP3+) were detected (Figure 5-1, D).  
Increased CD8+ T cells and increased IL-17+CD4+ T cells in NASH livers indicated impaired 
immunoregulation. Since Tregs are important regulators of T cell immunity, Treg proportions 
in NASH livers were next determined. Hepatic Treg proportions were increased 3 fold in 
mice fed an MCD diet compared to chow diet fed mice (Figure 5-1, E). CD4+Foxp3- T cells 
convert to Tregs during inflammation in peripheral organs and are characterised by absence 
of intracellular expression of helios, a marker of thymic derived Tregs (348). Analysis of 
helios expression in Tregs revealed that both helios+ and helios- Tregs increased in NASH 
livers compared to normal livers (Figure 5-1, F). Interestingly, proportions of Tregs positively 
correlated with proportion of IL-17A+ T cells (Figure 5-1, G). Moreover, hepatic Treg 
proportions also positively correlated with liver DCs (Figure 5-1, H). These findings support 
recent findings showing that Treg homeostasis is dependent on DCs and depletion of DCs 
reduces hepatic Tregs (95). Taken together this data indicates that NASH livers are 
characterised by increased adaptive immune responses with proinflammatory cytokine 
production, and hepatic Tregs expanded in this inflamed environment. 
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Figure 5-1: IL-17+ T cells and regulatory T-cells are increased in mice with MCD diet 
induced NASH. A&B: Immune cells isolated from livers of mice fed control diet or MCD diet 
for 3 weeks were stained for T cell surface markers and analysed by flow cytometry. C&D: 
Isolated hepatic immune cells were ex vivo stimulated with PMA/Ionomycin for 4 hours and 
stained for intracellular IL-17A in CD3+ T cells (C) and T cell subsets (D). E: Representative 
FACS plot and quantitation of the proportion of Foxp3+ CD4+ T cells isolated from livers of 
mice fed control diet or MCD diet. F: Percentage of intracellular helios+ and helios- hepatic 
Tregs in livers. G&H: Spearman correlation of hepatic Tregs with IL-17A expressing CD3+ 
T cells (G) and hepatic DCs (H). Data are ±SEM. Representative of two experiments 
analysing individual mice. n=5/group. *p<0.05, **p<0.01, ****p<0.0001 by Mann Whitney t-
test. 
 
5.4.2: Diphtheria toxin treatment to Foxp3-DTR mice fed MCD diet exacerbates 
steatohepatitis to liver fibrosis: 
To clarify the functional role of hepatic Tregs in NASH progression, we induced NASH in 
mice where Tregs could be depleted (DEREG-C57BL/6J mice which express human 
diphtheria toxin receptor (DTR) under Foxp3 promoter). DEREG mice were fed an MCD diet 
for 2 weeks and were given daily intraperitoneal injections of diphtheria toxin from day 15 
for 6 consecutive days while continuing on an MCD diet.  Mice were euthanized at day 21 
to assess efficiency of Treg depletion and parameters associated with NASH (Figure 5-2, 
A). DT treatment failed to reduce total numbers of hepatic Tregs and increased the 
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proportion of Tregs (Figure 5-2, B). Analysis of helios expression revealed that treatment 
with DT reduced helios-Tregs whereas helios+Tregs increased (Figure 5-2, C), indicating 
that helios- induced Tregs are more efficiently depleted than helios+Tregs.  
Consistent with immunoregulatory role of Tregs, DT treatment of DEREG mice fed an MCD 
diet caused scurfy phenotype (data not shown) and increased hepatocyte death and liver 
damage as indicated by increased serum ALT  (Figure 5-2, D) and elevated NAS scores 
(Figure 5-2, E). Interestingly, 6 doses of DT treatment induced liver fibrosis as assessed by 
Masson Trichrome staining on paraffin sections of liver (Figure 5-2, F). To characterize the 
immune cells in NASH livers following DT treatment, livers were processed to collect 
immune cells, stained for leukocyte markers and analysed by flow cytometry. DT treatment 
induced 9-fold higher proportions of neutrophils in livers of Treg depleted mice compared to 
non-DT treated mice (Figure 5-2, G). Moreover, the proportion of inflammatory monocytes 
(CD11b+ F4/80+) increased (Figure 5-2, H). In summary, DT treatment of DEREG mice fed 
MCD diet decreased helios-Tregs (induced Treg), and increased the proportion of 
neutrophils and inflammatory monocytes, and exacerbated liver damage including fibrosis. 
5.4.3: Targeting curcumin liposomes to myeloid cells reduces NASH and neutrophilia 
following diphtheria toxin treatment: 
In the previous chapters, I demonstrated that curcumin liposomes induced an alternative 
phenotype in targeted hepatic DCs and reduced diet induced NASH. I next determined 
whether treatment with curcumin liposomes reduced disease in DEREG mice treated with 
DT. DEREG mice were fed an MCD diet for 2 weeks and treated with curcumin liposomes. 
6 consecutive doses of diphtheria toxin was administered to curcumin liposome treated or 
untreated mice. At day 21 mice were culled and serum and livers harvested to assess 
disease parameters (Figure 5-2, A). Curcumin liposome treatment had no effect on reducing 
serum ALT, which increased following DT treatment (Figure 5-2, D). However, curcumin 
liposome treatment reduced liver disease as assessed by NAS scores on H&E stained 
sections (Figure 5-2, E). Consistent with reduced liver inflammation, targeting hepatic 
myeloid cells with curcumin liposomes prevented the increase in neutrophils proportions 
observed following DT treatment (Figure 5-2, G). In addition, inflammatory monocytes were 
reduced in DT treated and curcumin liposomes treated mice, compared to untreated mice 
(Figure 5-2, H). Overall, these results indicate that hepatic helios-Tregs may regulate liver 
inflammation, reducing hepatic monocytes and neutrophils. Moreover, curcumin liposome 
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based immunomodulation of hepatic myeloid cells can prevent hepatic neutrophilia induced 
by DT treatment.  
 
 
  
104 
 
Figure 5-2: Treatment of DEREG mice with MCD diet induced NASH with curcumin 
liposomes reduces disease and decreases neutrophilia following DT treatment. A: 
Experiment design. B&C: Immune cells isolated from the livers of DEREG mice fed MCD 
diet treated with or without diphtheria toxin (DTx) and curcumin liposomes were stained for 
T cell surface markers and analysed by flow cytometry. D: Serum alanine transaminase 
(ALT) levels in normal mice or DEREG mice fed MCD diet treated with or without DT and 
curcumin liposomes. E&F: Paraffin embedded livers sectioned and stained with hematoxylin 
and eosin (H&E) were used to determine NAS score (E), and Masson Trichrome to 
determine liver fibrosis score (F). G&H: Percentage of neutrophils (G) and monocytes (H) 
in the liver of DEREG mice fed MCD diet treated with or without DT and curcumin liposomes. 
Data are ±SEM of mice analysed individually from one experiment. n=5/group. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 by one-way anova followed by Bonferroni post hoc test 
 
 
5.4.4: Liposomally delivered OVA antigen is presented to adoptively transferred OVA-
specific CD4+ T-cells in the liver: 
My findings suggest that hepatic Tregs exhibit immunosuppressive effects in MCD diet 
induced liver disease. Therefore, increasing Tregs in the liver by either adoptive transfer or 
conversion from naïve T cells may reduce hepatic inflammation and prevent NASH 
progression. One way to increase Treg numbers would be to induce conversion from naïve 
T cells within the liver or promote Treg proliferation. To determine if Tregs expand in the 
liver, antigen (OVA) was delivered with liposome together with purified antigen specific 
CD4+ T cells (OT-2) into mice with MCD diet induced liver disease. C57BL/6J mice fed an 
MCD diet for 2 weeks were intravenously injected with OVA liposomes with or without 
curcumin, and 24 hours later both groups were adoptively transferred with Cell Trace Violet 
(CTV) labelled OT-2 (Figure 5-3, A). Four days after transfer, both CTV+ OT-2 Tregs and 
OT-2 non-Tregs proliferated in the liver and spleen (data not shown) of mice treated with 
OVA containing liposomes but not in mice receiving OT-2 but no antigen (Figure 5-3, B). No 
difference in OT-2 cell proliferation was observed in mice fed an MCD diet treated with OVA 
liposomes with or without curcumin. Next, CTV+ OT-2 cells isolated from the liver and spleen 
were stimulated with PMA and ionomycin in the presence of brefeldin-A for 4 hours, and 
cytokine production was determined by intracellular staining. Proliferating OT-2 cells in liver 
and spleen produced cytokines including IFNγ, IL-4 and IL-10 (Figure 5-3, C-H). In 
summary, this data confirms that OVA antigen entrapped in liposomes induces adoptively 
transferred OT-2 cell proliferation in liver and spleen, and the presence of curcumin does 
not prevent either antigen presentation or cytokine production.  
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Figure 5-3: Liposomally delivered OVA antigen is presented to adoptively transferred 
OVA-specific CD4+ T-cells in the liver. A: Experiment design. B: 3x106 CTV-labelled 
CD4+ T cells from OT-2 mice cells were intravenously injected into mice fed MCD diet for 2 
weeks. Livers and spleens were harvested 4 days after transfer, immune cells isolated, 
stained and analysed by flow cytometry. Representative FACS plots depicting the gating 
used to identify adoptively transferred OT-2 cells in the liver and quantitation of percent of 
dividing OT-2 cells in the liver and spleen. C-E: Hepatic immune cells isolated from mice fed 
MCD diet treated with or without OVA-liposomes and transferred OT-2 cells were stimulated 
ex vivo with PMA/Ionomycin for 4 hours and intracellularly stained for cytokines IFNγ, IL-4 
and IL-10 in the liver (C-E) and spleen (F-H). Absolute count of cytokine positive cells was 
determined using Flow count beads. Data are ±SEM of mice analysed individually from one 
experiment. n=5/group.  
 
5.4.5: Curcumin-OVA liposomes and adoptively transferred OVA-specific Treg 
suppress MCD diet induced NASH.  
In previous chapters, I demonstrated that treatment with curcumin liposomes induces 
immunomodulation in hepatic DCs leading to reduced NASH. Having shown that adoptively 
transferred OT-2 cells proliferate in the liver when OVA liposomes are injected, I next 
examined whether OVA liposomes together with adoptive transfer of sort purified OT-2 
Tregs further reduced disease. Curcumin liposomes containing OVA were injected 
intravenously into mice fed an MCD diet for 2 weeks and the next day mice were injected 
intravenously with either 8x105 OT-2 Tregs (CD4+CD25high FACs sorted from spleens of 
OT-2 mice (83% Foxp3+)), 8x105 polyclonal Tregs (CD4+CD25high FACs sorted from 
spleens of C57BL/6J mice) or 8x106 OT-2 non-Tregs (CD4+CD25- FACs sorted from 
spleens of OT-2 mice (0.90% Foxp3+)). One week later, serum was collected and livers and 
spleens harvested (Figure 5-4, A). Compared to curcumin liposomes alone, addition of OT-
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2 Tregs reduced serum ALT by 3-fold and reduced neutrophil proportions (Figure 5-4, B and 
C). Similar to curcumin liposome treatment, MHC-II expression on macrophages and DCs 
was reduced compared with untreated mice (Figure 5-4, D). However, liver disease as 
assessed by NAS scores was similar in mice treated with curcumin liposomes irrespective 
of whether OT-2 Tregs were given (Figure 5-4, E). Importantly, ALT levels were not reduced 
in mice receiving curcumin liposomes and either polyclonal Tregs or OT-2 non-Tregs, 
demonstrating the requirement for antigen recognition by Tregs for the observed effects 
(Figure 5-4, B). Taken together, the data indicate that antigen-specific Tregs require cognate 
interaction with hepatic APCs to reduce MCD diet induced hepatocyte death. 
 
 
Figure 5-4: Treatment of mice with MCD diet induced NASH with curcumin-OVA 
liposomes and adoptively transferred OVA-specific Tregs reduces disease. A: 
Experiment design and representative FACS plot showing purity of purified OT-2 Tregs and 
OT-2 non-Tregs. B: Change in serum ALT levels in mice treated with curcumin-OVA 
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liposomes and either OVA-specific Tregs, polyclonal Treg or non-Treg T cells. (**p<0.01, 
***p<0.001 by one-way ANOVA followed by Bonferroni post hoc test). Note that the same 
data set from the untreated and curcumin liposomes only treated groups are shown in Figure 
3-6A because the figures represent pooled data. C: Proportion of neutrophils in CD45.2+ 
cells following adoptive transfer of antigen-specific Tregs with curcumin-OVA liposomes. D: 
MHC-II expression on myeloid cells following adoptive transfer of OVA-specific Tregs with 
curcumin-OVA liposomes. E: NAS score following adoptive transfer of OVA-specific Tregs 
with curcumin-OVA liposomes. Data are ±SEM of each mice analysed individually from two 
independent experiments. n=5/group. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by Mann 
Whitney t- test or one-way anova followed by Bonferroni post hoc test.  
 
 
5.5 Discussion: 
Tregs are a subset of T-helper cells known for their ability to suppress antigen presenting 
cells and conventional T cell proliferation and cytokine production. Tregs develop in the 
thymus or are induced in peripheral organs and are characterised by expression of 
transcription factor Foxp3 (349). Tregs confer tolerance to auto antigenic and allo-antigenic 
immune responses by dampening inflammatory activation of myeloid and lymphoid cells and 
have been shown to be protective in autoimmune and graft versus host disease (350). 
Humans with loss of function mutations in Foxp3 develop autoimmune diseases. In mice, 
Treg deficiency or dysfunction is associated with severe autoimmunity and scurfy phenotype 
(351) (352). The role of Tregs in metabolic disorders came to light with studies showing 
decreased Tregs in adipose tissue of mice with obesity and restoration of Tregs with 
antibody or IL-33 treatment reduced metabolic dysfunction ((107) (353). In contrast to 
adipose tissue, livers from NASH patients have increased expression of Foxp3 mRNA and 
protein, which correlated with disease severity (346). I have demonstrated that mice fed an 
MCD diet have increased Treg proportions in the liver compared to control diet fed mice. 
NASH livers also have increased CD8 T cells and IL-17 producing CD4+ T cells, which 
correlate with disease severity. These observations are consistent with reports showing 
Tregs function inadequately in many inflammatory conditions (354). Recently it has been 
shown that DCs are required for hepatic Treg homeostasis and the proportion of Tregs 
positively correlate with hepatic DCs. I have demonstrated that in the MCD liver disease 
model, hepatic Treg numbers are increased and correlate with increased hepatic DCs. 
Depletion of Tregs in Ldlr knockout mice increased circulatory cholesterol levels, 
atherosclerosis and liver inflammation (344). Tregs are known to reduce neutrophil 
recruitment by downregulating expression of chemokine ligands CXCL1 and CXCL2 (355). 
Moreover, CCR4 expressing Tregs reduce neutrophil infiltration (356). I have used a well-
characterised system to examine whether depletion of Tregs promoted disease in DEREG 
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mice fed an MCD diet. Although we could only detect minor depletion of helios- Tregs, typical 
of induced Tregs, we observed worsening of liver disease as assessed by increased NAS 
score, serum ALT and proportions of monocytes and neutrophils in the liver. I hypothesize 
that during liver disease Tregs may proliferate at an increased rate, accounting for the lack 
of Treg depletion and that induced Tregs (helios-) may be more susceptible to DT mediated 
depletion, either through increased FoxP3 or reduced proliferative potential. Future studies, 
including staining for proliferative markers (Ki67) or DNA-labeling (BRdU) with or without DT 
depletion, in control and MCD diet fed mice would aid in answering this question. Induced 
Tregs may be an important cell subset that suppresses liver disease, as they may be 
induced by dietary or microbial antigens derived from the gut and be processed by liver 
antigen presenting cells. During inflammatory liver disease, these Tregs may recognise 
antigens and suppress inflammation by direct contact or through secretion of anti-
inflammatory cytokines. 
DT depletion of helios-Tregs worsened MCD diet induced liver disease and induced 
neutrophil expansion within the liver. Interestingly, immunomodulation of hepatic myeloid 
cells with curcumin liposomes prevented Treg depletion induced neutrophilia. Thus myeloid 
cell activation is key to recruitment of neutrophils to the liver in MCD diet induced liver 
disease. Importantly, absence of Tregs reversed the therapeutic effect of curcumin 
liposomes, thus hepatic Tregs are required for the immunomodulatory function of curcumin 
liposomes. This would be consistent with liposomes delivering curcumin to hepatic DCs, 
inducing Tregs to tissue, microbial or dietary antigens, and expanding the self-reactive 
suppressive Treg pool. Future work to address these questions would include isolating 
hepatic Tregs from mice with MCD diet induced liver disease, treated with or without 
curcumin liposomes, and using TCR sequencing to determine the oligo-clonality of TCRs.     
Importantly, small numbers of adoptively transferred Tregs, reactive to antigen in the liver, 
can reduce MCD diet induced liver disease. Tregs can be expanded in vivo by targeting 
receptors highly expressed on Tregs, for example CD25 (IL-2 receptor), CD28, CD45RB, 
(357-359). However, these approaches may also expand effector T cells leading to a 
cytokine storm as observed with low-dose of anti-CD28 treatment in humans (360) or 
expansion of other leukocyte subsets such as NK cells (361). Adoptive transfer of polyclonal 
or antigen-specific Tregs is an attractive alternative strategy to increase Treg numbers in 
the liver (362). Transfer of polyclonal Tregs to mice fed a high fat diet can reduce LPS 
induced liver inflammation and insulin resistance in obese mice (118) (343). Although 
transfer of polyclonal Tregs has been shown to suppress inflammation in mice and humans, 
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antigen specific Treg therapy may be more sensitive in immunosuppression (363). However, 
the challenge is to identify antigens within the liver that can be processed by liver APCs and 
subsequently recognised by the TCR of Tregs. Similar to autoimmune diseases, patients 
with metabolic disorders also develop autoantibodies, for example patients with type 2 
diabetes had high titres of autoantibodies to GFAP, a hepatic stellate cell derived antigen 
(108). This indicates existing adaptive immune response to liver antigens, which may 
augment liver damage in obese patients. Interestingly, adoptive transfer of in vitro generated 
type-1 regulatory T cells specific for the common food derived antigen, OVA, to patients with 
refractory Crohn’s disease decreased Crohn’s disease activity index, indicating that it is 
possible to use Tregs specific for non-immunogenic antigens like OVA in diseases where 
tissue antigens are unknown (364). As a proof-of-principle I have shown that a neo antigen 
OVA can target hepatic APCs when complexed in liposomes and induce OVA-specific Treg 
proliferation within the liver.  
In the healthy liver, tolerance mechanisms are active to prevent immune responses to 
dietary and microbial antigens. In liver diseases, such as NASH, there is an incomplete 
understanding of whether this tolerance mechanism is less efficient. In mice this appears to 
be true, with impaired antigen-specific tolerance, increased hepatic inflammation and liver 
dysfunction. However, tolerance mechanisms are active but may be insufficient to reverse 
disease (69). In support of this idea, I have shown that presentation of OVA in the liver of 
mice with MCD diet induced liver disease induces proliferation of OT-2 cells which can be 
restimulated to produce increased IL-4 and IL-10 compared with splenic OT-2 that mainly 
produce IFNγ. Future work could compare OT-2 proliferation, cytokine production and Treg 
induction from healthy mice and those with liver disease to determine if tolerance is less 
efficient. Either way, delivery of antigen in the context of liver disease can expand OT-2 
Tregs which exert suppression, leading to improvements in liver disease.  
My findings together with previous reports show that proinflammatory activation of myeloid 
cells is heightened in NASH. Anti-inflammatory drug loaded liposome formulations can 
target the hepatic inflammatory myeloid cells and reduce hepatic inflammation and reduce 
diet induced liver disease. Inclusion of Tregs with liver specificity profoundly reduced MCD 
diet induced NASH compared to curcumin liposome therapy alone. Overall, the findings 
presented in this chapter underscore the activation of adaptive immune responses in 
addition to innate immunity to progress NASH.  
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5.6 Future directions: 
MCD diet induced NASH is associated with increased hepatic Tregs. Treg depletion and 
curcumin liposomes therapy indicated that expanded Tregs are associated with neutrophilia 
and liver fibrosis. Moreover, combination therapy with curcumin–OVA liposomes and OVA-
specific Tregs further reduced neutrophilia. Future studies should investigate the interplay 
between Tregs, myeloid cells and neutrophils in NASH pathogenesis.  
As a proof-of-principle study to show that antigen-specific Tregs have therapeutic value to 
reduce metabolic diseases, in addition to autoimmune diseases, we have targeted a neo 
antigen, OVA, to the liver and treated with OVA-specific Tregs, which reduced MCD diet 
induced hepatocyte damage. Adaptive immune response to liver antigens have been 
reported, which indicate presence of antigen specific Tregs in the NASH liver (108) (109). 
Therefore, future investigations would characterize liver antigen specific Tregs and their 
potential to target liver without prior antigen targeting. 
The data represented in Figure 5-2 are preliminary and missing a control group treated with 
DT. Future experiments could include this group to determine DT liver toxicity. 
Figure 5-4 is missing a control group treated with empty liposomes. Therefore, future 
experiments could include a group treated with empty liposomes. 
5.7 Limitations of the study described in the chapter 5: 
A major limitation of the current study is that using markers CD4 and CD25 to purify Tregs, 
although 80% purity of Foxp3+ OT-2 Tregs was achieved. OT-2 mice expressing fluorescent 
proteins under Foxp3 promoter would be useful in purifying OVA-specific Tregs with highest 
purity for Treg adoptive transfer experiments.  
I found incomplete depletion of Tregs in the liver of MCD diet fed DEREG mice treated with 
DT. It has been shown previously that DT treatment, although efficient in depleting DTR-
transgenic Tregs, a subset of non-transgenic (DT-insensitive) Tregs rapidly replaces the 
depleted Tregs (365). Whether similar expansion of non-transgenic Tregs accounts for 
increased Treg proportions in MCD diet fed DEREG mice is unknown and could be 
evaluated in future experiments. 
The toxic effect of DT on liver from wild type and DEREG mice could also be evaluated 
together with the requirement of curcumin in the OVA liposomes in mediating the therapeutic 
effect of OT-2 Treg.  
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Chapter-6: Thesis discussion 
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Obesity is an ever growing epidemic in developed and developing countries affecting both 
children and adolescents. Obesity associated complications such as type 2 diabetes 
(T2DM), nonalcoholic steatohepatitis (NASH) and cardiovascular diseases are major 
burdens in society, reducing both life expectancy and quality. Recent epidemiological 
studies revealed that NASH is the second major cause for liver transplantations (1), a 
consequence of the lack of specific treatments to prevent or delay NASH progression to 
end-stage liver disease. Existing therapeutic options target risk factors of NASH but do not 
prevent disease, thus there is a need to develop new therapeutics to treat NASH.  
Several decades of research have shown that abnormalities in glucose and lipid metabolism 
due to either genetic mutations or over nutrition causes excess fat accumulation in the 
adipose tissue and liver, which results in tissue damage and inflammation. Pharmacological 
interventions with anti-inflammatory and/or antioxidants have been shown to reduce features 
of NASH in clinical trials (2-7), however these treatments have unwanted side effects and 
are given systemically, inducing whole body immunosuppression (9). Elegant studies in 
preclinical models of obesity determined a key role of myeloid cell mediated inflammation in 
obesity associated metabolic dysfunction in adipose tissue and liver (10-14). Increased 
myeloid cell recruitment and activity in affected organs augmented inflammation and 
depletion of myeloid cells or myeloid specific deficiency of key inflammatory regulators such 
as NF-κB and JNK was found to ameliorate obesity induced T2DM and NASH (15-17). 
These studies indicate that targeting inflammatory myeloid cells with anti-inflammatory 
compounds may reduce myeloid cell activation, thereby improving clinical features of NASH 
whilst avoiding whole body immunosuppression.  
My thesis evaluated cellular and molecular parameters of disease in mouse models of 
NASH. I tested the capability of delivering anti-inflammatory compounds complexed with 
liposomes to myeloid cells within the liver, and evaluated the outcomes of this treatment to 
suppress liver inflammation and reduce features of NASH in preclinical models. 
I have determined that mice fed MCD and HFHS diets develop NASH as measured by 
steatosis and hepatocyte damage, cellular infiltration and inflammation and liver fibrosis. By 
comparing mRNA expression between normal and NASH livers a number of mRNAs 
encoding proteins in signaling pathways were found to be dysregulated in diet-induced 
steatohepatitis. I also found that NASH livers from HFHS diet fed mice are characterised by 
reduced expression of mRNA encoding proteins that regulate hepatic β-oxidation, which 
supports previous reports of increased oxidative stress during NASH (18). Impaired hepatic 
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β-oxidation reduces secretion of synthesized lipid, promoting intracellular deposition of lipid, 
leading to enlargement of lipid vesicles and hepatocyte ballooning. My data indicate that 
compared with healthy liver, HFHS-induced NASH promoted upregulation of mRNAs 
encoding proteins that promote intracellular lipid deposition, for example FSP27/CIDEC, 
whose expression is correlated with increased hepatic steatosis and cell death in humans 
and mice with alcoholic steatohepatitis (19). I found upregulation of mRNAs encoding 
proteins mediating inflammatory signaling such as Jun, Fos and NF-κB in HFHS-NASH. 
Steatosis alone is insufficient in aggravating the disease to liver failure. However, activation 
and recruitment of immune cells associated with steatosis promotes liver disease 
progression. This process is mediated by chemokines released by stressed hepatocytes 
and immune cells surrounding steatotic hepatocytes, forming inflammatory foci, a hallmark 
of diet-induced steatohepatitis (20), (21). Importantly, I found that HFHS-induced NASH was 
associated with increased chemokine (CCL2, CCL3, CCL4, CCL5, CCL22, CX3CL1, 
CXCL10, CXCL16) mRNAs in the liver, which previously have been shown to be important 
in recruitment of myeloid and lymphoid cells. This correlated with increased monocytes in 
HFHS-NASH livers, and monocytes, macrophages, DCs, T cells and NK cells in the livers 
of mice with MCD-NASH compared with healthy livers.  
Among the immune cells, Ly6C expressing monocytes have previously been shown to be 
required for steatohepatitis, and mice deficient in monocyte chemoattractant CCL2 or 
treated with anti-CCL2 antibodies have delayed onset of NASH (22-25). In addition to 
activated Kupffer cells, proinflammatory macrophages converted from recruited monocytes 
express death ligands such as Fas ligand and TNFα, and thus promote hepatocyte death 
during chronic liver disease including NASH (366). Hepatic expression of Fas is correlated 
with NASH progression in humans (61). During parasitic infection, CCR2+ monocytes 
differentiated into F4/80+ DCs producing TNFα and iNOS in the liver and this differentiation 
was dependent on IFNγ signaling (27). I found that Kupffer cells from MCD diet induced 
NASH produce significantly higher IFNγ than similar cells isolated from healthy livers and 
that HFHS-NASH is associated with increased mRNA expression of RIG1/DDX58, an 
essential mediator of type-I interferon signaling. Interestingly, in livers of mice with HFHS-
NASH, IRF8, a key transcription factor for interferon regulatory factors, and associated 
mRNAs encoding proteins regulating IRF8 were increased. IRF8 is highly expressed in 
myeloid cells and IRF8 expression in myeloid precursors has been shown to be essential 
for their development (367, 368) (28). Recent studies identified an important role for IRF8 in 
the development of CD103+ cross presenting DCs as mice deficient in IRF8 specifically lack 
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CD103 expressing CD11b-CD8+ DCs in the liver (28). Previously it was shown that obesity-
induced hepatic inflammation is associated with increased numbers of DCs expressing 
F4/80, and that these DCs contribute to disease (29). I found that in HFHS-NASH, 
CD103+CD11b- DCs expressed higher levels of F4/80 compared to CD103-CD11b+ DCs 
and these F4/80+ DCs were also increased in MCD diet induced NASH. I hypothesise that 
Kupffer cell derived IFNγ may activate IRF8 in hepatic CD103+ DC precursors and promote 
their development and expansion during NASH. Future studies investigating the NASH 
development and progression in IRF8 knockout mice would elucidate the functional role of 
IRF8-dependent hepatic DCs in NASH. 
Previously, F4/80+ hepatic DCs in steatotic livers were shown to be proinflammatory with 
increased expression of NF-κB, TNFα and iNOS (29). F4/80+ DCs can be classified as 
classically activated DCs as they produce proinflammatory cytokines following stimulation 
with LPS (29). In general, activation of DCs with PAMPs, such as LPS through pathogen 
recognition receptors, increases mRNA expression related to inflammatory signaling and 
energy production. To meet the energy demands involved in this activation process, DCs 
undergo metabolic reprogramming (30). Treatment of DCs with LPS and IFNγ induces iNOS 
expression and nitric oxide to inhibit mitochondrial respiration through nitrosylation of 
proteins of the electron transport chain (31). LPS also reduces AMP-activated protein kinase 
(AMPK) activation, which promotes β-oxidation by increasing expression of PPAR-γ 
coactivator-1β (PGC-1β) (32). Macrophages from AMPK knockout mice have increased NF-
κB activation and polarize towards proinflammatory phenotype with increased IFNγ (369). 
Inhibition of mitochondrial respiration though nitric oxide reduces ATP production through 
OXPHOS, but increases ATP via the pentose phosphate pathway, known as the Warburg 
effect (33). Although OXPHOS is an efficient way of generating ATP, classically activated 
DCs and macrophages depend on glycolytic ATP production to meet their energy 
requirements. As a result of increased glycolysis and impaired mitochondrial β-oxidation 
intracellular lipid deposits increase, a characteristic of inflammatory DCs identified in mouse 
and human NASH (34). Inflammatory DCs isolated from livers of mice with T2D have 
previously been shown to promote glucose intolerance when adoptively transferred to non-
obese mice (29). Importantly, my data shows that compared to F4/80- hepatic DCs, F4/80+ 
hepatic DCs express increased mRNAs encoding proteins mediating fatty acid synthesis, 
catabolism and transport and these DCs are the main cell type taking up liposomes. 
F4/80+ DCs may play an important role in fibrosis as proinflammatory DCs and 
macrophages exacerbates steatohepatitis into liver fibrosis (35). DCs from fibrotic livers 
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have increased TNFα and induce NK cell activation and T cell proliferation. Blocking of TNFα 
with monoclonal antibodies prevented DC induced T cell and NK cell activation and cytokine 
production in vitro, and treatment with the anti-TNFα antibody, infliximab, reduced CCL4 
induced hepatic fibrosis (36) (37).  Myeloid cell derived proinflammatory cytokines such as 
TNFα, IL-1β, IL-6 and TGF-β promote hepatic steatosis, hepatocyte death and activate 
hepatic stellate cells, the main cell type producing of collagen (38). HFHS-NASH increased 
mRNAs encoding collagen and proteins within the pro-fibrogenic signaling cascades (Jun, 
Fos, NF-κB) and had increased collagen deposition as assessed by trichrome staining. 
Tregs modulate inflammation in many diseases, however the role of Tregs in the 
development of liver fibrosis is unknown. I have shown that Treg depletion accelerated liver 
fibrosis in mice fed an MCD diet, indicating a protective role. Along with innate immune cells, 
T cells also accelerate liver disease through production of proinflammatory cytokines such 
as IL-17 (39, 40), and I found increased IL-17+ T cells in NASH livers compared to normal 
livers.  
While classically activated or M1 DC/macrophages are pathogenic in NASH, alternatively 
activated or M2 DC/macrophages are protective and secrete proteases that cleave collagen 
and reduce liver fibrosis (26). These restorative M2 macrophages derive from CCR2+ 
monocytes recruited to the liver (26). Phenotypically M2 macrophages have increased 
surface expression of mannose receptors, for example CD206, and can suppress 
inflammation by secreting the anti-inflammatory cytokine IL-10 (42-44). Furthermore, IL-4 
stimulated M2 macrophages express increased PGC-1β, which activates PPAR-γ/PPAR-δ 
dependent anti-inflammatory response, in addition to promoting mitochondrial biogenesis 
and β-oxidation (45-47). PPAR-γ and PPAR-δ signaling induces M2 activation of Kupffer 
cells and ameliorates insulin resistance in obese mice (45, 48). Pharmacological activation 
of PPAR-γ with pioglitazones has been shown to promote M2 activation in adipose tissue 
macrophages, which reduced obesity-induced insulin resistance (45). In contrast to 
classical/M1 activation, alternative/M2 activation of myeloid cells is associated with 
stimulation of the electron transport chain and OXPHOS, and diminished NF-κB activation 
(30). Based on the above-mentioned findings and the literature it could be speculated that 
inducing alternative activation in myeloid cells of liver and adipose tissue could reduce 
metabolic abnormalities in obesity (49).  
Liposomes are well-characterised nanoparticles with low cytotoxic properties and have the 
ability to target and deliver drugs to myeloid cells, as mice treated with liposomes loaded 
with cytotoxic drug, clodronate, deplete myeloid cells from majority of organs including the 
117 
 
liver (23, 50). Previously, delivery of curcumin in liposomal formulation to hepatic and 
adipose tissue F4/80+ DCs reduced NF-κB and induced alternative activation with the 
capacity to produce the anti-inflammatory cytokine, IL-4, and reduced hepatic and peripheral 
insulin resistance (29). Moreover, curcumin liposomes also reduced oxidative stress in 
targeted macrophages, indicating that curcumin can alter cell metabolism and reduce 
mitochondrial dysfunction. My data support these observation and identify molecular 
mechanisms that underlie an alternative activation phenotype. Importantly, I found that 
curcumin targeted DCs have decreased expression of mRNAs encoding JNK-MAPK-NF-κB 
proteins, induced mRNAs of genes linked to mitochondrial activity, and increased mRNA 
expression of PPAR-γ and MMP13. Furthermore, targeting curcumin to liver DCs induced 
M2 activation with increased MRC1, and increased IL-4 and IL-10. Therefore, my findings 
demonstrate a clinically translatable approach whereby pathogenic proinflammatory myeloid 
cells can be targeted with NF-κB inhibitor, to dampen inflammatory activation and promote 
alternative phenotype correlating with reduced insulin resistance and reduced liver disease. 
These findings are in line with earlier reports that showed the role of activation of IKKβ and 
NF-κB in hepatic myeloid cells in promoting insulin resistance in obese mice (16). 
My data show that curcumin targeted DCs produced increased IL-10 and also upregulate 
mRNA of the receptor for IL-10, IL-10rb, which is required for autocrine dependent secretion 
of IL-10 and alternative macrophage function (51). It has been demonstrated that M2 Kupffer 
cell derived IL-10 specifically induces apoptosis of M1 Kupffer cells (52). Furthermore, Wan 
et al., have shown that increased M2 polarization of Kupffer cells correlates with reduced 
M1 macrophages in liver, diminished hepatic steatosis and hepatocyte death (52). Similarly, 
curcumin liposomes treatment reduced MCD diet induced recruitment of inflammatory DCs, 
which is associated with lower serum ALT levels and reduced NAS score.  
Previous studies, and my observations with curcumin liposomes, indicate that inhibition of 
NF-κB activation in hepatic myeloid cells reduces metabolic abnormalities. Notably, I further 
validated this strategy with another NF-κB inhibitor, vitamin D3 entrapped liposomes, in mice 
with HFHS-NASH. Vitamin D3 is an active component of vitamin D and known for its 
tolerogenic properties. In vitro treatment of vitamin D3 in human and mouse monocytes 
while maturing to DCs induced an immature phenotype with capacity to induce Foxp3 
expression in effector T cells (53). Vitamin D3 induced tolerogenic DCs have been shown 
to dampen inflammation in chronic inflammatory diseases like arthritis and type 1 diabetes 
(54) (55). Treatment of HFHS-NASH with vitamin D3 liposomes reduced steatosis, cell 
death, immune cell recruitment and inflammatory pathway activation, and thereby prevented 
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HFHS diet induced liver fibrosis development. VitaminD3 had the benefit over curcumin of 
also reducing fasting blood glucose and insulin resistance and reducing adipocyte size.  
Immunomodulation of myeloid cells is also mediated by tissue specific Tregs either through 
direct interaction or by secretion of IL-10 and IL-35 (58-60). Tregs are beneficial in limiting 
obesity-induced inflammation, and expansion of adipose tissue Tregs using agonists of 
PPAR-γ and IL-33 receptor promotes insulin sensitivity in obese mice (61) (62). Adoptively 
transferred polyclonal Tregs have been shown to reduce hepatic NF-κB activation, TNFα 
secretion and decrease hepatocyte apoptosis (63). Potential auto-antigens have been 
identified in autoimmune hepatitis including liver-expressed cytochrome P450 2D6 
(CYP2D6) and formiminotransferase-cyclodeaminase (FTCD). Since the MCD model 
induces extensive hepatocyte death as measured by serum ALT, these and other self-
antigens would be processed by DCs. Since DCs in the liver are tolerogenic, these antigens 
would be processed and presented to relevant Tregs within the liver and may expand their 
numbers and or function. To test this hypothesis I attempted to deplete Tregs in DEREG 
mice during MCD diet induced liver disease and found that helios-Tregs (induced Tregs) 
were reduced, correlated with increased hepatocyte death and increased neutrophils and 
increased fibrosis. I next examined whether exacerbation of disease by depletion of Tregs 
could be reversed by treatment with liposomal curcumin. To test this hypothesis, Tregs were 
depleted at the time of injection of liposomal curcumin. I found that liposomal curcumin had 
no effect on hepatocyte death but was able to reduce neutrophil proportions and reduce liver 
disease NAS score. This data identifies a role for Tregs in limiting neutrophil numbers in 
NASH liver and associated protection of hepatocytes from cell death, thereby limiting 
fibrosis.  
Although adoptive therapy could be used to expand Tregs there is a potential for whole body 
immunosuppression. Antigen specific Tregs, with specificity for the liver, may be more 
effective than polyclonal Tregs in suppressing liver disease (64). In the absence of defined 
autoantigens in NASH, I examined the capacity of ovalbumin-specific CD4 Tregs to 
suppress liver disease. In order to deliver ovalbumin to the liver, liposomal curcumin were 
complexed with ovalbumin and injected intravenously, followed by adoptive transfer of OT-
2 Tregs. I found that this protocol, compared with liposomal curcumin injected alone, 
reduced hepatocyte death as measured by serum ALT and significantly reduced the 
proportion of neutrophils within the liver.  
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Figure 6-1: A schematic representation showing immunomodulatory liposomes and 
antigen-specific Treg therapy to treat NASH. NASH is characterised by dysregulation in 
β-oxidation and lipid homeostasis, and associated lipid accumulation within hepatocytes, 
leading to hepatocyte death and inflammation. NASH is characterised by DC with increased 
proinflammatory phenotype with increased JNK-MAPK mRNA. Targeting DCs with 
immunomodulatory liposomes induces an alternative/tolerogenic phenotype and is 
associated with reduced disease. Improved therapeutic efficacy can be achieved by 
including neo-antigen and adoptively transferring small numbers of Tregs specific to this 
neo-antigen. 
 
In summary, I have demonstrated that hepatic myeloid cells in NASH are proinflammatory 
and are efficiently targeted with immunomodulatory liposomes, which induce an 
alternative/tolerogenic phenotype and prevent liver disease progression. I have 
demonstrated that neo-antigens can be delivered to the liver and induce adoptively 
transferred Tregs to suppress liver damage. These findings demonstrate a novel approach 
to treating NASH, which is important in the light of current growing epidemic of chronic liver 
diseases in patients with obesity, T2DM and metabolic syndrome. 
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8. Appendices 
 
DiI-Pos DC Sample ID
Number of 
cells
RNA 
Integrity 
Score 
(RIN)
RNA Stock 
Conc. 
(pg/ul)
Total RNA 
(pg)
ds-cDNA 
Stock 
Conc. 
(ng/ul)
ds-cDNA 
Sample 
Volume 
(ul)
Total ds-
cDNA (ng)
Blank lipo 2 4010 7.5 85 765 0.8 15 10.3
3 5530 8.5 39 351 0.6 15 7.6
5 8000 8.3 99 891 1.5 15 18.9
Curcumin 
lipo 7 5190 7.3 19 171 0.4 15 5.8
8 5300 7.4 37 333 0.7 15 9.5
10 12290 8.3 151 1359 2.4 15 30.7
DiI-Neg DC Sample ID
Number of 
cells
RNA 
Integrity 
Score 
(RIN)
RNA Stock 
Conc. 
(pg/ul)
Total RNA 
(pg)
ds-cDNA 
Stock 
Conc. 
(ng/ul)
ds-cDNA 
Sample 
Volume 
(ul)
Total ds-
cDNA (ng)
Blank lipo 2 3870 9.2 75 675 1.3 15 16.4
3 4380 8.4 109 981 1.2 15 15.7
5 6020 8.6 89 801 1 15 12.9
Curcumin 
lipo 6 3650 8.4 85 765 1 15 12.5
7 4170 8.6 51 459 1.3 15 16.5
10 10760 9.3 328 2952 4.9 15 63.1
Appendix table 3.1: Quality of RNA isolated from liposome targeted and non-targeted hepatic DCs
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Appendix table 3.2: Differentially expressed mRNAs in ELPDC compared to ELNDC
Gene Log2FC Gene Log2FC Gene Log2FC Gene Log2FC
Ighv11-2 5.01 Igkj4 1.67 Gm29439 1.45 Elmod3 1.32
Krt222 3.38 Cd55 1.66 Rsbn1 1.45 Siglecg 1.32
Adm 3.36 Kcna2 1.65 Fcmr 1.44 Cd22 1.32
Igkv14-126 3.34 Ephx1 1.64 Igkv8-27 1.44 Mccc2 1.32
Il18bp 3.27 Mertk 1.64 Ralgps2 1.44 A130048G24Rik 1.32
Fras1 2.82 P2ry12 1.64 Fam169b 1.43 Iglv1 1.31
Vsig4 2.66 Cpm 1.63 Il5ra 1.43 Tle6 1.31
Stac2 2.61 RP23-272P19 1.62 Cxcr5 1.43 RP24-277J22 1.31
Clec4f 2.60 Iglv3 1.62 Marveld2 1.42 Snord35b 1.30
Slc40a1 2.38 Abcc3 1.62 Cd207 1.42 Rccd1 1.30
1810046K07Rik 2.31 Iglj3 1.62 Iglj3p 1.42 Ppp1r16b 1.29
Mmp12 2.26 Ighv1-18 1.61 RP23-247I11 1.41 Srpk3 1.29
Clec1b 2.21 RP23-192O12 1.61 Gm19345 1.41 Plod1 1.29
Cd5l 2.15 Slc37a2 1.61 CAAA01098150 1.41 Tmem163 1.28
Vcam1 2.13 Hspa1l 1.61 Iglc3 1.41 Acp5 1.28
Dmpk 2.05 Blnk 1.60 Igkc 1.41 Dtx1 1.27
Fcnaos 2.04 Ighm 1.59 Cd79a 1.40 Kcnk5 1.27
Gm14023 2.00 Bcar3 1.59 Igkv16-104 1.40 Inadl 1.27
Gm10501 2.00 Sh3bp5 1.58 Mtss1 1.40 Abca1 1.27
Apoc1 1.99 Igkv17-127 1.58 Fabp7 1.39 Ccr7 1.27
Scn4a 1.97 Bank1 1.58 B3gnt5 1.39 Arhgef12 1.27
Gdf15 1.95 Ccdc176 1.58 Gm20506 1.39 Aff3 1.26
1110046J04Rik 1.95 Igkj2 1.57 Igkv6-20 1.39 2610008E11Rik 1.26
Igf1 1.93 Ighv7-3 1.57 Klhl14 1.39 R74862 1.26
Ighv1-72 1.90 Igkv8-19 1.57 Igkv17-121 1.39 2310057M21Rik 1.26
Ighv10-1 1.90 Spib 1.56 Cd79b 1.38 Cd2 1.25
Iglv2 1.90 Pgap1 1.56 Ighd 1.38 Ly6a 1.24
Igkv6-13 1.88 Rasgrp3 1.55 Pou2af1 1.38 RP23-454A14 1.24
Pik3c2b 1.88 Igkj5 1.55 Mterf1a 1.38 Nf1 1.24
Hpx 1.87 Pou6f1 1.54 Iglc2 1.38 Akap12 1.24
RP23-435I4 1.86 Igkj3 1.53 Mast4 1.37 1810021B22Rik 1.24
Mcoln2 1.83 Mapk12 1.53 Rap1gap 1.37 Ophn1 1.24
Fcrl5 1.83 Mapk11 1.52 Cnn3 1.37 Dennd6b 1.24
Fam129c 1.82 Igkv14-100 1.51 Snn 1.37 Cd200 1.23
Ighv9-3 1.82 Adgb 1.51 Ighv5-17 1.36 Lgals4 1.23
Cmah 1.81 Gdpd1 1.51 Sema4b 1.36 Serpinb1a 1.23
RP24-245I16 1.81 Ms4a1 1.51 Txnrd3 1.35 1700021K19Rik 1.23
Igkv3-7 1.79 Blk 1.51 Cd1d1 1.35 Fcer2a 1.22
Scd1 1.77 Ly6d 1.51 Chst3 1.35 Smagp 1.22
Mzb1 1.77 Cd19 1.50 4930426D05Rik 1.35 Itsn1 1.22
Phka1 1.76 Ffar1 1.50 Igkv1-110 1.35 Gm4951 1.22
Aldh6a1 1.76 Gm16083 1.49 Gm15675 1.35 C1qa 1.21
Igkv8-21 1.75 S1pr1 1.49 2700038G22Rik 1.34 Ighv1-64 1.21
Fcrla 1.74 Tmem26 1.49 Uox 1.34 E330020D12Rik 1.21
Ighv3-6 1.72 Ighv6-3 1.48 Cacna1i 1.34 Pltp 1.21
Cracr2b 1.71 Ighv5-4 1.48 Cd81 1.33 Pou2f1 1.21
Myo1e 1.70 Iglc1 1.48 Mir150 1.33 Cacna1e 1.20
Igkv1-117 1.68 Cd38 1.47 Igkj1 1.33 Ighv1-5 1.20
Igkv8-28 1.68 Ebf1 1.47 Adamts6 1.33 Zfp867 1.20
Cd300e 1.68 Fcrl1 1.46 Ighv8-12 1.33 Igkv6-17 1.20
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Gene Log2FC Gene Log2FC Gene Log2FC Gene Log2FC
Il12a 1.20 Mtrr 1.09 Tspan32 0.97 Ogfod2 0.85
Whrn 1.19 Tmem143 1.08 Scimp 0.97 Ltb 0.85
Trmu 1.19 Nr1h3 1.08 Gimap6 0.96 Traf3ip3 0.85
Igkv8-24 1.19 Hdac9 1.07 Slc29a1 0.96 Icam2 0.85
Pecam1 1.19 Snx30 1.07 Carns1 0.96 Maml2 0.85
Cd36 1.18 Bend5 1.07 Cdc25b 0.96 Pafah1b3 0.85
Gm12158 1.18 Clcf1 1.07 Polk 0.96 Mtfr1 0.85
H2-Ob 1.18 Slc7a8 1.07 Prr5 0.95 Card6 0.84
Zfp60 1.18 Zfp97 1.06 Ets1 0.95 Macf1 0.84
Lace1 1.18 2310061I04Rik 1.06 Gimap8 0.95 Rgs1 0.84
Chchd10 1.18 Hdac10 1.05 Mavs 0.95 Dnase2a 0.84
Spef1 1.17 Sit1 1.05 Arid4b 0.95 Prkd2 0.84
Fam57a 1.17 Cd37 1.05 C730034F03Rik 0.95 Pxk 0.84
Grap 1.16 mt-Rnr1 1.05 Akr1b10 0.94 Malat1 0.84
Itga9 1.16 Phtf1os 1.05 Tmcc3 0.94 Cd274 0.84
Snx29 1.16 Arhgap12 1.04 Dag1 0.94 Gm15135 0.83
Ptgs1 1.16 H2-DMb2 1.04 Zcchc11 0.94 Ash1l 0.83
Trim7 1.16 Tnfrsf26 1.04 Rabep2 0.93 mt-Nd4 0.83
C1qb 1.16 Gm3934 1.04 Slc28a2 0.93 Adrb2 0.83
Gpnmb 1.16 Slamf6 1.04 Rrm2b 0.93 mt-Rnr2 0.83
Ceacam16 1.16 Trp53i11 1.04 Akap11 0.93 Unc13a 0.83
Gm8369 1.16 N4bp3 1.04 Tlr1 0.93 Zfp90 0.82
Tnfrsf13c 1.15 Txnrd2 1.04 Fbxw17 0.92 Mar-05 0.82
Tctn1 1.15 Rtel1 1.03 Lnx2 0.92 Pkig 0.82
Atp5s 1.15 Pikfyve 1.03 Abcg3 0.91 Haao 0.82
Hvcn1 1.15 Arap2 1.03 St6gal1 0.91 Slc50a1 0.82
P2ry13 1.14 Rasgef1b 1.02 Tlr12 0.91 Stoml1 0.81
Spic 1.14 Ficd 1.02 Arhgef18 0.91 Grpel2 0.81
mt-Ty 1.14 Swap70 1.02 A630001G21Rik 0.91 Nfatc3 0.81
Snx8 1.14 Zfp26 1.01 Gbp8 0.90 Slc9a7 0.81
Cr2 1.14 Gga2 1.01 Ablim1 0.90 Trim39 0.81
Pax5 1.14 Pvt1 1.01 Gimap1 0.90 Pnisr 0.81
Scamp5 1.14 Zfp839 1.01 4930523C07Rik 0.90 Lmbrd1 0.81
Igkv1-135 1.14 Fchsd2 1.01 Gm37376 0.89 Dicer1 0.81
1110059E24Rik 1.14 Med13 1.01 Rapgef6 0.89 Tnrc6a 0.81
C1qc 1.13 Helz2 1.00 Rasgrp1 0.89 mt-Nd2 0.81
Cd69 1.13 Fam3c 1.00 Stab1 0.88 Recql5 0.80
Blvrb 1.13 Adck3 1.00 Pcmtd1 0.88 Birc2 0.80
Scai 1.12 Lgmn 1.00 Atg16l2 0.87 Timm21 0.80
Gm16170 1.12 Cfp 0.99 Zfp260 0.87 N4bp2 0.80
Pld3 1.12 Fam214a 0.99 Zhx2 0.87 Avpr2 0.80
Mast1 1.12 Phf1 0.99 Eaf1 0.87 Abcg1 0.80
Ahnak2 1.11 Foxp1 0.98 Gm17080 0.87 Pla2g4a 0.80
Scml4 1.11 Rbm48 0.98 Tcp11l2 0.87 Arhgap4 0.80
Nxpe3 1.11 Gm15674 0.98 Tpcn2 0.87 Ppcdc 0.80
Lpl 1.10 Acbd4 0.97 Ccdc186 0.86 Sesn1 0.80
Mapkbp1 1.10 Apoe 0.97 Phgdh 0.86 Myo1c 0.79
Iqsec1 1.10 Ctso 0.97 Tmod3 0.86 Pisd-ps1 0.79
Igkv6-23 1.09 Mapk8 0.97 Cbx7 0.86 Mga 0.79
Zfp809 1.09 Ppfibp2 0.97 Mgat4a 0.86 Slc25a46 0.79
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Pear1 0.79 Fam179b 0.69 Ppp4r1 0.57 Cdc37 -0.36
Ctsb 0.79 Tnfrsf13b 0.69 Phip 0.57 Arpc2 -0.36
Mif4gd 0.79 mt-Nd5 0.69 4833420G17Rik 0.57 Hdgfrp3 -0.37
4930538E20Rik 0.78 Cd164 0.69 Rock2 0.57 Pld4 -0.37
Pml 0.78 PISD 0.69 Crbn 0.57 Slc25a5 -0.38
Gm11724 0.78 Man1a 0.69 Cyth1 0.57 Elovl5 -0.38
Fli1 0.78 Sbk1 0.69 Trmt2a 0.57 Ppia -0.38
Zfp292 0.78 Lrrc57 0.68 Polr3d 0.57 Nrros -0.39
Ano6 0.78 Mgrn1 0.68 Ilvbl 0.56 Pfn1 -0.40
Akt3 0.77 Atp2a3 0.68 Smap2 0.56 Ranbp1 -0.40
mt-Cytb 0.77 Dpp7 0.68 Ccser2 0.56 Frmd8 -0.40
Cog6 0.76 Fam65b 0.67 Tcf3 0.56 Hsp90b1 -0.41
Tmc8 0.76 Zfp451 0.67 Gm16933 0.56 Snx1 -0.41
Rab3ip 0.76 Zfp36l1 0.67 Gm10552 0.55 Sh3bgrl3 -0.41
Tmem175 0.76 Tk2 0.67 Dctn5 0.55 Arpc4 -0.41
Gpd1l 0.76 Smim14 0.66 Malt1 0.54 Fam46a -0.41
mt-Nd6 0.76 Pold1 0.66 Uba7 0.54 Tfe3 -0.42
Gm11723 0.76 N4bp2l2 0.65 Crlf3 0.53 Laptm5 -0.42
Pde4b 0.75 Lrmp 0.65 Qdpr 0.53 Arl6ip5 -0.42
Clec2i 0.74 Akap8 0.65 Top3b 0.52 B4galnt1 -0.42
Dus3l 0.74 Syvn1 0.65 Map3k1 0.52 Gm20496 -0.42
Adap2 0.73 Slc25a19 0.64 Stap1 0.52 Esrra -0.42
Rab2b 0.73 Luc7l3 0.64 Rabif 0.51 Gnai2 -0.43
Snx2 0.73 Tpp1 0.64 Cnp 0.51 Capns1 -0.43
Akap8l 0.73 Anks3 0.64 Ifi27 0.51 Sub1 -0.43
Clk4 0.73 Slc39a13 0.63 Nhlrc3 0.51 Pcbp1 -0.43
Zufsp 0.73 Loxl3 0.63 Anapc2 0.48 Cct6a -0.43
Ubn2 0.73 Ggnbp2 0.63 0610039K10Rik 0.48 Tkt -0.43
Ptp4a3 0.73 Ddb2 0.63 Matr3 0.48 Relt -0.43
H2-K2 0.73 H2-Q6 0.63 Degs2 0.47 Dnah17 -0.45
Mef2c 0.73 mt-Nd1 0.63 Nipbl 0.46 Mkrn1 -0.45
RP24-223I19 0.73 Ndor1 0.63 AI413582 0.45 Atp5g1 -0.45
Ccnt2 0.73 Gabpb2 0.62 Sh3gl1 0.45 Ywhaz -0.45
Zkscan3 0.72 Mcoln1 0.62 Acin1 0.44 Copz1 -0.45
Snx5 0.72 Pgrmc1 0.61 Evl 0.44 Pdia6 -0.45
Tmem199 0.72 Arhgap25 0.61 Serinc3 0.43 Tap1 -0.46
Tbc1d14 0.72 BC004004 0.61 Ccnl2 0.43 Ppp1r18 -0.46
Kdm3a 0.71 Filip1l 0.60 Smarca4 0.43 Mfsd10 -0.46
Oard1 0.71 Pts 0.60 Ap1g2 0.41 Pgs1 -0.46
Rasgrp2 0.71 Pyroxd1 0.60 Abi1 0.38 Cd300a -0.46
Fcho1 0.71 Cd86 0.59 Mbnl2 0.34 Calr -0.46
Hmgn1 0.71 Slc3a2 0.59 Top1 0.33 Anxa7 -0.47
Tspyl2 0.71 Serpinb6a 0.59 Clic1 -0.30 Gm26602 -0.47
Cd84 0.71 Trim12a 0.59 Serbp1 -0.31 Myl6 -0.47
Rcan1 0.70 Tgfbr1 0.59 Polr2m -0.32 Trmt112 -0.47
Chkb 0.70 Uckl1 0.59 Atp5c1 -0.33 Pdia3 -0.48
Gm26786 0.70 Wipi2 0.59 Tm6sf1 -0.36 Psmb8 -0.48
Uckl1os 0.70 Gm26669 0.58 Etfa -0.36 Psma7 -0.49
A530040E14Rik 0.70 Hip1r 0.58 Brk1 -0.36 Milr1 -0.49
Nnt 0.69 Srrm2 0.57 Prpf6 -0.36 Sema4d -0.49
Mboat7 -0.50 Gm15396 -0.58 Leprotl1 -0.68 Etv6 -0.77
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Taldo1 -0.50 Atox1 -0.58 Csf2rb -0.68 Rbpj -0.77
Pepd -0.51 AI662270 -0.59 Tagap -0.68 Plekhg3 -0.77
Ldha -0.51 Otud5 -0.59 4921514A10Rik -0.69 Amz1 -0.77
Pycard -0.51 Gm15978 -0.59 Hnrnpab -0.69 Higd1a -0.77
Vdac3 -0.51 Nhp2 -0.59 Tmed9 -0.69 Gsn -0.77
Cfl1 -0.52 Tmem176a -0.59 Tspo -0.69 BC147527 -0.78
Psmd8 -0.52 Gm17122 -0.59 Sap30 -0.70 Mpp6 -0.78
Gosr2 -0.52 Ncbp2 -0.59 Lrrc14 -0.70 Stk40 -0.78
Mapkapk3 -0.52 Cdk2ap2 -0.60 Gm37885 -0.70 Map3k5 -0.78
Slc25a12 -0.52 Kmt2b -0.60 Pgm1 -0.70 Lfng -0.78
Myo1f -0.52 Gnb1 -0.60 E430024P14Rik -0.70 Vim -0.78
Gm26541 -0.52 Sdf2l1 -0.60 Gm12758 -0.71 Wdr46 -0.78
Hcls1 -0.52 Hdgf -0.60 Rnf130 -0.71 Scaf4 -0.78
Arhgap9 -0.53 Rinl -0.61 Tdrd3 -0.71 Tes -0.78
Cab39 -0.53 Actr10 -0.61 Ahcyl2 -0.71 Lrrfip2 -0.79
Eif4h -0.53 Drg2 -0.61 Srsf9 -0.71 Mbp -0.79
Ube2j2 -0.53 Sla -0.61 Plekhf2 -0.71 Pnpo -0.79
Ywhah -0.53 Ccdc43 -0.61 Actg1 -0.72 Pip4k2a -0.80
Tm2d2 -0.53 Runx3 -0.62 Stom -0.72 Prkch -0.80
Mob3a -0.54 R3hdm4 -0.62 Capn2 -0.72 Stx11 -0.80
Ndufb6 -0.54 Prpf19 -0.62 Smdt1 -0.72 Bag1 -0.80
Napsa -0.54 Cnn2 -0.62 Tle3 -0.73 4731419I09Rik -0.80
Dlst -0.54 Rnf220 -0.62 Fut7 -0.73 1600014C10Rik -0.80
Arf5 -0.54 Bloc1s2 -0.62 Mvb12a -0.73 Myd88 -0.81
Jarid2 -0.54 Itga5 -0.63 Glrx5 -0.73 Pid1 -0.81
Eif5a -0.55 Siva1 -0.64 Dcun1d2 -0.74 Zfp710 -0.81
Tab2 -0.55 Rgs2 -0.64 Adss -0.74 Marcksl1 -0.81
Abcf1 -0.55 Gm6180 -0.65 Ppp6r1 -0.74 4930473A02Rik -0.81
Thumpd1 -0.55 Fes -0.65 Slamf7 -0.74 B930036N10Rik -0.81
Ttc7 -0.55 Higd2a -0.65 Vopp1 -0.74 Nbeal2 -0.82
Rbms1 -0.55 Arih1 -0.65 Il6ra -0.74 Gm4876 -0.82
Tmem160 -0.56 Myadm -0.65 Prdx6 -0.74 Rab11fip1 -0.83
Pirb -0.56 Fam129a -0.66 Tmem165 -0.75 Gyg -0.83
H2-DMb1 -0.56 Usp18 -0.66 Tmem184b -0.75 H2afx -0.83
Pomp -0.56 Ap3s1 -0.66 AC122428 -0.75 Dtx3l -0.83
Def6 -0.56 Phf11b -0.66 Deptor -0.75 Prkx -0.83
Spi1 -0.57 Necap2 -0.66 Pitpna -0.76 Rgs3 -0.84
Ube2l3 -0.57 Evi2a -0.66 Sephs2 -0.76 Mesdc1 -0.84
Mdh2 -0.57 Tifab -0.66 Thap6 -0.76 Sh3bp1 -0.84
Tmem50b -0.57 Dap -0.66 Ptpro -0.76 Ppfia4 -0.84
Arhgap26 -0.57 Fbxw8 -0.66 Ccr2 -0.76 Ino80 -0.84
Panx1 -0.57 Pgp -0.66 Mcmbp -0.76 Prex1 -0.84
Sec61b -0.57 Smarcd2 -0.66 Prkd3 -0.77 Ppp1r9b -0.84
Ppp2r5a -0.58 Gatad2a -0.67 Tnfrsf1a -0.77 Ccna2 -0.85
Dhrs7 -0.58 Itgam -0.67 Abcd1 -0.77 Batf3 -0.85
Anp32b -0.58 Atg7 -0.67 Dpysl2 -0.77 Erlin1 -0.85
5830432E09Rik -0.58 Szrd1 -0.67 Rac1 -0.77 Ssbp4 -0.85
Xbp1 -0.58 Rps6ka1 -0.67 Bri3bp -0.77 Vrk1 -0.85
Fam105a -0.58 Sbno2 -0.68 Iqgap2 -0.77 Gm2a -0.85
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Ankrd13a -0.86 Hmgb2 -0.98 Fam151a -1.11 Ccdc102a -1.26
Zfp36l2 -0.86 Fosl2 -0.98 S100a11 -1.11 RP23-8L20 -1.26
Setd8 -0.87 Ifitm2 -0.98 Cdc42ep3 -1.11 Rnf43 -1.26
Slc9a6 -0.87 Srf -0.98 Gm15518 -1.11 Tpx2 -1.26
Gm16175 -0.87 Lsp1 -0.99 Ifitm1 -1.11 Glipr2 -1.26
Mapk14 -0.87 Car2 -0.99 G430095P16Rik -1.11 Stx3 -1.27
Sept9 -0.87 Ulk1 -0.99 Dna2 -1.11 Grasp -1.27
Edem1 -0.87 Orai1 -0.99 Tnni2 -1.11 Gm9887 -1.27
Reep3 -0.87 Asf1b -0.99 Slco3a1 -1.11 S100a6 -1.27
Slk -0.87 Glud1 -0.99 Slc35e1 -1.12 Fahd1 -1.28
Gm37787 -0.87 Ptpra -0.99 Itgb3 -1.12 Zyx -1.28
Ldlr -0.87 Mthfd2 -0.99 Gm17509 -1.12 Ifi205 -1.28
Bzw2 -0.88 Elmo2 -0.99 Fam49b -1.13 Smim5 -1.28
Gm17315 -0.89 Vav3 -1.00 Parp12 -1.13 Eml6 -1.28
Sla2 -0.89 Map7d1 -1.00 Mthfd1l -1.14 2010300F17Rik -1.28
Rara -0.90 Prr5l -1.00 Naaa -1.14 Trerf1 -1.28
Hspa2 -0.90 Taf7 -1.01 Ptprs -1.14 Gm10612 -1.28
Tgtp2 -0.90 Krt80 -1.01 Ncapg -1.14 Dapk2 -1.28
Gm8203 -0.90 Cxcl10 -1.01 Qpct -1.15 AC073562 -1.29
Plac8 -0.90 Gm9733 -1.01 Plbd1 -1.15 Mob3b -1.30
Ogfrl1 -0.91 Tpgs2 -1.01 Ms4a2 -1.15 Arhgap23 -1.31
Efhd2 -0.91 Lck -1.01 Gm15651 -1.16 Ccnd2 -1.31
1110008F13Rik -0.91 Gm26885 -1.01 Arap3 -1.17 Zap70 -1.31
Tagln2 -0.92 Fn1 -1.02 Cebpd -1.17 Arhgef10 -1.32
H2afy -0.92 Gm3571 -1.02 Fam129b -1.17 Chil3 -1.32
Sqle -0.92 Syngr2 -1.02 Emilin2 -1.18 Rab27a -1.32
Sc5d -0.92 H2afz -1.02 Gpc1 -1.18 Mcemp1 -1.32
Tmed7 -0.92 Cdca8 -1.02 Cbfa2t3 -1.18 Nod2 -1.32
Tmsb10 -0.92 Gm26765 -1.03 Gm4673 -1.18 Pacs2 -1.33
Arf6 -0.93 Lgals1 -1.03 Ccnd3 -1.19 Klrb1a -1.33
Ahnak -0.93 Itgb7 -1.03 Cd33 -1.19 Adora2b -1.33
Bcl3 -0.94 Ccnb2 -1.04 Ift57 -1.19 Klhl2 -1.33
Bysl -0.94 0610040J01Rik -1.04 Lef1 -1.19 Rarg -1.33
Gas7 -0.94 Nfix -1.05 Selplg -1.19 Camk4 -1.34
Ctnna1 -0.95 Slc39a14 -1.05 Emb -1.19 Klrb1f -1.34
Crip1 -0.95 Fxyd5 -1.05 Ramp1 -1.19 Ccnd1 -1.34
Magohb -0.96 Nfkb1 -1.05 Smim3 -1.19 Cited2 -1.35
Aes -0.96 D17Wsu92e -1.05 Alox5ap -1.20 Anxa1 -1.35
Tmpo -0.96 Lsr -1.06 Rbpms -1.20 Tppp3 -1.35
Tnfrsf21 -0.96 Acot11 -1.07 Ifit1 -1.21 Atp1a3 -1.36
Phf11a -0.96 Klhl5 -1.07 Tnfsf14 -1.21 Trbj1-1 -1.36
Rnf166 -0.96 Ccdc88b -1.07 Ank -1.21 Ppm1j -1.37
Ccdc109b -0.96 Rap2a -1.08 Lilra6 -1.21 Inpp4a -1.38
4933416M07Rik -0.97 Ifitm3 -1.08 Ctnnbip1 -1.22 Mki67 -1.38
Prkaca -0.97 Pi16 -1.08 WI1-1993I8 -1.23 Trbj1-2 -1.38
I830077J02Rik -0.97 Rab3d -1.08 Fam189b -1.23 Bex6 -1.40
Gm10642 -0.97 Atp8b4 -1.09 Tnfrsf9 -1.24 Stmn1 -1.40
Tnfrsf18 -0.97 Smad1 -1.09 Eml2 -1.24 E2f2 -1.41
Zcchc24 -0.98 Sulf2 -1.10 Mmp8 -1.24 Cd300lg -1.41
Hmgcs1 -0.98 Nfe2 -1.10 Ubash3a -1.25 Tiam1 -1.42
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Slc2a6 -1.42 Avpi1 -1.78
Rab44 -1.43 Ccl5 -1.81
Txk -1.43 Ly6c2 -1.82
Nfil3 -1.43 Klra13-ps -1.84
Lmnb1 -1.44 F13a1 -1.86
Vcl -1.44 Gm11775 -1.88
Cks1b -1.45 Padi2 -1.89
Sema4a -1.46 Cxcr6 -1.90
Cyp11a1 -1.46 Chl1 -1.92
Ifitm10 -1.46 Klrc1 -1.92
Ccl22 -1.46 Cd7 -1.96
RP24-80F7 -1.47 Nkg7 -1.99
Trbc2 -1.48 Ctsw -2.00
Rnd3 -1.48 Gm37940 -2.01
Acot7 -1.49 I830127L07Rik -2.03
Rrm2 -1.49 Samd3 -2.04
Gm16282 -1.49 Ltb4r1 -2.04
Xcl1 -1.49 Nrgn -2.05
Anxa2 -1.50 Cd209c -2.05
Ifitm6 -1.50 Plekhg5 -2.06
2810417H13Rik -1.52 Ddr1 -2.31
Klrk1 -1.53 Klrd1 -2.32
1700025G04Rik -1.54 Sytl3 -2.33
Tbx21 -1.55 Hrh4 -2.36
Ctla2a -1.55 Il2rb -2.40
Rgs18 -1.56 Ikzf2 -2.41
Dgkg -1.57 Skap1 -2.41
Olfm1 -1.57 Cd209a -2.42
Adgrg5 -1.58 Stk39 -2.53
Klre1 -1.59 Amot -2.66
Il18rap -1.59
Jazf1 -1.61
Tspan33 -1.62
Tcf19 -1.62
Ncr1 -1.63
St3gal2 -1.65
Ms4a4b -1.65
Trbc1 -1.65
Gm13031 -1.65
Fcer1a -1.67
Clec10a -1.68
Gpr141 -1.69
E2f8 -1.69
Cd160 -1.69
Casc5 -1.69
Cd177 -1.70
Klrb1c -1.71
Gata2 -1.72
Kcne3 -1.77
Cebpb -1.78
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Ighv11-2 3.98 Eva1b 1.68 Fam169b 1.44 Itga9 1.33
Adm 3.45 Ehd3 1.66 Igkj4 1.44 Igkj2 1.33
Il18bp 3.36 Mzb1 1.66 Slamf1 1.44 Ighv2-2 1.33
Clec1b 3.17 S1pr1 1.66 Gm8113 1.44 Plod1 1.33
Vsig4 3.10 C1qa 1.66 Cd79a 1.44 Gm15675 1.33
Slc40a1 3.09 Scd1 1.65 Ighd 1.44 Gm15674 1.33
Clec4f 2.94 C1qb 1.64 Cnn3 1.43 Hrsp12 1.33
Cracr2b 2.94 Ppap2b 1.62 Smyd4 1.43 Csrnp2 1.32
Gdf15 2.90 Ptgs1 1.62 Igkc 1.43 Lgmn 1.32
Vcam1 2.80 Adck3 1.61 Ccr7 1.42 Kcnk5 1.32
Igkv12-89 2.65 Pld3 1.61 Dnah12 1.42 Pou2af1 1.32
Fcnaos 2.56 Cmah 1.61 Itsn1 1.42 Sh3bp5 1.32
RP24-245I16 2.55 Blk 1.58 Spic 1.42 Ly6d 1.32
Cd5l 2.40 RP23-454A14 1.58 P2ry12 1.42 Atp5s 1.32
Apoc1 2.38 Gm20506 1.58 A230050P20Rik 1.42 Ccl7 1.32
Igf1 2.34 Scamp5 1.58 Wnt6 1.41 Tmco6 1.32
Igkv14-126 2.30 Igkv6-15 1.57 Ighv10-3 1.41 Alb 1.31
Ighv10-1 2.26 Cd55 1.57 Tfpi 1.41 Iglc2 1.31
Tmem26 2.18 C6 1.56 RP23-247I11 1.41 Ighv8-12 1.31
Iglv2 2.14 Adamdec1 1.56 Cr2 1.41 Pax5 1.31
Sema6d 2.13 Fcna 1.55 Gpx3 1.41 Gimap1 1.31
Dmpk 2.13 Il9r 1.55 Blvrb 1.41 Arhgef12 1.31
Fabp7 2.06 Adgb 1.55 Igkv4-55 1.40 Gm16083 1.30
Mmp12 1.98 Gm14023 1.53 Gm26540 1.40 Iglv1 1.30
Dysf 1.93 1110059E24Rik 1.53 Igkv8-27 1.40 Pex1 1.30
1110046J04Rik 1.92 Cpq 1.51 Hpx 1.39 Ctsd 1.30
Kcna2 1.91 Cd79b 1.50 Cd22 1.39 Lpl 1.30
Cxcr5 1.86 Cd19 1.50 Rnasel 1.39 Crb3 1.30
Serpina1b 1.85 3110057O12Rik 1.50 Dnase1l2 1.39 Rftn2 1.29
Cd81 1.85 Mtss1 1.49 Sfn 1.39 D330023K18Rik 1.29
Mcoln2 1.84 Gm29439 1.49 Bcl7a 1.39 Tctn1 1.29
R74862 1.84 Fcrl5 1.48 Il12a 1.39 Pbld2 1.28
Mertk 1.80 Tspan32 1.47 Serpinb6a 1.38 Hvcn1 1.28
Folr2 1.79 Igkj5 1.47 Ebf1 1.38 Tnfrsf26 1.28
Fpr1 1.78 Ralgps2 1.47 mt-Ty 1.38 F730311O21Rik 1.28
Pik3c2b 1.78 Tspan4 1.47 Krba1 1.38 Dph7 1.28
Cd38 1.78 Bank1 1.47 Ighm 1.37 Sidt1 1.27
Ighv1-55 1.78 Sit1 1.47 Cacna1i 1.37 Cd2 1.27
Igkv8-21 1.77 RP24-277J22 1.47 Bhmt 1.37 Gm17080 1.27
Cd300e 1.76 Pecam1 1.46 Cps1 1.37 Pltp 1.27
Ighv7-3 1.76 RP23-435I4 1.46 Fcer2a 1.36 Adh1 1.27
Mapk12 1.75 Apoe 1.46 Chst3 1.36 Gm4951 1.26
Ephx1 1.73 Gdpd1 1.46 Ighv1-5 1.36 Igkv4-57-1 1.26
Fcmr 1.72 Slc37a2 1.46 Nicn1 1.35 Igkv4-57 1.26
Zbtb10 1.72 Acp5 1.46 Ms4a1 1.35 Iglc3 1.26
Abcc3 1.70 Ighv6-3 1.45 Gm12164 1.35 BC065397 1.26
C1qc 1.69 Srpk3 1.45 Fam213a 1.35 Gm8369 1.26
Igkj1 1.69 Cpm 1.45 Stab1 1.34 Maml2 1.26
Fabp4 1.69 Bend5 1.44 Bach2os 1.34 Gpnmb 1.26
Lilra5 1.68 Ighv3-6 1.44 Hpgds 1.34 Hyal2 1.26
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Mir150 1.26 P2ry13 1.18 Icam2 1.10 Zfand1 0.99
Snord35b 1.26 Pou6f1 1.18 Slc12a7 1.09 Pon3 0.99
Cd207 1.26 Ets1 1.18 mt-Tp 1.09 Mpp5 0.99
Thbs1 1.26 Tbx6 1.18 Mapk11 1.09 Fam43a 0.99
Fcrl1 1.26 Tpp1 1.18 Fam3c 1.09 mt-Nd6 0.98
Igkj3 1.26 Pgap1 1.17 Pla2g15 1.09 Ddb2 0.98
Abca1 1.25 Sepp1 1.17 Klhdc9 1.08 Gm17552 0.98
Igkv12-46 1.25 Fcgr4 1.17 Spg20 1.08 Arhgef3 0.98
Slc5a11 1.25 Mrc1 1.17 Rab3il1 1.08 mt-Nd4 0.98
Il5ra 1.25 Adgre1 1.17 Dpp7 1.08 Dennd6b 0.98
Susd1 1.25 Ighv5-4 1.17 Polr3g 1.08 Gimap3 0.98
Slc29a1 1.25 mt-Tq 1.17 Hmox1 1.08 B3gnt5 0.98
Siglecg 1.24 Gga2 1.16 Npr1 1.08 Dennd3 0.98
RP23-192O12 1.24 Cd84 1.16 Actn1 1.07 Trp53i11 0.97
Krt222 1.24 Fbxl4 1.16 Abl2 1.07 Rasgrp3 0.97
Iglv3 1.24 Dclk2 1.16 Ppp1r16b 1.07 Tmem106c 0.97
Slc28a2 1.23 Ear2 1.15 Cxcr4 1.06 Hdac10 0.97
Myo1e 1.23 Igkv1-135 1.15 Nxpe3 1.06 Rad52 0.97
E330020D12Rik 1.23 Ighv1-53 1.15 Kcnk13 1.06 Gm10116 0.96
Iglc1 1.23 Manea 1.15 Qrsl1 1.06 Rbm48 0.96
Cd72 1.23 mt-Nd3 1.14 Ttpal 1.06 Ctso 0.96
Snn 1.23 Igkv1-117 1.14 Blnk 1.06 A130051J06Rik 0.96
Fcrla 1.23 Zhx2 1.14 Cd1d1 1.06 Agk 0.96
Ighv5-6 1.23 Spib 1.14 Ablim1 1.06 Gm26786 0.96
Cd63 1.23 Rbm12b2 1.14 Zdhhc18 1.05 Treml4 0.96
Oplah 1.23 Ctsb 1.14 Gm6977 1.05 Gbp8 0.95
Pdlim4 1.23 Tpcn2 1.14 Ndc80 1.05 Inpp5f 0.95
Snx8 1.22 2610507I01Rik 1.14 Rgl1 1.05 Rft1 0.95
Tnfrsf13c 1.22 Per2 1.13 Slc7a8 1.05 Sesn1 0.95
Gimap1os 1.22 St6gal1 1.13 Rhoh 1.04 Trim7 0.94
Igkv5-43 1.22 Tbxa2r 1.13 Fam129c 1.04 Gm21596 0.94
Clec4n 1.22 Ltb 1.13 Gm15931 1.04 Smagp 0.94
Mmp13 1.22 Cd63-ps 1.13 Cfp 1.04 Mef2c 0.94
Helz2 1.22 Lax1 1.12 Gm13340 1.04 Cd69 0.94
Adamts6 1.21 Cd274 1.12 Cd37 1.04 Zfp90 0.94
A430078G23Rik 1.21 Chchd10 1.12 Gm16153 1.04 Hpgd 0.93
Igkv1-110 1.21 Fmnl3 1.12 Itpkb 1.04 Nmt2 0.93
Bcar3 1.21 Clcf1 1.12 Slc7a11 1.04 Tesk1 0.92
Igkv10-96 1.21 Zcchc18 1.12 Tcp11l2 1.03 Tmcc3 0.92
Gm11707 1.21 Plk2 1.11 3110062M04Rik 1.03 RP24-224N3 0.92
Iglj3 1.20 Hemk1 1.11 Nr1d2 1.02 Mylip 0.92
Cd200 1.20 Iqsec1 1.11 H2-DMb2 1.02 Ptprcap 0.92
Pmp22 1.20 Slc1a3 1.11 Renbp 1.02 Edrf1 0.92
Ighv5-17 1.19 Tmem140 1.11 Ino80 1.01 Ecm1 0.92
mt-Ts1 1.19 Ighv1-64 1.11 Pparg 1.01 Gm15135 0.92
Lmbrd1 1.19 Gimap6 1.10 mt-Nd2 1.00 mt-Nd1 0.91
Cttn 1.19 Ighv9-3 1.10 Cipc 1.00 Dnase2a 0.91
Pxdc1 1.18 Engase 1.10 Chd6 1.00 Pilra 0.91
Serpinb1a 1.18 5830416P10Rik 1.10 Carns1 1.00 Kmt2a 0.91
Stac2 1.18 Crem 1.10 mt-Cytb 1.00 H2-Ob 0.91
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Cd300ld 0.90 Lpcat2 0.82 RP24-223I19 0.73 Clcn7 0.63
Fam213b 0.90 Swap70 0.82 Gaa 0.73 Klhl24 0.63
Arl2 0.90 Mfsd11 0.82 Gm11724 0.73 Tgif1 0.62
Mphosph8 0.90 Tex264 0.82 Gm37376 0.73 Tmc8 0.62
Slamf6 0.89 Dse 0.82 3110043O21Rik 0.73 Recql5 0.62
Rad18 0.89 Dopey2 0.82 Snx2 0.73 Ip6k1 0.61
Fam65b 0.89 H2-T10 0.82 Trp53inp1 0.72 Arhgap25 0.61
Gm21399 0.89 Dus3l 0.82 Clp1 0.72 Aga 0.60
Cers4 0.89 Tmem241 0.82 Mospd2 0.72 Cd86 0.60
Dalrd3 0.88 Creg1 0.81 Gm17233 0.72 Tk2 0.60
Zfp97 0.88 C330006A16Rik 0.81 Ftl2 0.72 Cat 0.60
Mif4gd 0.88 Nenf 0.81 Tlr1 0.71 Ccr5 0.59
Loxl3 0.88 Brwd1 0.81 Stambpl1 0.71 Cd9 0.59
Pde2a 0.88 Ppp4r1 0.81 Cyth1 0.71 Mdm2 0.58
Rc3h1 0.88 Fchsd2 0.81 Abcg1 0.71 Ptp4a3 0.58
Abcc5 0.88 Cept1 0.81 Ddit3 0.71 Gm8797 0.58
mt-Co1 0.87 Ocrl 0.81 Gm16892 0.71 Foxp1 0.58
2510002D24Rik 0.87 Wdr91 0.81 Ano10 0.71 Arid4b 0.58
mt-Rnr1 0.87 H2-Q6 0.80 Snx5 0.70 Slc48a1 0.58
Acp2 0.87 Axl 0.80 Oard1 0.70 Ddrgk1 0.58
Glmn 0.86 Pxk 0.79 Rabggta 0.70 0610039K10Rik 0.56
Naglu 0.86 Gm26879 0.79 Cyp4f13 0.69 Tgfbr2 0.55
Zfp560 0.86 Rasgef1b 0.79 Kif21b 0.69 Serinc3 0.55
4930523C07Rik 0.86 mt-Nd5 0.79 Tlr4 0.69 Fli1 0.54
Ulk3 0.86 Cbx7 0.79 Rcbtb2 0.68 Stap1 0.54
Trim59 0.86 mt-Rnr2 0.79 Rcsd1 0.68 Cirbp 0.53
Osgin1 0.86 Ly6a 0.78 Polr2a 0.68 Cnpy2 0.53
Ktn1 0.86 Tmem132a 0.78 Arap2 0.68 Aktip 0.52
Zcwpw1 0.86 Tnrc6c 0.78 Ly9 0.67 Crbn 0.52
Rcan1 0.86 Fam63a 0.78 Rnf167 0.67 Il10rb 0.52
Sgk1 0.85 Man1a 0.78 Uqcc1 0.67 Degs2 0.51
Gm12226 0.85 Mga 0.78 Pold1 0.67 Tmod3 0.51
Adap2 0.85 Fgd4 0.77 1700021K19Rik 0.67 Il21r 0.51
Aff3 0.85 C87436 0.77 Macf1 0.66 Fez2 0.50
Ing4 0.85 Stoml1 0.77 Syvn1 0.66 Add1 0.50
1600020E01Rik 0.85 Tcf7l2 0.77 Rasgrp1 0.66 Zgpat 0.50
Chst15 0.85 Psen2 0.77 Fam58b 0.66 Atp2a3 0.48
4930481A15Rik 0.84 Ano6 0.77 Gm26524 0.66 Nipsnap3b 0.46
Zcchc7 0.84 Atp6v0a1 0.76 Sypl 0.66 Il16 0.46
Prkd2 0.84 Scimp 0.76 Ntpcr 0.66 Evl 0.44
Zmynd8 0.84 Pla2g4a 0.76 Pnisr 0.66 Rhbdd3 0.44
Ublcp1 0.84 Man2b2 0.76 Cryzl1 0.66 Syk 0.43
Idua 0.84 Npc1 0.76 Tbc1d10c 0.65 Fam45a 0.43
Aldh6a1 0.84 Pkig 0.76 Gm17139 0.65 Qdpr 0.43
Tgfbr1 0.84 Zmym5 0.75 Zfp36l1 0.64 Vars 0.42
Slc3a2 0.84 Ifi27 0.75 Nagk 0.64 Prpf6 0.41
Slc15a3 0.83 Hmgn1 0.75 Adrb2 0.64 Cnp 0.41
Akap8l 0.83 Tmem243 0.75 Pyroxd1 0.64 Mgrn1 0.40
Yipf2 0.83 St3gal6 0.75 Gm26669 0.64 Stard5 0.38
Mast1 0.83 Fam149b 0.75 Gm1821 0.64 Gm10382 0.37
Polrmt 0.83 Cdip1 0.75 Bola1 0.64 Jak1 0.28
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Frs2 0.83 Grap 0.74 Ccm2 0.64 Tpm3 -0.25
Lipa 0.83 Trim34a 0.74 Map3k1 0.64 Calr -0.29
Il10ra -0.29 Dbnl -0.46 Set -0.57 Mrpl21 -0.65
Erp29 -0.30 Cct8 -0.46 Arf5 -0.57 Lck -0.65
Sec61a1 -0.31 Rxrb -0.46 Scand1 -0.57 Uri1 -0.65
Cct5 -0.33 Pdia6 -0.47 Tmem184b -0.57 5830432E09Rik -0.65
Serbp1 -0.33 Copz1 -0.47 Ranbp1 -0.57 Chuk -0.65
Lbr -0.34 Klf3 -0.48 Actb -0.57 Tpm4 -0.65
Smc1a -0.34 Nfkbia -0.48 Atox1 -0.57 Ankrd13c -0.66
Elovl1 -0.34 Kdm7a -0.48 Gm15396 -0.58 Vapa -0.66
Coro1a -0.35 Mbd3 -0.48 Tprgl -0.58 Trim44 -0.66
Clic1 -0.35 Frmd8 -0.49 Zfp263 -0.58 Gm15512 -0.66
Ptma -0.35 Spi1 -0.49 Evi2a -0.58 Fam129a -0.66
Eif5a -0.36 Pepd -0.49 Ppia -0.58 Gm16235 -0.67
Arl6ip5 -0.36 Snrpd2 -0.49 Gm17122 -0.58 Rps27l -0.67
Actr3 -0.36 Btg2 -0.50 Runx1 -0.58 Gm8203 -0.67
Arpc2 -0.36 Ndufb10 -0.50 Calm3 -0.59 Acadl -0.67
Cdc37 -0.37 Orai2 -0.50 Gm22953 -0.59 Smdt1 -0.67
Gnai2 -0.37 Tmem55b -0.50 Gm26541 -0.59 Msmo1 -0.67
Capzb -0.37 Prickle3 -0.50 Nfkbie -0.59 Pomp -0.68
Map2k3 -0.37 Pdia3 -0.50 Cycs -0.59 Txndc11 -0.68
Tm6sf1 -0.37 Smu1 -0.50 Gm10143 -0.59 Asap1 -0.68
Ppp1r18 -0.39 Atp5c1 -0.51 Mapkapk3 -0.60 Polr2m -0.68
Wbp11 -0.39 Psmb8 -0.51 Tifab -0.60 Prex1 -0.68
Nrros -0.40 Ttc7 -0.51 Twf2 -0.60 Pcyt2 -0.68
Prmt1 -0.40 Zfp36 -0.51 Sla -0.60 Csf2rb -0.68
Nhp2 -0.40 Ankle2 -0.51 Sbno2 -0.60 Map3k5 -0.68
Laptm5 -0.41 H2-DMb1 -0.51 Irf5 -0.61 Myd88 -0.68
Sfxn3 -0.41 Pycard -0.51 Zdhhc3 -0.61 Pip4k2a -0.69
Tmem173 -0.41 Psma7 -0.52 Mob3a -0.61 Ppp6c -0.69
Atp5g1 -0.41 Atp5h -0.53 Cab39 -0.61 Nsmce4a -0.69
Btf3 -0.42 Arhgdia -0.53 Arhgap22 -0.61 Fen1 -0.69
Krtcap2 -0.42 Brd7 -0.53 Cnn2 -0.62 Tnfrsf1a -0.69
Banf1 -0.42 Ssr1 -0.54 Rnf10 -0.62 Eed -0.69
Mtpn -0.42 Pirb -0.54 Zfp36l2 -0.62 Ppp6r1 -0.69
Ywhab -0.43 Top2b -0.54 Ddi2 -0.62 Pfkp -0.70
Tmem50b -0.43 Noc2l -0.54 Epn1 -0.63 Gm37787 -0.70
Eif4h -0.43 1110007C09Rik -0.55 Fam105a -0.63 Idh3a -0.70
Arpc4 -0.43 Lrrc59 -0.55 Ccdc88b -0.63 Actg1 -0.70
Ywhaz -0.43 Shc4 -0.55 Hdgf -0.63 Emp3 -0.71
Acat1 -0.43 Bmp2k -0.55 Rnf220 -0.63 Trp53rka -0.71
Mgat2 -0.44 Ywhah -0.55 Rnf166 -0.63 4933440N22Rik -0.71
Ltv1 -0.44 Eid1 -0.55 C1qbp -0.64 Rab6a -0.71
Rac1 -0.44 Napsa -0.56 Pnp -0.64 Chmp6 -0.71
Lsm14a -0.44 Rpn1 -0.56 Vopp1 -0.64 Itgam -0.71
Gm20496 -0.44 2210016F16Rik -0.56 1110035H17Rik -0.64 Ydjc -0.71
Eif3c -0.44 Coro1c -0.56 Ogfrl1 -0.64 Gnptab -0.72
Tm2d2 -0.45 Cfl1 -0.56 Prdx6 -0.64 Gm2a -0.72
Sub1 -0.46 Rassf3 -0.56 Fbl -0.65 Sap30 -0.72
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Gm26841 -0.72 Slc2a6 -0.80 Tle3 -0.89 Apobr -0.98
Gm37939 -0.72 Vrk1 -0.80 Bri3bp -0.90 Sh2b3 -0.98
Elmo2 -0.72 Mcmbp -0.81 Elavl1 -0.90 Rara -0.98
Ier2 -0.72 1810026J23Rik -0.81 Gm17509 -0.90 Mvd -0.99
Inpp4a -0.73 Cldnd1 -0.81 Lrrc42 -0.90 Aes -0.99
1110008F13Rik -0.73 Chic2 -0.81 Isoc1 -0.90 Mapk14 -1.00
Cep170 -0.73 Sec61b -0.81 Klhdc2 -0.90 Ptpra -1.01
Pink1 -0.73 Rab27a -0.81 Prkaca -0.91 Ifitm2 -1.01
Ldlr -0.74 Fbxo28 -0.82 B430218F22Rik -0.91 Efhd2 -1.02
Ifi47 -0.74 Gramd4 -0.82 Galnt10 -0.91 AI846148 -1.02
Trim27 -0.74 Coro2a -0.83 Plekhf2 -0.91 Gm10392 -1.02
Sep-13 -0.74 Grb2 -0.83 Anp32b -0.91 Cited2 -1.02
Ccdc117 -0.74 Pid1 -0.83 Ccdc109b -0.91 Kif20a -1.02
Elf4 -0.74 BC147527 -0.83 Stim2 -0.91 Orai1 -1.02
Eif3f -0.75 Fbxo31 -0.83 Ppm1d -0.91 Trerf1 -1.02
Slk -0.75 Runx3 -0.83 Pak4 -0.92 Upf1 -1.03
4930473A02Rik -0.75 Sumf1 -0.83 Ahcyl2 -0.92 Plac8 -1.03
Ubqln1 -0.75 Usp12 -0.84 Ppp2ca -0.92 Cdkn1a -1.03
Ifi35 -0.75 Usp18 -0.84 Ccnd2 -0.92 Gm24366 -1.03
Ms4a6b -0.76 Nudt3 -0.84 Odc1 -0.92 Hmgb2 -1.03
Itga5 -0.76 Myadm -0.84 Aim1 -0.92 Cbfa2t3 -1.04
Rbpj -0.76 Plp2 -0.84 Lgals1 -0.92 Lpcat4 -1.04
Cpox -0.76 Atp8b4 -0.85 Rnf130 -0.92 H2afz -1.04
Gm11626 -0.77 Prkd3 -0.85 Trbc1 -0.92 H2afx -1.04
Il6ra -0.77 Stom -0.85 Ptger4 -0.93 Whsc1 -1.04
Phf10 -0.77 Ctage5 -0.85 Dpysl2 -0.94 Clint1 -1.05
Mbp -0.77 Fbxo4 -0.85 Amz1 -0.94 Chil3 -1.05
Slfn5 -0.77 Rala -0.85 Gm16175 -0.94 WI1-1993I8 -1.05
Hnrnpab -0.77 Ascc1 -0.85 Ocstamp -0.94 Fgl2 -1.05
Rrs1 -0.77 Rasgrp4 -0.85 Trps1 -0.94 Smarcd2 -1.05
Syngr2 -0.77 Mettl1 -0.85 I830077J02Rik -0.95 AC122428 -1.05
Sla2 -0.77 Kctd20 -0.86 Acot7 -0.95 Cry1 -1.05
Tmem160 -0.77 Tgtp2 -0.86 Mx1 -0.95 Alox5ap -1.06
Ptpn11 -0.78 Hmgcr -0.86 Abhd15 -0.95 Gnb1 -1.06
Nfkb1 -0.78 Pacs2 -0.86 Gm9733 -0.95 Impa2 -1.07
Ms4a6c -0.78 Ppm1b -0.86 Ugt1a7c -0.95 Ppp6r2 -1.07
Srm -0.78 Sirt3 -0.86 Lrrfip2 -0.95 Tmem165 -1.07
Tspo -0.79 Ercc4 -0.87 Pitpna -0.96 Nbeal2 -1.07
Gpr141 -0.79 Abca2 -0.87 Rnf11 -0.96 Ralgapa1 -1.07
Apex1 -0.79 Reep3 -0.87 Camkk2 -0.96 Cdca8 -1.07
H13 -0.79 Ssbp4 -0.87 Fam189b -0.96 Lsp1 -1.07
Arl5c -0.79 Chmp4b -0.88 Tagln2 -0.96 Il18rap -1.08
Iqgap2 -0.79 Arl3 -0.88 Rnf187 -0.96 Bag1 -1.08
Utrn -0.79 Fam160b1 -0.89 Antxr2 -0.98 Cyp51 -1.08
BC035044 -0.80 Mrps30 -0.89 Ppm1m -0.98 Ifitm3 -1.08
Irgm1 -0.80 Otud5 -0.89 Ccr2 -0.98 Gm3571 -1.09
Golph3 -0.80 Selplg -0.89 Vim -0.98 Rgs18 -1.09
Atp2a2 -0.80 Mapk1 -0.89 9930021J03Rik -0.98 Lat -1.10
Mpp6 -0.80 Bysl -0.89 Itgb7 -0.98 Sema4a -1.10
E2f2 -0.80 Stk40 -0.89 Cdkn2c -0.98 Emb -1.10
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Prkx -1.10 Wee1 -1.24 Gm26765 -1.39 I830127L07Rik -1.65
Lmnb1 -1.10 Sulf2 -1.25 Arsb -1.40 Tbc1d2 -1.65
Fxyd5 -1.10 Gm26527 -1.26 Ccnb2 -1.40 Frat2 -1.66
Gm15448 -1.10 Cebpb -1.27 Trbj1-2 -1.41 Tbx21 -1.68
Zyx -1.10 Fasn -1.27 Bcl11b -1.41 Gm14455 -1.68
Sqle -1.10 Klrb1c -1.28 Nfil3 -1.41 Stmn1 -1.68
Met -1.11 Tmsb10 -1.28 Rab44 -1.42 Ddr1 -1.69
Parp12 -1.11 Dus4l -1.28 Fcor -1.42 Ncr1 -1.74
Dna2 -1.11 Ms4a4b -1.28 Cass4 -1.43 Klre1 -1.78
Adam8 -1.11 Tgtp1 -1.28 Jund -1.43 Ltb4r1 -1.85
Rnd3 -1.11 Tysnd1 -1.28 Olfm1 -1.43 Klrd1 -1.89
Nav1 -1.12 Klhdc10 -1.28 Ifitm6 -1.44 Cd160 -1.90
Edem1 -1.12 Crip1 -1.29 Kcne3 -1.44 Nkg7 -1.91
Ccnd1 -1.12 Nsmaf -1.29 Gm26885 -1.45 Srf -1.92
Tnip3 -1.12 Hmgcs1 -1.29 Rrm2 -1.45 Gm11775 -1.94
Gm37885 -1.13 Ptgs2 -1.29 Nhsl2 -1.45 Top2a -1.95
Cd163l1 -1.13 Gm37940 -1.29 Ccdc102a -1.47 F13a1 -1.97
Rbms1 -1.13 RP23-301L9 -1.29 Ank -1.47 Cd7 -1.97
Plbd1 -1.13 Bcl3 -1.30 Tiam1 -1.49 Cd209a -2.00
Gpr68 -1.13 Racgap1 -1.30 St3gal2 -1.49 2810417H13Rik -2.02
E130309D02Rik -1.14 G430095P16Rik -1.30 2010300C02Rik -1.49 Cd27 -2.02
Jak2 -1.14 Tnfsf14 -1.30 Clec10a -1.51 Klra1 -2.03
Glud1 -1.14 Ccnd3 -1.31 Zfp595 -1.51 Kif2c -3.25
Alox8 -1.14 Gm24157 -1.31 Ehf -1.51
Mcemp1 -1.15 Slco3a1 -1.31 Klrc1 -1.52
Ifitm1 -1.15 Fam49b -1.31 Adgrg5 -1.52
Capn2 -1.15 Gm14548 -1.31 Cks1b -1.53
Fam129b -1.15 Cd177 -1.32 Emilin2 -1.53
Lilra6 -1.16 Glipr2 -1.32 Il2rb -1.53
RP23-173N16 -1.16 Tppp3 -1.32 Mfsd6 -1.53
Zap70 -1.16 Slc7a5 -1.33 Bex6 -1.54
Ramp1 -1.17 Pim1 -1.34 Anxa2 -1.55
Tmem8 -1.17 1700025G04Rik -1.34 Skap1 -1.55
Bbc3 -1.18 Nacc1 -1.34 Ccl22 -1.57
Sytl3 -1.18 Ifitm10 -1.34 Alyref -1.58
Slc35e1 -1.19 Socs1 -1.34 Gata2 -1.58
Ptpro -1.19 Grasp -1.34 Galnt9 -1.59
Sestd1 -1.19 S100a6 -1.34 Klrk1 -1.59
Map7d1 -1.19 Rfng -1.35 Trbc2 -1.59
Nusap1 -1.20 Ube2c -1.35 Padi2 -1.60
Tbkbp1 -1.20 St3gal3 -1.36 Ctsw -1.60
Ifi205 -1.20 Xcl1 -1.37 Ccl5 -1.61
Nfatc2 -1.20 Cebpd -1.37 Hras -1.61
H2afy -1.20 RP24-80F7 -1.37 Ly6c2 -1.61
Gm19585 -1.22 Anxa1 -1.37 Ikzf2 -1.62
Bod1 -1.22 Ahnak -1.37 Samd3 -1.62
Ctbp1 -1.22 Gm13031 -1.37 Tspan33 -1.63
S100a11 -1.24 Trdv4 -1.39 Cenpf -1.64
Mki67 -1.24 Gm11175 -1.39 Hrh4 -1.64
Cxcr6 -1.24 Tmpo -1.39 Nrgn -1.64
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Amot 2.85 1810034E14Rik 1.18 Adcy6 1.00 Gpr141 0.91
Igkv12-89 2.20 Fktn 1.18 Gpx3 1.00 Hist2h2aa2 0.91
Serpina1b 1.89 Bhmt2 1.18 Chpt1 1.00 Cpq 0.91
Pbld2 1.87 Rps6kl1 1.18 Wash1 0.99 Susd1 0.91
Pde4d 1.78 Ddr1 1.18 Paip2b 0.99 Zfp287 0.91
Jazf1 1.59 Ino80 1.16 Cxcl10 0.99 Tlr3 0.90
Dlg3 1.59 Bag2 1.14 Igfbp4 0.99 Pcyox1l 0.90
Lef1 1.58 Vat1 1.13 Dnase1l2 0.98 Net1 0.90
Eng 1.55 Crem 1.13 Setbp1 0.98 Iffo2 0.90
Cd300lg 1.51 Klhdc9 1.13 Hmgn3 0.98 Taco1 0.90
Acaa1b 1.49 Sult1a1 1.12 Chid1 0.98 Gatb 0.89
Pvrl2 1.48 Erf 1.11 Celf4 0.98 1700023H06Rik 0.89
Aspa 1.48 Hbegf 1.11 Vezt 0.97 Gm37042 0.89
Mex3b 1.44 Avpi1 1.11 Gm11974 0.97 Sep-04 0.89
2810454H06Rik 1.44 Prtn3 1.10 Hmgb1-ps6 0.97 Gm20633 0.89
Tatdn3 1.43 Mrrf 1.10 Sytl3 0.96 Capn5 0.89
Tbc1d22bos 1.43 AU041133 1.10 Mettl8 0.96 Tgif2 0.88
Zfp873 1.40 Mical2 1.09 Zbtb49 0.96 Frs2 0.88
Cps1 1.37 Slc39a14 1.09 Fahd1 0.96 Aars2 0.88
Atl1 1.37 Gm14038 1.08 Fbxo25 0.96 Adcy4 0.88
Inpp4a 1.36 Rbm12b2 1.08 Gm14834 0.96 Gm15518 0.88
Tmem263 1.34 Zfp7 1.07 RP23-85H24 0.96 Gc 0.88
Mgll 1.33 Zbtb10 1.07 Slc9a9 0.96 Gmpr 0.88
Gm15317 1.33 Gm10612 1.06 Gm14636 0.95 Mx2 0.88
Fbp1 1.33 Gm15622 1.06 Azin2 0.95 Toe1 0.88
Ehd3 1.33 A330023F24Rik 1.05 Tat 0.95 Pcp2 0.88
Adh1 1.32 Uhrf1bp1 1.05 Dnmbp 0.95 Cav2 0.88
Aldh1a1 1.31 Brsk1 1.05 Ift46 0.95 Arhgef10 0.87
Bhmt 1.29 Plxnd1 1.05 Esyt3 0.94 Rnf43 0.87
Per2 1.29 Sik1 1.05 Hinfp 0.94 Adora2b 0.87
Thbs1 1.28 Gm29233 1.05 Fam72a 0.94 Ccnd1 0.87
Npr1 1.27 RP23-477N9 1.05 Fam206a 0.94 4931406P16Rik 0.87
Clcn2 1.26 Tex2 1.04 1700084E18Rik 0.94 Gm17077 0.87
Gm16559 1.26 Gm11688 1.03 Pah 0.94 Camsap2 0.87
AL662809 1.26 Tbx6 1.03 Gm27152 0.93 Rarg 0.86
Gm10499 1.25 Gm15347 1.03 Gm37560 0.93 Lmln 0.86
Olfr433 1.24 Ube2o 1.03 Ppap2b 0.93 Gm12164 0.86
Smim5 1.24 Cd209c 1.03 Slc39a1 0.93 Olfr1396 0.86
Rgcc 1.21 Alb 1.02 Iigp1 0.93 Odf2l 0.86
Wrb 1.21 Prepl 1.02 Hsf4 0.93 Rps27a-ps2 0.86
Raver2 1.21 Tnni2 1.02 Slc37a4 0.93 Atf3 0.86
Clip2 1.20 Zfp40 1.02 Diexf 0.93 Setd8 0.85
Hist3h2a 1.20 Rybp 1.01 Lrrc14b 0.93 Apoc1 0.85
Fabp1 1.20 Kptn 1.01 Tmem204 0.93 Fabp4 0.85
Slc36a1 1.19 Dgkg 1.01 Rab11fip5 0.92 Mettl7a1 0.85
Dysf 1.19 Fabp7 1.01 Plekhg5 0.92 B4galt6 0.85
Aldob 1.18 Snord100 1.01 Daam1 0.92 Gm12758 0.85
Stk39 1.18 Scyl2 1.01 Fam174b 0.92 Tinagl1 0.85
Eml6 1.18 1700056E22Rik 1.01 Agl 0.91 Il6st 0.85
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Gbp6 0.85 Fam220a 0.78 Nudt18 0.70 Dnajb9 0.64
Fcrlb 0.85 Zfp687 0.78 Slc25a47 0.70 Kdelc1 0.64
G2e3 0.85 mt-Nd3 0.77 Zfp426 0.70 Hspa2 0.64
Snx12 0.85 U2af1 0.77 Lcor 0.69 Itih4 0.64
Rpgrip1 0.84 Abhd1 0.77 Spsb2 0.69 Gdf15 0.64
Ipo8 0.84 Vars2 0.77 Acot11 0.69 Erlin1 0.64
Tprn 0.84 2410017I17Rik 0.77 Bzw2 0.69 Dchs1 0.64
Rcl1 0.84 RP24-500I24 0.77 Xpo4 0.69 Nckap1 0.64
Ocrl 0.84 Pi4k2a 0.76 Gas7 0.69 Plekha3 0.64
2810408I11Rik 0.84 Ggcx 0.76 Desi1 0.69 Rgs18 0.64
Gm37125 0.84 Gramd1b 0.76 Gng3 0.69 Ero1l 0.64
Zbtb40 0.84 Gm29331 0.76 Cfl2 0.69 Dopey2 0.64
2410131K14Rik 0.83 Dedd 0.76 Pfdn2 0.69 Gm26620 0.64
Harbi1 0.83 Tpgs2 0.76 mt-Ts1 0.69 Pigu 0.63
Plxdc2 0.83 Sidt1 0.76 Pla1a 0.69 Rab3d 0.63
Ccdc32 0.83 Rnf180 0.75 Repin1 0.69 mt-Nd2 0.63
Pcgf3 0.83 Osgin1 0.75 Mvb12a 0.68 Ggta1 0.63
Hmox1 0.82 Art3 0.75 Slx4 0.68 Sh3tc1 0.63
Deptor 0.82 Ache 0.75 Fut7 0.68 mt-Rnr2 0.63
2010103J01Rik 0.82 Zfand1 0.75 Atp1a3 0.68 Trim37 0.63
Csnk1e 0.82 Vcl 0.75 Slc7a11 0.68 Isca1 0.63
Arl10 0.82 Nipa2 0.75 WI1-2065I1 0.68 Spast 0.63
Rcor1 0.82 Tnfrsf21 0.75 Ccdc142 0.67 Ltbr 0.63
Stambpl1 0.82 Smim19 0.74 Cox18 0.67 Gm10640 0.63
Lamc1 0.82 Zdhhc21 0.74 P2rx7 0.67 Gtf2i 0.63
Ric1 0.82 Reep6 0.74 Havcr2 0.67 D10Wsu102e 0.63
Hdac4 0.82 Gm15475 0.74 5430405H02Rik 0.67 Ambp 0.62
Pdgfb 0.81 Fam118b 0.74 Gm16229 0.67 Gm15542 0.62
Gm7658 0.81 Rell1 0.73 Arhgef19 0.66 Fam150b 0.62
Gm37062 0.81 Stx3 0.73 Gm27184 0.66 Zfp131 0.62
Gm29054 0.81 mt-Rnr1 0.73 Trmt2b 0.66 Pzp 0.62
Gm37249 0.81 Gm15650 0.73 Rps19bp1 0.66 Tdrp 0.62
Sort1 0.81 mt-Ty 0.72 Ushbp1 0.66 Fgd4 0.62
Cald1 0.80 Syne1 0.72 Loxl4 0.65 Gm13340 0.61
Gm1965 0.80 Bmpr1a 0.72 Hspa1b 0.65 Prr5l 0.61
Plk2 0.80 Acad8 0.72 Trmt11 0.65 Nufip2 0.61
Ccrl2 0.80 Sepp1 0.72 Med19 0.65 Trib1 0.61
Ctsl 0.80 Eml2 0.72 Mak 0.65 Ppif 0.61
Fmnl2 0.79 Pdap1 0.72 Wbp1 0.65 Prpf19 0.61
Ptprs 0.79 Rap2a 0.72 Hspa1a 0.65 Gm15850 0.61
Cxcr4 0.79 Serpinb6a 0.72 Sc5d 0.65 Galnt18 0.61
Gm6768 0.79 Gm16059 0.71 Cox19 0.65 Mapk1ip1l 0.61
Hsph1 0.79 Bcl2a1d 0.71 Mnda 0.65 Arih1 0.61
Bbx 0.79 Rn18s-rs5 0.71 Ciao1 0.65 Osmr 0.60
Gsta3 0.79 Igkv6-29 0.71 Ccdc142os 0.65 Edrf1 0.60
Hpd 0.78 Fmnl3 0.71 mt-Co1 0.65 Csf2rb2 0.60
Rgn 0.78 2310010G23Rik 0.70 Gm20481 0.65 Rit1 0.60
Oplah 0.78 4931406C07Rik 0.70 Gm6733 0.65 C2cd2l 0.60
Cdpf1 0.78 Chst15 0.70 Rhbdd2 0.65 Nt5dc1 0.60
Gm28959 0.78 Cdc27 0.70 Hgd 0.65 Gzf1 0.60
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Nrp1 0.60 Marcksl1 0.54 Tdrd3 0.48 Gm16984 0.43
Zfp637 0.60 Syngr2 0.54 F420014N23Rik 0.48 3110002H16Rik 0.43
Rps6ka4 0.60 Tra2a 0.54 Plin2 0.48 Polb 0.43
4930405A21Rik 0.59 Dnah17 0.54 Psmd6 0.48 Ccdc88b 0.43
Sdc4 0.59 Fam76b 0.54 Zscan29 0.48 Dynll1 0.43
Vamp3 0.59 Gfm1 0.54 Dnaja1 0.48 Wdr74 0.43
Rtf1 0.59 Nab2 0.53 Gm15441 0.48 Ly9 0.43
Wdfy1 0.59 Fut8 0.53 Fam188a 0.48 Cd86 0.42
Nrbp2 0.59 2410004P03Rik 0.53 Gm37787 0.47 Psmc5 0.42
Fam134c 0.59 Eps15 0.53 Kmt2b 0.47 Mfsd10 0.42
Lhx6 0.59 Engase 0.53 Rnf41 0.47 Alg5 0.42
Ptdss1 0.59 Pqlc2 0.52 mt-Nd6 0.47 Ptpn18 0.42
Cacybp 0.59 Rab11fip1 0.52 Sod1 0.47 Elp2 0.42
Ulk1 0.58 Lacc1 0.52 Aco1 0.47 Hsd17b4 0.42
Spdya 0.58 Tcaf1 0.52 Yif1a 0.47 Gm17139 0.42
Nfic 0.58 mt-Nd4 0.52 Pno1 0.47 Mtch2 0.42
Pip4k2c 0.58 Zfp646 0.52 Ldah 0.47 Ndnl2 0.41
RP23-153H17 0.58 Arl1 0.52 Mfsd11 0.47 Mvp 0.41
Zfp358 0.58 Klhl5 0.52 Mme 0.47 Ate1 0.41
Gpr182 0.58 mt-Cytb 0.52 Nom1 0.46 Kars 0.41
Gm14549 0.58 Cmtm3 0.52 Cct6a 0.46 Rpl22l1 0.41
Dhrs4 0.57 Aagab 0.52 Armc8 0.46 Pgs1 0.41
Tmed9 0.57 Ndufv3 0.52 Farsa 0.46 Pgm1 0.41
Uqcc1 0.57 Slc52a2 0.52 Etf1 0.46 Trap1 0.41
Nit1 0.57 Mrps10 0.52 Rogdi 0.46 Ddx3x 0.41
Esam 0.57 Apol7a 0.51 Pgap2 0.45 Snrpb 0.40
Utp15 0.57 Casp9 0.51 Litaf 0.45 mt-Nd5 0.40
Poglut1 0.57 Vdac1 0.51 Pla2g3 0.45 Txnip 0.40
Sod2 0.56 Slamf7 0.51 Bola1 0.45 Hspa8 0.40
Slc25a51 0.56 Cdip1 0.51 Tagap 0.45 Gls 0.40
Taf13 0.56 Ccdc47 0.51 Yipf5 0.45 Fndc3a 0.40
Sarm1 0.56 Adss 0.51 Parp14 0.45 Jarid2 0.40
Tmem132a 0.56 Rab1 0.51 AI662270 0.45 Uhmk1 0.39
Gata4 0.56 Clp1 0.51 E2f2 0.44 Gm12715 0.39
Man2b2 0.56 Icam1 0.51 Gm17711 0.44 Gnb2l1 0.39
Fcgrt 0.55 Usp39 0.50 Trim25 0.44 Eif2b4 0.39
Rnmt 0.55 Ccnt1 0.50 Tpra1 0.44 Minos1 0.39
Epha4 0.55 Tctex1d2 0.50 Eci2 0.44 Bcl2l11 0.39
Mrpl51 0.55 Olfr110 0.50 Pdcd6 0.44 Fuca2 0.38
Cltb 0.55 Enoph1 0.50 Mapre2 0.44 Srpr 0.38
RP23-173N16 0.55 Actr10 0.50 2610001J05Rik 0.44 Prpf6 0.38
Klhdc3 0.55 Pak2 0.49 4930539J05Rik 0.44 Ywhag 0.38
Meis2 0.55 Ei24 0.49 Rpl22 0.44 Mff 0.38
Nip7 0.55 Fdft1 0.49 Fam63a 0.44 Nop10 0.38
Ctdnep1 0.55 Rhbdf2 0.49 Zzef1 0.44 Rgs2 0.38
Ccdc43 0.55 Tmem126b 0.49 Akr1a1 0.44 Cyp4f13 0.37
Isy1 0.55 Stap2 0.49 Acly 0.43 Mrpl47 0.37
Lmf1 0.54 Psap 0.49 Ube2w 0.43 Ndufb6 0.37
Cnpy2 0.54 mt-Nd1 0.49 P2ry6 0.43 Hdlbp 0.37
Orc4 0.54 Synj1 0.48 Arl8b 0.43 Eif3m 0.37
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Mrfap1 0.37 Vimp 0.28 Cirbp -0.34 Nxf1 -0.42
Etfa 0.37 Id3 0.28 Nosip -0.34 Ccnl1 -0.42
Hcls1 0.37 Calr 0.28 Ptpn22 -0.35 Smu1 -0.42
Ndufb5 0.37 Cox7a2l 0.28 Ikbkb -0.35 Pts -0.42
Tob2 0.37 Cript 0.27 Pcif1 -0.35 Pde4b -0.42
Sgk1 0.37 Rplp0 0.27 Hnrnpa1 -0.35 Ppp1cc -0.42
Sema4a 0.37 Ubap1 0.27 Tmem43 -0.35 Scand1 -0.42
Fth1 0.36 Sec13 0.27 Srrd -0.36 Brd7 -0.42
Slc25a12 0.36 Ostf1 0.26 Ppp1cb -0.36 Fen1 -0.42
Kctd10 0.36 Psma1 0.26 Nrm -0.36 Fam134a -0.42
Thumpd1 0.36 Tpt1 0.26 Glud1 -0.36 Txlna -0.42
Hint1 0.36 Eif4b 0.26 Mrps9 -0.36 Fam49b -0.42
Ddb1 0.36 Hdgfrp3 0.26 Grb2 -0.37 Rab2a -0.42
H2-DMb1 0.36 Fkbp1a 0.24 Dph5 -0.37 Sh3kbp1 -0.42
Tfg 0.36 Cct4 0.23 Nlrc5 -0.37 Ypel1 -0.42
Samm50 0.36 Mbnl2 0.22 Tmem55b -0.37 Nelfa -0.43
Trappc6b 0.34 Rps2 0.19 Tef -0.37 Sdr39u1 -0.43
Slc3a2 0.34 Ube2d3 0.16 Anp32b -0.38 Sap30bp -0.43
Top1 0.34 Dnm2 -0.16 Filip1l -0.38 Actr1b -0.43
Chmp7 0.34 Smc1a -0.21 Samd11 -0.38 Thap3 -0.43
Thap6 0.34 Abi1 -0.23 Elavl1 -0.38 Gpcpd1 -0.43
Esd 0.34 Acat1 -0.24 Ankrd54 -0.38 Birc3 -0.44
Mat2a 0.34 Smarca4 -0.24 Recql5 -0.38 Gm21958 -0.44
Abcd1 0.34 Polr2m -0.25 Pithd1 -0.38 Gnb1 -0.44
Pcbp1 0.34 Lsm14a -0.26 Tor4a -0.38 Tk2 -0.44
Myo1h 0.34 Mettl23 -0.26 Rexo1 -0.38 Wac -0.44
RP23-450O11 0.34 Ewsr1 -0.26 Sirt7 -0.38 Sltm -0.44
Gm10767 0.33 Prickle3 -0.28 Topbp1 -0.39 Mbip -0.44
Tox4 0.33 Ptprc -0.28 Nhlrc3 -0.39 Acadl -0.44
Uqcrb 0.33 Smarcb1 -0.28 Mar-05 -0.39 Xpo6 -0.44
Nfkb1 0.33 Zfp263 -0.29 Phf20l1 -0.39 Wbp11 -0.45
Cox7c 0.33 Eif3f -0.30 Chfr -0.40 Foxp1 -0.45
Atg101 0.33 Rnf220 -0.30 Rgl2 -0.40 Vps16 -0.45
Sumo3 0.33 Ppp3ca -0.30 Gm26613 -0.40 Sh3gl1 -0.45
Pld4 0.33 Polr2b -0.30 Tcf3 -0.40 Ptpra -0.45
Eif2ak1 0.32 Cdk9 -0.30 Hip1r -0.40 Slc25a19 -0.46
Scyl1 0.32 Zfp384 -0.30 Thrap3 -0.40 Srm -0.46
Pdhx 0.32 Cers2 -0.31 Eif2a -0.40 Otud5 -0.46
Cflar 0.31 Uimc1 -0.31 Rb1cc1 -0.40 Plcl2 -0.46
Tnks2 0.31 Mgea5 -0.31 Uckl1 -0.40 Sp2 -0.46
Rps17 0.31 Denr -0.31 Gpn1 -0.40 Nsmce4a -0.46
Ost4 0.31 Tecr -0.31 Hnrnpdl -0.40 Ufl1 -0.47
Vps41 0.31 Traf7 -0.31 Nup85 -0.41 Ogfod2 -0.47
Ostc 0.31 Jak3 -0.32 Cnot1 -0.41 Rqcd1 -0.47
Actg1 0.30 Nubp1 -0.32 Naa25 -0.41 Golga2 -0.47
Ppp2r2a 0.30 AI413582 -0.33 Selo -0.41 Iqcg -0.47
Isyna1 0.30 Atp2a3 -0.33 Smg1 -0.41 Rassf3 -0.48
Tmem50b 0.30 Apex1 -0.34 Ddx54 -0.41 Zfp410 -0.48
Srgn 0.30 Pias4 -0.34 Pi4ka -0.41 Vps36 -0.48
Mdh2 0.28 Sf3b3 -0.34 Rnf130 -0.41 Map7d1 -0.48
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Gene Log2FC Gene Log2FC Gene Log2FC Gene Log2FC
Kansl2 -0.48 Aaas -0.54 Cdk16 -0.59 Hist1h3b -0.63
Bad -0.48 Tmem242 -0.54 Slc30a9 -0.59 Gm10135 -0.64
Pml -0.48 Tyw1 -0.54 Chic2 -0.59 Slc1a5 -0.64
Cab39 -0.48 Ankrd11 -0.54 Supt7l -0.59 Fam160b2 -0.64
Recql -0.49 Gnptab -0.54 Trac -0.59 Pdcd2 -0.64
Taz -0.49 Cog1 -0.54 Slc25a28 -0.59 Atp11c -0.64
Med12 -0.49 Upf2 -0.55 Mrps35 -0.60 Nat6 -0.64
Ralgapb -0.49 Trak1 -0.55 Phf1 -0.60 Dusp22 -0.64
Gtf3c2 -0.49 Zc3h14 -0.55 Mbd3 -0.60 Gm27017 -0.64
Snx9 -0.49 Eed -0.55 Mtmr3 -0.60 Gltscr1 -0.64
Noc2l -0.49 Foxo1 -0.55 Trim44 -0.60 Cbx7 -0.64
Itgav -0.49 Lnx2 -0.55 Ankrd46 -0.60 Clock -0.64
Rhoq -0.50 F8a -0.55 Snhg5 -0.60 Aff1 -0.64
Golga1 -0.50 Cerk -0.56 Xylt2 -0.60 Aptx -0.64
Pdcd2l -0.50 Tmem165 -0.56 Txndc11 -0.60 2810417H13Rik -0.64
Gm37305 -0.50 Pink1 -0.56 Top2b -0.60 Slc38a9 -0.64
Gm11724 -0.50 Nf2 -0.56 Gm16276 -0.60 Ankrd13c -0.65
Tmpo -0.50 Trbc2 -0.56 Med31 -0.60 Adck5 -0.65
Cntrl -0.50 Gtf2h4 -0.56 Fbxl20 -0.60 Anapc4 -0.65
Ppp1r18os -0.51 Tprgl -0.56 Dcdc2b -0.60 Clasrp -0.65
Arhgap4 -0.51 Iws1 -0.56 Kdm6a -0.60 Ilkap -0.65
Ankrd52 -0.51 Gm18829 -0.56 Tmtc1 -0.60 Nr2f6 -0.65
Ubqln1 -0.51 Ndrg3 -0.57 Bag1 -0.60 Mre11a -0.65
Adsl -0.51 Dyrk2 -0.57 3110082I17Rik -0.60 Fam3b -0.66
Ndufaf4 -0.51 Anapc2 -0.57 Galt -0.61 Taf1 -0.66
Pigq -0.51 Gm5601 -0.57 Eral1 -0.61 Metap1d -0.66
Klf3 -0.51 Pik3r2 -0.57 Tmc8 -0.61 Gm12039 -0.66
Taf8 -0.52 Fbxo28 -0.57 Nfatc1 -0.61 Trp53bp2 -0.66
Atp2a2 -0.52 Ddx28 -0.57 RP24-303G10 -0.61 Ndor1 -0.66
Opa1 -0.52 Nomo1 -0.57 Slain2 -0.61 Cebpd -0.66
Gm26765 -0.52 Gm15675 -0.57 Chmp6 -0.61 Chd9 -0.67
L3mbtl3 -0.52 Mapk1 -0.57 Smarcd2 -0.61 Gm11575 -0.67
Avpr2 -0.52 Mrps30 -0.57 Kri1 -0.61 Zbtb11 -0.67
Zfpl1 -0.52 Rrs1 -0.57 Gm26770 -0.61 Col5a3 -0.67
Gm26773 -0.52 Gm37266 -0.57 Ppm1d -0.61 Fdxr -0.67
Itsn2 -0.52 Sharpin -0.58 Rsbn1 -0.62 Ice2 -0.67
Pik3ca -0.53 Gm16184 -0.58 Plk3 -0.62 Foxj2 -0.67
Pcyt2 -0.53 Zfp809 -0.58 Rufy3 -0.62 Gm12159 -0.68
Trim14 -0.53 Pank2 -0.58 Ap1g2 -0.62 Zfp12 -0.68
Dcp1a -0.53 Wars -0.58 Get4 -0.62 Gm11723 -0.68
Traf3ip3 -0.53 Snx30 -0.58 Mad2l1 -0.62 Rufy1 -0.68
Smarcc1 -0.53 Sh2b3 -0.58 Pomk -0.62 D630044L22Rik -0.68
Prkcb -0.53 Chadl -0.58 Nol9 -0.62 Trmu -0.68
Rasal3 -0.53 Gbp8 -0.58 Alg3 -0.62 Nsmaf -0.69
Rbms1 -0.53 Lactb -0.58 Pmpca -0.63 Klf2 -0.69
Peli1 -0.53 Gm15246 -0.58 Fasn -0.63 Kctd13 -0.69
Caskin1 -0.53 Rnf31 -0.58 B430218F22Rik -0.63 Tmem110 -0.69
Ttc17 -0.53 Rnf144a -0.58 Ppp2r2d -0.63 Fam129c -0.70
Mrpl21 -0.54 Rhno1 -0.59 Capn15 -0.63 Dstyk -0.70
Ppp2ca -0.54 Hist2h2bb -0.59 Srfbp1 -0.63 Mettl1 -0.70
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Kcnq1ot1 -0.70 Nacc1 -0.76 Uri1 -0.82 Kat2b -0.86
Samd10 -0.70 Dfna5 -0.76 Aff3 -0.82 Insl6 -0.86
Gm16907 -0.70 Setd6 -0.76 Zfp747 -0.82 Zfp597 -0.87
Nupl2 -0.70 Klhdc10 -0.76 Cdc25b -0.82 9930021J03Rik -0.87
Slc16a6 -0.71 4933427D14Rik -0.76 Slc38a6 -0.82 Fam160b1 -0.87
Kif20a -0.71 Rnf26 -0.76 Gm15448 -0.82 Crispld2 -0.87
U2surp -0.71 Cstf2 -0.77 Pou6f1 -0.82 Gm17435 -0.87
Fry -0.71 Fam111a -0.77 Galnt9 -0.82 Asb13 -0.87
Gm16235 -0.71 Cpox -0.77 Zfp94 -0.82 Zbtb48 -0.87
Prorsd1 -0.71 Gm20033 -0.77 Trim40 -0.83 Tbc1d2 -0.87
Wdr11 -0.72 Snupn -0.77 Sun1 -0.83 Apoh -0.87
Gm26737 -0.72 Gorab -0.77 Gm10306 -0.83 Rab24 -0.87
Gm11831 -0.72 BC065403 -0.77 Elmsan1 -0.83 RP23-130C18 -0.87
Fbxw7 -0.72 4932438A13Rik -0.77 Vis1 -0.83 Zfp960 -0.88
Khnyn -0.72 Snta1 -0.77 Klc2 -0.84 Gm9870 -0.88
Actr5 -0.72 Lins -0.77 Zbtb5 -0.84 Gm26733 -0.88
Zfp35 -0.73 Ccdc181 -0.78 1110002L01Rik -0.84 Herpud2 -0.88
Irf2bp1 -0.73 Gsk3b -0.78 Ctu1 -0.84 Rps19-ps3 -0.88
Slc2a3 -0.73 Mapk8 -0.78 Wipi2 -0.84 Ptrh2 -0.88
Dnmt1 -0.73 Trdmt1 -0.78 1700109H08Rik -0.84 Zfp420 -0.88
Ptcd3 -0.73 Chac1 -0.78 Alkbh8 -0.84 Zfp780b -0.88
Dynlt1b -0.73 Fam118a -0.78 Gm6712 -0.85 RP23-443N7 -0.88
Napb -0.73 Tysnd1 -0.78 Tmem245 -0.85 Dtx1 -0.89
Sac3d1 -0.73 Zfp771 -0.78 Gm26835 -0.85 Dmxl2 -0.89
Upf1 -0.73 Txnrd3 -0.78 Inafm1 -0.85 Gm37844 -0.89
Ppp3cc -0.73 Gm15466 -0.79 Gm24157 -0.85 Zbtb32 -0.89
Trim27 -0.73 Slc35e3 -0.79 Gm12158 -0.85 Krt222 -0.89
Timm9 -0.74 Ptdss2 -0.79 Tomm20l -0.85 Wdr34 -0.89
Gm11131 -0.74 Pou2f1 -0.79 Tmem62 -0.85 Faah -0.89
Slc26a11 -0.74 Grk6 -0.79 Ppard -0.85 Wee1 -0.90
1700048M11Rik -0.74 Polr3d -0.79 Zfp395 -0.85 Ighv8-2 -0.90
Rnf11 -0.74 B230377A18Rik -0.79 RP23-204A8 -0.85 Anln -0.90
Klhdc2 -0.75 Zcchc11 -0.79 Mettl18 -0.85 Xlr4b -0.90
Ltk -0.75 Gm16894 -0.80 Ighv1-42 -0.85 Gm11464 -0.90
Oxr1 -0.75 Ldb1 -0.80 9430098F02Rik -0.85 Ppp2r5e -0.91
Csad -0.75 Riok2 -0.81 Gm21738 -0.85 Abtb2 -0.91
Sbk1 -0.75 Gm12265 -0.81 Cbr2 -0.85 Ppfia1 -0.91
Ptgs2 -0.75 Clstn1 -0.81 Atrip -0.85 Snord89 -0.91
Gm26873 -0.75 Fbxl14 -0.81 Cep78 -0.85 Ubox5 -0.91
E130309D02Rik -0.75 Zw10 -0.81 Fbxw17 -0.85 Zgrf1 -0.91
Rfx1 -0.75 Aasdh -0.81 Nusap1 -0.86 Cmc2 -0.92
Chd1l -0.75 Erdr1 -0.81 Map3k7 -0.86 Igkv14-126 -0.92
Paqr3 -0.75 Gm8482 -0.81 Ppm1b -0.86 Gm16577 -0.92
Elmod3 -0.75 Taf5 -0.82 Gm16015 -0.86 Rps6ka5 -0.92
Mapk11 -0.75 Zdhhc8 -0.82 Pcgf1 -0.86 Habp4 -0.92
Galnt1 -0.76 Sun2 -0.82 Msh5 -0.86 Zfp26 -0.92
Csnk1g1 -0.76 Ralgapa1 -0.82 2900076A07Rik -0.86 Klhl17 -0.93
Wrap73 -0.76 Sssca1 -0.82 Klre1 -0.86 Gm15408 -0.93
1700037H04Rik -0.76 RP23-447N11 -0.82 Tbx21 -0.86 F630028O10Rik -0.93
Ficd -0.76 Zfp518a -0.82 Lsm7 -0.86 2010016I18Rik -0.93
160
Appendix table 3.4: Differentially expressed mRNAs in CLPDC compared to ELPDC 
Gene Log2FC Gene Log2FC Gene Log2FC Gene Log2FC
1810026J23Rik -0.93 Armcx5 -1.01 Zfp169 -1.16
Sox4 -0.93 Mss51 -1.02 Hras -1.17
Zfp275 -0.93 Gm19585 -1.02 RP23-371A16 -1.19
Lat -0.93 Nek11 -1.03 Zfp558 -1.20
Serpini1 -0.93 Klk8 -1.03 9430025C20Rik -1.22
Gm11787 -0.93 Fbxo31 -1.03 Ccdc116 -1.23
Rab4b -0.94 Sapcd1 -1.03 Ighv11-1 -1.25
Bloc1s4 -0.94 Ffar1 -1.03 H2-Q10 -1.25
Gm27201 -0.94 Rltpr -1.03 Usp27x -1.25
Ccsap -0.94 Frat2 -1.03 Ankrd33b -1.27
Rbm26 -0.94 4833417C18Rik -1.04 Gm16793 -1.29
Gm10501 -0.94 Srf -1.04 Klra1 -1.30
Cd163l1 -0.94 Jund -1.04 Zfp839 -1.30
Sfmbt2 -0.95 Cd5 -1.04 Zfp867 -1.30
RP23-106G24 -0.95 Acvr2b -1.04 Gm14276 -1.31
Btnl1 -0.95 Gng13 -1.05 Mterf1a -1.31
1700055D18Rik -0.95 1110008L16Rik -1.05 Zc3h6 -1.36
Sestd1 -0.95 Tbc1d13 -1.05 Cdc7 -1.37
B130006D01Rik -0.95 Gm27285 -1.05 Wdr89 -1.37
Pole -0.96 Igkv4-81 -1.05 Zfp955a -1.38
8030462N17Rik -0.96 Npas1 -1.05 Cd27 -1.42
Gm26699 -0.96 Dhx35 -1.06 Bod1 -1.43
Snord8 -0.96 Tacstd2 -1.06 Rnf103 -1.45
Dzip3 -0.96 Zfp236 -1.06 Ighv11-2 -1.47
Gm11592 -0.96 Yae1d1 -1.08 Top2a -1.49
RP23-286M3 -0.96 Cyp39a1 -1.08 Dnah8 -1.49
Rgs13 -0.97 Xrcc3 -1.08 Foxd4 -1.52
Shprh -0.97 Dpy19l3 -1.08 Casz1 -1.55
Zfp617 -0.97 Dtd2 -1.08 2500002B13Rik -1.58
Ahi1 -0.97 Gm11175 -1.09 Cass4 -1.66
Ighv14-4 -0.97 Rfng -1.09 Gm10676 -1.71
Gprasp1 -0.97 Gm21887 -1.10 Gm29236 -1.77
Zfp14 -0.98 RP23-301L9 -1.10 Zfp595 -1.83
Ceacam2 -0.98 Elp4 -1.10 Klhl38 -1.84
Setd4 -0.98 Slfn4 -1.11 Gm14455 -1.97
Cep83os -0.98 Scn4a -1.11 Kif2c -2.31
Wdr45 -0.98 Wdr44 -1.11 Fras1 -2.81
Ppp1r3b -0.99 1810021B22Rik -1.12
Dicer1 -0.99 Socs1 -1.12
Tnfsf14 -0.99 Bhlhe41 -1.12
Map10 -0.99 Rtel1 -1.12
Gm37379 -0.99 E130102H24Rik -1.13
Alyref -1.00 Ppp6r2 -1.13
Dcp1b -1.00 Zfp512 -1.13
Lgals4 -1.00 RP23-173N16 -1.14
Igkv3-7 -1.00 Vamp1 -1.14
Cep152 -1.00 B230217O12Rik -1.15
RP23-97M20 -1.00 Brca2 -1.15
Ctbp1 -1.01 Tmem40 -1.16
Spef1 -1.01 RP24-229D18 -1.16
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Appendix table 3.5: Gene ontology terms enriched in commonly upregulated mRNAs in ELPDC and CLPDC compared to ELNDC and CLNDC respectively
Gene Ontology Term Genes PValue Benjamini
GO:0002684~positive regulation of immune system 
process
FCER2A, CR2, TNFRSF13C, CD1D1, H2-Q6, C1QC, FOXP1, CFP, C1QA, C1QB, 
CD38, CD37, CD55, CD19, HPX, CD81, IL12A, CD79B, CD79A 2.09E-10 2.59E-07
GO:0050778~positive regulation of immune response FCER2A, CR2, TNFRSF13C, CD1D1, H2-Q6, C1QC, C1QA, CFP, C1QB, CD55, CD19, HPX, CD79B, CD79A 2.57E-08 1.59E-05
GO:0006955~immune response
GBP8, SIT1, CR2, SWAP70, TLR1, CD300E, TNFRSF13C, ACP5, CD1D1, H2-Q6, 
C1QC, H2-DMB2, FOXP1, CFP, C1QA, C1QB, CCR7, CD55, IL18BP, H2-OB, IL12A, 
CD79B, CD79A, LTB
5.30E-08 2.19E-05
GO:0048584~positive regulation of response to stimulus FCER2A, CR2, TNFRSF13C, CD1D1, H2-Q6, C1QC, CFP, C1QA, C1QB, CD55, S1PR1, CD19, HPX, CD79B, CD79A 1.53E-07 4.73E-05
GO:0001775~cell activation P2RY12, CD86, CR2, CXCR5, CLCF1, SWAP70, TLR1, MS4A1, EVL, BANK1, CD79A, CD1D1, LTB, FOXP1, BLNK 4.38E-06 0.001085079
GO:0042113~B cell activation CR2, CXCR5, CLCF1, SWAP70, MS4A1, CD79A, BANK1, FOXP1, BLNK 7.95E-06 0.001641146
GO:0002253~activation of immune response C1QA, CFP, C1QB, CD55, CR2, CD19, CD79B, CD79A, C1QC 1.65E-05 0.002910584
GO:0006956~complement activation C1QA, CFP, C1QB, CD55, CR2, C1QC 9.89E-05 0.015203133
GO:0002541~activation of plasma proteins involved in 
acute inflammatory response C1QA, CFP, C1QB, CD55, CR2, C1QC 9.89E-05 0.015203133
GO:0045321~leukocyte activation CD86, CR2, CXCR5, CLCF1, SWAP70, TLR1, MS4A1, CD79A, BANK1, CD1D1, FOXP1, BLNK 1.46E-04 0.019876601
GO:0046649~lymphocyte activation CD86, CR2, CXCR5, CLCF1, SWAP70, MS4A1, CD79A, BANK1, CD1D1, FOXP1, BLNK 2.10E-04 0.025714723
GO:0002252~immune effector process C1QA, CFP, C1QB, CD55, CR2, SWAP70, H2-Q6, C1QC, FOXP1 2.50E-04 0.027783228
GO:0002699~positive regulation of immune effector 
process FCER2A, CD37, HPX, CD1D1, H2-Q6, FOXP1 3.24E-04 0.03286158
GO:0002699~positive regulation of immune effector 
process FCER2A, CD37, HPX, CD1D1, H2-Q6, FOXP1 3.24E-04 0.03286158
GO:0045087~innate immune response C1QA, CFP, C1QB, CD55, CR2, TLR1, CD1D1, C1QC 5.10E-04 0.047476245
GO:0009897~external side of plasma membrane FCER2A, CR2, TNFRSF13C, CD1D1, H2-Q6, ABCG1, LY6A, CD86, CD55, CD19, S1PR1, CD69, APOE, CD274, CD2, CD22, CD79B, CD79A, CTSB 1.82E-10 3.11E-08
GO:0009986~cell surface FCER2A, CR2, TNFRSF13C, CD1D1, H2-Q6, ABCG1, LY6A, CD38, CD86, CD55, CD19, S1PR1, CD69, APOE, CD274, CD2, CD22, CD79B, CD79A, CTSB 1.62E-08 1.39E-06
GO:0005886~plasma membrane
TLR1, SLC7A8, FCRL1, CD1D1, ITSN1, FCRL5, S1PR1, CXCR5, APOE, SMAGP, LTB, 
SCAMP5, SIT1, ICAM2, SLC3A2, H2-DMB2, CD84, CD86, CCR7, MAST1, ADRB2, 
CD81, H2-OB, CTSB, SLC40A1, CLEC1B, FCER2A, CPM, RALGPS2, KCNA2, PXK, 
ABCA1, SLC29A1, VCAM1, SERINC3, LY6A, PPP1R16B, LY6D, CD69, RASGRP1, 
CD2, CD22, SLC28A2, GPNMB, BLNK, LPL, CR2, SWAP70, TGFBR1, TNFRSF13C, 
SLAMF6, CD300E, EVL, H2-Q6, ABCG1, P2RY12, P2RY13, ITGA9, CD55, ADAP2, 
CD19, PTP4A3, CD207, STAB1, PECAM1, CD274, ABCC3, CD79B, CD79A, CD200
4.29E-08 2.44E-06
GO:0000323~lytic vacuole TPP1, LGMN, H2-OB, ACP5, CTSB, CD1D1, LMBRD1, DPP7, H2-DMB2, DNASE2A 5.59E-04 0.015808206
GO:0005764~lysosome TPP1, LGMN, H2-OB, ACP5, CTSB, CD1D1, LMBRD1, DPP7, H2-DMB2, DNASE2A 5.37E-04 0.018204457
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Gene Symbol Log2FC Gene Symbol Log2FC Gene Symbol Log2FC Gene Symbol Log2FC Gene Symbol Log2FC
Cidec 3.02 Ccr7 1.58 Ccdc80 1.42 Smoc2 1.31 H2-Aa 1.26
Gpc1 2.69 Glipr1 1.58 Unc119 1.42 Trps1 1.31 Casc5 1.26
Themis 2.52 Olig1 1.57 Basp1 1.42 Fbln2 1.30 Sdk1 1.26
Ttc39a 2.23 C5ar1 1.57 Cx3cl1 1.42 Cdkn1a 1.30 Pcdh7 1.25
Cntnap1 2.20 Ccl22 1.57 Ccdc120 1.41 Atp1a2 1.30 Samd14 1.25
Ubd 2.18 Scube1 1.57 Snhg18 1.41 Fbln1 1.30 Adam19 1.25
Smpd3 2.17 Meox1 1.56 RP23-258C6 1.41 Epb4.1l1 1.30 Rab44 1.25
Ly6d 2.16 Mmp2 1.56 Ncapg2 1.41 Selplg 1.30 S100a6 1.25
Gpnmb 2.03 Cd63 1.56 Col4a2 1.41 Cdc20 1.30 Ttc39aos1 1.25
Svep1 2.02 Col1a2 1.56 Lgals3 1.41 Ccdc3 1.30 Sash3 1.25
Thbs2 2.02 Uhrf1 1.56 Aebp1 1.40 Unc5b 1.30 Cd300lb 1.25
Gprc5b 2.00 Synpo 1.55 Slc39a5 1.39 Rad51 1.30 Ermp1 1.25
Thbs1 1.98 Col4a1 1.54 Col6a1 1.39 Haus8 1.30 Adam8 1.25
Timp1 1.97 Emp1 1.54 Col6a3 1.39 Pik3r5 1.30 Sirpb1a 1.25
Fam83a 1.97 Abcc12 1.54 Acot2 1.39 Plaur 1.29 Mcm4 1.25
Serpine1 1.93 Lsp1 1.54 Ccl4 1.39 S100a11 1.29 Clec5a 1.24
Casc4 1.91 Prkar2b 1.53 Slc1a4 1.39 Chil3 1.29 Cd74 1.24
Pkp1 1.88 Loxl2 1.52 Nek2 1.39 Gdf6 1.29 Sdcbp2 1.24
Spon2 1.87 Corin 1.52 Capg 1.39 Hr 1.29 Efemp2 1.24
Adgrg2 1.85 Racgap1 1.52 Cd72 1.39 Tnfaip3 1.29 Diap3 1.24
Gpr35 1.85 Plxdc2 1.52 Trpm4 1.39 Adrbk2 1.29 Tbx20 1.24
Ccl5 1.84 Mcm2 1.51 1700024P16Rik 1.38 Mfap4 1.29 Col5a1 1.24
Anxa2 1.83 Adamts2 1.51 Prc1 1.38 Gipc2 1.29 H2-DMa 1.24
Cgref1 1.81 RP23-134K6 1.51 Tlr1 1.38 Zfp9 1.29 Plin4 1.24
Lrrc39 1.81 Sema4d 1.51 H2-DMb1 1.38 Ptgfrn 1.29 Zfp608 1.23
Uap1l1 1.80 Top2a 1.50 Myo1f 1.38 Lum 1.29 Lgi2 1.23
Fgf21 1.80 Tmem45b 1.50 Chst11 1.37 Wnt5a 1.29 C3ar1 1.23
Cxcr4 1.80 Acot6 1.50 Chek1 1.37 Ptafr 1.28 Plau 1.23
Tpm2 1.79 Nid1 1.50 Itga4 1.37 Pygb 1.28 Spib 1.23
Rgs1 1.77 Tlr12 1.49 Parvg 1.37 Scube3 1.28 Il1b 1.23
Kbtbd11 1.77 Gm13657 1.49 Pmepa1 1.37 Tnfrsf19 1.28 Prrg4 1.23
Col3a1 1.75 Mrc2 1.49 Fkbp10 1.37 2810417H13Rik 1.28 Fxyd5 1.23
Loxl1 1.74 Vnn1 1.49 Fndc5 1.37 Zfp618 1.28 Cd244 1.22
Mcm5 1.74 Cx3cr1 1.49 Dkk3 1.37 Bcl2l14 1.28 Adam12 1.22
Ltbp2 1.74 Lamb3 1.49 Ccl2 1.36 Tpx2 1.28 Stil 1.22
Bhlhb9 1.74 Shc2 1.49 H2-Eb1 1.36 Gpr12 1.28 Pparg 1.22
Apoa4 1.74 Ccna2 1.49 Adcy1 1.36 Cd8b1 1.28 Sema3b 1.22
Lox 1.73 Cytip 1.48 Mterf2 1.36 Cd180 1.28 Napsa 1.22
Tnc 1.73 Lrrc14b 1.48 Nupr1 1.36 Cenpf 1.27 Psat1 1.22
Itgax 1.72 Clec7a 1.48 Ckap2l 1.35 Bub1b 1.27 Eda2r 1.22
Adamts15 1.72 Tagln 1.48 Dsn1 1.35 Kif4 1.27 Gdf10 1.22
Stap1 1.71 Tspan8 1.48 Nr4a1 1.35 Sirpa 1.27 Coro2a 1.22
Cacnb3 1.71 Cyp4a31 1.48 Pkib 1.35 Adcy7 1.27 Itga8 1.21
Clstn3 1.71 Chaf1a 1.48 Zfp449 1.35 Gm11843 1.27 Cd14 1.21
Eln 1.70 Adamts5 1.48 Kntc1 1.34 Slamf7 1.27 Sorl1 1.21
Lpl 1.70 Aqp7 1.47 Ccr2 1.34 Ms4a6c 1.27 Gpr39 1.21
Cd36 1.70 Col5a2 1.47 Ppfia4 1.34 Iqgap3 1.27 Iqgap1 1.21
Rbl1 1.68 Aqp4 1.47 Slpi 1.34 Robo2 1.27 Foxj1 1.21
Mmp12 1.67 Gins2 1.47 Lgals1 1.34 Ehd2 1.27 Arhgap11a 1.21
Trem2 1.66 Adamts12 1.47 Serpinb6b 1.34 Rab7b 1.27 Anxa1 1.21
Phlda3 1.66 Fstl1 1.47 Cd93 1.33 Ace 1.27 Spag5 1.21
Col1a1 1.65 Tmem119 1.47 Samd4 1.33 Cav1 1.26 Cd34 1.21
Spn 1.65 Cpxm2 1.47 Foxs1 1.33 Col4a5 1.26 Nusap1 1.20
C1qtnf6 1.64 Atf3 1.47 Islr 1.33 Ckap2 1.26 RP24-487F9 1.20
Ifi27l2b 1.64 Plat 1.46 Fry 1.33 Bmp8b 1.26 Arhgap25 1.20
Cd8a 1.63 Creb3l1 1.46 Mdk 1.33 Mcm3 1.26 Ak1 1.20
Hpgds 1.63 Frzb 1.46 Tiam1 1.33 Cdh11 1.26 Myo5a 1.20
Mki67 1.62 Cd83 1.46 Nes 1.32 Gale 1.26 Arhgef2 1.20
H2-M2 1.62 Fignl1 1.46 2010003K11Rik 1.32 Neil3 1.26 Boc 1.20
Olfml3 1.62 Egr2 1.46 Amz1 1.32 Fblim1 1.26 Sh3pxd2b 1.20
Clmp 1.62 Fam180a 1.45 Fbn1 1.32 Kif1a 1.26 Ighg1 1.20
Plek 1.61 Esco2 1.45 Cdca3 1.31 Card11 1.26 Fam105a 1.20
Cyp1b1 1.61 Ms4a7 1.45 Myof 1.31 Ucp2 1.26 Hmmr 1.20
Mcm6 1.60 Lama2 1.44 Cd48 1.31 Kif20a 1.26 Cd4 1.19
Dpt 1.59 Fhl2 1.44 Lynx1 1.31 Gdf3 1.26 Tmem71 1.19
Enc1 1.59 Aurka 1.43 Kif20b 1.31 Ephb2 1.26 Pak1 1.19
Col12a1 1.59 Cfap54 1.43 Nrg1 1.31 Lrrc55 1.26 Sparc 1.19
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Flna 1.19 Gfpt2 1.15 Cacna2d1 1.10 Gabrb3 1.06 Mpzl1 1.03
Lax1 1.19 Mad2l1 1.14 Ackr3 1.10 Klf6 1.06 Mbp 1.03
Cenpe 1.19 Arl11 1.14 Il21r 1.10 Acot9 1.06 Ly6c2 1.03
Cyth4 1.19 Relb 1.14 Ighg3 1.10 Ikzf1 1.06 Ms4a6d 1.03
Gm37691 1.19 Kif22 1.14 Jrk 1.10 St8sia4 1.06 Spon1 1.03
Mrgprb11 1.19 Fam189a1 1.14 Obsl1 1.10 Oxct1 1.06 Rasal1 1.03
Cyp4f16 1.19 Sla 1.14 Clec4n 1.10 Zik1 1.06 Zfp423 1.03
Tmem45a 1.19 Lrrc8b 1.14 Fgl2 1.10 Espl1 1.06 Pamr1 1.03
Pi15 1.18 Lpcat2 1.14 Mical1 1.09 Apbb1ip 1.06 Lair1 1.03
Ube2c 1.18 Itgbl1 1.14 Nrarp 1.09 Ltbp3 1.06 Ap1s2 1.03
Plxna4 1.18 Epb4.1l4a 1.14 Col8a1 1.09 Ccr1 1.06 Ptprc 1.03
Gsn 1.18 Fam102b 1.14 Lpar1 1.09 Sulf1 1.06 Srxn1 1.03
Glipr2 1.18 Bicc1 1.14 Clec4a3 1.09 Map4k4 1.06 Csf2rb2 1.03
Htra3 1.18 Vcam1 1.14 Parp8 1.09 Apobr 1.06 Itpripl2 1.03
Col6a2 1.18 Gm37795 1.13 Cdc14a 1.09 Havcr2 1.06 Chtf18 1.03
Tlr2 1.18 Dtl 1.13 Csf2ra 1.09 Adcy3 1.06 Mest 1.03
Il4i1 1.18 B4galt2 1.13 Dram1 1.09 Cenpi 1.06 Pcdh17 1.03
Cdk1 1.18 Dlgap5 1.13 Tmem132a 1.09 Scamp5 1.05 Stk10 1.03
Adamtsl2 1.18 Pdk4 1.13 Mgp 1.09 Slc7a1 1.05 Nrxn2 1.02
Sox4 1.18 Snn 1.13 Sell 1.09 Slamf9 1.05 Ptrf 1.02
Kcnab2 1.18 Morc4 1.13 Fam118a 1.09 Acta2 1.05 Sparcl1 1.02
Fam65b 1.18 Kdelr3 1.13 Blnk 1.09 Rftn1 1.05 Rab8b 1.02
Cdc6 1.17 Gpr65 1.13 Milr1 1.09 Antxr1 1.05 Ly9 1.02
Mgat3 1.17 Dusp8 1.13 Shcbp1 1.09 Cnn2 1.05 Evl 1.02
Pappa 1.17 Timp2 1.13 Coro1a 1.08 Capn6 1.05 Tacc3 1.02
Ncam1 1.17 Tinag 1.13 Hk2 1.08 Ccdc149 1.05 Fxyd6 1.02
Dock2 1.17 Syk 1.12 Bub1 1.08 Cdc25b 1.05 Frem1 1.02
Lbh 1.17 Veph1 1.12 Serpinh1 1.08 Fgf12 1.05 Ms4a4a 1.02
Ncf2 1.17 Fxyd3 1.12 Asb4 1.08 Btg2 1.05 Plekhh1 1.02
Ssc5d 1.17 Sftpd 1.12 Itm2a 1.08 Angpt1 1.05 Map4k1 1.02
H2-Ab1 1.17 Gpx3 1.12 Ncf1 1.08 Csf2rb 1.05 Ctss 1.02
Vcan 1.17 Adap1 1.12 Tspan3 1.08 Ptpn7 1.05 Gadd45b 1.02
Ehf 1.17 Scd2 1.12 Tceal8 1.08 Cpz 1.05 Cd209a 1.02
Clec4d 1.17 Scara3 1.12 S100a4 1.08 Agap2 1.05 Pnldc1 1.02
Treml2 1.17 Anxa3 1.12 Myl9 1.08 1810011H11Rik 1.05 Cerk 1.02
Tgfb3 1.17 Dock11 1.12 Tlr9 1.08 Mtnr1a 1.05 Gab2 1.02
Trib2 1.17 Stoml1 1.12 Pdlim4 1.08 Prss23 1.05 Clec4a1 1.02
Ltb 1.17 Clip3 1.12 Cc2d2a 1.08 Fgd3 1.05 Runx2 1.02
Rhoc 1.17 Mms22l 1.12 Abr 1.08 Rasal3 1.05 Tgfbi 1.01
Sntg1 1.17 Gng2 1.12 Pgm3 1.08 Kcnj2 1.05 Gabra3 1.01
Rufy4 1.16 Maged2 1.12 Tm6sf1 1.08 Syne1 1.04 Ctse 1.01
Fabp2 1.16 Mybl1 1.12 Rcn3 1.08 Igsf10 1.04 Gltp 1.01
Pkm 1.16 Zfp462 1.11 Cdkn3 1.07 Tlr13 1.04 Psd4 1.01
Gal3st1 1.16 Arhgap44 1.11 Pld4 1.07 Arl5c 1.04 Fmnl1 1.01
Tnfrsf23 1.16 Knstrn 1.11 Fcer1g 1.07 Inhbb 1.04 Dact3 1.01
Myo1g 1.16 Fbn2 1.11 Sh2d1b1 1.07 Plekha1 1.04 Cercam 1.01
Ccl3 1.16 Jun 1.11 Elf4 1.07 Zgrf1 1.04 Slfn4 1.01
Mogat1 1.16 Dbn1 1.11 Plekhm3 1.07 Epha3 1.04 Cybb 1.01
Aspm 1.16 Atp1a3 1.11 Ltf 1.07 Cdca8 1.04 Pcp4l1 1.01
Tmem86a 1.16 Gpr153 1.11 Asb2 1.07 St14 1.04 Auts2 1.01
Fbln5 1.16 Oip5 1.11 Cyba 1.07 Clec4b1 1.04 Xrcc2 1.01
P2ry6 1.16 Cd7 1.11 Foxm1 1.07 Epcam 1.04 Plekha4 1.01
Vim 1.16 Ltbp1 1.11 Col4a4 1.07 Tmem136 1.04 Cxcl10 1.01
Gp49a 1.16 Slc16a13 1.11 Mmp23 1.07 Olfml2b 1.04 Clec2i 1.01
Ddias 1.16 Gpx8 1.11 Kctd17 1.07 Slc7a6 1.03 Ddr2 1.01
Airn 1.16 Pdgfra 1.11 Grb10 1.07 Pfkp 1.03 Dennd1c 1.01
Elovl7 1.16 Pxdn 1.11 Ect2 1.07 Ppic 1.03 Gpr141 1.01
Elmo1 1.15 Kirrel 1.11 Sema5a 1.07 H2-DMb2 1.03 Wdfy4 1.01
Traf1 1.15 Cd52 1.11 Fmod 1.06 Samsn1 1.03 Spsb1 1.01
Aldh18a1 1.15 Slc8a1 1.11 Col4a6 1.06 Hvcn1 1.03 Pdlim2 1.01
Sytl4 1.15 Ms4a4b 1.11 Fcgr4 1.06 Endod1 1.03 Inpp5d 1.01
Itgb2 1.15 Serinc2 1.10 Ddit4 1.06 Lrp11 1.03 Itgam 1.00
Ciita 1.15 Gpr137b 1.10 Smc2 1.06 Sphk1 1.03 Fermt1 1.00
Cyp4a14 1.15 Mrvi1 1.10 Adrb2 1.06 Src 1.03 Ugt1a7c 1.00
Filip1l 1.15 Gpr183 1.10 Crip1 1.06 Synpo2 1.03 Arsg 1.00
Tuba1a 1.15 Igfbp1 1.10 Ms4a4c 1.06 Cd300lf 1.03 Tifab 1.00
Dhrs9 1.15 Rgs10 1.10 Ddr1 1.06 Mastl 1.03 Olfml2a 1.00
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Itgb7 1.00 Gm14446 0.97 Cbx6 0.93 Cxcl16 0.91 Cxcr2 0.88
Plcg2 1.00 Plod2 0.97 Spdl1 0.93 Slc25a24 0.91 Ecm2 0.88
B3gnt9 1.00 Pcyox1l 0.97 Rab31 0.93 Slc7a8 0.91 Tbc1d9 0.88
Kif23 0.99 AI413582 0.97 Armcx4 0.93 Vcl 0.91 Mthfr 0.88
Cyp4f18 0.99 Fam131c 0.96 Setbp1 0.93 Bok 0.91 Cib3 0.88
Fbln7 0.99 Stk39 0.96 Ppp1r18 0.93 Adcy2 0.91 Rnf150 0.88
F13a1 0.99 Sgol1 0.96 Fam217b 0.93 Itgal 0.91 Fgf2 0.88
Pmaip1 0.99 Ear2 0.96 L1cam 0.93 Mgat4a 0.91 Zwilch 0.88
Rgs19 0.99 Ten1 0.96 Laptm5 0.93 Mfge8 0.91 Igsf9 0.88
Dpysl3 0.99 Ninl 0.96 Gria3 0.93 Adamts10 0.91 Itgae 0.88
Cdk14 0.99 Zc3hav1l 0.96 Ppp1r3d 0.93 Wnk2 0.91 Tgm2 0.88
Shisa3 0.99 Ophn1 0.96 Ppm1h 0.93 Bcl6b 0.90 Ikzf3 0.88
Cox6b2 0.99 Dzip1 0.96 Nfkb2 0.93 Wt1 0.90 Tnfaip8 0.88
Tspan13 0.99 Strip2 0.96 Cd68 0.93 Fam198b 0.90 Mlkl 0.88
Ncf4 0.99 Rhoh 0.96 Tenm4 0.93 Clcf1 0.90 Atp9a 0.88
Ncapg 0.99 Orai2 0.96 Hsf2bp 0.93 Nuf2 0.90 Msc 0.88
Epb4.1l3 0.99 Ikzf2 0.96 Sema3c 0.93 Art4 0.90 Pax5 0.88
Spire1 0.99 Car2 0.96 B4galt6 0.93 Bin2 0.90 Crat 0.87
Lilrb4 0.99 Rarb 0.96 9430037G07Rik 0.93 Glis2 0.90 Icosl 0.87
Ccnb2 0.99 H2-Eb2 0.96 Rad54b 0.93 Trbc1 0.90 Pycr1 0.87
Aurkb 0.99 Itk 0.96 Nfkbid 0.92 Fhl3 0.90 Tpm1 0.87
Col16a1 0.98 Cand2 0.96 Gpr171 0.92 Serpina7 0.90 Cldn6 0.87
Fcho1 0.98 Adamts9 0.96 Ighg2b 0.92 C1qtnf7 0.90 Ncs1 0.87
Zfp651 0.98 Fitm1 0.96 Kifc1 0.92 Gm1966 0.90 Tmtc1 0.87
Cd69 0.98 Spats2l 0.96 Ggta1 0.92 Ptgfr 0.90 Abcg1 0.87
Tor3a 0.98 Shank2 0.96 Stc2 0.92 Krt23 0.90 Slc15a3 0.87
Cebpd 0.98 Zfp532 0.95 Adgrv1 0.92 Ptpn13 0.90 Slc24a3 0.87
Kcnn4 0.98 Syt9 0.95 Bgn 0.92 Mthfd2 0.90 Hells 0.87
Tagap 0.98 Runx3 0.95 Ccdc92 0.92 Phf11b 0.90 Kif3c 0.87
Slfn2 0.98 Slc1a5 0.95 Polq 0.92 Limch1 0.90 Ccdc34 0.87
Plcb2 0.98 Fam78a 0.95 Igfbp7 0.92 Rrad 0.90 Ngfrap1 0.87
Chpf 0.98 Cd53 0.95 Apobec3 0.92 Flt3 0.90 Atp6v0e2 0.87
Rassf4 0.98 Lhfp 0.95 Anln 0.92 Gramd1b 0.90 C920009B18Rik0.87
Sgol2a 0.98 Rhoj 0.95 Mtbp 0.92 Prickle2 0.90 Cd44 0.87
Lrrn4 0.98 Rragd 0.95 Prr11 0.92 Agpat9 0.90 Gja1 0.87
Apaf1 0.98 Tubb6 0.95 Synm 0.92 Afap1 0.90 Fmnl3 0.87
Mtmr11 0.98 Adamtsl3 0.95 Mup20 0.92 Csf3r 0.90 Hcar2 0.87
Nbl1 0.98 Fanca 0.95 Pvrl4 0.92 Zfp13 0.90 Mmp11 0.87
Anxa5 0.98 Chrnb1 0.95 Def6 0.92 Tlr7 0.90 Mnda 0.87
Nckap1l 0.98 Ehd4 0.95 Kctd12b 0.92 Pdgfb 0.89 Akna 0.87
Slamf8 0.98 Plekho2 0.95 Cd200 0.92 Axl 0.89 Ubash3b 0.87
Wdhd1 0.98 Rap2b 0.95 Arhgef9 0.92 Mal 0.89 Slit2 0.87
Cygb 0.97 Tmem139 0.95 Dapp1 0.92 Msn 0.89 Slamf6 0.87
Exoc3l4 0.97 Ankrd1 0.95 Slc38a1 0.92 Cd200r1 0.89 Runx1 0.87
Fos 0.97 Ctsk 0.95 Lamb1 0.92 Panx1 0.89 Elovl3 0.87
Osbpl5 0.97 Atp8b5 0.95 Ptprs 0.92 Il7r 0.89 Ncoa7 0.87
Rnf122 0.97 Cd84 0.95 Tmsb4x 0.92 Ptk7 0.89 Rad54l 0.87
Kazald1 0.97 Pask 0.95 Tgtp1 0.92 Mef2c 0.89 Rgs2 0.87
Slc16a3 0.97 Thbd 0.94 Sdk2 0.92 Fscn1 0.89 Ly86 0.87
Tmsb10 0.97 Pqlc3 0.94 Slfn1 0.92 Ckb 0.89 Naalad2 0.87
Piezo1 0.97 Arhgef25 0.94 Prdm1 0.92 Prr15l 0.89 Acss1 0.87
Fanci 0.97 BC055324 0.94 Gna15 0.92 Cd300a 0.89 Emb 0.87
Arhgap27 0.97 Chrna2 0.94 Kif21b 0.92 Tyro3 0.89 Tagln2 0.86
Mamld1 0.97 C330027C09Rik0.94 Nkg7 0.91 Trdmt1 0.89 Dock10 0.86
Sh3kbp1 0.97 Tril 0.94 Tceal1 0.91 Plekhh2 0.89 Atp2a3 0.86
Tyrobp 0.97 Zc2hc1a 0.94 Hspa1a 0.91 Clip2 0.89 Muc1 0.86
Melk 0.97 Nr4a3 0.94 Cldn4 0.91 Klra17 0.89 Kif7 0.86
Srpx 0.97 Ngp 0.94 RP23-110C17 0.91 Soat1 0.89 Csrp1 0.86
Spin4 0.97 Zfp90 0.94 Fam49a 0.91 Grhl1 0.89 Kiss1r 0.86
Ereg 0.97 Batf 0.94 Irg1 0.91 Pitpnm1 0.89 Neat1 0.86
Arhgap22 0.97 Unc13a 0.94 Il1rl2 0.91 Incenp 0.89 Tenm3 0.86
Thsd4 0.97 Ralgds 0.94 Gpm6b 0.91 Fen1 0.89 Klhl6 0.86
Prkcb 0.97 Cep55 0.94 St3gal2 0.91 Slc11a1 0.89 Fermt3 0.86
Zfp202 0.97 S100a8 0.94 Rassf2 0.91 Lat2 0.88 Ano1 0.86
Clec4e 0.97 Cbr3 0.94 Abcg3 0.91 Hdac9 0.88 Pdgfrb 0.86
Galnt3 0.97 Lyz2 0.94 Gnai1 0.91 Gpm6a 0.88 Ttc3 0.86
Igf1r 0.97 Pkmyt1 0.94 Clec12a 0.91 Gm609 0.88 Mfap2 0.86
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Btc 0.86 Phldb1 0.83 Abhd2 0.79 BC052040 0.75 Clstn1 0.71
Wisp2 0.86 Ccnb1 0.83 Pea15a 0.79 Ppapdc1b 0.75 Impa2 0.71
Samd9l 0.86 Nup210 0.83 P3h3 0.79 Srgn 0.75 Cmpk2 0.71
Dcdc2a 0.86 2010107G23Rik0.82 Mob3a 0.79 Mxra7 0.75 Lrrcc1 0.71
St5 0.85 Ttk 0.82 Xxylt1 0.79 Evi2a 0.75 Oasl2 0.70
Pole 0.85 4933431E20Rik0.82 Trim2 0.79 Lacc1 0.75 Mettl15 0.70
Plgrkt 0.85 Ptpre 0.82 AU020206 0.79 Dlg5 0.75 Trub2 0.70
Mxra8 0.85 Mex3a 0.82 Naaa 0.79 Daam2 0.75 Cbfa2t3 0.70
Gm13021 0.85 Tnfaip8l2 0.82 Capn3 0.78 Cmtm3 0.74 Mfsd7c 0.70
Ahnak 0.85 Acad12 0.82 Hmox1 0.78 Nav1 0.74 E2f1 0.70
Cdr2 0.85 P3h4 0.82 Wipf1 0.78 Klf2 0.74 Tctn1 0.70
Atp8b2 0.85 Hck 0.82 Gem 0.78 Magee1 0.74 Marcks 0.70
Ptpn22 0.85 Arhgdib 0.82 Stx6 0.78 Gas8 0.74 Nagk 0.70
Armc9 0.85 Rtn1 0.82 Tlr8 0.78 Taf1c 0.74 Arl2bp 0.70
Sytl2 0.85 Myadm 0.82 Rxrg 0.78 Gls 0.74 Hexa 0.70
Atp8b4 0.85 Pfkfb4 0.82 Abi3bp 0.78 Sep-08 0.74 Smo 0.70
Ogn 0.85 Cd79b 0.82 Rac2 0.78 Apobec1 0.74 Esyt1 0.70
Tspan15 0.85 Stx3 0.82 Ndc80 0.78 Plscr1 0.74 Dck 0.70
Phf11d 0.85 Wls 0.82 Sep-11 0.78 Arhgap9 0.74 Cttnbp2nl 0.70
Hist1h1c 0.85 Pbk 0.82 Lrrc25 0.78 Ighj2 0.74 Agk 0.69
Neurl3 0.85 Spry1 0.82 Cmtm7 0.78 Entpd2 0.74 Bdh1 0.69
Pmp22 0.85 Hcls1 0.81 Rcan3 0.78 Lig1 0.74 Klra2 0.69
Gm5148 0.85 Tcf19 0.81 Iqcg 0.78 Anapc4 0.74 Susd2 0.69
Mcm8 0.84 Tmem173 0.81 Lmo2 0.77 Rrp1b 0.74 Ncapd2 0.69
Bcl2 0.84 Tcaf1 0.81 Emilin1 0.77 Lamb2 0.74 Dpysl2 0.69
Wfdc17 0.84 Cdcp1 0.81 Arhgap15 0.77 Rbm43 0.74 Man1c1 0.69
Arl4c 0.84 Lcp2 0.81 Rad9a 0.77 Col14a1 0.73 Rhob 0.69
Ccl6 0.84 Bcam 0.81 Dcaf12l1 0.77 Zbtb37 0.73 Tsc22d1 0.69
Hk3 0.84 Col6a5 0.81 Nfam1 0.77 Cd37 0.73 Prkab2 0.69
Spi1 0.84 Tnfrsf11a 0.81 Treml4 0.77 Trpv2 0.73 Rrm1 0.69
D330045A20Rik0.84 Rps6ka1 0.81 Pspc1 0.77 Vegfc 0.73 App 0.69
Il10ra 0.84 Gbp2 0.81 Tmem26 0.77 Far1 0.73 Strada 0.69
Irf8 0.84 Nipa1 0.81 Mvb12b 0.77 Ckap4 0.73 Pcolce 0.68
Eid1 0.84 2510009E07Rik0.81 Tlr4 0.77 Kctd12 0.73 Pvr 0.68
Rab11fip5 0.84 Myo9b 0.81 Ikbke 0.77 Renbp 0.73 Ntn1 0.68
AF251705 0.84 Kif18b 0.81 Adamts1 0.77 Nlrp12 0.73 Nrros 0.68
Tnip1 0.84 Tnxb 0.81 Rcn1 0.77 Themis2 0.73 Fam111a 0.68
Ano6 0.84 Hist2h2be 0.80 Rinl 0.77 Wrb 0.73 Il10rb 0.68
Ctps2 0.84 Sepn1 0.80 Cenpt 0.77 Gmip 0.73 Ppp1r9b 0.68
Emp3 0.84 Pam 0.80 Tor4a 0.77 Cldn2 0.73 F2r 0.68
Fam129b 0.84 Sgcb 0.80 Efs 0.77 Abi2 0.73 Nt5dc2 0.68
Lrat 0.83 Dnmt3b 0.80 Dcn 0.77 Cul7 0.73 Hspa1b 0.68
Npr3 0.83 Ncaph 0.80 Cd274 0.77 Hip1 0.73 Cep192 0.68
Efna5 0.83 Cotl1 0.80 Abcc1 0.77 Usp18 0.73 Mmp14 0.67
Ppip5k1 0.83 Ptprm 0.80 Cd22 0.77 Taf1b 0.73 Tmem165 0.67
Arhgap19 0.83 Ociad2 0.80 Impdh1 0.76 Plekho1 0.73 Setd7 0.67
Ms4a6b 0.83 Arrdc1 0.80 Vasn 0.76 Was 0.72 Tspyl2 0.67
Sfxn3 0.83 Homer3 0.80 Npdc1 0.76 Lfng 0.72 Steap4 0.67
Vstm4 0.83 Kcnj10 0.80 Pacs1 0.76 Adora1 0.72 Pilra 0.67
Vav1 0.83 St8sia6 0.80 Eps8 0.76 Ifngr2 0.72 Slc44a3 0.67
Ints2 0.83 Zfp438 0.80 Rasa4 0.76 Ptpn6 0.72 Insig2 0.67
Astn1 0.83 Rims3 0.80 Aldh3b1 0.76 Arhgap4 0.72 Pde4d 0.67
Pcdh18 0.83 Sh3bgrl3 0.80 C1qb 0.76 Mapk8ip1 0.72 Adgrl1 0.67
Smyd4 0.83 Galnt6 0.80 Appl1 0.76 Crtap 0.72 Agbl5 0.67
Elovl5 0.83 Tulp3 0.80 Pigp 0.76 Fam171b 0.72 Cmklr1 0.67
Akr1b3 0.83 Klrb1b 0.80 Pik3cd 0.76 Camk2d 0.72 Ly6a 0.67
Ank2 0.83 Btbd10 0.79 AI607873 0.76 Tmem237 0.72 Acvrl1 0.66
Gm26782 0.83 Lpxn 0.79 Epsti1 0.76 Hmgcs1 0.72 Srd5a3 0.66
Cyp26a1 0.83 Pyhin1 0.79 Nudt18 0.76 Col5a3 0.72 Des 0.66
Arntl 0.83 Epha2 0.79 A330035P11Rik 0.76 Tmem206 0.72 Plekhg1 0.66
Ifi27l2a 0.83 Nedd9 0.79 Pip4k2a 0.75 Pgm1 0.72 Stxbp1 0.66
Olfm3 0.83 Gbp8 0.79 Mcam 0.75 Igsf6 0.71 Tmem43 0.66
Hmgn2 0.83 Mppe1 0.79 Tbxas1 0.75 Plekha2 0.71 9430020K01Rik0.66
Cln6 0.83 Ccnd2 0.79 Rab34 0.75 Rhbdf1 0.71 Ncald 0.66
Cplx2 0.83 Ap3m2 0.79 Timeless 0.75 Ifi30 0.71 Sema4c 0.66
Det1 0.83 Alpl 0.79 Synj2 0.75 Actb 0.71 Hk1 0.66
Fam129a 0.83 Them6 0.79 Krt8 0.75 Paqr4 0.71 Slc44a2 0.66
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Vangl1 0.65 Nckipsd 0.59 Mdc1 0.52 Cadm1 0.44 Psap 0.27
Plac8 0.65 Pde3a 0.59 Evi5l 0.52 4930402H24Rik 0.43 Asah1 0.24
Rad1 0.65 E130311K13Rik0.59 Zfand2a 0.52 Slc39a3 0.43 Fermt2 -0.23
Igsf11 0.65 Pigh 0.59 Cul9 0.52 Hs1bp3 0.43 Usp19 -0.23
Plscr3 0.65 Ifngr1 0.59 Kifap3 0.52 Rfc2 0.43 Gnai3 -0.25
Zfp362 0.65 Arhgap24 0.59 Snapin 0.52 Nipal3 0.43 Etf1 -0.26
Eif2ak3 0.65 Cntrob 0.58 Clcn5 0.52 Unc93b1 0.43 Dvl1 -0.26
Lims1 0.65 Entpd1 0.58 Bckdk 0.51 Fam102a 0.43 C1s1 -0.26
Casp2 0.65 Hmgxb4 0.58 Uaca 0.51 Exoc2 0.43 Brd4 -0.26
Ccr5 0.65 Stk11ip 0.58 Srgap2 0.51 Dennd2d 0.43 Eef1a1 -0.26
A930038B10Rik0.65 Fam114a1 0.58 Csf1 0.51 Map4 0.42 Raf1 -0.27
Cxcl9 0.65 Supt20 0.58 Itgb5 0.51 Exoc4 0.42 Senp3 -0.27
Cyth3 0.65 Mast4 0.58 Exoc1 0.51 Sep-09 0.42 Csde1 -0.27
E2f8 0.65 Spc25 0.58 Wdr73 0.50 Armc8 0.42 Rnf6 -0.27
Celf2 0.65 Tbc1d1 0.58 Zfp367 0.50 Agps 0.42 Baz1b -0.27
Lgmn 0.64 Lgals3bp 0.58 Fktn 0.50 Smchd1 0.42 Vapa -0.27
Trp53i11 0.64 G6pc3 0.58 Ano10 0.50 Sike1 0.42 Papola -0.27
Gm2788 0.64 Dennd2a 0.58 Heg1 0.50 Ahr 0.42 Sirt2 -0.27
Ptp4a3 0.64 Nabp1 0.58 Dusp22 0.50 Tmem8 0.42 Apeh -0.28
Tmem263 0.64 Nfya 0.57 Nfkb1 0.50 Snx8 0.41 Tbcel -0.28
Marcksl1 0.64 Ralb 0.57 Myo1c 0.50 Brd9 0.41 Smad5 -0.28
Chchd6 0.64 Fam219b 0.57 Aaas 0.50 Calm3 0.41 Nucb1 -0.28
Trp53bp1 0.64 Rtn4 0.57 Pold3 0.50 Phldb2 0.41 Tmem50a -0.28
Tjp3 0.64 Trove2 0.57 Qsox2 0.49 Rpa1 0.41 Rnf114 -0.28
Pla2g6 0.64 Pomk 0.57 Fam195b 0.49 Ywhah 0.41 Gpbp1 -0.28
Msrb2 0.64 Prcp 0.57 Rps6ka3 0.49 Slc4a4 0.41 Acvr2a -0.28
Pcdhgc3 0.63 Tmem47 0.57 2310003H01Rik 0.49 Sirt5 0.41 Atad1 -0.28
Atad2 0.63 Mdfic 0.56 Stx2 0.49 Gmcl1 0.41 Dnajc7 -0.28
Skil 0.63 Tpm4 0.56 Capn2 0.49 Arhgef7 0.40 Ip6k1 -0.29
Aida 0.63 Add1 0.56 H2-Q4 0.48 Adam10 0.40 Pon2 -0.29
Stk17b 0.63 Hand2 0.56 BC029722 0.48 Sdcbp 0.40 Cd47 -0.29
Impact 0.63 Cd300ld 0.56 Ptpn9 0.48 Pvrl2 0.40 Wasl -0.29
4930556M19Rik0.63 2610034B18Rik0.56 Fus 0.48 Prrc1 0.40 Nploc4 -0.29
C1qc 0.63 Fundc2 0.56 Elmo2 0.48 Ednrb 0.39 Alkbh5 -0.29
Gatsl2 0.63 Tep1 0.55 Rhoq 0.48 Ppt1 0.39 Efhd2 -0.29
Galnt10 0.63 Adgre5 0.55 Abcg2 0.47 Arhgap1 0.39 Usp47 -0.29
Tmem106a 0.63 L3mbtl3 0.55 Gfpt1 0.47 Wdr1 0.39 Golph3 -0.29
Nin 0.62 Fcgr3 0.55 Entpd6 0.47 Anxa4 0.39 Gdi2 -0.29
Ctc1 0.62 Tfcp2l1 0.55 Prpf31 0.47 Glg1 0.38 Hnrnpc -0.29
5730409E04Rik0.62 Mast2 0.55 Pld3 0.47 Mlst8 0.38 Cops2 -0.29
C1qa 0.62 Ankrd44 0.55 Reep5 0.47 Xpo1 0.37 Psme4 -0.29
Rab3d 0.62 Tcf4 0.55 Cc2d1b 0.47 Lrp5 0.37 Cct5 -0.30
Zeb2 0.62 Dbnl 0.55 Ipo11 0.47 Fam98b 0.37 Naa50 -0.30
Fads2 0.62 Thra 0.55 Tap1 0.47 Dennd5a 0.37 Prep -0.30
Ctnnal1 0.62 Tsr2 0.55 Ralgapa1 0.47 Acp2 0.37 Usp32 -0.30
Cdk6 0.62 Nt5c2 0.54 Usp20 0.47 5031439G07Rik 0.37 Wbp2 -0.30
Golt1b 0.62 Dab2ip 0.54 Prkdc 0.47 Ccar2 0.37 Synj2bp -0.30
S100a10 0.61 Hexb 0.54 Myo1d 0.47 Trim37 0.36 Stim1 -0.30
Gatm 0.61 Crot 0.54 Fnbp1l 0.47 Clint1 0.36 Rpl7 -0.30
Gngt2 0.61 Ttc5 0.54 Stx7 0.47 Tmem184b 0.36 Las1l -0.30
Serpinb6a 0.61 Pold1 0.54 Drosha 0.46 Plcl2 0.35 Dtnbp1 -0.30
Tppp 0.61 Gyk 0.54 Agrn 0.46 Anapc2 0.35 Itih2 -0.30
Tjp2 0.61 Plin3 0.54 Tubgcp2 0.46 Wwp2 0.34 Slc6a13 -0.31
Syde1 0.61 Tra2a 0.54 Entpd5 0.45 Pitpna 0.34 St13 -0.31
Cep162 0.61 Cdc23 0.54 Slc22a15 0.45 Smarca4 0.34 Shoc2 -0.31
Traf3 0.61 Itm2c 0.54 Mlh3 0.45 Itgav 0.34 Fam63a -0.31
Tssc1 0.61 Dnmt1 0.54 Ptgs1 0.45 Cast 0.33 Wapal -0.31
Dph6 0.61 Ets1 0.53 Galk1 0.45 Eif4g3 0.32 Gpbp1l1 -0.31
Stard3nl 0.61 Abhd4 0.53 Snx1 0.44 Colgalt1 0.32 AU022252 -0.31
Cstb 0.61 Arhgef40 0.53 Itsn1 0.44 Elp3 0.31 Larp4b -0.31
Itga3 0.60 Stau2 0.53 Myl12a 0.44 Sf3b3 0.31 Axin1 -0.31
Sh3bgrl2 0.60 Rps6kc1 0.53 Mapk3 0.44 Cap1 0.30 Trim28 -0.31
Nphp1 0.60 Samhd1 0.53 Rogdi 0.44 Arel1 0.29 Mocos -0.31
Adcy6 0.60 Mfsd12 0.53 Gdf2 0.44 Bace1 0.29 Eif2a -0.31
Sdr39u1 0.60 Rpa2 0.53 Uba6 0.44 Erlin2 0.28 Mpp6 -0.31
Dhx34 0.60 Micu1 0.53 Morf4l2 0.44 Cdc42 0.27 Nom1 -0.31
Parp2 0.60 Tlr3 0.53 Arsb 0.44 Vps41 0.27 Tab2 -0.31
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Atg2a -0.32 Rnf139 -0.36 Kctd21 -0.39 Dcaf10 -0.42 Proc -0.45
Mtch1 -0.32 Ptcd1 -0.36 Eif3h -0.39 F9 -0.42 Spin1 -0.45
Riok3 -0.32 Ppp2r5d -0.36 Akt1s1 -0.39 Klhl2 -0.42 Aldh16a1 -0.45
Zfp106 -0.32 Bnip3l -0.36 2810459M11Rik -0.39 Gnl3 -0.42 Aph1a -0.45
Tatdn2 -0.32 Ubac2 -0.36 Tial1 -0.39 Pcgf3 -0.42 Ppp2r5e -0.45
C78339 -0.32 Hgsnat -0.36 Lamp2 -0.39 Rnf5 -0.42 Mttp -0.45
Man1a2 -0.32 Faf1 -0.36 Trim8 -0.39 Arih2 -0.42 Masp1 -0.45
Larp1 -0.32 Arf5 -0.36 Map3k11 -0.39 Midn -0.42 Nadk -0.45
Plbd2 -0.32 Xpo7 -0.36 Sh3d19 -0.40 Gc -0.42 Whamm -0.45
Nab1 -0.32 Mul1 -0.36 Cldn12 -0.40 Mospd3 -0.42 Rabgap1l -0.45
Esrp2 -0.32 Ctsh -0.36 Col4a3bp -0.40 Tmem57 -0.42 Epn1 -0.45
Scarb2 -0.32 Bcar3 -0.37 Cnn3 -0.40 Hpn -0.42 Cfi -0.45
Zfp598 -0.32 Gsdmd -0.37 Atp13a3 -0.40 Pfdn2 -0.43 Adk -0.45
Sppl2a -0.33 Cul3 -0.37 Gpr108 -0.40 H2afv -0.43 Hs3st3b1 -0.45
Ankrd13c -0.33 Plekhm1 -0.37 Vwce -0.40 Dctpp1 -0.43 Ube2q2 -0.45
Adipor1 -0.33 Smoc1 -0.37 Spast -0.40 F2 -0.43 Polrmt -0.45
Csnk2b -0.33 Osbpl1a -0.37 Hint1 -0.40 Rassf5 -0.43 Ugt3a2 -0.46
Naa30 -0.33 Pvrl3 -0.37 Esrra -0.40 Papd7 -0.43 Zc3h14 -0.46
Kpna1 -0.33 Rps2 -0.37 Trmt1 -0.40 Dnaja2 -0.43 Tmem30a -0.46
Tm9sf2 -0.33 Man2a1 -0.37 Dgcr2 -0.40 Marf1 -0.43 Zfp654 -0.46
Atf1 -0.33 Serpind1 -0.37 Eef2 -0.40 Necap1 -0.43 Setd3 -0.46
Rps6kb1 -0.33 Sh2b3 -0.37 Tecr -0.40 Bend7 -0.43 Rrn3 -0.46
Egln2 -0.33 Xpot -0.37 2310036O22Rik -0.40 Traf4 -0.43 0610040J01Rik-0.46
Atp13a1 -0.33 Pard3 -0.37 Ube2j2 -0.40 Mcts1 -0.43 Zhx2 -0.46
Crbn -0.33 Kiz -0.37 Rchy1 -0.40 Aup1 -0.43 H2-Q7 -0.46
Fam120a -0.33 Cdk8 -0.37 Clcc1 -0.40 Arhgef18 -0.43 Cdkn2aip -0.46
Tollip -0.33 Coq10a -0.37 Trim41 -0.40 Prdx1 -0.43 Apoe -0.46
Arfgap2 -0.33 Riok2 -0.37 Lap3 -0.41 Reps2 -0.43 Dazap1 -0.46
Mar-05 -0.33 Wac -0.37 Urgcp -0.41 Imp3 -0.43 Timm9 -0.46
Ulk2 -0.33 Yipf3 -0.37 Habp2 -0.41 Tspan12 -0.43 Bri3 -0.46
Eif5a -0.33 Btf3 -0.38 Nr2f2 -0.41 Alg11 -0.43 Ndufa6 -0.46
Slc25a39 -0.33 Ganab -0.38 Dnajc22 -0.41 Pias2 -0.43 Ninj1 -0.46
Rpl8 -0.34 Adi1 -0.38 Acot7 -0.41 Osbpl9 -0.44 Plekhf2 -0.47
Abhd13 -0.34 Prps1 -0.38 Gm16286 -0.41 Ift20 -0.44 Dera -0.47
Zfp191 -0.34 Kti12 -0.38 Ube2r2 -0.41 Plekhg3 -0.44 Lcat -0.47
Mtch2 -0.34 Mavs -0.38 Tor1aip2 -0.41 Ripk1 -0.44 Micall1 -0.47
Zfand3 -0.34 Emc7 -0.38 Mia3 -0.41 Rassf8 -0.44 Tm6sf2 -0.47
Sema4a -0.34 Pde8a -0.38 Pten -0.41 Derl2 -0.44 Asgr1 -0.47
Ppp1r37 -0.34 Atg9a -0.38 Rnf19b -0.41 Cbfa2t2 -0.44 Zfand2b -0.47
Apba3 -0.34 Slc19a2 -0.38 Epb4.1l4b -0.41 Txn2 -0.44 Utp14a -0.47
Rnf146 -0.34 Vdac1 -0.38 Zrsr1 -0.41 Utp3 -0.44 Zfp703 -0.47
Vcpip1 -0.34 Casd1 -0.38 Cmtm6 -0.41 Pdhb -0.44 Smek2 -0.47
Tmx1 -0.34 Cdv3 -0.38 Mst1 -0.41 Zfp219 -0.44 Pigx -0.47
Ammecr1l -0.35 Aldh2 -0.38 Akr1c13 -0.41 Rbfa -0.44 Met -0.47
Zfp318 -0.35 Polr1d -0.38 Rplp1 -0.41 Ahsa2 -0.44 Ndrg3 -0.47
Tlk2 -0.35 Chd1 -0.38 Larp1b -0.41 Fam53a -0.44 2900026A02Rik-0.47
Saraf -0.35 Usp15 -0.38 Mfn1 -0.41 Ndufb6 -0.44 Dhrs11 -0.47
Enpp1 -0.35 Ece1 -0.38 Tmem59 -0.41 Bcl2l1 -0.44 Uck2 -0.47
Agap3 -0.35 B4galnt1 -0.38 Sra1 -0.41 Dhcr24 -0.44 Rassf7 -0.47
Zfp148 -0.35 Zmym5 -0.38 Snap29 -0.41 Zfp444 -0.44 Slc38a4 -0.47
Col18a1 -0.35 Cxcl12 -0.38 Tmprss6 -0.41 Zmym2 -0.44 Nup50 -0.47
Tomm22 -0.35 Ndufc2 -0.38 Rb1cc1 -0.41 Mob1b -0.44 E130309D02Rik-0.47
Ybx1 -0.35 Cers2 -0.38 Plec -0.41 Zfp623 -0.44 Ctif -0.47
Fgfrl1 -0.35 Man1a -0.39 D17Wsu92e -0.41 Rbbp6 -0.44 Nr5a2 -0.47
Rbbp4 -0.35 Gltscr2 -0.39 Rhobtb2 -0.42 Erp44 -0.44 Ndufb5 -0.47
Ythdf1 -0.35 Foxo4 -0.39 Cpsf6 -0.42 Rnf126 -0.45 Il13ra1 -0.47
Suds3 -0.35 Emc6 -0.39 Emg1 -0.42 Ptpn3 -0.45 Camk2n1 -0.48
Crtc2 -0.36 Med25 -0.39 Lsr -0.42 Kcmf1 -0.45 Pgrmc1 -0.48
Sf1 -0.36 Dedd -0.39 Papd5 -0.42 Gorasp1 -0.45 Cdk18 -0.48
Ankle2 -0.36 Usp10 -0.39 Als2 -0.42 Fbrsl1 -0.45 Cnbp -0.48
Ergic2 -0.36 Atf6 -0.39 Pcyt2 -0.42 Chchd1 -0.45 Zfp141 -0.48
Fech -0.36 Fbxo8 -0.39 Ppat -0.42 Cox5a -0.45 Pcbp2 -0.48
Gpc4 -0.36 Nudt3 -0.39 Xiap -0.42 Usf2 -0.45 Usp3 -0.48
Slc35d2 -0.36 Upb1 -0.39 Grsf1 -0.42 Zcchc2 -0.45 Slc7a6os -0.48
Asun -0.36 Maoa -0.39 Scamp1 -0.42 Prkcz -0.45 Igf1 -0.48
Fam134a -0.36 Zfp180 -0.39 Ndufa4 -0.42 Bcar1 -0.45 Dlg3 -0.48
Usp16 -0.36 9530068E07Rik-0.39 Tmem205 -0.42 Kat2b -0.45 Crebl2 -0.48
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Nfix -0.48 Ceacam1 -0.51 Amigo2 -0.55 Csrnp1 -0.58 Gse1 -0.62
Zranb1 -0.48 Hdgf -0.51 F12 -0.55 Hgfac -0.58 Npr2 -0.62
Syne2 -0.48 Umps -0.51 Sdhb -0.55 Sorbs3 -0.58 Sptbn2 -0.62
Uri1 -0.48 Fbxo9 -0.51 Zbtb7b -0.55 Gjb2 -0.58 Paics -0.62
Aqp11 -0.48 Fxyd1 -0.51 Wdtc1 -0.55 Ppp1r15b -0.58 Klkb1 -0.62
Irf3 -0.48 Zfyve1 -0.51 Kng2 -0.55 Psmd9 -0.59 Mcm10 -0.62
Eif4b -0.48 C1ra -0.51 Hibadh -0.55 Ypel5 -0.59 Tars -0.62
Zfp524 -0.48 Mepce -0.52 Dohh -0.55 Snhg6 -0.59 Ggnbp2 -0.62
Fastkd1 -0.48 Sil1 -0.52 Tfr2 -0.55 Pi4k2b -0.59 Ugt2b5 -0.62
Zdhhc9 -0.48 Os9 -0.52 Marveld1 -0.55 H6pd -0.59 Aass -0.62
Zfp395 -0.48 Atp1a1 -0.52 Irf2 -0.55 Klhl21 -0.59 Hagh -0.62
Asgr2 -0.48 Dyrk1b -0.52 Nsun2 -0.55 Abcb11 -0.59 Hook2 -0.62
Mapre2 -0.49 Atp5h -0.52 Myo1e -0.55 1110002L01Rik -0.59 Nr2c1 -0.62
Kansl3 -0.49 Tmem183a -0.52 Mocs1 -0.55 Fbxo34 -0.59 Zbtb2 -0.62
S100a13 -0.49 Pth1r -0.52 Cobll1 -0.55 Dnajb6 -0.59 Zbtb7a -0.62
Amfr -0.49 Mar-02 -0.52 Zkscan14 -0.56 Crp -0.59 Arhgap42 -0.62
Kctd2 -0.49 BC021891 -0.52 Prkd3 -0.56 Atp1b1 -0.59 D16Ertd472e -0.62
Ccdc58 -0.49 Rbm15 -0.52 Tsc22d2 -0.56 Oaf -0.59 D930015E06Rik-0.63
Ogfod2 -0.49 Cpeb4 -0.52 Ubtd1 -0.56 Rnf103 -0.59 Grb7 -0.63
Mlycd -0.49 1300017J02Rik-0.52 Cluap1 -0.56 Nuak2 -0.59 Rilp -0.63
Sod1 -0.49 Rnf214 -0.52 Gemin2 -0.56 2410131K14Rik -0.59 Chchd7 -0.63
Zfp622 -0.49 Cdc37l1 -0.52 Gcnt2 -0.56 Nat2 -0.59 Ttc39c -0.63
Atg2b -0.49 Car8 -0.52 Vps13a -0.56 Glt1d1 -0.59 Gkap1 -0.63
Zkscan17 -0.49 Crcp -0.52 Fkbp8 -0.56 Cbx4 -0.59 Txlng -0.63
Ahctf1 -0.49 Fah -0.52 Aadac -0.56 Txndc15 -0.59 Ubr2 -0.63
Zbtb40 -0.49 Mief1 -0.52 Zbtb43 -0.56 Cyp2d10 -0.60 Map3k5 -0.63
Zbtb24 -0.49 Atp5j -0.52 Sox6 -0.56 Zkscan1 -0.60 Arg1 -0.63
Cdc42ep4 -0.49 Lyrm4 -0.53 Hc -0.56 Ndufb4 -0.60 Thrb -0.63
Zfand6 -0.49 Hexim1 -0.53 Atg14 -0.56 Topors -0.60 Cmtm8 -0.63
Ube2h -0.49 Sirt1 -0.53 Fzd5 -0.56 Slc8b1 -0.60 Akr1c14 -0.63
Nfx1 -0.50 Mettl7a1 -0.53 Dna2 -0.56 Irf2bpl -0.60 Ccdc84 -0.63
Sema4g -0.50 AI182371 -0.53 Klb -0.56 Elk4 -0.60 Otc -0.63
Itpr1 -0.50 Foxa1 -0.53 Mdh1 -0.56 Dgat2 -0.60 Zfp385b -0.63
Zfp281 -0.50 1110001J03Rik-0.53 Pxmp2 -0.56 Inpp4a -0.60 B4galt5 -0.63
C130074G19Rik-0.50 Nrbp2 -0.53 Gstm6 -0.56 Pdia5 -0.60 Mar-01 -0.64
Fam207a -0.50 Ces1c -0.53 2610021A01Rik -0.57 9030616G12Rik -0.60 Tspan4 -0.64
Arhgef10l -0.50 Rab20 -0.53 Foxa3 -0.57 Aes -0.60 Bmf -0.64
Yy1 -0.50 Pqlc1 -0.53 Slc30a1 -0.57 Iffo2 -0.60 D130020L05Rik-0.64
Tmem256 -0.50 Abhd17b -0.53 Anks4b -0.57 Fbxo30 -0.60 Apoc1 -0.64
Csnk2a2 -0.50 Kalrn -0.53 Serpinc1 -0.57 S100pbp -0.60 F10 -0.64
Slc2a8 -0.50 Ddx3x -0.53 Rdh7 -0.57 Nr1h4 -0.60 Clcn2 -0.64
Nags -0.50 Pdcd4 -0.53 Ell -0.57 8430419L09Rik -0.60 Pigr -0.64
Romo1 -0.50 Fam104a -0.53 Repin1 -0.57 Amdhd1 -0.61 Ctnnbip1 -0.64
Ap3m1 -0.50 Nr1d2 -0.53 Rapgef4 -0.57 Gpd1l -0.61 Ttc7b -0.64
Akr1c12 -0.50 Ahdc1 -0.53 Irf6 -0.57 C3 -0.61 Itih1 -0.64
Gramd3 -0.50 Slc29a1 -0.54 Pop5 -0.57 Brap -0.61 Fndc4 -0.64
Iyd -0.50 Ak3 -0.54 Fam53b -0.57 Igfals -0.61 Cwf19l1 -0.64
Iws1 -0.50 Fn1 -0.54 Tprkb -0.57 Bach1 -0.61 Pipox -0.64
Adh5 -0.50 Ssfa2 -0.54 Ndufb11 -0.57 Tfeb -0.61 Arhgap29 -0.64
Deptor -0.50 Tkfc -0.54 Fam46a -0.57 Lonrf1 -0.61 Rnd2 -0.64
Eif5 -0.50 Fdx1 -0.54 Aste1 -0.57 Tpd52l1 -0.61 Tef -0.64
Adh4 -0.50 Fbp1 -0.54 Por -0.57 Lgr4 -0.61 Acy1 -0.64
Hnf4a -0.50 Ccdc101 -0.54 Tpst1 -0.57 Sos1 -0.61 Cyp2c39 -0.64
Ppm1l -0.50 Zbtb20 -0.54 Kynu -0.57 Abca2 -0.61 Stard10 -0.65
Rmnd5a -0.50 Nmd3 -0.54 Uox -0.57 Cnppd1 -0.61 Ndfip1 -0.65
Oaz1 -0.50 Ahsg -0.54 Hgd -0.57 Lin52 -0.61 1810013L24Rik-0.65
Igfbp4 -0.50 Gpr146 -0.54 Azgp1 -0.57 Acsm1 -0.62 Apoh -0.65
Lipc -0.50 Sgms2 -0.54 Nit2 -0.58 Apom -0.62 Pygl -0.65
Prdx5 -0.51 Uroc1 -0.54 Bag4 -0.58 Vps37b -0.62 Afm -0.65
Hmgn5 -0.51 Clk3 -0.54 Ubxn7 -0.58 Srsf4 -0.62 Pah -0.65
Tmem19 -0.51 Stk35 -0.54 Ddx19b -0.58 Cebpa -0.62 Samd8 -0.65
Prr16 -0.51 Lims2 -0.54 Dpm3 -0.58 Sdc2 -0.62 Plekhb1 -0.65
Ddi2 -0.51 Ftcd -0.55 Sntg2 -0.58 Cyb5r3 -0.62 Sertad1 -0.65
Mocs2 -0.51 Slc25a44 -0.55 Ank -0.58 Rab3ip -0.62 Iah1 -0.65
Brpf3 -0.51 Jade1 -0.55 Slc6a12 -0.58 Ndufaf6 -0.62 Nfkbil1 -0.66
Tgds -0.51 Dmd -0.55 Zcchc24 -0.58 Tesk2 -0.62 Cyp2d22 -0.66
Aldh8a1 -0.51 Zfp597 -0.55 Phyh -0.58 Aldh7a1 -0.62 Serping1 -0.66
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Scap -0.66 Gstm7 -0.70 Fbxo31 -0.77 mt-Tm -0.84 Snord118 -1.01
Dll1 -0.66 Id3 -0.70 Ern1 -0.77 Cyp3a25 -0.85 Gm16062 -1.01
Cbs -0.66 Cyp7b1 -0.70 Zpr1 -0.77 Pgap1 -0.86 Slc3a1 -1.01
Ngef -0.66 Rcl1 -0.71 Fbxl20 -0.77 Rpl36a -0.86 Ahcy -1.02
Hs6st1 -0.66 Mcc -0.71 Gm4788 -0.78 Marcksl1-ps4 -0.86 Cml1 -1.02
Gch1 -0.66 Ier2 -0.71 Ankrd33b -0.78 Zfand4 -0.86 mt-Rnr2 -1.02
Pecr -0.66 Gm16548 -0.71 Syde2 -0.78 Kcnn2 -0.86 Pdgfrl -1.03
Rbpms2 -0.66 Pdxk -0.71 Hes6 -0.78 BC029214 -0.87 Fasn -1.04
Pcdh1 -0.66 Dbp -0.71 Cyp2c68 -0.78 Enpep -0.87 Srd5a1 -1.04
Khk -0.66 Atg4d -0.71 Cyp2a4 -0.78 Mup6 -0.87 Ccbl1 -1.05
Ambp -0.66 Timd2 -0.71 Paox -0.78 Slc27a5 -0.88 Elovl6 -1.05
Hrsp12 -0.66 Ndrg2 -0.71 Gsto1 -0.78 Cpb2 -0.88 Aldh1l1 -1.07
Prr14 -0.66 Hnf1aos1 -0.71 Inmt -0.78 Gfra1 -0.88 Slc2a5 -1.07
Ptms -0.66 Plg -0.71 Rgn -0.78 Slc37a4 -0.88 Cps1 -1.07
Urah -0.66 Fnip2 -0.71 Fgfr4 -0.78 Cyp2c44 -0.88 Gstt3 -1.08
Zfp354a -0.66 Zfp768 -0.71 Cyp2r1 -0.78 Kng1 -0.88 Cyp2c70 -1.08
Cyp4f15 -0.66 Fgg -0.71 Cyp4f13 -0.79 Gm26967 -0.88 Tiam2 -1.10
Cxxc5 -0.67 Acly -0.71 Srebf1 -0.79 Il12rb1 -0.88 Dleu2 -1.10
Adprm -0.67 Ralgapa2 -0.71 Haao -0.79 Lrit2 -0.89 1700018L02Rik-1.10
Sephs2 -0.67 Hhex -0.72 BC089597 -0.79 Tigd5 -0.89 Asl -1.11
C8g -0.67 Tbx3 -0.72 Tmem25 -0.79 Cela1 -0.89 Car14 -1.11
Ipmk -0.67 Serpina1b -0.72 Esr1 -0.79 RP24-556H22 -0.89 Serpina1d -1.13
Gjb1 -0.67 Fkbp5 -0.72 Wfdc21 -0.79 Gm16573 -0.90 Gm4737 -1.13
Cyp3a13 -0.67 Slco1a1 -0.72 Cfhr3 -0.79 Gcat -0.90 Mid1ip1 -1.14
Depdc7 -0.67 Ttc23 -0.72 Homer2 -0.79 Ces1b -0.90 A930036K24Rik-1.14
Ebp -0.67 Xrcc6bp1 -0.72 Gpank1 -0.79 Aspg -0.91 Slc22a28 -1.14
Ugt2a3 -0.67 Rnf39 -0.72 Gys2 -0.79 Gls2 -0.91 mt-Rnr1 -1.14
Acadsb -0.67 Ttc39b -0.72 1600002H07Rik -0.79 Phlda1 -0.91 Srgap3 -1.15
Me1 -0.67 Hist1h2bc -0.72 Apol9a -0.80 Cyp3a59 -0.92 Fam81a -1.15
Sertad2 -0.67 Agfg2 -0.72 Sdsl -0.80 Slco2a1 -0.92 Gm16587 -1.15
Adarb1 -0.67 Atp5sl -0.73 Cpm -0.80 1700001L05Rik -0.92 Urad -1.15
Tcp11l2 -0.67 Endog -0.73 2310001H17Rik -0.80 Cecr2 -0.93 mt-Ti -1.16
Ifitm2 -0.67 Garem -0.73 Fam84a -0.80 Dclk3 -0.93 Gm16551 -1.16
Aspdh -0.68 Pde4c -0.73 Cry2 -0.80 Adam11 -0.93 Serpina3k -1.16
Bst2 -0.68 Hpd -0.73 N4bp2l1 -0.80 mt-Nd6 -0.93 Ces3b -1.17
Mrpl15 -0.68 Ulk1 -0.73 Hsd17b2 -0.80 Ccno -0.93 Eif4ebp3 -1.17
Magix -0.68 Ugt2b1 -0.74 Arhgap6 -0.81 Hal -0.93 Ass1 -1.18
Celsr1 -0.68 Dpyd -0.74 Tmie -0.81 Mup16 -0.93 Hsd3b5 -1.19
Slc30a10 -0.68 Fgb -0.74 Acaca -0.81 Zfp707 -0.94 Mup14 -1.20
Cd302 -0.68 Vtn -0.74 Snrnp48 -0.81 Lrrc28 -0.94 Cux2 -1.20
Mpnd -0.68 Rbm47 -0.74 Tcf24 -0.81 1810008I18Rik -0.94 Cyp2g1 -1.22
Itpr2 -0.68 Ctsc -0.74 Cth -0.81 Osgin1 -0.95 Neb -1.23
Gm16536 -0.68 Dact2 -0.74 Cyp2c50 -0.82 Jph1 -0.95 Ugt2b37 -1.24
Crybg3 -0.68 Eva1a -0.74 Slc22a30 -0.82 Cyp2f2 -0.95 Fras1 -1.24
Fga -0.68 Gne -0.74 Bhlhe40 -0.82 Sftpa1 -0.96 Nup62cl -1.24
Gchfr -0.68 Hbs1l -0.74 Nrg4 -0.82 Sytl1 -0.96 Slc43a1 -1.24
Ak4 -0.68 Usp2 -0.75 Cyp2c29 -0.82 Cyp39a1 -0.96 Hnf4aos -1.25
Slc10a1 -0.69 Erf -0.75 Gm10658 -0.82 Gbp2b -0.96 Scnn1a -1.27
Zhx3 -0.69 Qdpr -0.75 Serpinf1 -0.82 P2ry2 -0.96 Mir22hg -1.28
Prdm2 -0.69 Mn1 -0.75 Gm2a -0.82 Plcxd1 -0.97 Gm6484 -1.29
Smim13 -0.69 Ttc36 -0.76 Mlxipl -0.82 Apol9b -0.97 Acvr2b -1.32
Tfdp2 -0.69 Apoc3 -0.76 Gpld1 -0.83 Gm13522 -0.97 Dlgap1 -1.32
Dedd2 -0.69 Gm10319 -0.76 C9 -0.83 4921513D11Rik -0.97 Egfr -1.34
Mbl2 -0.69 Slc38a3 -0.76 Fetub -0.83 Rbm33 -0.97 Gm5424 -1.34
Usmg5 -0.69 Ndufaf4 -0.76 Dct -0.83 Ppargc1b -0.97 Serpina1c -1.35
Porcn -0.69 Serpina1a -0.76 Gpcpd1 -0.83 S1pr5 -0.98 Gnmt -1.36
Slc25a23 -0.70 Shroom1 -0.76 Sult1d1 -0.83 Cyp27a1 -0.98 Slc22a26 -1.36
Hrg -0.70 Fam109a -0.76 Dnaja4 -0.84 Upp2 -0.98 Cadm4 -1.37
Slc9a3r1 -0.70 Them4 -0.76 C77080 -0.84 Bdh2 -0.98 C8b -1.37
Fzd7 -0.70 Slc16a10 -0.76 Pla1a -0.84 Mmd2 -0.98 Enho -1.38
4732465J04Rik-0.70 Tuba4a -0.76 Clec2d -0.84 Akr1c19 -0.98 Acmsd -1.38
Slc17a2 -0.70 Afmid -0.76 F7 -0.84 Mup-ps18 -0.99 Mup3 -1.40
Timm8a1 -0.70 Ccdc171 -0.77 Cfhr2 -0.84 E130012A19Rik -0.99 Lifr -1.41
Serpinf2 -0.70 Nab2 -0.77 Cfhr1 -0.84 Foxq1 -0.99 Cyp2c40 -1.44
Kin -0.70 Got1 -0.77 Angptl3 -0.84 Acsm2 -1.00 Cyp3a44 -1.45
AI661453 -0.70 Slc22a4 -0.77 Keg1 -0.84 Mup11 -1.00 Acpp -1.46
0610005C13Rik-0.70 Polg2 -0.77 Tk1 -0.84 Mast3 -1.00 Eci3 -1.52
170
Appendix table 4.1: Differentially expressed mRNA in livers of mice fed HFHS diet compared to control diet
Gene Symbol Log2FC Gene Symbol Log2FC Gene Symbol Log2FC Gene Symbol Log2FC Gene Symbol Log2FC
Cyp2c54 -1.53
Cyp4f14 -1.58
Adgrf1 -1.61
Cyp2c69 -1.67
Gm15375 -1.72
Gm8893 -1.77
RP23-437C24 -1.78
Ranbp3l -1.80
Ces2a -1.82
Slc13a2 -2.65
Sult5a1 -3.06
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Gene ontology term Genes PValue Benjamini
GO:0022610~biologi
cal adhesion
CTNNAL1, PVR, THRA, CADM1, L1CAM, VCL, APP, CD44, TGFBI, COL12A1, CSF3R, VNN1, ROBO2, ADAM8, 
SPON2, SPON1, TYRO3, PTPRM, PTPRS, MFGE8, CERCAM, SIRPA, NCAM1, CD36, CD34, MFAP4, ITGAL, 
ITGAE, ASTN1, PTK7, ITGB5, NEDD9, ITGB2, CX3CL1, SRC, ITGAM, ITGBL1, PVRL4, LGALS3BP, LAMB3, 
LAMB2, ITGAX, ITGAV, ITGB7, PVRL2, LGALS1, EFS, ITGA3, ITGA4, PCDH17, MCAM, COL16A1, EMILIN1, 
PCDH18, LAMA2, COL14A1, PKP1, ITGA8, FREM1, CLEC7A, ANTXR1, AEBP1, CLDN4, CLSTN3, CLDN6, 
FERMT3, IGFBP7, CLSTN1, FERMT1, BCAM, LY9, DDR2, CDC42, WISP2, CGREF1, CD93, RHOB, CNTNAP1, 
BOC, PARVG, SDK2, SDK1, FBLIM1, CPXM2, PCDH7, CD84, DDR1, CLDN2, VCAN, ADAM12, LIMS1, TNC, 
PCDHGC3, VCAM1, IGSF11, BCL2, COL6A2, CD22, COL6A1, CD4, GPNMB, THBS1, COL8A1, THBS2, 
SELPLG, KLRA2, DPT, PTPRC, TNXB, SVEP1, PLEK, SELL, TMEM8, NID1, COL5A3, COL5A1, FBLN5, FBLN7, 
PSPC1, CDH11 3.03E-23 4.78E-20
GO:0007155~cell 
adhesion
CTNNAL1, PVR, THRA, CADM1, L1CAM, VCL, APP, CD44, TGFBI, COL12A1, CSF3R, VNN1, ROBO2, ADAM8, 
SPON2, SPON1, TYRO3, PTPRM, PTPRS, MFGE8, CERCAM, SIRPA, NCAM1, CD36, CD34, MFAP4, ITGAL, 
ITGAE, ASTN1, PTK7, ITGB5, NEDD9, ITGB2, CX3CL1, SRC, ITGAM, ITGBL1, PVRL4, LGALS3BP, LAMB3, 
LAMB2, ITGAX, ITGAV, ITGB7, PVRL2, LGALS1, EFS, ITGA3, ITGA4, PCDH17, MCAM, COL16A1, EMILIN1, 
PCDH18, LAMA2, COL14A1, PKP1, ITGA8, FREM1, CLEC7A, ANTXR1, AEBP1, CLDN4, CLSTN3, CLDN6, 
FERMT3, IGFBP7, CLSTN1, FERMT1, BCAM, LY9, DDR2, CDC42, WISP2, CGREF1, CD93, RHOB, CNTNAP1, 
BOC, PARVG, SDK2, SDK1, FBLIM1, CPXM2, PCDH7, CD84, DDR1, CLDN2, VCAN, ADAM12, LIMS1, TNC, 
PCDHGC3, VCAM1, IGSF11, BCL2, COL6A2, CD22, COL6A1, CD4, GPNMB, THBS1, COL8A1, THBS2, 
SELPLG, KLRA2, DPT, PTPRC, TNXB, SVEP1, PLEK, SELL, TMEM8, NID1, COL5A3, COL5A1, FBLN5, FBLN7, 
PSPC1, CDH11 2.58E-23 8.15E-20
GO:0007049~cell 
cycle
ADCY3, KIFC1, S100A6, PRC1, KNTC1, PKMYT1, AURKA, AURKB, APP, CDCA8, CUL7, OIP5, INCENP, 
CCNA2, ASPM, CDCA3, ANAPC2, LIG1, RBL1, ANAPC4, SGOL1, ESPL1, TACC3, ESCO2, AHR, NCAPD2, 
UHRF1, MAD2L1, TIMELESS, SPAG5, CNTROB, MAPK3, PMP22, EID1, NEK2, LRRCC1, NEDD9, CHEK1, 
ANLN, SPC25, NCAPG2, SKIL, LFNG, HELLS, CKAP2, IKZF1, MKI67, AK1, NUF2, CDC23, NDC80, CDC20, 
CDKN1A, RGS2, CHAF1A, E2F1, CDC14A, E2F8, MLH3, SLFN1, MCM8, CGREF1, FANCI, MTBP, FANCA, 
CDC6, CDK1, ARHGEF2, DSN1, TPX2, NUSAP1, CDK6, MCM2, UBE2C, MCM3, RAD51, MCM6, EREG, CCND2, 
BUB1B, HAUS8, CEP55, RPA1, NCAPH, TSPYL2, MDC1, BCL2, CAMK2D, BUB1, ZWILCH, DLGAP5, ANXA1, 
STRADA, CENPF, CENPE, RACGAP1, CDKN3, APPL1, SMC2, CDC25B, CCNB1, RASSF4, CCNB2, RASSF2, 
KIF20B, CALM3, CHTF18, SMPD3 1.25E-14 9.89E-12
GO:0006796~phosp
hate metabolic 
process
PASK, TGFB3, PTPN22, TTK, PKMYT1, AURKA, LPAR1, AURKB, ADORA1, PRKAR2B, APP, MDFIC, STK39, 
MLKL, TYRO3, PTPRM, PIK3CD, RPS6KC1, PTPRS, WNK2, MAP4K4, MAPK3, PDGFRA, PDGFRB, EIF2AK3, 
WNT5A, NEK2, STK10, STK17B, PTK7, MAP4K1, ADRBK2, CHEK1, CD74, SRC, EPHB2, PTPN7, ITK, PTPN6, 
PTPN9, PTPN13, DUSP22, EPHA2, EPHA3, IKBKE, ATP6V0E2, IMPA2, BCKDK, ACVRL1, CDC14A, DDR2, 
SH2D1B1, SYNJ2, MASTL, PAK1, FGF2, CDK14, CDK1, ADAM10, CDK6, PBK, PRKCB, MAST4, DDR1, 
MTMR11, MAST2, PPM1H, BUB1B, GADD45B, MELK, HK2, PRKDC, ABI2, TRIB2, IGSF10, GALK1, IGF1R, 
BCL2, CAMK2D, BUB1, AGK, PTPRC, PTPRE, FLT3, HCK, PDK4, STRADA, AXL, CDKN3, CDC25B, CCNB1, 
RPS6KA3, PTP4A3, RPS6KA1, MAPK8IP1, GYK, DUSP8, F2R 7.10E-04 0.0205412
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GO:0006793~phosp
horus metabolic 
process
PASK, TGFB3, PTPN22, TTK, PKMYT1, AURKA, LPAR1, AURKB, ADORA1, PRKAR2B, APP, MDFIC, STK39, 
MLKL, TYRO3, PTPRM, PIK3CD, RPS6KC1, PTPRS, WNK2, MAP4K4, MAPK3, PDGFRA, PDGFRB, EIF2AK3, 
WNT5A, NEK2, STK10, STK17B, PTK7, MAP4K1, ADRBK2, CHEK1, CD74, SRC, EPHB2, PTPN7, ITK, PTPN6, 
PTPN9, PTPN13, DUSP22, EPHA2, EPHA3, IKBKE, ATP6V0E2, IMPA2, BCKDK, ACVRL1, CDC14A, DDR2, 
SH2D1B1, SYNJ2, MASTL, PAK1, FGF2, CDK14, CDK1, ADAM10, CDK6, PBK, PRKCB, MAST4, DDR1, 
MTMR11, MAST2, PPM1H, BUB1B, GADD45B, MELK, HK2, PRKDC, ABI2, TRIB2, IGSF10, GALK1, IGF1R, 
BCL2, CAMK2D, BUB1, AGK, PTPRC, PTPRE, FLT3, HCK, PDK4, STRADA, AXL, CDKN3, CDC25B, CCNB1, 
RPS6KA3, PTP4A3, RPS6KA1, MAPK8IP1, GYK, DUSP8, F2R 7.10E-04 0.0205412
GO:0006468~protein 
amino acid 
phosphorylation
BCKDK, ACVRL1, PASK, TGFB3, PKMYT1, TTK, AURKA, LPAR1, AURKB, DDR2, ADORA1, PRKAR2B, APP, 
SH2D1B1, MDFIC, STK39, MLKL, MASTL, PAK1, FGF2, CDK14, TYRO3, CDK1, ADAM10, RPS6KC1, CDK6, 
WNK2, PBK, PRKCB, MAP4K4, MAST4, DDR1, MAST2, MAPK3, PDGFRA, PDGFRB, BUB1B, GADD45B, 
EIF2AK3, MELK, WNT5A, NEK2, STK10, PTK7, STK17B, MAP4K1, ADRBK2, ABI2, PRKDC, CHEK1, CD74, 
TRIB2, SRC, EPHB2, IGSF10, IGF1R, BCL2, CAMK2D, BUB1, PTPRC, ITK, PTPRE, FLT3, HCK, PDK4, 
STRADA, AXL, EPHA2, EPHA3, CCNB1, IKBKE, RPS6KA3, RPS6KA1, MAPK8IP1, F2R 0.0013097 0.0327844
GO:0022402~cell 
cycle process
ADCY3, KIFC1, KNTC1, AURKB, MLH3, SLFN1, APP, CGREF1, CDCA8, OIP5, INCENP, MTBP, FANCA, 
CCNA2, ASPM, CDCA3, CDC6, CDK1, ANAPC2, ARHGEF2, DSN1, SGOL1, ANAPC4, TPX2, NUSAP1, ESPL1, 
TACC3, UBE2C, RAD51, NCAPD2, MAD2L1, EREG, TIMELESS, SPAG5, CCND2, CNTROB, BUB1B, HAUS8, 
PMP22, NEK2, LRRCC1, NEDD9, CHEK1, ANLN, CEP55, RPA1, SPC25, NCAPH, NCAPG2, BCL2, BUB1, 
CAMK2D, SKIL, ZWILCH, LFNG, HELLS, MKI67, DLGAP5, AK1, NUF2, CENPF, CDC23, CDC20, CENPE, 
NDC80, CDKN3, RACGAP1, SMC2, CDC25B, CCNB1, CDKN1A, CCNB2, KIF20B 3.99E-11 1.40E-08
GO:0016192~vesicle-
mediated transport
IGHG1, CD209A, SORL1, ITSN1, CDC42, APP, AP1S2, GSN, RHOB, CAP1, AGAP2, CLINT1, SCAMP5, STX6, 
KDELR3, DBNL, STX3, STX2, GOLT1B, STXBP1, ARHGAP27, MFGE8, SPIRE1, VPS41, WAS, SIRPA, FLNA, 
ELMO2, ELMO1, ADRB2, LAT2, CD36, FNBP1L, LRP11, SH3KBP1, OPHN1, UNC13A, MYO5A, PACS1, CAV1, 
CPLX2, STX7, RAB3D, PPT1, SRC, RIMS3, SLC11A1, AP3M2, ITGAV, EXOC4, FCER1G, EHD2, EXOC2, 
EXOC1, HIP1, PLEK, HCK, MRC2, MYO1F, SNAPIN, VAV1, FCGR3, RAB34, IRF8, SYTL4, SYTL2, MAPK8IP1, 
CLEC7A, CLCN5, LRP5 7.48E-07 6.94E-05
GO:0043067~regulat
ion of programmed 
cell death
IGHG1, STIL, XRCC2, BTC, TGFB3, PMAIP1, ITSN1, ADORA1, CUL7, ANK2, BOK, HMOX1, CHST11, VNN1, 
NGFRAP1, RARB, DLG5, CASP2, FGF2, LTB, SPN, BCL2L14, ARHGEF7, CARD11, SMO, ADRB2, BTG2, 
CX3CR1, EIF2AK3, TRAF1, NFKBID, STK17B, PRKDC, PPT1, HSPA1A, CX3CL1, HSPA1B, CD74, SRC, TIMP1, 
BCL2, TGM2, FCER1G, SKIL, INPP5D, PHLDA3, RUNX3, HELLS, TRAF3, HIP1, PTPRC, PTPN6, SPHK1, 
CENPF, NR4A1, MAL, PEA15A, FCGR3, CIDEC, CDKN1A, YWHAH, UACA, NUPR1, PLCG2, NLRP12, APAF1, 
MAPK8IP1, F2R 0.0014319 0.034692
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GO:0010941~regulat
ion of cell death
IGHG1, STIL, XRCC2, BTC, TGFB3, PMAIP1, ITSN1, ADORA1, CUL7, ANK2, BOK, HMOX1, CHST11, VNN1, 
NGFRAP1, RARB, DLG5, CASP2, FGF2, LTB, SPN, BCL2L14, ARHGEF7, CARD11, SMO, ADRB2, BTG2, 
CX3CR1, EIF2AK3, TRAF1, NFKBID, STK17B, PRKDC, PPT1, HSPA1A, CX3CL1, HSPA1B, CD74, SRC, TIMP1, 
BCL2, TGM2, FCER1G, SKIL, INPP5D, PHLDA3, RUNX3, HELLS, TRAF3, HIP1, PTPRC, PTPN6, SPHK1, 
CENPF, NR4A1, MAL, PEA15A, FCGR3, CIDEC, CDKN1A, YWHAH, UACA, NUPR1, PLCG2, NLRP12, APAF1, 
MAPK8IP1, F2R 0.0016352 0.0392231
GO:0009891~positiv
e regulation of 
biosynthetic process
MEF2C, E2F1, THRA, ELF4, TLR1, TBX20, PPARG, TLR2, TGFB3, TLR3, NFKB1, TLR4, TLR7, TLR8, TLR9, 
FOS, APP, MDFIC, IL1B, RARB, FAM129A, FGF2, CCNA2, TOP2A, LTB, SPN, CIITA, ICOSL, EGR2, RXRG, 
ARNTL, AHR, CARD11, SMO, ADRB2, ZFP462, EREG, JUN, FUS, FOXM1, GLIS2, SOX4, ITGB2, EHF, NFYA, 
WT1, SLC11A1, HAND2, AGRN, RUNX1, RUNX2, KLF6, IKZF2, IKZF1, CEBPD, NR4A1, NR4A3, SAMD4, 
ABCG1, FCGR3, YWHAH, MEOX1, ETS1, IRF8, NLRP12, KLF2 0.0019919 0.0448648
GO:0022403~cell 
cycle phase
ADCY3, KIFC1, KNTC1, AURKB, MLH3, SLFN1, APP, CDCA8, OIP5, INCENP, MTBP, FANCA, CCNA2, ASPM, 
CDCA3, CDC6, ANAPC2, CDK1, ARHGEF2, DSN1, SGOL1, ANAPC4, TPX2, NUSAP1, ESPL1, UBE2C, TACC3, 
NCAPD2, RAD51, MAD2L1, EREG, TIMELESS, SPAG5, CCND2, BUB1B, HAUS8, NEK2, LRRCC1, NEDD9, 
CHEK1, ANLN, CEP55, RPA1, SPC25, NCAPH, NCAPG2, BCL2, BUB1, CAMK2D, ZWILCH, LFNG, HELLS, 
MKI67, DLGAP5, NUF2, CENPF, CDC23, CDC20, CENPE, NDC80, SMC2, CDC25B, CCNB1, CCNB2, KIF20B 3.17E-11 1.25E-08
GO:0006952~defens
e response
IGHG1, LY86, TLR1, PPARG, TLR2, TLR3, TLR4, C1QC, TLR7, TLR8, TLR9, CXCL10, APOA4, TMEM173, 
CD44, VNN1, IL1B, SPN, CIITA, C5AR1, NGP, NCF1, C1QA, C1QB, CCR5, CCR2, H2-AA, PTAFR, TNFAIP8L2, 
CCL3, CCL2, NFKBID, CCR1, CXCL9, ITGB2, CCL5, CCL4, CD74, SLC11A1, CCL22, BCL2, TAP1, FCER1G, 
THBS1, TLR12, PTPRC, PTPN6, LYZ2, HCK, IL1RL2, SPHK1, TLR13, SAMHD1, MYO1F, COTL1, CD180, 
FCGR3, LSP1, NUPR1, IRF8, APAF1, CLEC7A, HDAC9, CD14, F2R 6.33E-06 3.77E-04
GO:0009611~respon
se to wounding
IGHG1, LY86, F13A1, TLR1, PPARG, TLR2, GJA1, TLR3, TLR4, C1QC, TLR7, TLR8, TLR9, CXCL10, CD44, 
VNN1, IL1B, CIITA, GATM, NCF1, PLAUR, C1QA, C1QB, THBD, CCR5, CCR2, PTAFR, CCL3, CCL2, NFKBID, 
CCR1, CXCL9, ABHD2, ITGB2, CX3CL1, CCL5, MDK, CCL4, SLC11A1, CCL22, LAMB2, BCL2, THBS1, 
ENTPD1, ENTPD2, TLR12, KLF6, PTPN6, PLEK, EFEMP2, SPHK1, TLR13, EVL, ANXA5, CD180, FCGR3, 
NUPR1, CLEC7A, HDAC9, CD14, F2R 1.68E-08 2.21E-06
GO:0007010~cytosk
eleton organization
RHOJ, PDGFB, RHOQ, GSN, CAP1, AGAP2, FMNL1, DBNL, ARHGEF2, FMNL3, FOXJ1, TPX2, NUSAP1, 
TMSB10, ESPL1, TACC3, WAS, SIRPA, FLNA, ELMO1, NAV1, TAGLN, TPPP, LIMCH1, CNTROB, OPHN1, 
TMSB4X, HAUS8, DBN1, SGCB, ELN, FHL3, DAAM2, SPC25, DOCK2, RAC2, BCL2, CNN2, EHD2, SYNPO, 
TNXB, CEP192, NUF2, EVL, CENPE, NDC80, CSRP1, RACGAP1, TUBGCP2, CAPN3, LSP1, PPP1R9B, 
EPB4.1L3, CORO1A, YWHAH, EPB4.1L1, EPS8, ANTXR1, DIAP3 1.01E-08 1.45E-06
GO:0000279~M 
phase
ADCY3, KIFC1, KNTC1, MLH3, AURKB, CDCA8, OIP5, INCENP, FANCA, CCNA2, ASPM, CDCA3, CDC6, 
ANAPC2, CDK1, ARHGEF2, DSN1, SGOL1, ANAPC4, TPX2, NUSAP1, ESPL1, UBE2C, TACC3, NCAPD2, 
RAD51, MAD2L1, EREG, TIMELESS, SPAG5, BUB1B, HAUS8, NEK2, LRRCC1, NEDD9, ANLN, CEP55, RPA1, 
SPC25, NCAPH, NCAPG2, BUB1, ZWILCH, LFNG, HELLS, MKI67, DLGAP5, NUF2, CENPF, CDC23, CDC20, 
CENPE, NDC80, SMC2, CDC25B, CCNB1, CCNB2, KIF20B 1.08E-10 3.40E-08
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GO:0001775~cell 
activation
CD8A, ELF4, TLR1, PTPN22, TLR4, NFKB2, CD48, CXCR4, CLCF1, IMPDH1, LTB, SPN, RHOH, ICOSL, 
PIK3CD, RELB, NFAM1, WAS, CARD11, LAT2, LAX1, CX3CR1, LCP2, GPR183, ITGAL, CPLX2, SOX4, PRKDC, 
ITGB2, IL7R, ITGAM, CD74, TIMP1, SLC11A1, DOCK2, ITGAX, BCL2, FCER1G, CD4, ENTPD1, ENTPD2, 
HELLS, BLNK, PTPRC, IKZF1, PLEK, FLT3, THEMIS, MYO1F, EVL, HS1BP3, VAV1, FCGR3, PLCG2, H2-DMA, 
HDAC9 3.19E-12 2.01E-09
GO:0051301~cell 
division
KIFC1, PRC1, CDC14A, KNTC1, AURKB, CDC42, CDCA8, OIP5, INCENP, CCNA2, TOP2A, ASPM, CDCA3, 
CDC6, ANAPC2, CDK1, ARHGEF2, STX2, DSN1, LIG1, SGOL1, ANAPC4, NUSAP1, CDK6, UBE2C, MCM5, 
NCAPD2, MAD2L1, TIMELESS, SPAG5, CCND2, CNTROB, BUB1B, HAUS8, NEK2, LRRCC1, NEDD9, ANLN, 
CEP55, SPC25, NCAPH, NCAPG2, BUB1, ZWILCH, HELLS, NUF2, CDC23, CDC20, CENPE, NDC80, 
RACGAP1, SMC2, CDC25B, CCNB1, CCNB2, KIF20B 7.02E-10 1.30E-07
GO:0007610~behavi
or
ADCY1, S100A8, HEXA, HEXB, CXCR2, CXCL10, PRKAR2B, APP, EAR2, CSF3R, IL1B, ROBO2, NRG1, 
C5AR1, EGR2, SLIT2, CCR7, AAAS, CX3CR1, CSTB, PTAFR, CLN6, MYO5A, C3AR1, CCL3, CCL2, CCR1, 
ASTN1, ABI2, PPT1, ITGB2, CX3CL1, CCL5, CCL4, ITGAM, EPHB2, CCL6, CCL22, DOCK2, RAC2, BCL2, 
FCER1G, RUNX1, ATP1A3, ITGA3, NR4A3, ATP1A2, FCGR3, LSP1, CORO1A, EPS8, ITGA8, CXCL16, GLS, 
CMTM7, CMTM3 1.14E-04 0.004183
GO:0000278~mitotic 
cell cycle
KIFC1, KNTC1, AURKA, AURKB, SLFN1, CDCA8, APP, OIP5, INCENP, MTBP, CCNA2, ASPM, CDCA3, CDC6, 
ANAPC2, CDK1, ARHGEF2, DSN1, SGOL1, ANAPC4, NUSAP1, UBE2C, NCAPD2, MAD2L1, TIMELESS, 
SPAG5, CCND2, BUB1B, HAUS8, NEK2, LRRCC1, NEDD9, ANLN, CHEK1, CEP55, SPC25, NCAPH, NCAPG2, 
BCL2, BUB1, CAMK2D, ZWILCH, HELLS, DLGAP5, NUF2, CENPF, CDC23, CDC20, CENPE, NDC80, SMC2, 
CDC25B, CCNB1, CCNB2, KIF20B 7.68E-12 4.04E-09
GO:0006928~cell 
motion
PVR, PDGFB, GJA1, ZEB2, L1CAM, EDNRB, APP, GAB2, CXCR4, CSF3R, IL1B, SEMA3C, ROBO2, CAP1, 
NRG1, BOC, FMNL1, C5AR1, EGR2, FOXJ1, MMP14, SIRPA, SLIT2, ELMO1, SMO, NAV1, CD34, CX3CR1, 
ST14, EFNA5, CCR1, ASTN1, PRKDC, ABI2, ITGB2, CX3CL1, SRC, ITGAM, EPHB2, SEMA5A, CCL22, 
FCER1G, SELPLG, RUNX3, PLAT, ATP1A3, ITGA3, EVL, ITGA4, GAS8, NTN1, FCGR3, CORO1A, PLAU, LRP5 1.44E-05 7.58E-04
GO:0033554~cellular 
response to stress
KIF22, PXDN, XRCC2, MORF4L2, 2310003H01RIK, PMAIP1, FGF12, MLH3, FANCI, MDFIC, HMOX1, GPX3, 
FAM129A, FANCA, CDK1, DTL, LIG1, NEIL3, POLE, ESCO2, RAD51, RAD1, PYCR1, UHRF1, BTG2, 
TIMELESS, MAPK3, EIF2AK3, WNT5A, PRKDC, CHEK1, HSPA1A, HSPA1B, TTC5, RPA1, TRP53BP1, LAMB2, 
MDC1, BCL2, POLQ, MYOF, PHLDA3, FEN1, RAD54L, CDKN1A, UACA, NUPR1, POLD1, RAD54B, MAPK8IP1, 
CHAF1A, PARP2 0.0018909 0.0438914
GO:0002520~immun
e system 
development
CD8A, PTPN22, NFKB1, NFKB2, CBFA2T3, TNFRSF11A, CLCF1, SPIB, LTB, SPN, RHOH, ICOSL, STAP1, 
FOXJ1, RELB, CDK6, NFAM1, TACC3, PGM3, CARD11, CCR2, CD300LF, ADD1, GPR183, CCR1, SOX4, 
PRKDC, IL7R, CD74, TIMP1, RPA1, DOCK2, BCL2, CD4, RUNX1, HELLS, PTPRC, IKZF1, FLT3, THEMIS, 
HCLS1, ROGDI, HS1BP3, VAV1, PLSCR1, CCNB2, IRF8, PLCG2, H2-DMA, HDAC9 1.18E-06 1.03E-04
175
Appendix Table 4.2: Gene ontology terms significantly enriched in upregulated genes of HFHS diet fed mice compared to control diet fed mice
Gene ontology term Genes PValue Benjamini
GO:0044093~positiv
e regulation of 
molecular function
ADCY3, ADCY1, CAV1, GNA15, ADCY2, ADCY7, CSF1, TLR1, ADCY6, TLR2, TGFB3, TLR3, ZEB2, TLR4, 
ITGB2, LPAR1, ADORA1, CD74, CDC42, SLC11A1, SERINC2, MDFIC, BCL2, TGM2, CERK, NRG1, FGF2, 
AGAP2, AGK, HIP1, PTPRC, FOXJ1, SPHK1, STRADA, EDA2R, ARHGAP27, CENPE, NPR3, NFAM1, CDC25B, 
ADRB2, UACA, EREG, SYDE1, PLCG2, CALM3, APAF1, GADD45B, EIF2AK3, F2R 3.45E-06 2.42E-04
GO:0045321~leukoc
yte activation
GPR183, ITGAL, CPLX2, CD8A, ELF4, TLR1, SOX4, PTPN22, PRKDC, TLR4, ITGB2, IL7R, CD74, ITGAM, 
CD48, SLC11A1, DOCK2, ITGAX, CLCF1, CXCR4, BCL2, FCER1G, CD4, IMPDH1, SPN, HELLS, BLNK, RHOH, 
PTPRC, ICOSL, IKZF1, THEMIS, FLT3, PIK3CD, RELB, MYO1F, NFAM1, HS1BP3, WAS, VAV1, FCGR3, 
CARD11, LAT2, LAX1, CX3CR1, PLCG2, HDAC9, H2-DMA, LCP2 1.62E-10 4.25E-08
GO:0048534~hemop
oietic or lymphoid 
organ development
GPR183, CD8A, CCR1, SOX4, PTPN22, PRKDC, NFKB1, NFKB2, CBFA2T3, IL7R, CD74, TIMP1, RPA1, 
DOCK2, TNFRSF11A, CLCF1, BCL2, CD4, SPIB, RUNX1, LTB, SPN, HELLS, RHOH, PTPRC, IKZF1, STAP1, 
THEMIS, FLT3, HCLS1, RELB, ROGDI, CDK6, NFAM1, HS1BP3, TACC3, VAV1, CARD11, PGM3, PLSCR1, 
CCNB2, PLCG2, CCR2, IRF8, CD300LF, HDAC9, H2-DMA, ADD1 1.59E-06 1.32E-04
GO:0000087~M 
phase of mitotic cell 
cycle
KIFC1, NEK2, LRRCC1, KNTC1, NEDD9, ANLN, CEP55, AURKB, SPC25, CDCA8, NCAPH, OIP5, NCAPG2, 
INCENP, BUB1, ZWILCH, CCNA2, ASPM, HELLS, CDCA3, CDC6, ANAPC2, CDK1, ARHGEF2, DSN1, DLGAP5, 
SGOL1, ANAPC4, NUF2, NUSAP1, CDC23, CENPF, NDC80, CDC20, CENPE, UBE2C, SMC2, NCAPD2, 
CDC25B, CCNB1, MAD2L1, CCNB2, TIMELESS, SPAG5, KIF20B, BUB1B, HAUS8 2.31E-11 1.04E-08
GO:0016044~membr
ane organization
IGHG1, CAV1, CD209A, SORL1, PPT1, PMAIP1, ITSN1, SLC11A1, APP, DOCK2, AP1S2, ITGAV, BCL2, 
FCER1G, CAP1, AGRN, EHD2, CLINT1, HIP1, DBNL, STX2, HCK, MRC2, STXBP1, ARHGAP27, MFGE8, ITGA3, 
LPCAT2, SIRPA, VAV1, ELMO2, FCGR3, ELMO1, KCNN4, ADRB2, CD36, FNBP1L, RAB34, IRF8, LRP11, 
SH3KBP1, OPHN1, CLEC7A, UNC13A, CLCN5, LRP5, SGCB 1.49E-06 1.27E-04
GO:0007067~mitosis
KIFC1, NEK2, LRRCC1, KNTC1, NEDD9, ANLN, CEP55, AURKB, SPC25, CDCA8, NCAPH, OIP5, NCAPG2, 
INCENP, BUB1, ZWILCH, CCNA2, ASPM, HELLS, CDCA3, CDC6, ANAPC2, CDK1, ARHGEF2, DSN1, SGOL1, 
ANAPC4, NUF2, NUSAP1, CDC23, NDC80, CDC20, CENPE, UBE2C, SMC2, NCAPD2, CDC25B, CCNB1, 
MAD2L1, CCNB2, TIMELESS, SPAG5, KIF20B, BUB1B, HAUS8 1.44E-10 4.12E-08
GO:0000280~nuclea
r division
KIFC1, NEK2, LRRCC1, KNTC1, NEDD9, ANLN, CEP55, AURKB, SPC25, CDCA8, NCAPH, OIP5, NCAPG2, 
INCENP, BUB1, ZWILCH, CCNA2, ASPM, HELLS, CDCA3, CDC6, ANAPC2, CDK1, ARHGEF2, DSN1, SGOL1, 
ANAPC4, NUF2, NUSAP1, CDC23, NDC80, CDC20, CENPE, UBE2C, SMC2, NCAPD2, CDC25B, CCNB1, 
MAD2L1, CCNB2, TIMELESS, SPAG5, KIF20B, BUB1B, HAUS8 1.44E-10 4.12E-08
GO:0048285~organe
lle fission
KIFC1, NEK2, LRRCC1, KNTC1, NEDD9, ANLN, CEP55, AURKB, SPC25, CDCA8, NCAPH, OIP5, NCAPG2, 
INCENP, BUB1, ZWILCH, CCNA2, ASPM, HELLS, CDCA3, CDC6, ANAPC2, CDK1, ARHGEF2, DSN1, SGOL1, 
ANAPC4, NUF2, NUSAP1, CDC23, NDC80, CDC20, CENPE, UBE2C, SMC2, NCAPD2, CDC25B, CCNB1, 
MAD2L1, CCNB2, TIMELESS, SPAG5, KIF20B, BUB1B, HAUS8 4.97E-10 1.12E-07
GO:0002684~positiv
e regulation of 
immune system 
process
IGHG1, ITGAL, CADM1, UNC93B1, TLR2, PTPN22, TLR4, CACNB3, IL7R, C1QC, TLR8, CD74, SLC11A1, 
KLHL6, VNN1, FCER1G, CD4, INPP5D, THBS1, SPN, CLEC2I, PTPRC, PTPN6, ICOSL, IKZF1, THEMIS, FOXJ1, 
NFAM1, FCGR3, C1QA, C1QB, CARD11, CD83, CD37, CORO1A, CDKN1A, LAT2, EREG, LAX1, PLCG2, H2-AA, 
CD79B, CLEC7A, H2-DMA, SASH3 2.21E-09 3.48E-07
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GO:0002684~positiv
e regulation of 
immune system 
process
IGHG1, ITGAL, CADM1, UNC93B1, TLR2, PTPN22, TLR4, CACNB3, IL7R, C1QC, TLR8, CD74, SLC11A1, 
KLHL6, VNN1, FCER1G, CD4, INPP5D, THBS1, SPN, CLEC2I, PTPRC, PTPN6, ICOSL, IKZF1, THEMIS, FOXJ1, 
NFAM1, FCGR3, C1QA, C1QB, CARD11, CD83, CD37, CORO1A, CDKN1A, LAT2, EREG, LAX1, PLCG2, H2-AA, 
CD79B, CLEC7A, H2-DMA, SASH3 2.21E-09 3.48E-07
GO:0042325~regulat
ion of 
phosphorylation
CAV1, PDGFB, IMPACT, CSF1, TLR1, TGFB3, ZEB2, TLR4, LPAR1, ADORA1, CD74, TRIB2, PRKAR2B, 
SLC11A1, CDC42, SPRY1, APP, SH2D1B1, MDFIC, BCL2, IL1B, CD4, CERK, MLST8, FAM129A, NRG1, AGK, 
FGF2, AGAP2, PTPRC, PTPN6, TNXB, HCLS1, SPHK1, STRADA, PKIB, CENPE, CDC25B, PPP1R9B, CDKN1A, 
EREG, JUN, PDGFRB, GADD45B, F2R 4.20E-05 0.0019757
GO:0019220~regulat
ion of phosphate 
metabolic process
CAV1, PDGFB, IMPACT, CSF1, TLR1, TGFB3, ZEB2, TLR4, LPAR1, ADORA1, CD74, TRIB2, PRKAR2B, 
SLC11A1, CDC42, SPRY1, APP, SH2D1B1, MDFIC, BCL2, IL1B, CD4, CERK, MLST8, FAM129A, NRG1, AGK, 
FGF2, AGAP2, PTPRC, PTPN6, TNXB, HCLS1, SPHK1, STRADA, PKIB, CENPE, CDC25B, PPP1R9B, CDKN1A, 
EREG, JUN, PDGFRB, GADD45B, F2R 1.03E-04 0.0039426
GO:0051174~regulat
ion of phosphorus 
metabolic process
CAV1, PDGFB, IMPACT, CSF1, TLR1, TGFB3, ZEB2, TLR4, LPAR1, ADORA1, CD74, TRIB2, PRKAR2B, 
SLC11A1, CDC42, SPRY1, APP, SH2D1B1, MDFIC, BCL2, IL1B, CD4, CERK, MLST8, FAM129A, NRG1, AGK, 
FGF2, AGAP2, PTPRC, PTPN6, TNXB, HCLS1, SPHK1, STRADA, PKIB, CENPE, CDC25B, PPP1R9B, CDKN1A, 
EREG, JUN, PDGFRB, GADD45B, F2R 1.03E-04 0.0039426
GO:0007626~locomo
tory behavior
MYO5A, C3AR1, CCL3, CCL2, S100A8, CCR1, HEXA, HEXB, ASTN1, CXCR2, PPT1, ITGB2, CX3CL1, CCL5, 
CCL4, ITGAM, CCL6, CXCL10, APP, CCL22, DOCK2, EAR2, RAC2, CSF3R, IL1B, FCER1G, ROBO2, NRG1, 
C5AR1, ATP1A3, ATP1A2, SLIT2, FCGR3, LSP1, CORO1A, CCR7, EPS8, CXCL16, CX3CR1, CSTB, CMTM7, 
CMTM3, PTAFR, CLN6 5.96E-07 5.70E-05
GO:0006954~inflam
matory response
IGHG1, CCL3, CCL2, NFKBID, LY86, CCR1, PPARG, TLR1, TLR2, CXCL9, TLR3, TLR4, ITGB2, CCL5, TLR7, 
CCL4, C1QC, TLR8, TLR9, CXCL10, SLC11A1, CCL22, CD44, VNN1, IL1B, THBS1, TLR12, CIITA, NCF1, 
TLR13, SPHK1, CD180, FCGR3, C1QA, C1QB, CCR5, NUPR1, CCR2, CLEC7A, HDAC9, CD14, PTAFR, F2R 2.87E-07 3.02E-05
GO:0030097~hemop
oiesis
GPR183, CD8A, CCR1, SOX4, PTPN22, PRKDC, CBFA2T3, IL7R, CD74, TIMP1, RPA1, DOCK2, CLCF1, BCL2, 
CD4, SPIB, RUNX1, HELLS, SPN, RHOH, PTPRC, IKZF1, STAP1, THEMIS, FLT3, HCLS1, RELB, ROGDI, 
CDK6, NFAM1, TACC3, HS1BP3, VAV1, CARD11, PGM3, PLSCR1, PLCG2, CCR2, IRF8, CD300LF, H2-DMA, 
HDAC9, ADD1 5.57E-06 3.44E-04
GO:0043085~positiv
e regulation of 
catalytic activity
ADCY3, GNA15, CAV1, ADCY1, ADCY2, ADCY7, CSF1, TLR1, ADCY6, TGFB3, ZEB2, TLR4, LPAR1, ADORA1, 
CD74, SERINC2, SLC11A1, CDC42, MDFIC, BCL2, TGM2, CERK, NRG1, AGK, FGF2, AGAP2, HIP1, PTPRC, 
FOXJ1, SPHK1, STRADA, ARHGAP27, CENPE, NPR3, CDC25B, ADRB2, UACA, EREG, SYDE1, APAF1, 
GADD45B, EIF2AK3, F2R 1.50E-05 7.75E-04
GO:0030029~actin 
filament-based 
process
MYO5A, RHOJ, PDGFB, ELN, FHL3, RHOQ, MYO9B, DAAM2, RAC2, GSN, BCL2, CNN2, WIPF1, CAP1, EHD2, 
AGAP2, FMNL1, DBNL, FMNL3, ARHGEF2, TNXB, FOXJ1, TMSB10, EVL, CSRP1, RACGAP1, WAS, SIRPA, 
CAPN3, FLNA, ELMO1, EPB4.1L3, PPP1R9B, CORO1A, EPB4.1L1, EPS8, LIMCH1, OPHN1, TMSB4X, 
ANTXR1, DBN1, DIAP3 5.04E-10 1.06E-07
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GO:0048870~cell 
motility
PVR, PDGFB, CCR1, ASTN1, GJA1, ABI2, PRKDC, ZEB2, ITGB2, CX3CL1, ITGAM, SRC, EDNRB, CCL22, 
GAB2, CXCR4, CSF3R, SEMA3C, IL1B, FCER1G, CAP1, NRG1, SELPLG, FMNL1, PLAT, C5AR1, FOXJ1, 
ATP1A3, ITGA3, ITGA4, MMP14, GAS8, NTN1, FCGR3, SMO, CORO1A, NAV1, CD34, CX3CR1, ST14, PLAU, 
LRP5 2.29E-04 0.0077298
GO:0051674~localiz
ation of cell
PVR, PDGFB, CCR1, ASTN1, GJA1, ABI2, PRKDC, ZEB2, ITGB2, CX3CL1, ITGAM, SRC, EDNRB, CCL22, 
GAB2, CXCR4, CSF3R, SEMA3C, IL1B, FCER1G, CAP1, NRG1, SELPLG, FMNL1, PLAT, C5AR1, FOXJ1, 
ATP1A3, ITGA3, ITGA4, MMP14, GAS8, NTN1, FCGR3, SMO, CORO1A, NAV1, CD34, CX3CR1, ST14, PLAU, 
LRP5 2.29E-04 0.0077298
GO:0046649~lympho
cyte activation
GPR183, ITGAL, CD8A, ELF4, SOX4, PTPN22, PRKDC, ITGB2, IL7R, CD74, ITGAM, CD48, SLC11A1, DOCK2, 
ITGAX, CLCF1, CXCR4, BCL2, CD4, IMPDH1, SPN, HELLS, BLNK, RHOH, PTPRC, ICOSL, IKZF1, THEMIS, 
FLT3, PIK3CD, RELB, NFAM1, HS1BP3, WAS, VAV1, CARD11, LAT2, LAX1, PLCG2, HDAC9, H2-DMA 2.13E-08 2.58E-06
GO:0016477~cell 
migration
PVR, PDGFB, CCR1, ASTN1, GJA1, ABI2, PRKDC, ZEB2, ITGB2, CX3CL1, ITGAM, SRC, EDNRB, CCL22, 
GAB2, CXCR4, CSF3R, IL1B, FCER1G, SEMA3C, CAP1, NRG1, SELPLG, FMNL1, PLAT, C5AR1, FOXJ1, 
ITGA3, ITGA4, MMP14, NTN1, FCGR3, SMO, CORO1A, NAV1, CD34, CX3CR1, ST14, PLAU, LRP5 2.38E-05 0.0011745
GO:0030036~actin 
cytoskeleton 
organization
RHOJ, PDGFB, ELN, FHL3, RHOQ, DAAM2, RAC2, GSN, BCL2, CNN2, CAP1, EHD2, AGAP2, FMNL1, DBNL, 
FMNL3, ARHGEF2, TNXB, FOXJ1, TMSB10, EVL, CSRP1, RACGAP1, WAS, SIRPA, CAPN3, FLNA, ELMO1, 
EPB4.1L3, PPP1R9B, CORO1A, EPB4.1L1, EPS8, LIMCH1, OPHN1, TMSB4X, ANTXR1, DBN1, DIAP3 3.05E-09 4.59E-07
GO:0006974~respon
se to DNA damage 
stimulus
KIF22, XRCC2, MORF4L2, PRKDC, HSPA1A, CHEK1, 2310003H01RIK, HSPA1B, PMAIP1, MLH3, TTC5, RPA1, 
TRP53BP1, FANCI, MDC1, HMOX1, POLQ, FANCA, PHLDA3, FEN1, CDK1, DTL, LIG1, NEIL3, POLE, RAD54L, 
ESCO2, RAD51, RAD1, CDKN1A, UHRF1, UACA, NUPR1, TIMELESS, BTG2, POLD1, MAPK3, RAD54B, 
CHAF1A, PARP2 0.0019836 0.0450046
GO:0010324~membr
ane invagination
IGHG1, CAV1, CD209A, SORL1, PPT1, ITSN1, SLC11A1, APP, AP1S2, ITGAV, FCER1G, CAP1, EHD2, CLINT1, 
HIP1, DBNL, HCK, MRC2, STXBP1, ARHGAP27, MFGE8, SIRPA, VAV1, ELMO2, FCGR3, ELMO1, ADRB2, 
CD36, FNBP1L, RAB34, IRF8, LRP11, SH3KBP1, OPHN1, CLEC7A, UNC13A, CLCN5, LRP5 3.75E-07 3.82E-05
GO:0006897~endocy
tosis
IGHG1, CAV1, CD209A, SORL1, PPT1, ITSN1, SLC11A1, APP, AP1S2, ITGAV, FCER1G, CAP1, EHD2, CLINT1, 
HIP1, DBNL, HCK, MRC2, STXBP1, ARHGAP27, MFGE8, SIRPA, VAV1, ELMO2, FCGR3, ELMO1, ADRB2, 
CD36, FNBP1L, RAB34, IRF8, LRP11, SH3KBP1, OPHN1, CLEC7A, UNC13A, CLCN5, LRP5 3.75E-07 3.82E-05
GO:0001568~blood 
vessel development
RTN4, MEF2C, CAV1, ACVRL1, FOXM1, COL3A1, TBX20, GJA1, CX3CL1, MMP2, WT1, SEMA5A, ARHGAP22, 
CUL7, HAND2, CXCR4, HMOX1, ITGAV, TGM2, IL1B, RHOB, SEMA3C, ANGPT1, LOX, FGF2, SPHK1, ITGA4, 
ARHGAP24, MMP14, EPHA2, COL5A1, ANXA2, SMO, VEGFC, EREG, COL1A1, SMARCA4 3.52E-04 0.0113841
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GO:0001944~vascul
ature development
RTN4, MEF2C, CAV1, ACVRL1, FOXM1, COL3A1, TBX20, GJA1, CX3CL1, MMP2, WT1, SEMA5A, ARHGAP22, 
CUL7, HAND2, CXCR4, HMOX1, ITGAV, TGM2, IL1B, RHOB, SEMA3C, ANGPT1, LOX, FGF2, SPHK1, ITGA4, 
ARHGAP24, MMP14, EPHA2, COL5A1, ANXA2, SMO, VEGFC, EREG, COL1A1, SMARCA4 5.62E-04 0.0170555
GO:0001817~regulat
ion of cytokine 
production
PANX1, PPARG, TLR1, TLR2, TLR3, NFKB1, TLR4, CX3CL1, TLR7, TLR8, TLR9, SLC11A1, SH2D1B1, HMOX1, 
IL1B, FCER1G, INPP5D, LTB, SRGN, SPN, SCAMP5, CLEC2I, ICOSL, FOXJ1, SPHK1, CENPF, FCGR3, INHBB, 
CARD11, CD83, MAST2, EREG, CLEC7A, CD14, SASH3, F2R 1.02E-09 1.80E-07
GO:0001817~regulat
ion of cytokine 
production
PANX1, PPARG, TLR1, TLR2, TLR3, NFKB1, TLR4, CX3CL1, TLR7, TLR8, TLR9, SLC11A1, SH2D1B1, HMOX1, 
IL1B, FCER1G, INPP5D, LTB, SRGN, SPN, SCAMP5, CLEC2I, ICOSL, FOXJ1, SPHK1, CENPF, FCGR3, INHBB, 
CARD11, CD83, MAST2, EREG, CLEC7A, CD14, SASH3, F2R 1.02E-09 1.80E-07
GO:0048584~positiv
e regulation of 
response to stimulus
IGHG1, CADM1, TLR2, UNC93B1, PTPN22, TLR3, CACNB3, TLR4, C1QC, TLR8, SRC, SLC11A1, KLHL6, 
TGM2, IL1B, FCER1G, THBS1, CLEC2I, PTPRC, PTPN6, THEMIS, EDA2R, DUSP22, NFAM1, FCGR3, C1QA, 
C1QB, LAT2, EREG, LAX1, PLCG2, H2-AA, CD79B, CLEC7A, H2-DMA, SASH3 2.29E-06 1.72E-04
GO:0010647~positiv
e regulation of cell 
communication
ITGAL, PDGFB, CD8A, CSF1, NCS1, TGFB3, SOX4, TLR3, ZEB2, L1CAM, TLR4, LPAR1, ITSN1, SRC, IGF1R, 
DOCK2, TGM2, IL1B, CD4, NRG1, THBS1, LTB, PTPRC, HCLS1, EDA2R, DUSP22, FGF21, NFAM1, FLNA, 
LAMA2, NCAM1, CARD11, ADRB2, EREG, ITGA8, EIF2AK3 3.34E-06 2.40E-04
GO:0009967~positiv
e regulation of signal 
transduction
ITGAL, PDGFB, CD8A, CSF1, TGFB3, SOX4, TLR3, ZEB2, L1CAM, TLR4, LPAR1, ITSN1, SRC, IGF1R, DOCK2, 
TGM2, IL1B, CD4, NRG1, THBS1, LTB, PTPRC, HCLS1, EDA2R, DUSP22, FGF21, NFAM1, FLNA, NCAM1, 
CARD11, ADRB2, EREG, ITGA8, EIF2AK3 2.85E-06 2.09E-04
GO:0051338~regulat
ion of transferase 
activity
CAV1, CSF1, TLR1, TGFB3, ZEB2, TLR4, LPAR1, ADORA1, CD74, TRIB2, SERINC2, SLC11A1, CDC42, 
SPRY1, APP, MDFIC, IL1B, CERK, NRG1, AGK, FGF2, AGAP2, PTPRC, PTPN6, TNXB, SPHK1, STRADA, 
PKIB, CENPE, CDC25B, CDKN1A, EREG, GADD45B, F2R 6.57E-05 0.0027581
GO:0051056~regulat
ion of small GTPase 
mediated signal 
transduction
TBC1D9, CSF1, CYTH4, IQGAP3, CYTH3, LPAR1, ITSN1, IQGAP1, ADAP1, RASAL1, SPRY1, DOCK2, 
PLEKHG1, TIAM1, RASAL3, MLST8, NRG1, TBC1D1, AGAP2, RASA4, FGD3, DAB2IP, ARHGEF2, ABR, 
ARHGEF7, FOXJ1, PSD4, ARHGAP27, ARHGEF9, ECT2, VAV1, RALGDS, RALGAPA1, SYDE1 8.56E-04 0.0232031
GO:0043549~regulat
ion of kinase activity
CAV1, CSF1, TLR1, TGFB3, ZEB2, TLR4, LPAR1, ADORA1, CD74, TRIB2, SLC11A1, CDC42, SPRY1, APP, 
MDFIC, IL1B, CERK, NRG1, AGK, FGF2, AGAP2, PTPRC, PTPN6, TNXB, SPHK1, STRADA, PKIB, CENPE, 
CDC25B, CDKN1A, EREG, GADD45B, F2R 7.63E-05 0.0030805
GO:0006935~chemo
taxis
C3AR1, CCL3, CCL2, S100A8, CCR1, CXCR2, ITGB2, CX3CL1, CCL5, CCL4, ITGAM, CCL6, CXCL10, CCL22, 
DOCK2, EAR2, RAC2, CSF3R, IL1B, FCER1G, ROBO2, C5AR1, SLIT2, FCGR3, LSP1, CCR7, CORO1A, 
CXCL16, CX3CR1, CMTM7, CMTM3, PTAFR 3.58E-10 8.69E-08
GO:0042330~taxis
C3AR1, CCL3, CCL2, S100A8, CCR1, CXCR2, ITGB2, CX3CL1, CCL5, CCL4, ITGAM, CCL6, CXCL10, CCL22, 
DOCK2, EAR2, RAC2, CSF3R, IL1B, FCER1G, ROBO2, C5AR1, SLIT2, FCGR3, LSP1, CCR7, CORO1A, 
CXCL16, CX3CR1, CMTM7, CMTM3, PTAFR 3.58E-10 8.69E-08
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GO:0045859~regulat
ion of protein kinase 
activity
CAV1, CSF1, TLR1, TGFB3, ZEB2, TLR4, LPAR1, ADORA1, TRIB2, CD74, SLC11A1, SPRY1, APP, MDFIC, 
IL1B, CERK, NRG1, AGK, FGF2, AGAP2, PTPRC, PTPN6, TNXB, SPHK1, STRADA, PKIB, CENPE, CDC25B, 
CDKN1A, EREG, GADD45B, F2R 9.82E-05 0.003815
GO:0048514~blood 
vessel 
morphogenesis
MEF2C, RTN4, CAV1, ACVRL1, FOXM1, TBX20, GJA1, CX3CL1, WT1, SEMA5A, ARHGAP22, CUL7, HAND2, 
CXCR4, HMOX1, ITGAV, TGM2, IL1B, RHOB, SEMA3C, ANGPT1, FGF2, ITGA4, ARHGAP24, MMP14, EPHA2, 
ANXA2, VEGFC, SMO, EREG, SMARCA4 6.79E-04 0.0201978
GO:0042110~T cell 
activation
ITGAL, CD8A, ELF4, SOX4, PRKDC, PTPN22, ITGB2, IL7R, ITGAM, CD74, CD48, SLC11A1, DOCK2, ITGAX, 
CXCR4, BCL2, CD4, SPN, RHOH, PTPRC, ICOSL, IKZF1, FLT3, THEMIS, RELB, HS1BP3, WAS, VAV1, 
CARD11, H2-DMA 3.27E-08 3.82E-06
GO:0042110~T cell 
activation
ITGAL, CD8A, ELF4, SOX4, PRKDC, PTPN22, ITGB2, IL7R, ITGAM, CD74, CD48, SLC11A1, DOCK2, ITGAX, 
CXCR4, BCL2, CD4, SPN, RHOH, PTPRC, ICOSL, IKZF1, FLT3, THEMIS, RELB, HS1BP3, WAS, VAV1, 
CARD11, H2-DMA 3.27E-08 3.82E-06
GO:0050778~positiv
e regulation of 
immune response
IGHG1, CADM1, TLR2, UNC93B1, PTPN22, CACNB3, TLR4, C1QC, TLR8, SLC11A1, KLHL6, FCER1G, CLEC2I, 
PTPN6, PTPRC, THEMIS, NFAM1, FCGR3, C1QA, C1QB, LAT2, EREG, LAX1, PLCG2, H2-AA, CD79B, 
CLEC7A, H2-DMA, SASH3 3.88E-06 2.55E-04
GO:0002521~leukoc
yte differentiation
GPR183, CD8A, SOX4, PRKDC, PTPN22, IL7R, CBFA2T3, CD74, DOCK2, CLCF1, BCL2, CD4, SPIB, HELLS, 
SPN, RHOH, PTPRC, IKZF1, FLT3, THEMIS, RELB, NFAM1, HS1BP3, VAV1, CARD11, PLCG2, CD300LF, H2-
DMA, HDAC9 9.25E-06 5.30E-04
GO:0033043~regulat
ion of organelle 
organization
XPO1, CAV1, BTC, ELN, PAX5, CDC42, CUL7, GSN, CUL9, MLST8, LTB, SYNPO, CLEC2I, DBNL, ARHGEF2, 
PLEK, CEP192, NUSAP1, CDC23, MYO1F, TMSB10, CENPE, EVL, CORO1A, YWHAH, MAD2L1, EREG, CAPG, 
TMSB4X 4.39E-05 0.0020064
GO:0033043~regulat
ion of organelle 
organization
XPO1, CAV1, BTC, ELN, PAX5, CDC42, CUL7, GSN, CUL9, MLST8, LTB, SYNPO, CLEC2I, DBNL, ARHGEF2, 
PLEK, CEP192, NUSAP1, CDC23, MYO1F, TMSB10, CENPE, EVL, CORO1A, YWHAH, MAD2L1, EREG, CAPG, 
TMSB4X 4.39E-05 0.0020064
GO:0010627~regulat
ion of protein kinase 
cascade
CAV1, NFKBID, TLR3, ZEB2, TLR4, LPAR1, ITSN1, TIMP2, IGF1R, SPRY1, MDFIC, TGM2, IL1B, PHLDA3, LTB, 
PTPN6, PTPRC, TNXB, PSAP, HCLS1, DUSP22, EDA2R, FGF21, FLNA, CARD11, ADRB2, AIDA, NLRP12, 
MAPK8IP1 4.95E-05 0.002168
GO:0050865~regulat
ion of cell activation
ITGAL, NFKBID, TLR4, IL7R, CD74, HMOX1, VNN1, FCER1G, CD4, INPP5D, SPN, CLEC2I, PTPRC, PTPN6, 
ICOSL, PLEK, IKZF1, FLT3, FOXJ1, CENPF, NFAM1, CARD11, CD83, CDKN1A, CORO1A, CD274, H2-AA, H2-
DMA, SASH3 5.58E-05 0.002375
GO:0007169~transm
embrane receptor 
protein tyrosine 
kinase signaling 
pathway
CCL2, PTK7, DDR2, SRC, EPHB2, IGSF10, IGF1R, TIAM1, ANGPT1, AGRN, PAK1, FGF2, CLEC2I, PLAT, 
STAP1, FLT3, AXL, FGF21, EPHA2, FLNA, EPHA3, DDR1, VEGFC, GRB10, EREG, PDGFRA, PDGFRB, 
EIF2AK3, PLEKHA1 0.0018182 0.0425524
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GO:0002694~regulat
ion of leukocyte 
activation
ITGAL, NFKBID, TLR4, IL7R, CD74, HMOX1, VNN1, FCER1G, CD4, INPP5D, SPN, CLEC2I, PTPRC, PTPN6, 
ICOSL, IKZF1, FLT3, FOXJ1, CENPF, NFAM1, CARD11, CD83, CDKN1A, CORO1A, CD274, H2-AA, H2-DMA, 
SASH3 1.14E-04 0.0042095
GO:0030155~regulat
ion of cell adhesion
ITGAL, CYTIP, CSF1, L1CAM, CYTH3, SRC, ABI3BP, SMOC2, KIFAP3, BCL2, TGM2, COL8A1, THBS1, SPN, 
ADAM10, TNXB, CCDC80, MYO1F, NID1, ECM2, MMP14, VAV1, EMILIN1, LAMA2, DDR1, FBLN2, COL1A1 1.78E-08 2.25E-06
GO:0051130~positiv
e regulation of 
cellular component 
organization
IGHG1, CAV1, PLEK, BTC, TGFB3, NUSAP1, MFGE8, PPT1, CENPE, CD63, NTN1, SIRPA, AHR, FCGR3, 
SIRPB1A, SLC11A1, EREG, TIAM1, TPPP, FCER1G, ROBO2, SEMA4D, CLEC7A, MLST8, LTB, HIP1, SYNPO 4.39E-06 2.77E-04
GO:0051240~positiv
e regulation of 
multicellular 
organismal process
CAV1, PANX1, CSF1, TLR2, NCS1, TLR3, TLR4, CX3CL1, TLR7, TPM1, FOXS1, SLC11A1, BCL2, IL1B, 
FCER1G, LTB, PTPRM, IKZF1, LAMA2, CD83, ADRB2, EREG, SYTL2, CLEC7A, CD14, SASH3, F2R 6.93E-04 0.0204085
GO:0030098~lympho
cyte differentiation
GPR183, CD8A, SOX4, PRKDC, PTPN22, IL7R, CD74, DOCK2, CLCF1, BCL2, CD4, HELLS, SPN, RHOH, 
PTPRC, IKZF1, FLT3, THEMIS, RELB, NFAM1, HS1BP3, VAV1, CARD11, PLCG2, H2-DMA, HDAC9 3.88E-06 2.50E-04
GO:0051050~positiv
e regulation of 
transport
IGHG1, CAV1, PANX1, TGFB3, PPT1, ADORA1, SIRPB1A, SLC11A1, FCER1G, LTB, EXOC2, SCAMP5, HIP1, 
MFGE8, CD63, SIRPA, FLNA, FCGR3, INHBB, KCNN4, SMO, UACA, PLCG2, SYTL2, CLEC7A, F2R 5.54E-05 0.0023922
GO:0051249~regulat
ion of lymphocyte 
activation
PTPRC, ITGAL, PTPN6, ICOSL, IKZF1, NFKBID, FOXJ1, FLT3, CENPF, TLR4, NFAM1, IL7R, CD74, CARD11, 
CD83, CORO1A, CDKN1A, CD274, H2-AA, VNN1, CD4, INPP5D, H2-DMA, SASH3, SPN, CLEC2I 2.35E-04 0.0078619
GO:0002252~immun
e effector process
IGHG1, CPLX2, CD8A, PRKDC, IL7R, C1QC, TLR7, CD74, TLR8, SLC11A1, FCER1G, INPP5D, PTPRC, PTPN6, 
ICOSL, NCF1, SAMHD1, MYO1F, FCGR3, C1QA, C1QB, LAT2, LAX1, H2-AA, H2-DMA 7.05E-05 0.0028857
GO:0051347~positiv
e regulation of 
transferase activity
PTPRC, CSF1, TLR1, SPHK1, STRADA, TGFB3, ZEB2, CENPE, TLR4, LPAR1, ADORA1, CD74, CDC25B, 
CDC42, SLC11A1, SERINC2, EREG, MDFIC, CERK, GADD45B, NRG1, AGK, AGAP2, FGF2, F2R 2.15E-04 0.0074239
GO:0033674~positiv
e regulation of kinase 
activity
PTPRC, CSF1, TLR1, SPHK1, STRADA, TGFB3, ZEB2, CENPE, TLR4, LPAR1, ADORA1, CD74, CDC25B, 
CDC42, SLC11A1, EREG, MDFIC, CERK, GADD45B, NRG1, AGK, AGAP2, FGF2, F2R 3.10E-04 0.0101423
GO:0045087~innate 
immune response
TLR12, CIITA, TNFAIP8L2, PTPN6, IL1RL2, TLR13, TLR1, TLR2, SAMHD1, TLR3, TLR4, TLR7, C1QC, TLR8, 
CD180, TLR9, APOA4, C1QA, C1QB, SLC11A1, TMEM173, VNN1, CLEC7A 4.21E-05 0.0019486
GO:0045860~positiv
e regulation of 
protein kinase activity
PTPRC, CSF1, TLR1, SPHK1, STRADA, TGFB3, ZEB2, CENPE, TLR4, LPAR1, ADORA1, CD74, CDC25B, 
SLC11A1, EREG, MDFIC, CERK, GADD45B, NRG1, AGK, AGAP2, FGF2, F2R 3.99E-04 0.0127596
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GO:0002253~activati
on of immune 
response
IGHG1, PTPN6, PTPRC, THEMIS, TLR2, UNC93B1, PTPN22, CACNB3, TLR4, NFAM1, C1QC, C1QA, C1QB, 
LAT2, KLHL6, LAX1, PLCG2, FCER1G, CD79B, CLEC7A, CLEC2I 1.41E-05 7.55E-04
GO:0050863~regulat
ion of T cell 
activation
PTPN6, PTPRC, ITGAL, ICOSL, IKZF1, NFKBID, FOXJ1, CENPF, IL7R, CD74, CARD11, CD83, CORO1A, 
CD274, VNN1, H2-AA, CD4, H2-DMA, SPN, SASH3, CLEC2I 4.06E-04 0.0128406
GO:0030217~T cell 
differentiation
PTPRC, IKZF1, CD8A, FLT3, THEMIS, RELB, PRKDC, SOX4, PTPN22, HS1BP3, IL7R, VAV1, CD74, CARD11, 
DOCK2, BCL2, CD4, H2-DMA, SPN, RHOH 7.55E-06 4.41E-04
GO:0007229~integri
n-mediated signaling 
pathway
ITGAL, ADAM10, ITGAE, ITGB5, ITGB2, ITGA3, ITGA4, VAV1, ITGAM, ITGBL1, GAB2, ITGAX, ITGA8, ITGB7, 
ITGAV, ADAM19, ADAM8, CIB3, ADAMTS2, ADAMTS5 7.55E-06 4.41E-04
GO:0043408~regulat
ion of MAPKKK 
cascade
PTPN6, PTPRC, CAV1, TNXB, PSAP, EDA2R, DUSP22, TLR3, ZEB2, TLR4, FGF21, LPAR1, TIMP2, IGF1R, 
ADRB2, SPRY1, AIDA, MDFIC, IL1B, MAPK8IP1 1.50E-04 0.005309
GO:0050867~positiv
e regulation of cell 
activation
PTPRC, ITGAL, ICOSL, PLEK, IKZF1, TLR4, IL7R, CD74, CARD11, CD83, CORO1A, CDKN1A, FCER1G, VNN1, 
H2-AA, CD4, INPP5D, H2-DMA, SPN, SASH3 4.57E-04 0.0141671
GO:0042035~regulat
ion of cytokine 
biosynthetic process
ICOSL, FOXJ1, TLR1, TLR3, NFKB1, TLR4, TLR7, TLR8, TLR9, FCGR3, INHBB, CARD11, MAST2, EREG, IL1B, 
INPP5D, LTB, SPN, CLEC2I 2.12E-06 1.67E-04
GO:0002696~positiv
e regulation of 
leukocyte activation
PTPRC, ITGAL, ICOSL, IKZF1, TLR4, IL7R, CD74, CARD11, CD83, CORO1A, CDKN1A, FCER1G, VNN1, H2-
AA, CD4, INPP5D, H2-DMA, SPN, SASH3 9.69E-04 0.0260151
GO:0045785~positiv
e regulation of cell 
adhesion
ITGAL, TNXB, CSF1, CCDC80, NID1, L1CAM, CYTH3, ECM2, VAV1, ABI3BP, SRC, EMILIN1, SMOC2, FBLN2, 
KIFAP3, TGM2, COL8A1, THBS1 1.49E-08 2.05E-06
GO:0002443~leukoc
yte mediated 
immunity
IGHG1, PTPN6, CPLX2, ICOSL, CD8A, NCF1, MYO1F, C1QC, CD74, FCGR3, C1QA, C1QB, SLC11A1, LAT2, 
FCER1G, H2-AA, INPP5D, H2-DMA 7.46E-04 0.0211623
GO:0044087~regulat
ion of cellular 
component 
biogenesis
DBNL, CAV1, PLEK, ELN, TGFB3, EVL, TMSB10, MMP14, AHR, CORO1A, GSN, TPPP, CAPG, TMSB4X, 
AGRN, MLST8, SYNPO, CLEC2I 7.46E-04 0.0211623
GO:0051098~regulat
ion of binding
THRA, NFKBID, FOXJ1, TLR2, EDA2R, TLR3, ITGB2, TLR4, NFAM1, FLNA, SMO, ADRB2, AIDA, ZFP462, 
HMOX1, MAPK3, CALM3, EIF2AK3 8.51E-04 0.0232798
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GO:0030334~regulat
ion of cell migration
RTN4, PDGFB, CSF1, TLR2, MYO1F, ABHD2, ADORA1, NTN1, VCL, CXCL10, LAMA2, KISS1R, CORO1A, 
CXCR4, BCL2, CCR2, TMSB4X, THBS1 0.0011001 0.0287521
GO:0051129~negativ
e regulation of 
cellular component 
organization
RTN4, DBNL, ARHGEF2, CEP192, PAX5, RHOQ, EVL, CENPE, TMSB10, MMP14, NTN1, TTC3, EPHB2, 
YWHAH, MAD2L1, GSN, CAPG, TMSB4X 0.0012462 0.0319825
GO:0051251~positiv
e regulation of 
lymphocyte activation
PTPRC, ITGAL, ICOSL, IKZF1, TLR4, IL7R, CD74, CARD11, CD83, CORO1A, CDKN1A, VNN1, H2-AA, CD4, 
INPP5D, H2-DMA, SPN, SASH3 0.0014085 0.0343986
GO:0007346~regulat
ion of mitotic cell 
cycle
CDK1, CEP192, BTC, CENPF, CDC23, NUSAP1, CENPE, CDC42, APP, YWHAH, MAD2L1, EREG, CUL7, BCL2, 
CUL9, MTBP, ZWILCH, LTB 0.0017869 0.0424641
GO:0002764~immun
e response-
regulating signal 
transduction
PTPN6, PTPRC, THEMIS, TLR2, UNC93B1, PTPN22, CACNB3, NFAM1, LAT2, KLHL6, SH2D1B1, LAX1, 
PLCG2, FCER1G, CD79B, CLEC7A, CLEC2I 2.11E-06 1.70E-04
GO:0002768~immun
e response-
regulating cell 
surface receptor 
signaling pathway
PTPN6, PTPRC, THEMIS, TLR2, PTPN22, CACNB3, NFAM1, LAT2, KLHL6, SH2D1B1, LAX1, PLCG2, FCER1G, 
CD79B, CLEC7A, CLEC2I 1.01E-06 9.11E-05
GO:0002757~immun
e response-activating 
signal transduction
PTPN6, PTPRC, THEMIS, TLR2, UNC93B1, PTPN22, CACNB3, NFAM1, LAT2, KLHL6, LAX1, PLCG2, FCER1G, 
CD79B, CLEC7A, CLEC2I 3.52E-06 2.42E-04
GO:0045619~regulat
ion of lymphocyte 
differentiation
PTPN6, PTPRC, NFKBID, IKZF1, FOXJ1, FLT3, NFAM1, IL7R, CD74, CARD11, CD83, H2-AA, VNN1, INPP5D, 
H2-DMA, SASH3 4.42E-05 0.001989
GO:0002429~immun
e response-activating 
cell surface receptor 
signaling pathway
PTPN6, PTPRC, THEMIS, TLR2, PTPN22, CACNB3, NFAM1, LAT2, KLHL6, LAX1, PLCG2, FCER1G, CD79B, 
CLEC7A, CLEC2I 2.27E-06 1.75E-04
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GO:0050870~positiv
e regulation of T cell 
activation
PTPRC, ITGAL, ICOSL, IKZF1, IL7R, CD74, CARD11, CD83, CORO1A, H2-AA, VNN1, CD4, H2-DMA, SPN, 
SASH3 7.28E-04 0.0208541
GO:0010564~regulat
ion of cell cycle 
process
XPO1, CEP192, BTC, CENPF, CDC23, NUSAP1, PDE3A, CENPE, CDC42, YWHAH, MAD2L1, EREG, CUL7, 
CUL9, LTB 0.0020382 0.045239
GO:0010810~regulat
ion of cell-substrate 
adhesion
CSF1, CCDC80, NID1, ECM2, MMP14, ABI3BP, EMILIN1, SMOC2, DDR1, FBLN2, BCL2, COL1A1, COL8A1, 
THBS1 9.72E-06 5.47E-04
GO:0050900~leukoc
yte migration
C5AR1, FOXJ1, CCR1, ITGB2, CX3CL1, ITGAM, FCGR3, CORO1A, CD34, CX3CR1, FCER1G, CSF3R, IL1B, 
SELPLG 2.35E-05 0.001174
GO:0006909~phago
cytosis
IGHG1, SLC11A1, CD36, ITGAV, HCK, IRF8, FCER1G, MFGE8, CLEC7A, SIRPA, VAV1, ELMO2, FCGR3, 
ELMO1 1.06E-04 0.0040327
GO:0001819~positiv
e regulation of 
cytokine production PANX1, TLR2, TLR3, TLR4, CX3CL1, TLR7, SLC11A1, CD83, EREG, FCER1G, IL1B, CLEC7A, SASH3, CD14 0.0012482 0.0317722
GO:0001819~positiv
e regulation of 
cytokine production PANX1, TLR2, TLR3, TLR4, CX3CL1, TLR7, SLC11A1, CD83, EREG, FCER1G, IL1B, CLEC7A, SASH3, CD14 0.0012482 0.0317722
GO:0043254~regulat
ion of protein 
complex assembly DBNL, CAV1, PLEK, ELN, EVL, TMSB10, AHR, CORO1A, GSN, TPPP, CAPG, TMSB4X, MLST8, CLEC2I 0.0019646 0.0452319
GO:0048585~negativ
e regulation of 
response to stimulus PTPRC, PTPN6, FOXJ1, IL7R, ADORA1, ADRB2, GRB10, UACA, SH2D1B1, AIDA, IL1B, INPP5D, KLRB1B, SPN 0.0019646 0.0452319
GO:0048002~antige
n processing and 
presentation of 
peptide antigen
UNC93B1, IFI30, H2-DMB1, H2-AB1, CD74, H2-DMB2, FCGR3, SLC11A1, H2-EB1, CTSE, H2-AA, FCER1G, H2-
DMA 1.15E-05 6.25E-04
GO:0042108~positiv
e regulation of 
cytokine biosynthetic 
process ICOSL, TLR1, TLR3, TLR4, TLR7, TLR8, TLR9, FCGR3, CARD11, EREG, IL1B, LTB, SPN 8.93E-05 0.0035575
GO:0046651~lympho
cyte proliferation ITGAL, PTPRC, SLC11A1, DOCK2, ITGAX, ELF4, CXCR4, BCL2, ITGB2, IL7R, IMPDH1, HELLS, ITGAM 8.93E-05 0.0035575
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GO:0042108~positiv
e regulation of 
cytokine biosynthetic 
process ICOSL, TLR1, TLR3, TLR4, TLR7, TLR8, TLR9, FCGR3, CARD11, EREG, IL1B, LTB, SPN 8.93E-05 0.0035575
GO:0032943~monon
uclear cell 
proliferation ITGAL, PTPRC, SLC11A1, DOCK2, ITGAX, ELF4, CXCR4, BCL2, ITGB2, IL7R, IMPDH1, HELLS, ITGAM 1.15E-04 0.0041509
GO:0070661~leukoc
yte proliferation ITGAL, PTPRC, SLC11A1, DOCK2, ITGAX, ELF4, CXCR4, BCL2, ITGB2, IL7R, IMPDH1, HELLS, ITGAM 1.15E-04 0.0041509
GO:0002237~respon
se to molecule of 
bacterial origin C5AR1, TLR1, TLR2, TLR4, SLC11A1, THBD, MAPK3, PLCG2, IL1B, IRG1, PTAFR, CD14, F2R 4.37E-04 0.0137025
GO:0002504~antige
n processing and 
presentation of 
peptide or 
polysaccharide 
antigen via MHC 
class II H2-EB2, H2-EB1, CTSE, UNC93B1, H2-AA, FCER1G, H2-DMB1, IFI30, H2-AB1, H2-DMA, CD74, H2-DMB2 4.10E-08 4.62E-06
GO:0002478~antige
n processing and 
presentation of 
exogenous peptide 
antigen H2-EB1, CTSE, UNC93B1, H2-AA, FCER1G, H2-DMB1, IFI30, H2-AB1, H2-DMA, CD74, H2-DMB2, FCGR3 5.40E-07 5.32E-05
GO:0019884~antige
n processing and 
presentation of 
exogenous antigen H2-EB1, CTSE, UNC93B1, H2-AA, FCER1G, H2-DMB1, IFI30, H2-AB1, H2-DMA, CD74, H2-DMB2, FCGR3 5.86E-06 3.55E-04
GO:0002274~myeloi
d leukocyte activation SLC11A1, CPLX2, LAT2, RELB, CX3CR1, TLR1, MYO1F, FCER1G, TLR4, LCP2, RHOH, FCGR3 6.69E-05 0.0027714
GO:0050851~antige
n receptor-mediated 
signaling pathway PTPN6, PTPRC, LAT2, KLHL6, THEMIS, LAX1, PLCG2, PTPN22, CD79B, CACNB3, NFAM1, CLEC2I 8.93E-05 0.0035133
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GO:0051783~regulat
ion of nuclear 
division CDC42, YWHAH, MAD2L1, EREG, CUL7, CEP192, CUL9, BTC, CDC23, NUSAP1, CENPE, LTB 8.93E-05 0.0035133
GO:0007088~regulat
ion of mitosis CDC42, YWHAH, MAD2L1, EREG, CUL7, CEP192, CUL9, BTC, CDC23, NUSAP1, CENPE, LTB 8.93E-05 0.0035133
GO:0045580~regulat
ion of T cell 
differentiation CARD11, CD83, PTPRC, IKZF1, NFKBID, FOXJ1, H2-AA, VNN1, IL7R, H2-DMA, CD74, SASH3 0.0013578 0.0334392
GO:0045580~regulat
ion of T cell 
differentiation CARD11, CD83, PTPRC, IKZF1, NFKBID, FOXJ1, H2-AA, VNN1, IL7R, H2-DMA, CD74, SASH3 0.0013578 0.0334392
GO:0002495~antige
n processing and 
presentation of 
peptide antigen via 
MHC class II H2-EB1, CTSE, UNC93B1, H2-AA, FCER1G, H2-DMB1, IFI30, H2-AB1, H2-DMA, CD74, H2-DMB2 6.29E-08 6.84E-06
GO:0019886~antige
n processing and 
presentation of 
exogenous peptide 
antigen via MHC 
class II H2-EB1, CTSE, UNC93B1, H2-AA, FCER1G, H2-DMB1, IFI30, H2-AB1, H2-DMA, CD74, H2-DMB2 6.29E-08 6.84E-06
GO:0030595~leukoc
yte chemotaxis CORO1A, C5AR1, CCR1, CX3CR1, FCER1G, IL1B, CSF3R, ITGB2, CX3CL1, ITGAM, FCGR3 2.88E-05 0.001397
GO:0060326~cell 
chemotaxis CORO1A, C5AR1, CCR1, CX3CR1, FCER1G, IL1B, CSF3R, ITGB2, CX3CL1, ITGAM, FCGR3 2.88E-05 0.001397
GO:0045807~positiv
e regulation of 
endocytosis IGHG1, SIRPB1A, SLC11A1, FCER1G, MFGE8, PPT1, CLEC7A, CD63, SIRPA, HIP1, FCGR3 2.64E-04 0.008744
GO:0010811~positiv
e regulation of cell-
substrate adhesion SMOC2, FBLN2, CSF1, CCDC80, NID1, THBS1, ECM2, COL8A1, ABI3BP, EMILIN1 1.86E-04 0.0065079
GO:0032680~regulat
ion of tumor necrosis 
factor production TLR1, TLR2, FCER1G, TLR3, TLR4, CLEC7A, SASH3, CD14, SPN, FCGR3 1.86E-04 0.0065079
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GO:0032675~regulat
ion of interleukin-6 
production EREG, FOXJ1, TLR1, TLR2, FCER1G, TLR3, IL1B, TLR4, INPP5D, TLR7 7.69E-04 0.0214331
GO:0032675~regulat
ion of interleukin-6 
production EREG, FOXJ1, TLR1, TLR2, FCER1G, TLR3, IL1B, TLR4, INPP5D, TLR7 7.69E-04 0.0214331
GO:0032675~regulat
ion of interleukin-6 
production EREG, FOXJ1, TLR1, TLR2, FCER1G, TLR3, IL1B, TLR4, INPP5D, TLR7 7.69E-04 0.0214331
GO:0051235~mainte
nance of location KDELR3, NUF2, CD4, TMSB10, TMSB4X, CENPE, TACC3, ASPM, SRGN, FLNA 9.82E-04 0.0259191
GO:0045621~positiv
e regulation of 
lymphocyte 
differentiation CD83, PTPRC, IKZF1, H2-AA, VNN1, INPP5D, IL7R, H2-DMA, CD74, SASH3 0.0012403 0.0320937
GO:0045621~positiv
e regulation of 
lymphocyte 
differentiation CD83, PTPRC, IKZF1, H2-AA, VNN1, INPP5D, IL7R, H2-DMA, CD74, SASH3 0.0012403 0.0320937
GO:0045058~T cell 
selection CARD11, PTPRC, DOCK2, THEMIS, BCL2, CD4, H2-DMA, CD74, SPN 1.47E-04 0.0052558
GO:0042098~T cell 
proliferation ITGAL, PTPRC, SLC11A1, DOCK2, ITGAX, ELF4, CXCR4, ITGB2, ITGAM 0.0013432 0.0333462
GO:0045185~mainte
nance of protein 
location KDELR3, NUF2, CD4, TMSB10, TMSB4X, CENPE, TACC3, SRGN, FLNA 0.0013432 0.0333462
GO:0007159~leukoc
yte adhesion VCAM1, ITGAL, PTPRC, L1CAM, ITGB2, ITGA4, SELPLG, ITGAM 4.81E-05 0.002135
GO:0030593~neutro
phil chemotaxis C5AR1, FCER1G, IL1B, CSF3R, ITGB2, CX3CL1, ITGAM, FCGR3 2.19E-04 0.0074862
GO:0002698~negativ
e regulation of 
immune effector 
process PTPN6, PTPRC, SH2D1B1, FOXJ1, HMOX1, IL7R, KLRB1B, SPN 7.03E-04 0.0205125
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GO:0048873~homeo
stasis of number of 
cells within a tissue RPA1, CORO1A, BCL2, CSF1, SASH3, F2R, CD7, ADD1 9.81E-04 0.026106
GO:0050766~positiv
e regulation of 
phagocytosis IGHG1, SIRPB1A, SLC11A1, FCER1G, MFGE8, CLEC7A, SIRPA, FCGR3 0.0017901 0.0422212
GO:0050766~positiv
e regulation of 
phagocytosis IGHG1, SIRPB1A, SLC11A1, FCER1G, MFGE8, CLEC7A, SIRPA, FCGR3 0.0017901 0.0422212
GO:0002707~negativ
e regulation of 
lymphocyte mediated 
immunity PTPN6, PTPRC, SH2D1B1, FOXJ1, IL7R, KLRB1B, SPN 4.89E-04 0.0150097
GO:0002704~negativ
e regulation of 
leukocyte mediated 
immunity PTPN6, PTPRC, SH2D1B1, FOXJ1, IL7R, KLRB1B, SPN 4.89E-04 0.0150097
GO:0006911~phago
cytosis, engulfment IGHG1, FCER1G, MFGE8, CLEC7A, SIRPA, FCGR3, ELMO1 7.59E-04 0.0213447
GO:0032760~positiv
e regulation of tumor 
necrosis factor 
production TLR2, FCER1G, TLR3, TLR4, CLEC7A, SASH3, CD14 7.59E-04 0.0213447
GO:0006911~phago
cytosis, engulfment IGHG1, FCER1G, MFGE8, CLEC7A, SIRPA, FCGR3, ELMO1 7.59E-04 0.0213447
GO:0043368~positiv
e T cell selection PTPRC, DOCK2, THEMIS, BCL2, H2-DMA, CD74 6.33E-04 0.019019
GO:0045359~positiv
e regulation of 
interferon-beta 
biosynthetic process TLR3, TLR4, TLR7, TLR8, TLR9 0.0012549 0.0316868
GO:0045357~regulat
ion of interferon-beta 
biosynthetic process TLR3, TLR4, TLR7, TLR8, TLR9 0.0012549 0.0316868
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GO:0045356~positiv
e regulation of 
interferon-alpha 
biosynthetic process TLR3, TLR7, TLR8, TLR9 0.002026 0.0452939
GO:0045354~regulat
ion of interferon-
alpha biosynthetic 
process TLR3, TLR7, TLR8, TLR9 0.002026 0.0452939
GO:0031012~extracellula
r matrix
LTBP1, LTBP3, TGFB3, MMP23, MMP2, OGN, TGFBI, COL12A1, LOX, SPON2, LOXL1, GPC1, SPN, SPON1, ADAM10, SPARCL1, OLFML2B, 
CRTAP, OLFML2A, MMP14, MMP12, MMP11, ADAMTS9, BGN, COL1A2, MFAP2, ADAMTS1, VCAN, COL1A1, ADAM19, ADAM12, MFAP4, 
ADAMTS2, ADAMTS5, WNT5A, FMOD, ADAMTSL2, TNC, LUM, ADAMTS15, COL3A1, ELN, DCN, TIMP2, ABI3BP, TIMP1, CPZ, SMOC2, 
LAMB3, LGALS3BP, LAMB2, COL6A3, COL6A2, SFTPD, TGM2, ADAMTS10, COL6A1, AGRN, FBN2, ADAMTS12, ENTPD1, COL8A1, ENTPD2, 
DPT, COL4A4, COL4A2, COL4A1, TNXB, LGALS3, LGALS1, EFEMP2, FBN1, CCDC80, NID1, SPARC, ECM2, COL16A1, COL5A3, COL5A2, NTN1, 
COL5A1, COL4A6, COL4A5, ANXA2, EMILIN1, LAMA2, FBLN1, COL14A1, FBLN2, FREM1, KAZALD1, THSD4, FBLN7 9.14E-28 4.20E-25
GO:0005578~proteinaceo
us extracellular matrix
LTBP1, LTBP3, MMP23, MMP2, OGN, TGFBI, COL12A1, LOX, SPON2, LOXL1, GPC1, SPN, SPON1, ADAM10, SPARCL1, CRTAP, MMP14, 
MMP12, MMP11, ADAMTS9, BGN, COL1A2, MFAP2, ADAMTS1, VCAN, COL1A1, ADAM19, ADAM12, MFAP4, ADAMTS2, ADAMTS5, 
WNT5A, FMOD, ADAMTSL2, TNC, LUM, ADAMTS15, COL3A1, ELN, DCN, TIMP2, ABI3BP, TIMP1, CPZ, SMOC2, LAMB3, LGALS3BP, LAMB2, 
COL6A2, SFTPD, TGM2, ADAMTS10, COL6A1, AGRN, FBN2, ADAMTS12, ENTPD1, COL8A1, ENTPD2, DPT, COL4A4, COL4A2, COL4A1, TNXB, 
LGALS3, LGALS1, EFEMP2, FBN1, CCDC80, NID1, SPARC, ECM2, COL16A1, COL5A3, COL5A2, NTN1, COL5A1, COL4A6, COL4A5, ANXA2, 
EMILIN1, LAMA2, FBLN1, COL14A1, FBLN2, FREM1, KAZALD1, THSD4, FBLN7 1.99E-26 4.57E-24
GO:0044421~extracellula
r region part
GDF3, GDF2, LTBP1, LTBP3, GDF6, BTC, TGFB3, MMP2, CXCL10, APOA4, OGN, TGFBI, IL1B, COL12A1, VNN1, LOX, SPON2, SPN, SPON1, 
SPARCL1, OLFML2B, CRTAP, OLFML2A, MGP, MFGE8, VEGFC, ADAMTS9, THBD, COL1A2, MFAP2, ADAMTS1, COL1A1, MFAP4, ADAMTS2, 
ADAMTS5, WNT5A, CCL3, CCL2, ADAMTSL2, ELN, PPT1, CX3CL1, TIMP2, CCL5, CCL4, ABI3BP, CCL6, TIMP1, LAMB3, LGALS3BP, LAMB2, 
SFTPD, TCTN1, AGRN, OLFM3, ENTPD1, ENTPD2, SRGN, PLAT, LPL, LGALS3, EFEMP2, LGALS1, CCDC80, ECM2, COL16A1, NTN1, EMILIN1, 
LAMA2, COL14A1, FREM1, CXCL16, THSD4, BMP8B, IGHG1, LY86, SORL1, MMP23, CLCF1, GPX3, SEMA3C, LOXL2, LOXL1, GPC1, LTB, FGF2, 
ADAM10, CPXM2, MMP14, MMP12, SLIT2, MMP11, BGN, EREG, VCAN, ADAM19, ADAM12, FMOD, CSF1, LUM, TNC, ADAMTS15, COL3A1, 
CXCL9, DCN, CPZ, C1QTNF7, SMOC2, CCL22, COL6A3, TGM2, COL6A2, ADAMTS10, COL6A1, ADAMTS12, FBN2, COL8A1, THBS1, DPT, 
COL4A4, COL4A2, TNXB, COL4A1, PSAP, FBN1, NID1, SPARC, COL5A3, COL5A2, COL4A6, COL5A1, ANXA2, COL4A5, DKK3, FBLN1, FBLN2, 
KAZALD1, SULF1, FBLN7, GDF10, CMTM7, IGFBP1, CMTM3 2.98E-19 4.56E-17
GO:0044420~extracellula
r matrix part
TNC, COL3A1, TIMP2, TIMP1, SMOC2, LAMB3, LAMB2, FBN2, AGRN, LOX, COL8A1, ENTPD1, ENTPD2, SPN, COL4A4, COL4A2, COL4A1, 
TNXB, FBN1, CCDC80, NID1, SPARC, COL5A3, COL5A2, NTN1, COL5A1, COL4A6, COL4A5, ANXA2, LAMA2, FBLN1, FREM1, COL1A2, MFAP2, 
ADAMTS1, COL1A1 7.48E-15 8.54E-13
GO:0044420~extracellula
r matrix part
TNC, COL3A1, TIMP2, TIMP1, SMOC2, LAMB3, LAMB2, FBN2, AGRN, LOX, COL8A1, ENTPD1, ENTPD2, SPN, COL4A4, COL4A2, COL4A1, 
TNXB, FBN1, CCDC80, NID1, SPARC, COL5A3, COL5A2, NTN1, COL5A1, COL4A6, COL4A5, ANXA2, LAMA2, FBLN1, FREM1, COL1A2, MFAP2, 
ADAMTS1, COL1A1 7.48E-15 8.54E-13
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GO:0005604~basement 
membrane
COL4A4, COL4A2, COL4A1, TNC, CCDC80, NID1, SPARC, TIMP2, NTN1, COL4A6, COL5A1, COL4A5, TIMP1, ANXA2, LAMA2, SMOC2, LAMB3, 
FBLN1, LAMB2, FREM1, ADAMTS1, AGRN, ENTPD1, COL8A1, ENTPD2, SPN 7.34E-10 4.81E-08
GO:0005581~collagen COL4A4, COL4A2, TNXB, COL4A1, COL3A1, COL5A3, COL5A2, COL5A1, COL4A6, COL4A5, COL1A2, LOX, COL1A1 4.43E-09 2.54E-07
GO:0005581~collagen COL4A4, COL4A2, TNXB, COL4A1, COL3A1, COL5A3, COL5A2, COL5A1, COL4A6, COL4A5, COL1A2, LOX, COL1A1 4.43E-09 2.54E-07
GO:0005581~collagen COL4A4, COL4A2, TNXB, COL4A1, COL3A1, COL5A3, COL5A2, COL5A1, COL4A6, COL4A5, COL1A2, LOX, COL1A1 4.43E-09 2.54E-07
GO:0005576~extracellula
r region
GDF3, GDF2, LTBP1, LTBP2, LTBP3, GDF6, BTC, FSTL1, C1QC, OGN, SERPINE1, COL12A1, VNN1, HTRA3, PI15, STC2, OLFML2B, CRTAP, 
OLFML2A, PLAUR, C1QA, C1QB, VEGFC, ADAMTS9, ST14, ADAMTS1, ADAMTS2, ADAMTS5, ELN, PPT1, ITGBL1, ACE, LGALS3BP, LAMB3, 
LAMB2, FGL2, TCTN1, AGRN, OLFM3, PLAT, MGAT4A, LGALS3, LGALS1, CCDC80, COL16A1, ECM2, EPHA3, EMILIN1, LAMA2, COL14A1, 
BMP8B, PLAU, IGHG1, PXDN, LY86, MMP23, CGREF1, SERPINA7, GPX3, SEMA3C, ANGPT1, SEMA3B, CAP1, FGF2, ADAM10, CPXM2, 
MMP14, SLIT2, MMP12, MMP11, INHBB, BGN, EREG, TMSB4X, VCAN, ADAM19, ADAM12, FMOD, CSF1, COL3A1, CXCL9, PCOLCE, IGSF10, 
GLIPR2, CCL22, GLIPR1, COL6A3, COL6A2, COL6A1, THBS1, THBS2, NID1, DKK3, FBLN1, FAM180A, FBLN2, FBLN5, CAPG, FBLN7, CMTM7, 
PRSS23, CMTM3, PDGFB, F13A1, TGFB3, MMP2, CXCL10, APOA4, OLFML3, ST3GAL2, PAPPA, TGFBI, IL1B, LOX, LGI2, SPON2, SPN, SPON1, 
SCUBE3, NGP, SPARCL1, SCUBE1, MGP, MFGE8, FGF21, THBD, COL1A2, MFAP2, COL1A1, MFAP4, WNT5A, CCL3, CCL2, ADAMTSL2, 
PAMR1, CX3CL1, TIMP2, CCL5, CCL4, MDK, ABI3BP, CCL6, TIMP1, SFTPD, ENTPD1, ENTPD2, SRGN, LPL, EFEMP2, ENDOD1, NTN1, FREM1, 
CXCL16, THSD4, AEBP1, IGFBP7, SORL1, CLSTN1, WISP2, GSN, CLCF1, LTF, LOXL2, GPC1, LTB, LOXL1, PCYOX1L, SLPI, TREM2, TNC, LUM, 
ADAMTS15, DCN, CPZ, AI413582, C1QTNF7, ISLR, SMOC2, PRRG4, C1QTNF6, TGM2, ADAMTS10, TNFRSF19, ADAMTS12, FBN2, COL8A1, 
DPT, COL4A4, COL4A2, SVEP1, COL4A1, TNXB, PSAP, FBN1, SPARC, FRZB, COL5A3, COL5A2, COL4A6, COL5A1, COL4A5, ANXA2, NBL1, 
KAZALD1, SULF1, GDF10, IGFBP1 2.51E-08 1.28E-06
GO:0005856~cytoskeleto
n
CTNNAL1, KIFC1, PRC1, KNTC1, PDLIM2, AURKA, AURKB, ADORA1, VCL, APP, CDCA8, ANK2, HOMER3, INCENP, KIFAP3, ASPM, DBNL, 
ENC1, PDE4D, TMSB10, SPIRE1, VPS41, TACC3, MAD2L1, NAV1, FNBP1L, SPAG5, CNTROB, CC2D2A, SNTG1, OPHN1, MFAP2, CLIP2, DBN1, 
ADD1, NEK2, STK17B, LRRCC1, NEDD9, CHEK1, ANLN, MYO9B, KRT23, MYL9, DOCK2, FGD3, CKAP2, MYO1C, NIN, MYO1D, MYO1G, 
MYO1F, PTPN13, EVL, CSRP1, GAS8, SHANK2, KIF3C, CORO1A, UACA, EPS8, EPB4.1L4A, MARCKS, WDR1, KIF23, KIF22, CDC14A, FERMT3, 
NCS1, FERMT1, ARL2BP, SLC1A4, DES, GSN, TUBB6, MICAL1, CAP1, MSN, TUBA1A, IFNGR1, PARVG, CDC6, ARHGEF2, ADAM10, ACTA2, 
TPX2, FBLIM1, NUSAP1, PLEKHH1, ARHGAP24, WAS, ELMO2, FLNA, ELMO1, KIF1A, MAST2, PLEKHH2, SEMA4C, SH3KBP1, TMSB4X, 
HAUS8, SGCB, MYO5A, VIM, FHL3, ABI2, CEP55, TPM2, APBB1IP, TPM1, TPM4, TRIB2, STAU2, KIF7, KIF4, KRT8, WIPF1, KIF21B, AFAP1, 
SYNPO, ACTB, NES, CEP192, DLGAP5, KIF18B, CENPF, CENPE, GRIA3, PEA15A, RACGAP1, COTL1, TUBGCP2, ANXA2, CDC25B, CCNB1, 
EPB4.1L3, PPP1R9B, EPB4.1L1, RPS6KA1, NINL, PSPC1, KIF20B, CALM3, SYNM, KIF20A 3.53E-07 1.35E-05
GO:0000775~chromosom
e, centromeric region
XPO1, NEK2, KNTC1, AURKB, JRK, SPC25, CDCA8, TRP53BP1, OIP5, INCENP, BUB1, ZWILCH, DNMT3B, HELLS, MKI67, IKZF1, DSN1, SGOL1, 
NUF2, CENPF, NDC80, CENPE, CENPI, MAD2L1, SPAG5, BUB1B, DNMT1, CENPT 5.25E-07 1.85E-05
GO:0008305~integrin 
complex ITGAL, ITGAX, ITGAE, ITGAV, ITGA8, ITGB7, ITGB5, ITGA3, ITGB2, ITGA4, ITGAM, ITGBL1 9.91E-06 3.25E-04
GO:0043235~receptor 
complex
PTPN6, ITGAL, CSF1, ITGAE, ITGB5, ITGB2, ITGA3, TLR4, ITGA4, ITGAM, ITGBL1, ADRB2, EPS8, ITGAX, ITGA8, ITGB7, ITGAV, SDCBP, CD79B, 
CHRNB1, CD14 1.78E-05 5.11E-04
GO:0042613~MHC class II 
protein complex H2-EB2, H2-EB1, H2-AA, H2-DMB1, H2-AB1, H2-DMA, H2-DMB2 6.21E-05 0.001582689
GO:0000793~condensed 
chromosome
MKI67, NEK2, DSN1, SGOL1, NUF2, KNTC1, CENPF, CENPE, NDC80, MLH3, RAD51, NCAPD2, RPA1, SPC25, TRP53BP1, MAD2L1, SPAG5, 
INCENP, BUB1, BUB1B, CENPT, ZWILCH, TOP2A 9.46E-05 0.002282565
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GO:0000777~condensed 
chromosome kinetochore DSN1, NUF2, KNTC1, CENPF, CENPE, NDC80, SPC25, TRP53BP1, MAD2L1, SPAG5, INCENP, BUB1, BUB1B, CENPT, ZWILCH 1.11E-04 0.002533423
GO:0000779~condensed 
chromosome, 
centromeric region DSN1, SGOL1, NUF2, KNTC1, CENPF, CENPE, NDC80, SPC25, TRP53BP1, MAD2L1, SPAG5, INCENP, BUB1, BUB1B, CENPT, ZWILCH 1.25E-04 0.002736293
GO:0000776~kinetochore XPO1, DSN1, NUF2, KNTC1, CENPF, CENPE, NDC80, SPC25, TRP53BP1, MAD2L1, SPAG5, INCENP, BUB1, BUB1B, CENPT, ZWILCH 1.86E-04 0.003878757
GO:0030935~sheet-
forming collagen COL4A4, COL4A2, COL4A1, COL4A6, COL4A5 7.10E-04 0.012956502
GO:0005587~collagen 
type IV COL4A4, COL4A2, COL4A1, COL4A6, COL4A5 7.10E-04 0.012956502
GO:0044430~cytoskeletal 
part
KIF23, KIFC1, KIF22, CDC14A, PRC1, FERMT3, FERMT1, NCS1, KNTC1, AURKA, AURKB, ADORA1, ARL2BP, SLC1A4, APP, CDCA8, DES, 
HOMER3, INCENP, KIFAP3, TUBB6, CAP1, TUBA1A, ASPM, IFNGR1, CDC6, ARHGEF2, ADAM10, TPX2, NUSAP1, PDE4D, VPS41, TACC3, 
KIF1A, MAD2L1, NAV1, SPAG5, CNTROB, CC2D2A, SEMA4C, MFAP2, CLIP2, HAUS8, MYO5A, NEK2, VIM, LRRCC1, FHL3, MYO9B, ANLN, 
CEP55, TPM2, TPM1, KRT23, STAU2, TPM4, MYL9, KIF7, KIF4, KRT8, KIF21B, SYNPO, CKAP2, NES, MYO1C, NIN, CEP192, DLGAP5, MYO1D, 
MYO1G, MYO1F, CENPF, KIF18B, CENPE, GRIA3, PEA15A, GAS8, RACGAP1, TUBGCP2, KIF3C, SHANK2, ANXA2, CDC25B, CCNB1, PPP1R9B, 
RPS6KA1, EPS8, NINL, KIF20B, CALM3, SYNM, MARCKS, KIF20A 7.89E-04 0.013830214
GO:0015630~microtubule 
cytoskeleton
KIF23, KIFC1, KIF22, PRC1, CDC14A, KNTC1, AURKA, AURKB, ARL2BP, CDCA8, APP, KIFAP3, INCENP, TUBB6, TUBA1A, ASPM, CDC6, 
ARHGEF2, TPX2, NUSAP1, PDE4D, VPS41, TACC3, KIF1A, MAST2, MAD2L1, NAV1, SPAG5, CNTROB, CC2D2A, CLIP2, HAUS8, NEK2, LRRCC1, 
CEP55, STAU2, KIF7, KIF4, KIF21B, CKAP2, NIN, CEP192, DLGAP5, KIF18B, CENPF, CENPE, PEA15A, RACGAP1, GAS8, TUBGCP2, KIF3C, 
CDC25B, CCNB1, RPS6KA1, NINL, KIF20B, CALM3, MARCKS, KIF20A 0.001164913 0.019620041
GO:0005583~fibrillar 
collagen TNXB, COL3A1, COL1A2, COL1A1, COL5A3 0.001543806 0.025008904
GO:0030246~carbohydra
te binding
CD209A, KLRA17, SUSD2, L1CAM, FSTL1, FGF12, APP, CD93, CLEC4E, CD44, CLEC4A1, LTF, CLEC4D, CLEC4A3, FGF2, CLEC4N, NCAM1, BGN, 
CLEC12A, CLEC4B1, ADAMTS1, VCAN, CLEC5A, GLG1, GALNT3, GALNT6, DCN, CD72, MDK, ABI3BP, ITGAM, HMMR, SMOC2, GALNT10, 
CD69, SFTPD, CD22, THBS1, GPNMB, SELPLG, THBS2, CLEC2I, KLRA2, LPL, PTPRC, TNXB, LGALS3, SELL, LGALS1, FBN1, MRC2, CCDC80, 
COL5A3, ECM2, COL5A1, GFPT1, FREM1, GFPT2, FBLN7, CLEC7A, KLRB1B 5.90E-11 5.28E-08
GO:0030246~carbohydra
te binding
CD209A, KLRA17, SUSD2, L1CAM, FSTL1, FGF12, APP, CD93, CLEC4E, CD44, CLEC4A1, LTF, CLEC4D, CLEC4A3, FGF2, CLEC4N, NCAM1, BGN, 
CLEC12A, CLEC4B1, ADAMTS1, VCAN, CLEC5A, GLG1, GALNT3, GALNT6, DCN, CD72, MDK, ABI3BP, ITGAM, HMMR, SMOC2, GALNT10, 
CD69, SFTPD, CD22, THBS1, GPNMB, SELPLG, THBS2, CLEC2I, KLRA2, LPL, PTPRC, TNXB, LGALS3, SELL, LGALS1, FBN1, MRC2, CCDC80, 
COL5A3, ECM2, COL5A1, GFPT1, FREM1, GFPT2, FBLN7, CLEC7A, KLRB1B 5.90E-11 5.28E-08
GO:0008092~cytoskeletal 
protein binding
VCL, TRIM2, GSN, KIFAP3, MSN, CAP1, DLG5, FMNL1, PARVG, DBNL, ARHGEF2, FMNL3, ENC1, NUSAP1, VPS41, TMSB10, SPIRE1, FLNA, 
RAB11FIP5, MAST2, SPAG5, TPPP, LIMCH1, SNTG1, OPHN1, MFAP2, TMSB4X, DBN1, ADD1, MYO5A, FHL3, MYO9B, ANLN, TPM2, TPM1, 
DAAM2, TPM4, CORO2A, CNN2, WIPF1, AFAP1, SYNPO, HIP1, MYO1C, MYO1D, FSCN1, MYO1G, MYO1F, SYNPO2, EVL, COTL1, RACGAP1, 
ANXA2, LSP1, PPP1R9B, EPB4.1L3, CORO1A, SYNE1, YWHAH, EPB4.1L1, CAPG, EPB4.1L4A, MARCKS, SYNM, MAPK8IP1, WDR1, ANTXR1, 
DIAP3 4.63E-09 1.38E-06
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GO:0005201~extracellula
r matrix structural 
constituent COL4A4, COL4A2, COL4A1, FBN1, COL3A1, ELN, COL5A3, COL5A2, COL4A6, COL5A1, EMILIN1, COL4A5, COL1A2, COL1A1, FBN2 1.13E-08 2.53E-06
GO:0005201~extracellula
r matrix structural 
constituent COL4A4, COL4A2, COL4A1, FBN1, COL3A1, ELN, COL5A3, COL5A2, COL4A6, COL5A1, EMILIN1, COL4A5, COL1A2, COL1A1, FBN2 1.13E-08 2.53E-06
GO:0032553~ribonucleoti
de binding
ADCY3, KIFC1, ADCY1, ADCY2, XRCC2, ADCY7, ADCY6, AURKA, AURKB, CUL9, OASL2, DHX34, GBP8, TYRO3, LIG1, PIK3CD, ABCC12, GEM, 
WNK2, NAV1, RFC2, MAPK3, PDGFRA, PDGFRB, EIF2AK3, PFKFB4, GNAI1, NEK2, STK17B, ADRBK2, UBA6, CHEK1, MYO9B, HSPA1A, 
HSPA1B, NAGK, EPHB2, RAC2, POLQ, GM1966, SPHK1, ABCG3, RAD54L, KIF3C, ABCG1, EPHA2, ABCG2, EPHA3, ATP2A3, RAD54B, CLCN5, 
BCKDK, ACVRL1, KCNJ10, MLH3, CKB, TUBB6, MASTL, ARL5C, DOCK10, DOCK11, AGAP2, TOP2A, RAP2B, CDC6, ACTA2, RAD51, MAST4, 
MAST2, RRM1, ARL4C, MYO5A, ALDH18A1, RAB3D, HK2, HK1, ITM2C, IGSF10, GALK1, RAB44, MORC4, HK3, BUB1, CERK, KIF21B, AGK, 
PDK4, AXL, STRADA, ATP1A3, ATP1A2, RPS6KA3, RAB31, RPS6KA1, RAB34, KIF20B, CHTF18, ABCC1, GYK, KIF20A, GNA15, F13A1, PASK, 
TTK, PKMYT1, RRAD, PRKAR2B, ARL11, ACSS1, RALB, STK39, MLKL, CIITA, RPS6KC1, MAP4K4, ATP9A, GBP2, SRXN1, SMARCA4, STK10, 
PTK7, MAP4K1, CTPS2, RRAGD, SRC, CMPK2, ENTPD1, RUNX1, RUNX2, RUNX3, HELLS, ITK, RAB8B, SMCHD1, MYO1C, NIN, AK1, MYO1D, 
MYO1G, MYO1F, ATAD2, IKBKE, TGTP1, PIP4K2A, KIF23, RHOJ, KIF22, FIGNL1, PPIP5K1, RHOQ, SLFN4, DDR2, SLFN1, SLFN2, CDC42, 
TOR3A, MCM8, ATP8B2, RHOB, RHOC, PAK1, TUBA1A, CDK14, ATP8B4, RHOH, TRPM4, CDK1, PFKP, CDK6, PBK, MCM2, UBE2C, MCM3, 
MCM4, MCM5, PRKCB, MCM6, DDR1, KIF1A, BUB1B, H2-AA, MELK, DCK, PRKDC, TRIB2, IGF1R, KIF7, KIF4, TAP1, CAMK2D, TGM2, EHD2, 
EHD4, ACTB, FLT3, HCK, KIF18B, CENPE, SMC2, TEP1, APAF1, H2-DMA 1.98E-08 3.54E-06
GO:0032555~purine 
ribonucleotide binding
ADCY3, KIFC1, ADCY1, ADCY2, XRCC2, ADCY7, ADCY6, AURKA, AURKB, CUL9, OASL2, DHX34, GBP8, TYRO3, LIG1, PIK3CD, ABCC12, GEM, 
WNK2, NAV1, RFC2, MAPK3, PDGFRA, PDGFRB, EIF2AK3, PFKFB4, GNAI1, NEK2, STK17B, ADRBK2, UBA6, CHEK1, MYO9B, HSPA1A, 
HSPA1B, NAGK, EPHB2, RAC2, POLQ, GM1966, SPHK1, ABCG3, RAD54L, KIF3C, ABCG1, EPHA2, ABCG2, EPHA3, ATP2A3, RAD54B, CLCN5, 
BCKDK, ACVRL1, KCNJ10, MLH3, CKB, TUBB6, MASTL, ARL5C, DOCK10, DOCK11, AGAP2, TOP2A, RAP2B, CDC6, ACTA2, RAD51, MAST4, 
MAST2, RRM1, ARL4C, MYO5A, ALDH18A1, RAB3D, HK2, HK1, ITM2C, IGSF10, GALK1, RAB44, MORC4, HK3, BUB1, CERK, KIF21B, AGK, 
PDK4, AXL, STRADA, ATP1A3, ATP1A2, RPS6KA3, RAB31, RPS6KA1, RAB34, KIF20B, CHTF18, ABCC1, GYK, KIF20A, GNA15, F13A1, PASK, 
TTK, PKMYT1, RRAD, PRKAR2B, ARL11, ACSS1, RALB, STK39, MLKL, CIITA, RPS6KC1, MAP4K4, ATP9A, GBP2, SRXN1, SMARCA4, STK10, 
PTK7, MAP4K1, CTPS2, RRAGD, SRC, CMPK2, ENTPD1, RUNX1, RUNX2, RUNX3, HELLS, ITK, RAB8B, SMCHD1, MYO1C, NIN, AK1, MYO1D, 
MYO1G, MYO1F, ATAD2, IKBKE, TGTP1, PIP4K2A, KIF23, RHOJ, KIF22, FIGNL1, PPIP5K1, RHOQ, SLFN4, DDR2, SLFN1, SLFN2, CDC42, 
TOR3A, MCM8, ATP8B2, RHOB, RHOC, PAK1, TUBA1A, CDK14, ATP8B4, RHOH, TRPM4, CDK1, PFKP, CDK6, PBK, MCM2, UBE2C, MCM3, 
MCM4, MCM5, PRKCB, MCM6, DDR1, KIF1A, BUB1B, H2-AA, MELK, DCK, PRKDC, TRIB2, IGF1R, KIF7, KIF4, TAP1, CAMK2D, TGM2, EHD2, 
EHD4, ACTB, FLT3, HCK, KIF18B, CENPE, SMC2, TEP1, APAF1, H2-DMA 1.98E-08 3.54E-06
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GO:0005524~ATP binding
ADCY3, KIFC1, ADCY1, ADCY2, XRCC2, ADCY7, F13A1, ADCY6, PASK, PKMYT1, TTK, AURKA, AURKB, ACSS1, OASL2, CUL9, DHX34, MLKL, 
STK39, CIITA, TYRO3, LIG1, PIK3CD, RPS6KC1, ABCC12, WNK2, MAP4K4, NAV1, RFC2, ATP9A, MAPK3, PDGFRA, PDGFRB, EIF2AK3, SRXN1, 
SMARCA4, PFKFB4, NEK2, STK10, PTK7, STK17B, UBA6, ADRBK2, MAP4K1, CHEK1, CTPS2, HSPA1A, MYO9B, HSPA1B, NAGK, SRC, CMPK2, 
EPHB2, RUNX1, POLQ, ENTPD1, RUNX2, RUNX3, HELLS, ITK, SMCHD1, MYO1C, AK1, SPHK1, MYO1D, MYO1G, MYO1F, ATAD2, ABCG3, 
RAD54L, KIF3C, ABCG1, EPHA2, EPHA3, ABCG2, IKBKE, ATP2A3, RAD54B, PIP4K2A, CLCN5, KIF23, KIF22, BCKDK, ACVRL1, FIGNL1, PPIP5K1, 
KCNJ10, MLH3, DDR2, SLFN4, SLFN1, SLFN2, CKB, TOR3A, MCM8, ATP8B2, MASTL, PAK1, TOP2A, AGAP2, CDK14, ATP8B4, TRPM4, CDK1, 
CDC6, ACTA2, PFKP, CDK6, MCM2, PBK, MCM3, UBE2C, MCM4, MCM5, PRKCB, MCM6, RAD51, DDR1, MAST4, KIF1A, MAST2, RRM1, 
BUB1B, H2-AA, MELK, MYO5A, ALDH18A1, DCK, HK2, HK1, PRKDC, ITM2C, TRIB2, IGSF10, GALK1, IGF1R, KIF7, MORC4, HK3, KIF4, TAP1, 
BUB1, CAMK2D, CERK, KIF21B, AGK, EHD2, EHD4, ACTB, FLT3, HCK, PDK4, ATP1A3, AXL, STRADA, KIF18B, CENPE, ATP1A2, SMC2, 
RPS6KA3, RPS6KA1, KIF20B, CHTF18, TEP1, ABCC1, GYK, APAF1, H2-DMA, KIF20A 2.93E-08 4.38E-06
GO:0032559~adenyl 
ribonucleotide binding
ADCY3, KIFC1, ADCY1, ADCY2, XRCC2, ADCY7, F13A1, ADCY6, PASK, PKMYT1, TTK, AURKA, AURKB, PRKAR2B, ACSS1, OASL2, CUL9, DHX34, 
MLKL, STK39, CIITA, TYRO3, LIG1, PIK3CD, RPS6KC1, ABCC12, WNK2, MAP4K4, NAV1, RFC2, ATP9A, MAPK3, PDGFRA, PDGFRB, EIF2AK3, 
SRXN1, SMARCA4, PFKFB4, NEK2, STK10, PTK7, STK17B, UBA6, ADRBK2, MAP4K1, CHEK1, CTPS2, HSPA1A, MYO9B, HSPA1B, NAGK, SRC, 
CMPK2, EPHB2, RUNX1, POLQ, ENTPD1, RUNX2, RUNX3, HELLS, ITK, SMCHD1, MYO1C, AK1, SPHK1, MYO1D, MYO1G, MYO1F, ATAD2, 
ABCG3, RAD54L, KIF3C, ABCG1, EPHA2, EPHA3, ABCG2, IKBKE, ATP2A3, RAD54B, PIP4K2A, CLCN5, KIF23, KIF22, BCKDK, ACVRL1, FIGNL1, 
PPIP5K1, KCNJ10, MLH3, DDR2, SLFN4, SLFN1, SLFN2, CKB, TOR3A, MCM8, ATP8B2, MASTL, PAK1, TOP2A, AGAP2, CDK14, ATP8B4, 
TRPM4, CDK1, CDC6, ACTA2, PFKP, CDK6, MCM2, PBK, MCM3, UBE2C, MCM4, MCM5, PRKCB, MCM6, RAD51, DDR1, MAST4, KIF1A, 
MAST2, RRM1, BUB1B, H2-AA, MELK, MYO5A, ALDH18A1, DCK, HK2, HK1, PRKDC, ITM2C, TRIB2, IGSF10, GALK1, IGF1R, KIF7, MORC4, 
HK3, KIF4, TAP1, BUB1, CAMK2D, CERK, KIF21B, AGK, EHD2, EHD4, ACTB, FLT3, HCK, PDK4, ATP1A3, AXL, STRADA, KIF18B, CENPE, 
ATP1A2, SMC2, RPS6KA3, RPS6KA1, KIF20B, CHTF18, TEP1, ABCC1, GYK, APAF1, H2-DMA, KIF20A 3.93E-08 5.03E-06
GO:0003779~actin 
binding
VCL, GSN, CAP1, PARVG, FMNL1, DBNL, FMNL3, ENC1, TMSB10, SPIRE1, FLNA, LIMCH1, SNTG1, OPHN1, TMSB4X, DBN1, ADD1, MYO5A, 
FHL3, ANLN, MYO9B, TPM2, TPM1, DAAM2, TPM4, CORO2A, CNN2, WIPF1, AFAP1, SYNPO, HIP1, MYO1C, FSCN1, MYO1D, MYO1G, 
MYO1F, EVL, SYNPO2, COTL1, LSP1, PPP1R9B, EPB4.1L3, SYNE1, CORO1A, YWHAH, EPB4.1L1, CAPG, MARCKS, WDR1, ANTXR1, DIAP3 4.62E-08 5.18E-06
GO:0017076~purine 
nucleotide binding
ADCY3, KIFC1, ADCY1, ADCY2, XRCC2, ADCY7, ADCY6, AURKA, AURKB, AGPS, CUL9, OASL2, DHX34, GBP8, TYRO3, LIG1, PIK3CD, ABCC12, 
GEM, WNK2, NAV1, RFC2, MAPK3, PDGFRA, PDGFRB, EIF2AK3, PFKFB4, GNAI1, NEK2, STK17B, ADRBK2, UBA6, CHEK1, MYO9B, HSPA1A, 
HSPA1B, NAGK, EPHB2, RAC2, POLQ, GM1966, SPHK1, ABCG3, RAD54L, KIF3C, ABCG1, EPHA2, ABCG2, EPHA3, ATP2A3, RAD54B, CLCN5, 
STEAP4, BCKDK, ACVRL1, KCNJ10, MLH3, CKB, TUBB6, MASTL, ARL5C, DOCK10, DOCK11, AGAP2, TOP2A, RAP2B, CDC6, ACTA2, RAD51, 
MAST4, MAST2, RRM1, ARL4C, MYO5A, ALDH18A1, RAB3D, HK2, HK1, ITM2C, IGSF10, GALK1, RAB44, MORC4, HK3, BUB1, CERK, KIF21B, 
AGK, PDK4, AXL, STRADA, ATP1A3, ATP1A2, RPS6KA3, RAB31, RPS6KA1, RAB34, KIF20B, CHTF18, ABCC1, GYK, KIF20A, GNA15, F13A1, 
PASK, TTK, PKMYT1, RRAD, PRKAR2B, ARL11, ACSS1, RALB, STK39, MLKL, CIITA, RPS6KC1, MAP4K4, ATP9A, GBP2, SRXN1, SMARCA4, 
STK10, PTK7, MAP4K1, CTPS2, RRAGD, SRC, CMPK2, ENTPD1, RUNX1, RUNX2, RUNX3, HELLS, ITK, RAB8B, SMCHD1, MYO1C, NIN, AK1, 
MYO1D, MYO1G, MYO1F, ATAD2, IKBKE, TGTP1, PIP4K2A, KIF23, RHOJ, KIF22, FIGNL1, PPIP5K1, RHOQ, SLFN4, DDR2, SLFN1, SLFN2, 
CDC42, TOR3A, MCM8, ATP8B2, RHOB, RHOC, PAK1, TUBA1A, CDK14, ATP8B4, RHOH, TRPM4, CDK1, PFKP, CDK6, PBK, MCM2, UBE2C, 
MCM3, MCM4, MCM5, PRKCB, MCM6, DDR1, KIF1A, BUB1B, H2-AA, MELK, DCK, PRKDC, TRIB2, IGF1R, KIF7, KIF4, TAP1, CAMK2D, TGM2, 
EHD2, EHD4, ACTB, FLT3, HCK, KIF18B, CENPE, SMC2, CYBB, TEP1, APAF1, H2-DMA 1.16E-07 1.04E-05
GO:0030247~polysacchar
ide binding
SUSD2, FSTL1, DCN, FGF12, MDK, ABI3BP, ITGAM, HMMR, SMOC2, APP, CD44, LTF, GPNMB, THBS1, FGF2, THBS2, LPL, PTPRC, TNXB, 
FBN1, CCDC80, COL5A3, ECM2, COL5A1, NCAM1, BGN, FBLN7, ADAMTS1, VCAN, CLEC7A 1.07E-07 1.07E-05
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GO:0001871~pattern 
binding
SUSD2, FSTL1, DCN, FGF12, MDK, ABI3BP, ITGAM, HMMR, SMOC2, APP, CD44, LTF, GPNMB, THBS1, FGF2, THBS2, LPL, PTPRC, TNXB, 
FBN1, CCDC80, COL5A3, ECM2, COL5A1, NCAM1, BGN, FBLN7, ADAMTS1, VCAN, CLEC7A 1.07E-07 1.07E-05
GO:0030695~GTPase 
regulator activity
DENND5A, ARHGAP19, IQGAP3, ITSN1, ARHGAP15, IQGAP1, ARL2BP, ARHGAP22, SRPX, RINL, TIAM1, KIFAP3, ARHGAP1, ARHGAP11A, 
DOCK10, DOCK11, AGAP2, ARHGAP9, ARHGEF2, DAB2IP, ARHGEF7, PSD4, ARHGAP27, ARHGEF9, ARHGAP24, ECT2, WAS, ARHGAP25, 
MAP4K4, RALGAPA1, OPHN1, SRGAP2, TBC1D9, CYTH4, MAP4K1, MYO9B, CYTH3, ADAP1, RASAL1, TAGAP, DOCK2, PLEKHG1, GMIP, 
RASAL3, TBC1D1, RASA4, FGD3, ARHGDIB, ABR, RACGAP1, VAV1, RALGDS, RGS1, RGS2, SYDE1, SYTL4, SYTL2, EVI5L 1.61E-07 1.32E-05
GO:0001883~purine 
nucleoside binding
ADCY3, KIFC1, ADCY1, ADCY2, XRCC2, ADCY7, F13A1, ADCY6, PASK, PKMYT1, TTK, AURKA, AURKB, ADORA1, PRKAR2B, ACSS1, AGPS, 
OASL2, CUL9, DHX34, MLKL, STK39, CIITA, TYRO3, LIG1, PIK3CD, RPS6KC1, ABCC12, WNK2, MAP4K4, NAV1, RFC2, ATP9A, MAPK3, 
PDGFRA, PDGFRB, EIF2AK3, SRXN1, SMARCA4, PFKFB4, NEK2, STK10, PTK7, STK17B, UBA6, ADRBK2, MAP4K1, CHEK1, CTPS2, HSPA1A, 
MYO9B, HSPA1B, NAGK, SRC, CMPK2, EPHB2, RUNX1, POLQ, ENTPD1, RUNX2, RUNX3, HELLS, ITK, SMCHD1, MYO1C, AK1, SPHK1, 
MYO1D, MYO1G, MYO1F, ATAD2, ABCG3, RAD54L, KIF3C, ABCG1, EPHA2, EPHA3, ABCG2, IKBKE, ATP2A3, RAD54B, PIP4K2A, CLCN5, 
KIF23, KIF22, STEAP4, BCKDK, ACVRL1, FIGNL1, PPIP5K1, KCNJ10, MLH3, DDR2, SLFN4, SLFN1, SLFN2, CKB, TOR3A, MCM8, ATP8B2, RHOB, 
MASTL, PAK1, TOP2A, AGAP2, CDK14, ATP8B4, TRPM4, CDK1, CDC6, ACTA2, PFKP, CDK6, MCM2, PBK, MCM3, UBE2C, MCM4, MCM5, 
PRKCB, MCM6, RAD51, DDR1, MAST4, KIF1A, MAST2, RRM1, BUB1B, H2-AA, MELK, MYO5A, ALDH18A1, DCK, HK2, HK1, PRKDC, ITM2C, 
TRIB2, IGSF10, GALK1, IGF1R, KIF7, MORC4, HK3, KIF4, TAP1, BUB1, CAMK2D, CERK, KIF21B, AGK, EHD2, EHD4, ACTB, FLT3, HCK, PDK4, 
ATP1A3, AXL, STRADA, KIF18B, CENPE, ATP1A2, SMC2, RPS6KA3, CYBB, RPS6KA1, KIF20B, CHTF18, TEP1, ABCC1, GYK, APAF1, H2-DMA, 
KIF20A 1.77E-07 1.32E-05
GO:0060589~nucleoside-
triphosphatase regulator 
activity
DENND5A, ARHGAP19, IQGAP3, ITSN1, ARHGAP15, IQGAP1, ARL2BP, ARHGAP22, SRPX, RINL, TIAM1, KIFAP3, ARHGAP1, ARHGAP11A, 
DOCK10, DOCK11, AGAP2, ARHGAP9, ARHGEF2, DAB2IP, ARHGEF7, PSD4, ARHGAP27, ARHGEF9, ARHGAP24, ECT2, WAS, ARHGAP25, 
MAP4K4, RALGAPA1, OPHN1, SRGAP2, TBC1D9, CYTH4, MAP4K1, MYO9B, CYTH3, ADAP1, RASAL1, TAGAP, DOCK2, PLEKHG1, GMIP, 
RASAL3, TBC1D1, RASA4, FGD3, ARHGDIB, ABR, RACGAP1, VAV1, RALGDS, RGS1, RGS2, SYDE1, SYTL4, SYTL2, EVI5L 2.84E-07 1.70E-05
GO:0001882~nucleoside 
binding
ADCY3, KIFC1, ADCY1, ADCY2, XRCC2, ADCY7, F13A1, ADCY6, PASK, PKMYT1, TTK, AURKA, AURKB, ADORA1, PRKAR2B, ACSS1, AGPS, 
OASL2, CUL9, DHX34, MLKL, STK39, CIITA, TYRO3, LIG1, PIK3CD, RPS6KC1, ABCC12, WNK2, MAP4K4, NAV1, RFC2, ATP9A, MAPK3, 
PDGFRA, PDGFRB, EIF2AK3, SRXN1, SMARCA4, PFKFB4, NEK2, STK10, PTK7, STK17B, UBA6, ADRBK2, MAP4K1, CHEK1, CTPS2, HSPA1A, 
MYO9B, HSPA1B, NAGK, SRC, CMPK2, EPHB2, RUNX1, POLQ, ENTPD1, RUNX2, RUNX3, HELLS, ITK, SMCHD1, MYO1C, AK1, SPHK1, 
MYO1D, MYO1G, MYO1F, ATAD2, ABCG3, RAD54L, KIF3C, ABCG1, EPHA2, EPHA3, ABCG2, IKBKE, ATP2A3, RAD54B, PIP4K2A, CLCN5, 
KIF23, KIF22, STEAP4, BCKDK, ACVRL1, FIGNL1, PPIP5K1, KCNJ10, MLH3, DDR2, SLFN4, SLFN1, SLFN2, CKB, TOR3A, MCM8, ATP8B2, RHOB, 
MASTL, PAK1, TOP2A, AGAP2, CDK14, ATP8B4, TRPM4, CDK1, CDC6, ACTA2, PFKP, CDK6, MCM2, PBK, MCM3, UBE2C, MCM4, MCM5, 
PRKCB, MCM6, RAD51, DDR1, MAST4, KIF1A, MAST2, RRM1, BUB1B, H2-AA, MELK, MYO5A, ALDH18A1, DCK, HK2, HK1, PRKDC, ITM2C, 
TRIB2, IGSF10, GALK1, IGF1R, KIF7, MORC4, HK3, KIF4, TAP1, BUB1, CAMK2D, CERK, KIF21B, AGK, EHD2, EHD4, ACTB, FLT3, HCK, PDK4, 
ATP1A3, AXL, STRADA, KIF18B, CENPE, ATP1A2, SMC2, RPS6KA3, CYBB, RPS6KA1, KIF20B, CHTF18, TEP1, ABCC1, GYK, APAF1, H2-DMA, 
KIF20A 2.77E-07 1.77E-05
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GO:0030554~adenyl 
nucleotide binding
ADCY3, KIFC1, ADCY1, ADCY2, XRCC2, ADCY7, F13A1, ADCY6, PASK, PKMYT1, TTK, AURKA, AURKB, PRKAR2B, ACSS1, AGPS, OASL2, CUL9, 
DHX34, MLKL, STK39, CIITA, TYRO3, LIG1, PIK3CD, RPS6KC1, ABCC12, WNK2, MAP4K4, NAV1, RFC2, ATP9A, MAPK3, PDGFRA, PDGFRB, 
EIF2AK3, SRXN1, SMARCA4, PFKFB4, NEK2, STK10, PTK7, STK17B, UBA6, ADRBK2, MAP4K1, CHEK1, CTPS2, HSPA1A, MYO9B, HSPA1B, 
NAGK, SRC, CMPK2, EPHB2, RUNX1, POLQ, ENTPD1, RUNX2, RUNX3, HELLS, ITK, SMCHD1, MYO1C, AK1, SPHK1, MYO1D, MYO1G, MYO1F, 
ATAD2, ABCG3, RAD54L, KIF3C, ABCG1, EPHA2, EPHA3, ABCG2, IKBKE, ATP2A3, RAD54B, PIP4K2A, CLCN5, KIF23, KIF22, STEAP4, BCKDK, 
ACVRL1, FIGNL1, PPIP5K1, KCNJ10, MLH3, DDR2, SLFN4, SLFN1, SLFN2, CKB, TOR3A, MCM8, ATP8B2, MASTL, PAK1, TOP2A, AGAP2, 
CDK14, ATP8B4, TRPM4, CDK1, CDC6, ACTA2, PFKP, CDK6, MCM2, PBK, MCM3, UBE2C, MCM4, MCM5, PRKCB, MCM6, RAD51, DDR1, 
MAST4, KIF1A, MAST2, RRM1, BUB1B, H2-AA, MELK, MYO5A, ALDH18A1, DCK, HK2, HK1, PRKDC, ITM2C, TRIB2, IGSF10, GALK1, IGF1R, 
KIF7, MORC4, HK3, KIF4, TAP1, BUB1, CAMK2D, CERK, KIF21B, AGK, EHD2, EHD4, ACTB, FLT3, HCK, PDK4, ATP1A3, AXL, STRADA, KIF18B, 
CENPE, ATP1A2, SMC2, RPS6KA3, CYBB, RPS6KA1, KIF20B, CHTF18, TEP1, ABCC1, GYK, APAF1, H2-DMA, KIF20A 2.68E-07 1.85E-05
GO:0017124~SH3 domain 
binding
PTPN6, ADAM10, HCLS1, ARHGAP27, EFS, EVL, SIRPA, SHANK2, ELMO2, ELMO1, PLSCR1, ARHGAP1, PLSCR3, SH3KBP1, SH3BGRL2, 
CNTNAP1, MICAL1, ADAM19, INPP5D, NCKIPSD, ADAM12, AFAP1 3.64E-07 2.04E-05
GO:0005539~glycosamin
oglycan binding
FSTL1, DCN, FGF12, MDK, ITGAM, ABI3BP, HMMR, SMOC2, APP, CD44, LTF, GPNMB, THBS1, FGF2, THBS2, LPL, PTPRC, TNXB, CCDC80, 
ECM2, COL5A3, COL5A1, NCAM1, BGN, FBLN7, ADAMTS1, VCAN 4.23E-07 2.23E-05
GO:0019904~protein 
domain specific binding
CADM1, LPAR1, SRC, CBX6, HOMER3, ARHGAP1, TGM2, EXOC4, MICAL1, CNTNAP1, NCKIPSD, INPP5D, EHD2, AFAP1, SH3PXD2B, RAP2B, 
PTPN6, ADAM10, HCLS1, EFS, ARHGAP27, GRIA3, EVL, TACC3, SHANK2, SIRPA, ELMO2, ELMO1, PLSCR1, LAT2, YWHAH, PLSCR3, 
SH3BGRL2, SH3KBP1, ADAM19, ADAM12, SHCBP1 5.27E-07 2.62E-05
GO:0008201~heparin 
binding
LPL, PTPRC, TNXB, CCDC80, FSTL1, FGF12, ECM2, COL5A3, MDK, ITGAM, COL5A1, ABI3BP, NCAM1, SMOC2, APP, FBLN7, LTF, ADAMTS1, 
THBS1, GPNMB, FGF2, THBS2 8.89E-07 4.19E-05
GO:0019899~enzyme 
binding
MEF2C, EID1, CAV1, DENND5A, AURKA, CHEK1, DAAM2, IGF1R, CUL7, CUL9, DOCK10, DOCK11, AGAP2, EXOC2, FMNL1, PTPRC, ANAPC2, 
ARHGEF2, FMNL3, ADAM10, NCF2, FLT3, PRKAB2, TPX2, CENPE, PEA15A, COTL1, ECT2, FLNA, ADRB2, CLEC12A, CD300A, CCND2, CSTB, 
SYTL4, SYTL2, MARCKS, MAPK8IP1, DIAP3 5.71E-06 2.56E-04
GO:0005083~small 
GTPase regulator activity
DENND5A, TBC1D9, CYTH4, IQGAP3, MAP4K1, MYO9B, CYTH3, ITSN1, ARHGAP15, IQGAP1, ARL2BP, ADAP1, DOCK2, PLEKHG1, TIAM1, 
KIFAP3, ARHGAP1, DOCK10, TBC1D1, DOCK11, AGAP2, FGD3, ARHGDIB, ARHGEF2, ABR, ARHGEF7, PSD4, ARHGAP27, ARHGEF9, ECT2, 
WAS, VAV1, MAP4K4, RALGAPA1, SYDE1, SYTL4, SYTL2, EVI5L 7.58E-06 3.23E-04
GO:0005529~sugar 
binding
GLG1, GALNT3, CD209A, KLRA17, GALNT6, L1CAM, CD72, GALNT10, CLEC4E, CD93, CD69, SFTPD, CD22, CLEC4A1, CLEC4A3, CLEC4D, 
SELPLG, CLEC2I, KLRA2, LGALS3, SELL, LGALS1, MRC2, CLEC4N, CLEC12A, GFPT1, FREM1, GFPT2, CLEC4B1, VCAN, CLEC7A, KLRB1B, 
CLEC5A 8.12E-06 3.31E-04
GO:0048407~platelet-
derived growth factor 
binding COL4A1, COL3A1, COL1A2, PDGFRA, COL6A1, COL1A1, COL5A1 1.45E-05 5.41E-04
GO:0005096~GTPase 
activator activity
TBC1D9, ARHGAP19, IQGAP3, MYO9B, ARHGAP15, IQGAP1, ADAP1, RASAL1, ARHGAP22, DOCK2, GMIP, RINL, RASAL3, ARHGAP1, 
ARHGAP11A, TBC1D1, AGAP2, RASA4, ARHGDIB, ARHGAP9, DAB2IP, ABR, ARHGAP27, RACGAP1, ARHGAP24, ARHGAP25, RALGAPA1, 
RGS1, RGS2, SYDE1, OPHN1, EVI5L, SRGAP2 2.80E-05 9.65E-04
GO:0008047~enzyme 
activator activity
CAV1, TBC1D9, IQGAP3, ARHGAP19, MYO9B, ITSN1, ARHGAP15, TIMP2, IQGAP1, ADAP1, RASAL1, ARHGAP22, DOCK2, GMIP, RINL, 
RASAL3, ARHGAP1, ARHGAP11A, TBC1D1, AGAP2, RASA4, ARHGDIB, ARHGAP9, DAB2IP, ABR, ARHGAP27, RACGAP1, ARHGAP24, MMP14, 
ARHGAP25, FBLN1, RALGAPA1, RGS1, RGS2, SYDE1, OPHN1, APAF1, EVI5L, SRGAP2 4.01E-05 0.001330131
195
Appendix Table 4.2: Gene ontology terms significantly enriched in upregulated genes of HFHS diet fed mice compared to control diet fed mice
Gene ontology term Genes PValue Benjamini
GO:0017048~Rho GTPase 
binding FMNL1, FMNL3, ARHGEF2, NCF2, DOCK10, DAAM2, DOCK11, DIAP3, ECT2, FLNA 4.32E-05 0.001381214
GO:0017048~Rho GTPase 
binding FMNL1, FMNL3, ARHGEF2, NCF2, DOCK10, DAAM2, DOCK11, DIAP3, ECT2, FLNA 4.32E-05 0.001381214
GO:0000166~nucleotide 
binding
ADCY3, KIFC1, ADCY1, ADCY2, XRCC2, ADCY7, ADCY6, AURKA, AURKB, AGPS, CUL9, OASL2, NT5C2, DHX34, GBP8, TYRO3, LIG1, PIK3CD, 
POLE, ABCC12, GEM, WNK2, NAV1, RFC2, MAPK3, PDGFRA, PDGFRB, EIF2AK3, FUS, PFKFB4, GNAI1, NEK2, STK17B, ADRBK2, UBA6, 
CHEK1, MYO9B, HSPA1A, HSPA1B, NAGK, EPHB2, RAC2, POLQ, GM1966, SPHK1, ABCG3, RAD54L, KIF3C, ABCG1, EPHA2, EPHA3, ABCG2, 
ATP2A3, RAD54B, CLCN5, STEAP4, BCKDK, ACVRL1, KCNJ10, MLH3, CKB, TUBB6, MASTL, DOCK10, ARL5C, DOCK11, AGAP2, TOP2A, 
RAP2B, CDC6, ACTA2, RAD51, MAST4, MAST2, RRM1, ARL4C, MYO5A, ALDH18A1, RAB3D, HK2, HK1, ITM2C, IGSF10, GALK1, RAB44, 
MORC4, HK3, BUB1, CERK, KIF21B, AGK, PDK4, AXL, STRADA, ATP1A3, ATP1A2, RPS6KA3, RAB31, RPS6KA1, RAB34, KIF20B, CHTF18, 
ABCC1, GYK, KIF20A, GNA15, F13A1, PASK, TTK, PKMYT1, RRAD, PRKAR2B, ARL11, ACSS1, RALB, STK39, MLKL, CIITA, RPS6KC1, MAP4K4, 
ATP9A, CELF2, GBP2, SRXN1, SMARCA4, STK10, PTK7, MAP4K1, CTPS2, RRAGD, SRC, CMPK2, P2RY6, SKIL, ENTPD1, RUNX1, RUNX2, 
RUNX3, HELLS, ITK, SMCHD1, RAB8B, MYO1C, NIN, AK1, MYO1D, MYO1G, ATAD2, MYO1F, IKBKE, POLD1, TGTP1, PIP4K2A, KIF23, RHOJ, 
KIF22, FIGNL1, PPIP5K1, RHOQ, DDR2, SLFN4, SLFN1, SLFN2, CDC42, TOR3A, MCM8, ATP8B2, RHOB, RHOC, PAK1, TUBA1A, CDK14, 
ATP8B4, RHOH, TRPM4, CDK1, PFKP, CDK6, PBK, MCM2, MCM3, UBE2C, MCM4, MCM5, PRKCB, MCM6, DDR1, KIF1A, BUB1B, H2-AA, 
MELK, TRA2A, DCK, PRKDC, TRIB2, IGF1R, KIF7, KIF4, TAP1, CAMK2D, TGM2, EHD2, EHD4, ACTB, FLT3, HCK, KIF18B, SIRT5, CENPE, SMC2, 
CYBB, PSPC1, TEP1, APAF1, H2-DMA 9.94E-05 0.003065698
GO:0042802~identical 
protein binding
S100A4, IMPA2, THRA, CD8A, CLDN4, CADM1, CSF1, CLDN6, GDF6, HEXB, E2F8, TRA2A, NFKB1, L1CAM, PRRC1, SDCBP2, HAND2, TAP1, 
PVRL2, ROBO2, ADAM10, PTPRE, IKZF2, CEBPD, OLFML2B, NR4A1, OLFML2A, CENPF, NPR3, WAS, EMILIN1, INHBB, C1QB, ADRB2, 
CORO1A, TIMELESS, CTSE, CLDN2, APAF1, KLRB1B, CLN6 2.45E-04 0.007057162
GO:0017016~Ras GTPase 
binding FMNL1, ARHGEF2, FMNL3, DENND5A, NCF2, DAAM2, ECT2, FLNA, SYTL4, SYTL2, DOCK10, DOCK11, DIAP3, EXOC2 3.26E-04 0.009101678
GO:0019955~cytokine 
binding CSF2RB2, IL1RL2, CCR1, IL21R, CXCR2, IL7R, CD74, CCR7, CCR5, IL10RB, CXCR4, IL10RA, CCR2, CX3CR1, CSF3R, CSF2RB, CSF2RA, IFNGR1 3.59E-04 0.009705944
GO:0031267~small 
GTPase binding FMNL1, ARHGEF2, FMNL3, DENND5A, NCF2, DAAM2, ECT2, FLNA, SYTL4, SYTL2, DOCK10, DOCK11, DIAP3, EXOC2 4.67E-04 0.01223775
GO:0051020~GTPase 
binding FMNL1, ARHGEF2, FMNL3, DENND5A, NCF2, DAAM2, ECT2, FLNA, SYTL4, SYTL2, DOCK10, DOCK11, DIAP3, EXOC2 7.72E-04 0.019584657
GO:0045309~protein 
phosphorylated amino 
acid binding PTPN6, SH2D1B1, MAPK3, ACP2, SAMSN1, SIRPA 8.54E-04 0.0204753
GO:0042803~protein 
homodimerization 
activity
IMPA2, THRA, CD8A, CADM1, GDF6, CSF1, HEXB, E2F8, NFKB1, SDCBP2, HAND2, TAP1, PVRL2, IKZF2, ADAM10, PTPRE, CEBPD, OLFML2B, 
OLFML2A, NR4A1, CENPF, NPR3, INHBB, C1QB, ADRB2, TIMELESS, CTSE, KLRB1B, CLN6 9.05E-04 0.021122487
GO:0046983~protein 
dimerization activity
IMPA2, THRA, CD8A, CADM1, CSF1, GDF6, HEXA, HEXB, E2F8, NFKB1, ITGB2, SDCBP2, ADORA1, ZFP618, BATF, FOS, HAND2, BCL2, TAP1, 
PVRL2, CREB3L1, ROBO2, IKZF3, ADAM10, PTPRE, IKZF2, IKZF1, CEBPD, OLFML2B, SCUBE1, CENPF, NR4A1, OLFML2A, NPR3, AHR, INHBB, 
C1QB, ADRB2, ATF3, TIMELESS, JUN, CTSE, KLRB1B, CLN6 9.40E-04 0.021376552
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GO:0004714~transmemb
rane receptor protein 
tyrosine kinase activity IGSF10, DDR1, TYRO3, IGF1R, FLT3, AXL, PTK7, PDGFRA, PDGFRB, DDR2, EPHA2, EPHB2, EPHA3 9.95E-04 0.022044049
GO:0005516~calmodulin 
binding
MYO5A, TRPM4, ADCY3, ADCY1, SLC8A1, MYO1C, MARCKSL1, MYO1D, SPHK1, MYO1G, MYO1F, RRAD, MYO9B, IQGAP1, KCNN4, 
CAMK2D, MARCKS, CNN2, ASPM, ADD1 0.001133668 0.024484132
GO:0001784~phosphotyr
osine binding PTPN6, SH2D1B1, MAPK3, ACP2, SAMSN1 0.001935437 0.040486911
GO:0008009~chemokine 
activity CCL3, CCL22, CCL2, CXCL16, CXCL9, CX3CL1, CCL5, CCL4, CCL6, CXCL10 0.002011922 0.041096715
GO:0042379~chemokine 
receptor binding CCL3, CCL22, CCL2, CXCL16, CXCL9, CX3CL1, CCL5, CCL4, CCL6, CXCL10 0.002439126 0.047461772
GO:0008237~metallopep
tidase activity
AMZ1, ERMP1, AEBP1, ADAMTSL2, ADAMTS15, MMP23, MMP2, CPZ, ACE, PAPPA, ADAMTS10, ADAMTS12, ADAM8, ADAM10, AGBL5, 
CPXM2, MMP14, MMP12, MMP11, NAALAD2, ADAMTS9, THSD4, ADAMTS1, ADAM19, ADAM12, ADAMTS2, ADAMTS5 0.002500129 0.047589495
mmu03030:DNA 
replication LIG1, POLE, MCM2, MCM3, MCM4, MCM5, MCM6, POLD3, RPA1, RPA2, RFC2, POLD1, FEN1 3.76E-05 7.18E-04
mmu03030:DNA 
replication LIG1, POLE, MCM2, MCM3, MCM4, MCM5, MCM6, POLD3, RPA1, RPA2, RFC2, POLD1, FEN1 3.76E-05 7.18E-04
mmu05414:Dilated 
cardiomyopathy
ACTB, ADCY3, CACNA2D1, ADCY1, SLC8A1, ADCY2, ADCY7, ADCY6, TGFB3, ITGB5, CACNB3, ITGA3, ITGA4, TPM2, TPM1, TPM4, LAMA2, 
DES, ITGA8, ITGB7, ITGAV, SGCB 6.58E-05 0.001028842
mmu00520:Amino sugar 
and nucleotide sugar 
metabolism HEXA, HEXB, HK2, HK1, NAGK, GALK1, PGM3, RENBP, GFPT1, HK3, GFPT2, PGM1, GALE 4.39E-04 0.004711958
mmu04666:Fc gamma R-
mediated phagocytosis
PTPRC, MARCKSL1, NCF1, HCK, PIK3CD, SPHK1, VAV1, WAS, PRKCB, CDC42, DOCK2, RAC2, GAB2, GSN, MAPK3, PLCG2, PLA2G6, PIK3R5, 
MARCKS, INPP5D, PAK1 4.84E-04 0.004888946
mmu05410:Hypertrophic 
cardiomyopathy (HCM)
ACTB, CACNA2D1, SLC8A1, PRKAB2, TGFB3, ITGB5, CACNB3, ITGA3, ITGA4, TPM2, TPM1, TPM4, LAMA2, ACE, DES, ITGA8, ITGB7, ITGAV, 
SGCB 4.96E-04 0.004483212
mmu05214:Glioma E2F1, PDGFB, PIK3CD, CDK6, PRKCB, IGF1R, CDKN1A, MAPK3, PLCG2, CAMK2D, PDGFRA, CALM3, PDGFRB, PIK3R5, SHC2 0.001662667 0.013536907
mmu04540:Gap junction
ADCY3, CDK1, ADCY1, ADCY2, PDGFB, ADCY7, GNAI1, ADCY6, GJA1, LPAR1, SRC, PRKCB, MAPK3, PDGFRA, PDGFRB, TUBB6, TUBA1A, 
PLCB2 0.001821462 0.014152402
mmu00052:Galactose 
metabolism GALK1, B4GALT2, AKR1B3, HK3, PGM1, HK2, PFKP, HK1, GALE 0.002233982 0.016585903
mmu04612:Antigen 
processing and 
presentation
CIITA, CD8B1, CD8A, H2-M2, LGMN, IFI30, H2-DMB1, HSPA1A, H2-AB1, HSPA1B, CTSS, NFYA, H2-DMB2, CD74, TAP1, H2-EB1, H2-AA, CD4, 
H2-DMA 0.003412 0.024196926
mmu03440:Homologous 
recombination POLD3, RPA1, RPA2, XRCC2, POLD1, RAD54B, RAD54L, RAD51 0.009321431 0.057914704
mmu03440:Homologous 
recombination POLD3, RPA1, RPA2, XRCC2, POLD1, RAD54B, RAD54L, RAD51 0.009321431 0.057914704
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mmu03430:Mismatch 
repair POLD3, RPA1, RPA2, RFC2, POLD1, LIG1, MLH3 0.012240448 0.072864267
mmu05412:Arrhythmoge
nic right ventricular 
cardiomyopathy (ARVC) ACTB, SLC8A1, CACNA2D1, GJA1, ITGB5, ITGA3, CACNB3, ITGA4, LAMA2, DES, ITGB7, ITGAV, ITGA8, SGCB 0.018113107 0.102744223
mmu04142:Lysosome ARSB, PSAP, ARSG, HEXA, LGMN, HEXB, PPT1, ACP2, NAPSA, CTSS, CD63, ASAH1, SLC11A1, CTSK, CD68, LAPTM5, AP1S2, AP3M2, CTSE 0.023357881 0.126727242
mmu04672:Intestinal 
immune network for IgA 
production ICOSL, CXCR4, ITGB7, H2-EB1, TGFB3, H2-AA, H2-DMB1, H2-AB1, ITGA4, H2-DMA, H2-DMB2 0.023553937 0.12387811
mmu05218:Melanoma E2F1, PDGFB, PIK3CD, CDK6, FGF12, FGF21, IGF1R, CDKN1A, MAPK3, PDGFRA, PDGFRB, PIK3R5, FGF2 0.027190838 0.137719369
mmu04912:GnRH 
signaling pathway ADCY3, ADCY1, ADCY2, ADCY7, ADCY6, MMP14, MMP2, SRC, PRKCB, CDC42, JUN, MAPK3, CAMK2D, CALM3, PLA2G6, PLCB2 0.030603141 0.141648746
mmu05020:Prion 
diseases C1QA, NCAM1, C1QB, MAPK3, IL1B, HSPA1A, HSPA1B, CCL5, C1QC 0.03725753 0.165905864
mmu05416:Viral 
myocarditis ACTB, ITGAL, CAV1, H2-M2, H2-DMB1, ITGB2, H2-AB1, H2-DMB2, LAMA2, EIF4G3, RAC2, H2-EB1, H2-AA, H2-DMA, SGCB 0.04736636 0.192657387
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GO:0055114~oxidation reduction
ALDH8A1, CYB5R3, CYP2D10, ASPDH, ALDH1L1, CYP2C69, CYP2C68, AKR1C12, PRDX5, PRDX1, 
AKR1C14, PDHB, HIBADH, AKR1C13, PECR, RDH7, CYP39A1, BC089597, SRD5A1, DHCR24, 
CYP3A44, HPD, NDUFB11, CYP2C54, CYP2D22, CYP3A13, CYP2C29, NDUFC2, QDPR, ALDH16A1, 
TECR, POR, CYP2C50, OGFOD2, ALDH7A1, CYP27A1, H6PD, CYP3A59, CYP2A4, MDH1, ME1, TMX1, 
NDUFB4, ACADSB, NDUFB5, CYP3A25, NDUFB6, CYP2F2, HSD17B2, CYP2C44, TXN2, FDX1, 
HSD3B5, CYP2C40, ADH5, AASS, EGLN2, PAH, PIPOX, GPD1L, ADH4, HAAO, FASN, BDH2, NDUFA4, 
CYP2C70, CYP2G1, PAOX, NDUFA6, MAOA, DHRS11, CYP4F13, HGD, CYP4F14, SOD1, PHYH, IYD, 
ADI1, CYP7B1, SDHB, UOX, DOHH, AKR1C19, CYP4F15, ALDH2, CYP2R1, DPYD, CYP2C39
3.30E-15 7.95E-12
GO:0007599~hemostasis KNG1, F12, F10, C9, MST1, F9, SERPING1, F7, DTNBP1, PLG, PROC, FGG, FGA, FGB, KLKB1, F2, SERPINC1, APOH, SERPIND1 1.04E-08 8.30E-06
GO:0007596~blood coagulation KNG1, F12, F10, C9, MST1, F9, SERPING1, F7, DTNBP1, PLG, PROC, FGG, FGA, FGB, KLKB1, F2, SERPINC1, APOH, SERPIND1 8.17E-09 9.75E-06
GO:0050817~coagulation KNG1, F12, F10, C9, MST1, F9, SERPING1, F7, DTNBP1, PLG, PROC, FGG, FGA, FGB, KLKB1, F2, SERPINC1, APOH, SERPIND1 8.17E-09 9.75E-06
GO:0008202~steroid metabolic process
CYB5R3, GC, HSD17B2, HSD3B5, SLC37A4, APOC1, ABCA2, CYP39A1, APOE, LCAT, OSBPL1A, 
APOC3, SRD5A1, NR1H4, DHCR24, SREBF1, EBP, FECH, OSBPL9, ESR1, TECR, SCAP, CYP7B1, 
CYP2R1, LIPC, NR5A2, SLC27A5
1.55E-07 9.26E-05
GO:0055088~lipid homeostasis ASGR2, GOT1, APOE, COL4A3BP, SLC37A4, ACACA, ABCA2, LIPC, NR5A2, ANGPTL3, USF2, MTTP 5.39E-07 1.84E-04
GO:0002526~acute inflammatory 
response
MBL2, C9, MASP1, HC, C3, CRP, SERPING1, C8G, AHSG, C1RA, C8B, SERPINA1B, SERPINF2, 
SERPINA1A, F2, CFI, AI182371, FN1 5.15E-07 2.05E-04
GO:0002526~acute inflammatory 
response
MBL2, C9, MASP1, HC, C3, CRP, SERPING1, C8G, AHSG, C1RA, C8B, SERPINA1B, SERPINF2, 
SERPINA1A, F2, CFI, AI182371, FN1 5.15E-07 2.05E-04
GO:0050878~regulation of body fluid 
levels
KNG1, F12, F10, C9, MST1, F9, SERPING1, F7, DTNBP1, PLG, PROC, FGG, FGA, FGB, KLKB1, F2, 
SERPINC1, APOH, SERPIND1 4.30E-07 2.05E-04
GO:0042060~wound healing KNG1, F12, F10, C9, MST1, NINJ1, F9, SERPING1, F7, DTNBP1, PLG, PROC, FGG, FGA, FGB, KLKB1, F2, SERPINC1, APOH, SERPIND1, FN1 8.20E-07 2.45E-04
GO:0000050~urea cycle CEBPA, ARG1, ASS1, NAGS, OTC, ASL, CPS1 1.26E-06 3.33E-04
GO:0019627~urea metabolic process CEBPA, ARG1, ASS1, NAGS, OTC, ASL, CPS1 1.26E-06 3.33E-04
GO:0043604~amide biosynthetic 
process CEBPA, ARG1, ASS1, NAGS, OTC, ASL, CPS1 3.01E-06 5.12E-04
GO:0030193~regulation of blood 
coagulation F12, KLKB1, APOH, HRG, TMPRSS6, CPB2, PLG, PROC 2.16E-06 5.16E-04
GO:0016054~organic acid catabolic 
process
KYNU, AHCY, HAL, FTCD, HGD, AASS, PAH, PHYH, FAH, AFMID, AMDHD1, ACOT7, CYP39A1, GOT1, 
BDH2, UROC1, HPD 2.60E-06 5.17E-04
GO:0046395~carboxylic acid catabolic 
process
KYNU, AHCY, HAL, FTCD, HGD, AASS, PAH, PHYH, FAH, AFMID, AMDHD1, ACOT7, CYP39A1, GOT1, 
BDH2, UROC1, HPD 2.60E-06 5.17E-04
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GO:0009611~response to wounding
MBL2, C9, MASP1, C3, TOLLIP, CRP, MST1, NINJ1, DTNBP1, AHSG, C1RA, ARG1, FGG, FGA, 
SERPINA1B, SERPINA1A, FGB, KLKB1, APOH, SERPINC1, CFI, FN1, KNG1, F12, F10, HC, F9, 
SERPING1, F7, SOD1, PLG, C8G, PROC, C8B, SERPINF2, F2, ID3, SERPIND1, IGFBP4, AI182371
2.82E-06 5.18E-04
GO:0043603~cellular amide metabolic 
process CEBPA, ASPDH, ARG1, KYNU, ASS1, NAGS, H6PD, OTC, ASL, CPS1, HIBADH, MDH1 2.50E-06 5.42E-04
GO:0043603~cellular amide metabolic 
process CEBPA, ASPDH, ARG1, KYNU, ASS1, NAGS, H6PD, OTC, ASL, CPS1, HIBADH, MDH1 2.50E-06 5.42E-04
GO:0009310~amine catabolic process PAOX, KYNU, AHCY, MAOA, HAL, FTCD, HGD, AASS, PAH, FAH, AFMID, AMDHD1, GOT1, UROC1, HPD 3.76E-06 5.98E-04
GO:0006956~complement activation MBL2, C1RA, C8B, C9, MASP1, HC, C3, SERPING1, CFI, C8G, AI182371 8.36E-06 0.001246
GO:0002541~activation of plasma 
proteins involved in acute inflammatory 
response
MBL2, C1RA, C8B, C9, MASP1, HC, C3, SERPING1, CFI, C8G, AI182371 8.36E-06 0.001246
GO:0009063~cellular amino acid 
catabolic process KYNU, AHCY, HAL, FTCD, HGD, AASS, PAH, FAH, AFMID, AMDHD1, GOT1, UROC1, HPD 1.32E-05 0.001849
GO:0044271~nitrogen compound 
biosynthetic process
MOCOS, ASPDH, ATP1B1, KYNU, ASS1, NAGS, PAH, ASL, PPAT, GCH1, ARG1, GOT1, HAAO, ATP5H, 
MOCS1, ATP5J, CEBPA, FECH, MOCS2, OTC, QDPR, NPR2, ATP1A1, ATP13A3, CPS1, ADI1, UMPS, 
CTH, ATP13A1, ADK, DPYD, PAICS, CBS, PRPS1
2.90E-05 0.003841
GO:0006508~proteolysis
MASP1, CBX4, ENPEP, OS9, CUL3, DDI2, USP19, C1RA, USP10, CFI, USP16, USP15, DHCR24, NFX1, 
VCPIP1, AUP1, F12, ADAM11, F10, FBXL20, F9, SERPING1, UBR2, F7, TOPORS, UBE2J2, UBE2H, 
XRCC6BP1, BRAP, C8G, PROC, LAP3, SENP3, C8B, ATG4D, F2, RNF139, PIAS2, CTSC, AMFR, CTSH, 
PREP, MBL2, DERL2, CPM, C9, XIAP, USP3, APH1A, C3, USP2, MST1, UBE2R2, ARIH2, ECE1, KLKB1, 
HGFAC, FBXO9, FBXO8, USP32, NPLOC4, HPN, ACY1, HC, MUL1, UBE2Q2, CELA1, TMPRSS6, PLG, 
APEH, RNF6, CRBN, KCMF1, RNF5, FBXO30, USP47, ZRANB1, FBXO31, RNF19B, FBXO34, CPB2, 
AI182371, HABP2
3.35E-05 0.004201
GO:0050818~regulation of coagulation F12, KLKB1, APOH, HRG, TMPRSS6, CPB2, PLG, PROC 3.73E-05 0.00423
GO:0042558~pteridine and derivative 
metabolic process MOCOS, ALDH1L1, MOCS2, QDPR, PAH, PIPOX, MOCS1, GCH1 3.73E-05 0.00423
GO:0042558~pteridine and derivative 
metabolic process MOCOS, ALDH1L1, MOCS2, QDPR, PAH, PIPOX, MOCS1, GCH1 3.73E-05 0.00423
GO:0006525~arginine metabolic 
process ARG1, ASS1, NAGS, OTC, ASL, FAH 3.58E-05 0.004268
GO:0008203~cholesterol metabolic 
process
SREBF1, CYB5R3, EBP, FECH, APOC1, ABCA2, SCAP, CYP7B1, CYP39A1, APOE, LCAT, APOC3, 
LIPC, DHCR24 4.46E-05 0.004831
GO:0006641~triglyceride metabolic 
process DGAT2, APOC3, SLC37A4, APOC1, SLC22A4, LIPC, ANGPTL3, SIRT1, SLC27A5, MTTP 5.95E-05 0.005902
GO:0019439~aromatic compound 
catabolic process KYNU, ALDH1L1, HGD, PAH, AFMID, HPD, FAH 5.75E-05 0.005949
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GO:0019439~aromatic compound 
catabolic process KYNU, ALDH1L1, HGD, PAH, AFMID, HPD, FAH 5.75E-05 0.005949
GO:0006662~glycerol ether metabolic 
process DGAT2, TXN2, APOC3, SLC37A4, APOC1, SLC22A4, LIPC, ANGPTL3, SIRT1, SLC27A5, MTTP 6.93E-05 0.006588
GO:0046890~regulation of lipid 
biosynthetic process SREBF1, WDTC1, HNF4A, MLXIPL, SF1, ATP1A1, SOD1, SCAP 7.51E-05 0.006864
GO:0046890~regulation of lipid 
biosynthetic process SREBF1, WDTC1, HNF4A, MLXIPL, SF1, ATP1A1, SOD1, SCAP 7.51E-05 0.006864
GO:0046890~regulation of lipid 
biosynthetic process SREBF1, WDTC1, HNF4A, MLXIPL, SF1, ATP1A1, SOD1, SCAP 7.51E-05 0.006864
GO:0006958~complement activation, 
classical pathway MBL2, C1RA, C8B, C9, HC, C3, SERPING1, CFI, C8G 9.36E-05 0.00767
GO:0051605~protein maturation by 
peptide bond cleavage MBL2, C1RA, C8B, ECE1, C9, MASP1, HC, C3, SERPING1, CFI, C8G, AI182371, DHCR24 9.26E-05 0.007862
GO:0030195~negative regulation of 
blood coagulation KLKB1, TMPRSS6, CPB2, PLG, PROC 9.21E-05 0.008109
GO:0016125~sterol metabolic process SREBF1, CYB5R3, EBP, FECH, APOC1, ABCA2, SCAP, CYP7B1, CYP39A1, APOE, LCAT, APOC3, LIPC, DHCR24 1.24E-04 0.00924
GO:0018904~organic ether metabolic 
process DGAT2, TXN2, APOC3, SLC37A4, APOC1, SLC22A4, LIPC, ANGPTL3, SIRT1, SLC27A5, MTTP 1.24E-04 0.009474
GO:0009074~aromatic amino acid 
family catabolic process KYNU, HGD, PAH, AFMID, HPD, FAH 1.21E-04 0.009551
GO:0009074~aromatic amino acid 
family catabolic process KYNU, HGD, PAH, AFMID, HPD, FAH 1.21E-04 0.009551
GO:0019216~regulation of lipid 
metabolic process SREBF1, WDTC1, HNF4A, THRB, MLYCD, APOE, MLXIPL, SF1, ATP1A1, SOD1, ANGPTL3, SCAP 1.40E-04 0.010093
GO:0019216~regulation of lipid 
metabolic process SREBF1, WDTC1, HNF4A, THRB, MLYCD, APOE, MLXIPL, SF1, ATP1A1, SOD1, ANGPTL3, SCAP 1.40E-04 0.010093
GO:0016481~negative regulation of 
transcription
COPS2, THRB, DEDD, CBX4, SOX6, CBFA2T2, PDCD4, NR2C1, SORBS3, AES, HEXIM1, ZKSCAN17, 
BHLHE40, NR2F2, NFX1, CEBPA, ZBTB7A, WDTC1, TBX3, FOXA1, TRIM28, ZHX2, MLXIPL, ZHX3, 
SIRT1, SIRT2, CTNNBIP1, HHEX, NAB2, NAB1, ZFP281, ZRANB1, CUX2, ID3, RBM15, SUDS3, DNAJB6
1.63E-04 0.011341
GO:0009890~negative regulation of 
biosynthetic process
COPS2, THRB, DEDD, CBX4, SOX6, CBFA2T2, PDCD4, NR2C1, EIF4EBP3, SORBS3, AES, HEXIM1, 
ZKSCAN17, BHLHE40, NR2F2, GCHFR, NFX1, CEBPA, ZBTB7A, WDTC1, TBX3, FOXA1, TRIM28, ZHX2, 
MLXIPL, ZHX3, ATP1A1, SOD1, SIRT1, SIRT2, CTNNBIP1, HHEX, NAB2, NAB1, ZRANB1, ZFP281, 
CUX2, ID3, RBM15, SUDS3, DNAJB6
2.05E-04 0.013864
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GO:0010629~negative regulation of 
gene expression
UTP3, COPS2, THRB, DEDD, CBX4, SOX6, CBFA2T2, PDCD4, NR2C1, SORBS3, AES, HEXIM1, 
ZKSCAN17, BHLHE40, NR2F2, NFX1, CEBPA, ZBTB7A, WDTC1, TBX3, FOXA1, TRIM28, ZHX2, MLXIPL, 
ZHX3, SIRT1, SIRT2, CTNNBIP1, HHEX, NAB2, NAB1, BNIP3L, ZRANB1, ZFP281, CUX2, ID3, RBM15, 
SUDS3, DNAJB6
2.62E-04 0.016781
GO:0006639~acylglycerol metabolic 
process DGAT2, APOC3, SLC37A4, APOC1, SLC22A4, LIPC, ANGPTL3, SIRT1, SLC27A5, MTTP 2.59E-04 0.017027
GO:0009064~glutamine family amino 
acid metabolic process GLS2, ARG1, AMDHD1, GOT1, ASS1, NAGS, OTC, ASL, CPS1, FAH 2.59E-04 0.017027
GO:0045934~negative regulation of 
nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process
COPS2, THRB, DEDD, CBX4, SOX6, CBFA2T2, PDCD4, NR2C1, SORBS3, AES, HEXIM1, ZKSCAN17, 
BHLHE40, NR2F2, NFX1, CEBPA, ZBTB7A, WDTC1, TBX3, FOXA1, TRIM28, ZHX2, NDFIP1, MLXIPL, 
ZHX3, SIRT1, SIRT2, CTNNBIP1, HHEX, NAB2, NAB1, ZRANB1, ZFP281, CUX2, ID3, RBM15, SUDS3, 
DNAJB6
2.83E-04 0.017593
GO:0002455~humoral immune 
response mediated by circulating 
immunoglobulin
MBL2, C1RA, C8B, C9, HC, C3, SERPING1, CFI, C8G 3.00E-04 0.018204
GO:0051172~negative regulation of 
nitrogen compound metabolic process
COPS2, THRB, DEDD, CBX4, SOX6, CBFA2T2, PDCD4, NR2C1, SORBS3, AES, HEXIM1, ZKSCAN17, 
BHLHE40, NR2F2, NFX1, CEBPA, ZBTB7A, WDTC1, TBX3, FOXA1, TRIM28, ZHX2, NDFIP1, MLXIPL, 
ZHX3, SIRT1, SIRT2, CTNNBIP1, HHEX, NAB2, NAB1, ZRANB1, ZFP281, CUX2, ID3, RBM15, SUDS3, 
DNAJB6
3.45E-04 0.019411
GO:0006959~humoral immune 
response MBL2, C1RA, C8B, C9, MASP1, HC, C3, SERPING1, CFI, C8G, AI182371 3.43E-04 0.019788
GO:0051604~protein maturation MBL2, C9, MASP1, APH1A, HC, C3, SERPING1, C8G, AMBP, C1RA, C8B, ECE1, CFI, AI182371, DHCR24 3.43E-04 0.020232
GO:0006638~neutral lipid metabolic 
process DGAT2, APOC3, SLC37A4, APOC1, SLC22A4, LIPC, ANGPTL3, SIRT1, SLC27A5, MTTP 3.72E-04 0.020416
GO:0031668~cellular response to 
extracellular stimulus SREBF1, ASGR1, AES, ATG9A, NUAK2, FOXA3, RB1CC1, GSDMD, SIRT1, USF2 3.72E-04 0.020416
GO:0009072~aromatic amino acid 
family metabolic process DCT, KYNU, HGD, PAH, AFMID, HPD, FAH 4.80E-04 0.025675
GO:0009072~aromatic amino acid 
family metabolic process DCT, KYNU, HGD, PAH, AFMID, HPD, FAH 4.80E-04 0.025675
GO:0006526~arginine biosynthetic 
process ASS1, NAGS, OTC, ASL 5.06E-04 0.026487
GO:0016485~protein processing MBL2, C9, MASP1, APH1A, HC, C3, SERPING1, C8G, C1RA, C8B, ECE1, CFI, AI182371, DHCR24 6.06E-04 0.030977
GO:0031327~negative regulation of 
cellular biosynthetic process
COPS2, THRB, DEDD, CBX4, SOX6, CBFA2T2, PDCD4, NR2C1, EIF4EBP3, SORBS3, AES, HEXIM1, 
ZKSCAN17, BHLHE40, NR2F2, NFX1, CEBPA, ZBTB7A, WDTC1, TBX3, FOXA1, TRIM28, ZHX2, MLXIPL, 
ZHX3, ATP1A1, SIRT1, SIRT2, CTNNBIP1, HHEX, NAB2, NAB1, ZRANB1, ZFP281, CUX2, ID3, RBM15, 
SUDS3, DNAJB6
6.59E-04 0.032935
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GO:0050819~negative regulation of 
coagulation KLKB1, TMPRSS6, CPB2, PLG, PROC 6.84E-04 0.033443
GO:0042304~regulation of fatty acid 
biosynthetic process SREBF1, WDTC1, HNF4A, MLXIPL, SCAP 6.84E-04 0.033443
GO:0010558~negative regulation of 
macromolecule biosynthetic process
COPS2, THRB, DEDD, CBX4, SOX6, CBFA2T2, PDCD4, NR2C1, EIF4EBP3, SORBS3, AES, HEXIM1, 
ZKSCAN17, BHLHE40, NR2F2, NFX1, CEBPA, ZBTB7A, WDTC1, TBX3, FOXA1, TRIM28, ZHX2, MLXIPL, 
ZHX3, SIRT1, SIRT2, CTNNBIP1, HHEX, NAB2, NAB1, ZRANB1, ZFP281, CUX2, ID3, RBM15, SUDS3, 
DNAJB6
7.54E-04 0.036056
GO:0016053~organic acid biosynthetic 
process
ASS1, NAGS, OTC, ACACA, PAH, ASL, ADI1, CYP7B1, PECR, CTH, ACSM1, CYP39A1, GOT1, MLYCD, 
FASN, ELOVL6, GSTO1, CBS 8.21E-04 0.037714
GO:0046394~carboxylic acid 
biosynthetic process
ASS1, NAGS, OTC, ACACA, PAH, ASL, ADI1, CYP7B1, PECR, CTH, ACSM1, CYP39A1, GOT1, MLYCD, 
FASN, ELOVL6, GSTO1, CBS 8.21E-04 0.037714
GO:0006511~ubiquitin-dependent 
protein catabolic process
NPLOC4, DERL2, USP3, USP2, UBR2, OS9, CUL3, USP19, RNF6, ARIH2, USP47, FBXO31, USP10, 
AMFR, USP16, USP15, USP32, FBXO8 8.21E-04 0.037714
GO:0006511~ubiquitin-dependent 
protein catabolic process
NPLOC4, DERL2, USP3, USP2, UBR2, OS9, CUL3, USP19, RNF6, ARIH2, USP47, FBXO31, USP10, 
AMFR, USP16, USP15, USP32, FBXO8 8.21E-04 0.037714
GO:0006511~ubiquitin-dependent 
protein catabolic process
NPLOC4, DERL2, USP3, USP2, UBR2, OS9, CUL3, USP19, RNF6, ARIH2, USP47, FBXO31, USP10, 
AMFR, USP16, USP15, USP32, FBXO8 8.21E-04 0.037714
GO:0010565~regulation of cellular 
ketone metabolic process SREBF1, WDTC1, HNF4A, MLYCD, MLXIPL, GNMT, SCAP 8.18E-04 0.03828
GO:0010565~regulation of cellular 
ketone metabolic process SREBF1, WDTC1, HNF4A, MLYCD, MLXIPL, GNMT, SCAP 8.18E-04 0.03828
GO:0019438~aromatic compound 
biosynthetic process MOCOS, MOCS2, QDPR, PAH, MOCS1, GCH1 9.22E-04 0.041433
GO:0006732~coenzyme metabolic 
process
MOCOS, ASPDH, KYNU, ALDH1L1, MOCS2, ACLY, GSTT3, SOD1, HIBADH, PIPOX, GCH1, SDHB, 
HNF4A, MLYCD, H6PD, HAAO, MDH1, MOCS1 9.64E-04 0.041701
GO:0034097~response to cytokine 
stimulus SERPINA3K, SERPINA1B, SERPINA1A, SERPINA1D, ENDOG, SERPINA1C, GM8893, BCL2L1 9.49E-04 0.041859
GO:0043434~response to peptide 
hormone stimulus
WDTC1, BCAR1, GM8893, ASL, FOXO4, SCAP, AHSG, SLC2A8, SERPINA3K, ZFP106, SERPINA1B, 
SERPINA1A, SERPINA1D, SERPINA1C 0.0010202 0.043316
GO:0006570~tyrosine metabolic 
process DCT, HGD, PAH, HPD, FAH 0.0010943 0.045579
GO:0006957~complement activation, 
alternative pathway C8B, C9, HC, C3, C8G 0.0010943 0.045579
GO:0009991~response to extracellular 
stimulus
SREBF1, RPL36A, ATG9A, NUAK2, FOXA3, GSDMD, SLC37A4, CSNK2B, ASL, SIRT1, USF2, ASGR1, 
AES, RB1CC1, SERPINC1, APOM, CBS 0.0011837 0.048368
GO:0042730~fibrinolysis KLKB1, TMPRSS6, CPB2, PLG 0.0012174 0.048876
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GO:0010605~negative regulation of 
macromolecule metabolic process
UTP3, COPS2, THRB, DEDD, CBX4, SOX6, CBFA2T2, PDCD4, NR2C1, EIF4EBP3, SORBS3, AES, 
HEXIM1, ZKSCAN17, BHLHE40, NR2F2, NFX1, CEBPA, ZBTB7A, WDTC1, TBX3, FOXA1, TRIM28, 
ZHX2, NDFIP1, MLXIPL, ZHX3, SERPING1, SIRT1, SIRT2, CTNNBIP1, HHEX, HNF4A, NAB2, NAB1, 
BNIP3L, ZRANB1, ZFP281, CUX2, ID3, RBM15, SUDS3, DNAJB6
0.0012568 0.049585
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S.No Gene Name Degree Centrality
Betweenness 
Centrality
Log2 Fold Change 
(HFHS Vs Control) 
1 Irf8 72 1892.83 0.84
2 Jun 18 483.5 1.11
3 Tlr9 8 320 1.08
4 Cxcl9 2 234.33 0.65
5 Sirt1 15 203 -0.53
6 Fos 8 182 0.97
7 Tcf4 7 179 0.55
8 Ciita 4 144 1.15
9 Bcl2 8 128.67 0.84
10 Cebpa 14 120 -0.62
11 Smarca4 12 120 0.34
12 Ccl2 4 112.17 1.36
13 Wipf1 4 96 0.78
14 Yy1 5 65 -0.50
15 Nfkb1 12 63 0.50
16 Usp18 3 61 0.73
Appendix table 4.4: Zero-order protein-protein interaction 
network analysis of differentially expressed genes in NASH liver
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GO:0031012~extracellular matrix
TNC, LUM, ADAMTS15, COL3A1, ELN, MMP23, TIMP2, MMP2, CPZ, TIMP1, SMOC2, 
COL6A3, TGM2, COL6A2, COL6A1, COL12A1, ADAMTS12, LOX, FBN2, SPON2, COL8A1, 
LOXL1, SPN, DPT, SPON1, COL4A4, COL4A2, COL4A1, LGALS3, EFEMP2, FBN1, CCDC80, 
OLFML2A, NID1, SPARC, COL5A2, MMP12, ANXA2, LAMA2, FBLN1, ADAMTS9, FBLN2, 
COL1A2, VCAN, ADAMTS1, MFAP2, COL1A1, MFAP4, ADAMTS2, ADAMTS5 9.24E-30 2.21E-27
GO:0005578~proteinaceous 
extracellular matrix
TNC, LUM, ADAMTS15, COL3A1, ELN, MMP23, TIMP2, MMP2, CPZ, TIMP1, SMOC2, TGM2, 
COL6A2, COL6A1, COL12A1, ADAMTS12, LOX, FBN2, SPON2, COL8A1, LOXL1, SPN, DPT, 
SPON1, COL4A4, COL4A2, COL4A1, LGALS3, EFEMP2, FBN1, CCDC80, NID1, SPARC, 
COL5A2, MMP12, ANXA2, LAMA2, FBLN1, ADAMTS9, FBLN2, COL1A2, VCAN, ADAMTS1, 
MFAP2, COL1A1, MFAP4, ADAMTS2, ADAMTS5 1.67E-28 2.00E-26
GO:0044421~extracellular region part
IGHG1, GDF3, GDF6, SORL1, MMP23, MMP2, CXCL10, COL12A1, LOX, LOXL2, SPON2, 
FGF2, LTB, LOXL1, SPN, SPON1, MGP, OLFML2A, CPXM2, MMP12, ADAMTS9, COL1A2, 
VCAN, ADAMTS1, MFAP2, COL1A1, MFAP4, ADAMTS2, ADAMTS5, TNC, LUM, ADAMTS15, 
COL3A1, ELN, CX3CL1, CCL5, TIMP2, TIMP1, CPZ, SMOC2, CCL22, COL6A3, TGM2, 
COL6A2, COL6A1, ADAMTS12, FBN2, THBS1, COL8A1, DPT, PLAT, COL4A4, LPL, COL4A2, 
COL4A1, LGALS3, EFEMP2, FBN1, CCDC80, NID1, SPARC, COL5A2, ANXA2, LAMA2, DKK3, 
FBLN1, FBLN2, GDF10, BMP8B 1.65E-25 1.31E-23
GO:0005576~extracellular region
IGHG1, GDF3, LTBP2, IGFBP7, GDF6, SORL1, FSTL1, MMP23, MMP2, CXCL10, OLFML3, 
PAPPA, GSN, SERPINE1, COL12A1, SEMA3B, CAP1, LOX, LGI2, SPON2, LOXL2, FGF2, 
LOXL1, LTB, SPN, PI15, SPON1, SCUBE3, SCUBE1, CPXM2, MGP, OLFML2A, MMP12, 
PLAUR, ADAMTS9, ST14, COL1A2, VCAN, ADAMTS1, MFAP2, COL1A1, TREM2, MFAP4, 
ADAMTS2, ADAMTS5, TNC, LUM, ADAMTS15, ELN, COL3A1, CX3CL1, TIMP2, CCL5, MDK, 
TIMP1, CPZ, ISLR, SMOC2, GLIPR2, ACE, CCL22, C1QTNF6, PRRG4, GLIPR1, COL6A3, 
TGM2, COL6A2, TNFRSF19, COL6A1, ADAMTS12, FBN2, COL8A1, THBS1, THBS2, DPT, 
PLAT, COL4A4, LPL, COL4A2, SVEP1, COL4A1, LGALS3, EFEMP2, FBN1, CCDC80, NID1, 
SPARC, FRZB, COL5A2, ANXA2, LAMA2, DKK3, FBLN1, FAM180A, FBLN2, GDF10, BMP8B 2.53E-22 1.51E-20
GO:0044420~extracellular matrix part
COL4A4, COL4A2, COL4A1, TNC, FBN1, COL3A1, CCDC80, NID1, SPARC, TIMP2, COL5A2, 
TIMP1, ANXA2, LAMA2, SMOC2, FBLN1, COL1A2, MFAP2, ADAMTS1, COL1A1, LOX, FBN2, 
COL8A1, SPN 5.26E-19 2.51E-17
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GO:0005604~basement membrane
COL4A4, COL4A2, COL4A1, TNC, CCDC80, NID1, SPARC, TIMP2, TIMP1, ANXA2, LAMA2, 
SMOC2, FBLN1, ADAMTS1, COL8A1, SPN 1.84E-11 7.33E-10
GO:0022610~biological adhesion
PVR, CLDN4, TNC, IGFBP7, ASTN1, NEDD9, CX3CL1, VCL, CDC42, ITGAX, COL6A2, 
COL6A1, COL12A1, ROBO2, SPON2, ADAM8, COL8A1, GPNMB, THBS1, BOC, THBS2, 
SPON1, DPT, SVEP1, SDK1, CPXM2, NID1, NCAM1, LAMA2, DDR1, PKP1, CD34, ITGA8, 
VCAN, ANTXR1, MFAP4, CDH11 4.02E-10 3.08E-07
GO:0005201~extracellular matrix 
structural constituent COL4A4, COL4A2, COL4A1, FBN1, ELN, COL3A1, COL1A2, FBN2, COL1A1, COL5A2 1.34E-09 4.58E-07
GO:0007049~cell cycle
EID1, PRC1, KNTC1, PKMYT1, NEDD9, CHEK1, NCAPG2, CCNA2, HELLS, CDCA3, CKAP2, 
CDC6, CDK1, MKI67, LIG1, AK1, RBL1, ANXA1, CENPF, CDC20, CDK6, MCM2, RACGAP1, 
CDKN3, MCM3, SMC2, ESCO2, AHR, MCM6, CCNB1, UHRF1, MAD2L1, SPAG5, CCND2, 
KIF20B, BUB1B, HAUS8, CHAF1A 1.05E-09 5.38E-07
GO:0007155~cell adhesion
PVR, CLDN4, TNC, IGFBP7, ASTN1, NEDD9, CX3CL1, VCL, CDC42, ITGAX, COL6A2, 
COL6A1, COL12A1, ROBO2, SPON2, ADAM8, COL8A1, GPNMB, THBS1, BOC, THBS2, 
SPON1, DPT, SVEP1, SDK1, CPXM2, NID1, NCAM1, LAMA2, DDR1, PKP1, CD34, ITGA8, 
VCAN, ANTXR1, MFAP4, CDH11 3.79E-10 5.81E-07
GO:0005581~collagen COL4A4, COL4A2, COL4A1, COL3A1, COL1A2, COL1A1, LOX, COL5A2 6.15E-08 2.10E-06
GO:0005581~collagen COL4A4, COL4A2, COL4A1, COL3A1, COL1A2, COL1A1, LOX, COL5A2 6.15E-08 2.10E-06
GO:0043062~extracellular structure 
organization
MYO5A, LGALS3, TNC, ELN, COL3A1, CCDC80, OLFML2A, NID1, COL5A2, SERPINH1, 
ANXA2, SMOC2, FBLN1, ITGA8, LOX, NRG1, ADAMTS2, DPT 5.81E-09 2.23E-06
GO:0051301~cell division
CDK1, CDC6, PRC1, LIG1, KNTC1, NEDD9, CDK6, CDC20, RACGAP1, SMC2, MCM5, 
CCNB1, CDC42, MAD2L1, CCND2, SPAG5, NCAPG2, KIF20B, BUB1B, HAUS8, CCNA2, 
TOP2A, HELLS, CDCA3 8.15E-09 2.50E-06
GO:0030198~extracellular matrix 
organization
LGALS3, ELN, COL3A1, CCDC80, OLFML2A, NID1, COL5A2, SERPINH1, ANXA2, SMOC2, 
FBLN1, ITGA8, LOX, ADAMTS2, DPT 1.07E-08 2.73E-06
GO:0005509~calcium ion binding
MYO5A, S100A4, LTBP2, CACNB3, FSTL1, MMP2, TPM4, SMOC2, PRRG4, ITGAX, GSN, 
TGM2, FBN2, SPON2, THBS1, EHD2, CIB3, THBS2, SVEP1, SCUBE3, SCUBE1, EFEMP2, 
FBN1, MRC2, ANXA1, S100A11, MGP, NID1, SPARC, CAPN2, ANXA5, MMP12, ANXA2, 
FBLN1, FBLN2, ITGA8, VCAN, MFAP4, RCN3, CDH11 1.72E-08 2.94E-06
GO:0001871~pattern binding
LPL, FBN1, CCDC80, FSTL1, MDK, HMMR, NCAM1, SMOC2, ADAMTS1, VCAN, THBS1, 
GPNMB, THBS2, FGF2 3.59E-07 4.09E-05
GO:0030247~polysaccharide binding
LPL, FBN1, CCDC80, FSTL1, MDK, HMMR, NCAM1, SMOC2, ADAMTS1, VCAN, THBS1, 
GPNMB, THBS2, FGF2 3.59E-07 4.09E-05
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GO:0005539~glycosaminoglycan 
binding
LPL, CCDC80, FSTL1, MDK, HMMR, NCAM1, SMOC2, ADAMTS1, VCAN, THBS1, GPNMB, 
FGF2, THBS2 6.94E-07 5.91E-05
GO:0008237~metallopeptidase activity
AMZ1, ERMP1, ADAMTS15, CPXM2, MMP23, MMP2, MMP12, CPZ, ACE, ADAMTS9, PAPPA, 
ADAMTS1, ADAMTS12, ADAM8, ADAMTS2, ADAMTS5 9.77E-07 6.66E-05
GO:0008201~heparin binding NCAM1, SMOC2, LPL, CCDC80, FSTL1, ADAMTS1, GPNMB, THBS1, THBS2, FGF2, MDK 1.73E-06 9.83E-05
GO:0000278~mitotic cell cycle
CDK1, CDC6, KNTC1, CENPF, NEDD9, CDC20, CHEK1, SMC2, CCNB1, MAD2L1, CCND2, 
SPAG5, NCAPG2, KIF20B, BUB1B, HAUS8, CCNA2, HELLS, CDCA3 1.65E-06 3.17E-04
GO:0000087~M phase of mitotic cell 
cycle
CDK1, CDC6, KNTC1, CENPF, NEDD9, CDC20, SMC2, CCNB1, MAD2L1, SPAG5, NCAPG2, 
KIF20B, BUB1B, HAUS8, CCNA2, HELLS, CDCA3 1.48E-06 3.25E-04
GO:0030199~collagen fibril 
organization COL3A1, LOX, ADAMTS2, SERPINH1, COL5A2, ANXA2, DPT 2.36E-06 4.02E-04
GO:0048407~platelet-derived growth 
factor binding COL4A1, COL3A1, COL1A2, COL6A1, COL1A1 1.07E-05 4.54E-04
GO:0007067~mitosis
CDK1, CDC6, KNTC1, NEDD9, CDC20, SMC2, CCNB1, MAD2L1, SPAG5, NCAPG2, KIF20B, 
BUB1B, HAUS8, CCNA2, HELLS, CDCA3 5.45E-06 8.36E-04
GO:0000280~nuclear division
CDK1, CDC6, KNTC1, NEDD9, CDC20, SMC2, CCNB1, MAD2L1, SPAG5, NCAPG2, KIF20B, 
BUB1B, HAUS8, CCNA2, HELLS, CDCA3 5.45E-06 8.36E-04
GO:0042613~MHC class II protein 
complex H2-EB1, H2-AA, H2-DMB1, H2-AB1, H2-DMA 3.42E-05 9.09E-04
GO:0048285~organelle fission
CDK1, CDC6, KNTC1, NEDD9, CDC20, SMC2, CCNB1, MAD2L1, SPAG5, NCAPG2, KIF20B, 
BUB1B, HAUS8, CCNA2, HELLS, CDCA3 8.43E-06 0.001176
GO:0010810~regulation of cell-
substrate adhesion SMOC2, DDR1, FBLN2, CCDC80, NID1, COL1A1, THBS1, COL8A1 1.15E-05 0.001257
GO:0022402~cell cycle process
CDK1, CDC6, MKI67, AK1, KNTC1, CENPF, NEDD9, CHEK1, CDC20, RACGAP1, CDKN3, 
SMC2, CCNB1, MAD2L1, CCND2, SPAG5, NCAPG2, KIF20B, BUB1B, HAUS8, CCNA2, 
HELLS, CDCA3 1.10E-05 0.001302
GO:0019886~antigen processing and 
presentation of exogenous peptide 
antigen via MHC class II H2-EB1, H2-AA, H2-DMB1, H2-AB1, H2-DMA, CD74 1.05E-05 0.001344
GO:0002495~antigen processing and 
presentation of peptide antigen via 
MHC class II H2-EB1, H2-AA, H2-DMB1, H2-AB1, H2-DMA, CD74 1.05E-05 0.001344
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GO:0002495~antigen processing and 
presentation of peptide antigen via 
MHC class II H2-EB1, H2-AA, H2-DMB1, H2-AB1, H2-DMA, CD74 1.05E-05 0.001344
GO:0019886~antigen processing and 
presentation of exogenous peptide 
antigen via MHC class II H2-EB1, H2-AA, H2-DMB1, H2-AB1, H2-DMA, CD74 1.05E-05 0.001344
GO:0030155~regulation of cell 
adhesion LAMA2, SMOC2, DDR1, FBLN2, CCDC80, TGM2, NID1, COL1A1, THBS1, COL8A1, SPN 1.59E-05 0.001622
GO:0006270~DNA replication initiation MCM2, MCM3, MCM4, MCM5, MCM6 2.83E-05 0.002411
GO:0022403~cell cycle phase
CDK1, CDC6, MKI67, KNTC1, CENPF, NEDD9, CDC20, CHEK1, SMC2, CCNB1, MAD2L1, 
CCND2, SPAG5, NCAPG2, KIF20B, BUB1B, HAUS8, CCNA2, HELLS, CDCA3 2.79E-05 0.002516
GO:0002504~antigen processing and 
presentation of peptide or 
polysaccharide antigen via MHC class 
II H2-EB1, H2-AA, H2-DMB1, H2-AB1, H2-DMA, CD74 2.67E-05 0.002554
GO:0002504~antigen processing and 
presentation of peptide or 
polysaccharide antigen via MHC class 
II H2-EB1, H2-AA, H2-DMB1, H2-AB1, H2-DMA, CD74 2.67E-05 0.002554
GO:0005615~extracellular space
IGHG1, GDF3, GDF6, SORL1, CX3CL1, CCL5, MMP2, CXCL10, CCL22, COL6A3, LOX, 
LOXL2, THBS1, LOXL1, LTB, FGF2, SPN, PLAT, LPL, CPXM2, MGP, DKK3, ADAMTS9, 
GDF10, BMP8B 1.58E-04 0.003769
GO:0000279~M phase
CDK1, CDC6, MKI67, KNTC1, CENPF, NEDD9, CDC20, SMC2, CCNB1, MAD2L1, SPAG5, 
NCAPG2, KIF20B, BUB1B, HAUS8, CCNA2, HELLS, CDCA3 4.73E-05 0.003818
GO:0030246~carbohydrate binding
LPL, LGALS3, FBN1, MRC2, CCDC80, FSTL1, MDK, HMMR, NCAM1, SMOC2, ADAMTS1, 
VCAN, THBS1, GPNMB, FGF2, THBS2, CLEC5A 1.44E-04 0.004883
GO:0004222~metalloendopeptidase 
activity
ADAMTS9, ADAMTS15, ADAMTS1, ADAMTS12, MMP23, ADAM8, ADAMTS2, MMP2, MMP12, 
ADAMTS5 1.71E-04 0.005277
GO:0002478~antigen processing and 
presentation of exogenous peptide 
antigen H2-EB1, H2-AA, H2-DMB1, H2-AB1, H2-DMA, CD74 7.23E-05 0.005534
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GO:0002478~antigen processing and 
presentation of exogenous peptide 
antigen H2-EB1, H2-AA, H2-DMB1, H2-AB1, H2-DMA, CD74 7.23E-05 0.005534
GO:0008092~cytoskeletal protein 
binding
MYO5A, FSCN1, RACGAP1, TPM1, TPM4, VCL, ANXA2, LSP1, EPB4.1L1, SPAG5, GSN, 
EPB4.1L4A, MFAP2, CNN2, ANTXR1, CAP1, WDR1, DIAP3, ADD1 3.53E-04 0.009981
GO:0010811~positive regulation of cell-
substrate adhesion SMOC2, FBLN2, CCDC80, NID1, THBS1, COL8A1 1.63E-04 0.011819
GO:0045785~positive regulation of cell 
adhesion SMOC2, FBLN2, CCDC80, TGM2, NID1, THBS1, COL8A1 1.84E-04 0.012748
GO:0019884~antigen processing and 
presentation of exogenous antigen H2-EB1, H2-AA, H2-DMB1, H2-AB1, H2-DMA, CD74 1.95E-04 0.01292
GO:0019884~antigen processing and 
presentation of exogenous antigen H2-EB1, H2-AA, H2-DMB1, H2-AB1, H2-DMA, CD74 1.95E-04 0.01292
GO:0006260~DNA replication GINS2, CDC6, DTL, LIG1, RRM1, MCM2, CHAF1A, MCM3, MCM4, FEN1, MCM5, MCM6 2.13E-04 0.013522
GO:0009897~external side of plasma 
membrane
LY6A, NCAM1, CD83, ICOSL, CD8B1, ITGAX, CD8A, CD34, SCUBE1, H2-AA, H2-AB1, CD74, 
SPN 0.001219 0.022176
GO:0070011~peptidase activity, acting 
on L-amino acid peptides
CAPN6, AMZ1, PLAT, ERMP1, ADAMTS15, CPXM2, NAPSA, CAPN2, MMP23, TINAG, MMP2, 
MMP12, CPZ, ACE, ADAMTS9, PAPPA, ST14, SERPINE1, ADAMTS1, ADAMTS12, ADAM8, 
ADAMTS2, ADAMTS5 8.72E-04 0.022617
GO:0006955~immune response
IGHG1, ICOSL, CD8B1, CD8A, FOXJ1, H2-M2, H2-DMB1, H2-AB1, CX3CL1, CCL5, CD74, 
CXCL10, CCL22, CX3CR1, H2-EB1, CCR2, H2-AA, TGTP1, SPON2, H2-DMA, LTB, CLEC5A 4.33E-04 0.025261
GO:0004175~endopeptidase activity
CAPN6, PLAT, ADAMTS15, NAPSA, CAPN2, MMP23, TINAG, MMP2, MMP12, ADAMTS9, 
PAPPA, ST14, SERPINE1, ADAMTS1, ADAMTS12, ADAM8, ADAMTS2, ADAMTS5 0.001177 0.028287
GO:0003779~actin binding
MYO5A, FSCN1, TPM1, TPM4, VCL, LSP1, EPB4.1L1, GSN, CNN2, ANTXR1, CAP1, WDR1, 
DIAP3, ADD1 0.001668 0.031123
GO:0070271~protein complex 
biogenesis
XPO1, CAV1, SCUBE3, SCUBE1, ANXA5, CD74, PTRF, GSN, RRM1, TGM2, TUBB6, TUBA1A, 
H2-DMA, EIF2AK3 5.78E-04 0.031223
GO:0006461~protein complex 
assembly
XPO1, CAV1, SCUBE3, SCUBE1, ANXA5, CD74, PTRF, GSN, RRM1, TGM2, TUBB6, TUBA1A, 
H2-DMA, EIF2AK3 5.78E-04 0.031223
GO:0019838~growth factor binding COL4A1, LTBP2, IGFBP7, COL3A1, COL1A2, COL6A1, COL1A1 0.001587 0.031362
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GO:0008233~peptidase activity
CAPN6, AMZ1, PLAT, ERMP1, ADAMTS15, CPXM2, NAPSA, CAPN2, MMP23, TINAG, MMP2, 
MMP12, CPZ, ACE, ADAMTS9, PAPPA, ST14, SERPINE1, ADAMTS1, ADAMTS12, ADAM8, 
ADAMTS2, ADAMTS5 0.001525 0.03201
GO:0005819~spindle KIF22, CDC6, MAD2L1, PRC1, SPAG5, KNTC1, CENPF, HAUS8, RACGAP1 0.001907 0.032054
GO:0048002~antigen processing and 
presentation of peptide antigen H2-EB1, H2-AA, H2-DMB1, H2-AB1, H2-DMA, CD74 5.75E-04 0.032171
GO:0048002~antigen processing and 
presentation of peptide antigen H2-EB1, H2-AA, H2-DMB1, H2-AB1, H2-DMA, CD74 5.75E-04 0.032171
GO:0032555~purine ribonucleotide 
binding
RHOJ, KIF22, GNA15, FIGNL1, PKMYT1, CDC42, PRKAR2B, RALB, TUBB6, RHOC, MASTL, 
TUBA1A, TOP2A, CDK1, CDC6, ACTA2, LIG1, PFKP, CDK6, MCM2, ABCC12, MCM3, MCM4, 
MCM5, MCM6, DDR1, KIF1A, RRM1, H2-AA, PDGFRB, BUB1B, EIF2AK3, SRXN1, MYO5A, 
GNAI1, CTPS2, CHEK1, HSPA1B, TGM2, EHD2, HELLS, AK1, ATAD2, ATP1A2, SMC2, 
KIF20B, TGTP1, H2-DMA, KIF20A 0.001511 0.033796
GO:0032553~ribonucleotide binding
RHOJ, KIF22, GNA15, FIGNL1, PKMYT1, CDC42, PRKAR2B, RALB, TUBB6, RHOC, MASTL, 
TUBA1A, TOP2A, CDK1, CDC6, ACTA2, LIG1, PFKP, CDK6, MCM2, ABCC12, MCM3, MCM4, 
MCM5, MCM6, DDR1, KIF1A, RRM1, H2-AA, PDGFRB, BUB1B, EIF2AK3, SRXN1, MYO5A, 
GNAI1, CTPS2, CHEK1, HSPA1B, TGM2, EHD2, HELLS, AK1, ATAD2, ATP1A2, SMC2, 
KIF20B, TGTP1, H2-DMA, KIF20A 0.001511 0.033796
GO:0030029~actin filament-based 
process
MYO5A, RHOJ, EPB4.1L1, FOXJ1, GSN, ELN, CNN2, CAP1, ANTXR1, RACGAP1, EHD2, 
DIAP3 7.42E-04 0.036104
GO:0017076~purine nucleotide 
binding
RHOJ, KIF22, GNA15, FIGNL1, PKMYT1, CDC42, PRKAR2B, AGPS, RALB, TUBB6, RHOC, 
MASTL, TUBA1A, TOP2A, CDK1, CDC6, ACTA2, LIG1, PFKP, CDK6, MCM2, ABCC12, MCM3, 
MCM4, MCM5, MCM6, DDR1, KIF1A, RRM1, H2-AA, PDGFRB, BUB1B, EIF2AK3, SRXN1, 
MYO5A, GNAI1, CTPS2, CHEK1, HSPA1B, TGM2, EHD2, HELLS, AK1, ATAD2, ATP1A2, 
SMC2, KIF20B, TGTP1, H2-DMA, KIF20A 0.002056 0.03626
GO:0006259~DNA metabolic process
GINS2, KIF22, CDC6, ICOSL, DTL, LIG1, CHEK1, HSPA1B, MCM2, MCM3, MCM4, ESCO2, 
MCM5, MCM6, UHRF1, RRM1, CHAF1A, TOP2A, FEN1, HELLS 7.00E-04 0.036372
GO:0042611~MHC protein complex H2-M2, H2-EB1, H2-AA, H2-DMB1, H2-AB1, H2-DMA 0.004311 0.062495
GO:0030036~actin cytoskeleton 
organization RHOJ, EPB4.1L1, FOXJ1, GSN, ELN, CNN2, CAP1, ANTXR1, RACGAP1, EHD2, DIAP3 0.001615 0.070359
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GO:0005856~cytoskeleton
MYO5A, KIF22, PRC1, VIM, KNTC1, NEDD9, CHEK1, TPM1, TPM4, VCL, SLC1A4, ANK2, 
GSN, TUBB6, CAP1, TUBA1A, CKAP2, CDC6, NES, ACTA2, CENPF, PLEKHH1, RACGAP1, 
SHANK2, ANXA2, CCNB1, KIF1A, MAD2L1, EPB4.1L1, SPAG5, KIF20B, EPB4.1L4A, MFAP2, 
HAUS8, WDR1, KIF20A, ADD1 0.005418 0.07354
GO:0005856~cytoskeleton
MYO5A, KIF22, PRC1, VIM, KNTC1, NEDD9, CHEK1, TPM1, TPM4, VCL, SLC1A4, ANK2, 
GSN, TUBB6, CAP1, TUBA1A, CKAP2, CDC6, NES, ACTA2, CENPF, PLEKHH1, RACGAP1, 
SHANK2, ANXA2, CCNB1, KIF1A, MAD2L1, EPB4.1L1, SPAG5, KIF20B, EPB4.1L4A, MFAP2, 
HAUS8, WDR1, KIF20A, ADD1 0.005418 0.07354
GO:0005587~collagen type IV COL4A4, COL4A2, COL4A1 0.006068 0.077634
GO:0030935~sheet-forming collagen COL4A4, COL4A2, COL4A1 0.006068 0.077634
GO:0005583~fibrillar collagen COL3A1, COL1A2, COL1A1 0.008379 0.095665
GO:0000776~kinetochore XPO1, MAD2L1, SPAG5, KNTC1, BUB1B, CENPF 0.009086 0.098669
GO:0000775~chromosome, 
centromeric region XPO1, MAD2L1, MKI67, SPAG5, KNTC1, BUB1B, CENPF, HELLS 0.008249 0.09895
GO:0043933~macromolecular 
complex subunit organization
XPO1, CAV1, SCUBE3, SCUBE1, MCM2, ANXA5, CD74, PTRF, GSN, RRM1, TGM2, TUBB6, 
TUBA1A, H2-DMA, NRG1, EIF2AK3, HELLS 0.002596 0.107757
GO:0043933~macromolecular 
complex subunit organization
XPO1, CAV1, SCUBE3, SCUBE1, MCM2, ANXA5, CD74, PTRF, GSN, RRM1, TGM2, TUBB6, 
TUBA1A, H2-DMA, NRG1, EIF2AK3, HELLS 0.002596 0.107757
GO:0003924~GTPase activity RHOJ, CDC42, GNA15, GNAI1, TUBB6, TGTP1, TUBA1A, EHD2 0.00717 0.110279
GO:0032559~adenyl ribonucleotide 
binding
MYO5A, KIF22, FIGNL1, PKMYT1, CHEK1, CTPS2, HSPA1B, PRKAR2B, MASTL, EHD2, 
TOP2A, HELLS, CDC6, CDK1, ACTA2, AK1, LIG1, PFKP, ATAD2, CDK6, MCM2, ATP1A2, 
ABCC12, MCM3, MCM4, SMC2, MCM5, MCM6, DDR1, KIF1A, RRM1, KIF20B, BUB1B, 
PDGFRB, H2-AA, H2-DMA, EIF2AK3, SRXN1, KIF20A 0.007673 0.112539
GO:0065003~macromolecular 
complex assembly
XPO1, CAV1, SCUBE3, SCUBE1, MCM2, ANXA5, CD74, PTRF, GSN, RRM1, TGM2, TUBB6, 
TUBA1A, H2-DMA, EIF2AK3, HELLS 0.002956 0.115567
GO:0065003~macromolecular 
complex assembly
XPO1, CAV1, SCUBE3, SCUBE1, MCM2, ANXA5, CD74, PTRF, GSN, RRM1, TGM2, TUBB6, 
TUBA1A, H2-DMA, EIF2AK3, HELLS 0.002956 0.115567
GO:0051259~protein oligomerization CAV1, SCUBE3, SCUBE1, RRM1, TGM2, ANXA5, EIF2AK3 0.002929 0.117555
GO:0001775~cell activation
ICOSL, CD8A, SOX4, CD74, TIMP1, ITGAX, CXCR4, CX3CR1, H2-DMA, LTB, SPN, HELLS, 
BLNK 0.00358 0.13488
GO:0005771~multivesicular body H2-AB1, H2-DMA, CD74 0.013977 0.136073
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GO:0051260~protein 
homooligomerization CAV1, SCUBE3, SCUBE1, TGM2, ANXA5, EIF2AK3 0.003812 0.139561
GO:0030554~adenyl nucleotide 
binding
MYO5A, KIF22, FIGNL1, PKMYT1, CHEK1, CTPS2, HSPA1B, PRKAR2B, AGPS, MASTL, 
EHD2, TOP2A, HELLS, CDC6, CDK1, ACTA2, AK1, LIG1, PFKP, ATAD2, CDK6, MCM2, 
ATP1A2, ABCC12, MCM3, MCM4, SMC2, MCM5, MCM6, DDR1, KIF1A, RRM1, KIF20B, 
BUB1B, PDGFRB, H2-AA, H2-DMA, EIF2AK3, SRXN1, KIF20A 0.010153 0.140412
GO:0005524~ATP binding
MYO5A, KIF22, FIGNL1, PKMYT1, CHEK1, CTPS2, HSPA1B, MASTL, EHD2, TOP2A, HELLS, 
CDC6, CDK1, ACTA2, AK1, LIG1, PFKP, ATAD2, CDK6, MCM2, ATP1A2, ABCC12, MCM3, 
MCM4, SMC2, MCM5, MCM6, DDR1, KIF1A, RRM1, KIF20B, BUB1B, PDGFRB, H2-AA, H2-
DMA, EIF2AK3, SRXN1, KIF20A 0.010703 0.141775
GO:0001883~purine nucleoside 
binding
MYO5A, KIF22, FIGNL1, PKMYT1, CHEK1, CTPS2, HSPA1B, PRKAR2B, AGPS, MASTL, 
EHD2, TOP2A, HELLS, CDC6, CDK1, ACTA2, AK1, LIG1, PFKP, ATAD2, CDK6, MCM2, 
ATP1A2, ABCC12, MCM3, MCM4, SMC2, MCM5, MCM6, DDR1, KIF1A, RRM1, KIF20B, 
BUB1B, PDGFRB, H2-AA, H2-DMA, EIF2AK3, SRXN1, KIF20A 0.011578 0.146868
GO:0006261~DNA-dependent DNA 
replication MCM2, MCM3, MCM4, MCM5, MCM6 0.004308 0.152696
GO:0001882~nucleoside binding
MYO5A, KIF22, FIGNL1, PKMYT1, CHEK1, CTPS2, HSPA1B, PRKAR2B, AGPS, MASTL, 
EHD2, TOP2A, HELLS, CDC6, CDK1, ACTA2, AK1, LIG1, PFKP, ATAD2, CDK6, MCM2, 
ATP1A2, ABCC12, MCM3, MCM4, SMC2, MCM5, MCM6, DDR1, KIF1A, RRM1, KIF20B, 
BUB1B, PDGFRB, H2-AA, H2-DMA, EIF2AK3, SRXN1, KIF20A 0.012783 0.155266
GO:0005125~cytokine activity GDF3, CCL22, GDF6, GDF10, CX3CL1, CCL5, LTB, BMP8B, CXCL10 0.013772 0.160664
GO:0044430~cytoskeletal part
MYO5A, CKAP2, KIF22, CDC6, NES, PRC1, VIM, KNTC1, CENPF, RACGAP1, TPM1, 
SHANK2, TPM4, ANXA2, SLC1A4, CCNB1, KIF1A, MAD2L1, SPAG5, KIF20B, TUBB6, MFAP2, 
HAUS8, CAP1, TUBA1A, KIF20A 0.018153 0.166758
GO:0044430~cytoskeletal part
MYO5A, CKAP2, KIF22, CDC6, NES, PRC1, VIM, KNTC1, CENPF, RACGAP1, TPM1, 
SHANK2, TPM4, ANXA2, SLC1A4, CCNB1, KIF1A, MAD2L1, SPAG5, KIF20B, TUBB6, MFAP2, 
HAUS8, CAP1, TUBA1A, KIF20A 0.018153 0.166758
GO:0001503~ossification MGP, FHL2, UBD, COL1A1, GPNMB, EIF2AK3, MMP2, BMP8B 0.004983 0.166869
GO:0050863~regulation of T cell 
activation CD83, ICOSL, FOXJ1, H2-AA, CENPF, H2-DMA, CD74, SPN 0.005516 0.179174
GO:0050863~regulation of T cell 
activation CD83, ICOSL, FOXJ1, H2-AA, CENPF, H2-DMA, CD74, SPN 0.005516 0.179174
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GO:0050863~regulation of T cell 
activation CD83, ICOSL, FOXJ1, H2-AA, CENPF, H2-DMA, CD74, SPN 0.005516 0.179174
GO:0000777~condensed 
chromosome kinetochore MAD2L1, SPAG5, KNTC1, BUB1B, CENPF 0.023835 0.198884
GO:0000793~condensed 
chromosome MAD2L1, MKI67, SPAG5, KNTC1, BUB1B, CENPF, TOP2A 0.023731 0.205153
GO:0019882~antigen processing and 
presentation H2-M2, H2-EB1, H2-AA, H2-DMB1, H2-AB1, H2-DMA, CD74 0.007417 0.224256
GO:0019882~antigen processing and 
presentation H2-M2, H2-EB1, H2-AA, H2-DMB1, H2-AB1, H2-DMA, CD74 0.007417 0.224256
GO:0016477~cell migration PLAT, PVR, CCL22, CXCR4, FOXJ1, CD34, ST14, CX3CR1, ASTN1, CAP1, CX3CL1, NRG1 0.008176 0.235182
GO:0042110~T cell activation ICOSL, ITGAX, CD8A, CXCR4, SOX4, H2-DMA, CD74, SPN 0.008083 0.237252
GO:0042110~T cell activation ICOSL, ITGAX, CD8A, CXCR4, SOX4, H2-DMA, CD74, SPN 0.008083 0.237252
GO:0060348~bone development MGP, FHL2, UBD, COL1A1, GPNMB, EIF2AK3, MMP2, BMP8B 0.008844 0.247284
GO:0000166~nucleotide binding
RHOJ, KIF22, GNA15, FIGNL1, PKMYT1, CDC42, PRKAR2B, AGPS, RALB, TUBB6, RHOC, 
MASTL, TUBA1A, TOP2A, CDK1, CDC6, ACTA2, LIG1, PFKP, CDK6, MCM2, ABCC12, MCM3, 
MCM4, MCM5, MCM6, DDR1, KIF1A, RRM1, H2-AA, PDGFRB, BUB1B, EIF2AK3, SRXN1, 
MYO5A, GNAI1, TRA2A, CTPS2, CHEK1, HSPA1B, TGM2, EHD2, HELLS, AK1, ATAD2, 
ATP1A2, SMC2, KIF20B, TGTP1, H2-DMA, KIF20A 0.023695 0.253268
GO:0044449~contractile fiber part ANK2, ACTA2, ANKRD1, TPM1, MMP2, VCL 0.032911 0.256381
GO:0050870~positive regulation of T 
cell activation CD83, ICOSL, H2-AA, H2-DMA, CD74, SPN 0.009658 0.257662
GO:0000779~condensed 
chromosome, centromeric region MAD2L1, SPAG5, KNTC1, BUB1B, CENPF 0.035522 0.265615
GO:0008009~chemokine activity CCL22, CX3CL1, CCL5, CXCL10 0.028297 0.286474
GO:0008047~enzyme activator activity RASAL1, FBLN1, CAV1, ABR, RGS1, IQGAP3, ARHGAP11A, TIMP2, RACGAP1, ARHGAP25 0.030899 0.291959
GO:0006974~response to DNA 
damage stimulus
CDK1, KIF22, DTL, LIG1, CHEK1, HSPA1B, ESCO2, UHRF1, NUPR1, BTG2, CHAF1A, 
PHLDA3, FEN1 0.011748 0.294497
GO:0042379~chemokine receptor 
binding CCL22, CX3CL1, CCL5, CXCL10 0.030271 0.294887
GO:0045321~leukocyte activation ICOSL, ITGAX, CD8A, CXCR4, CX3CR1, SOX4, H2-DMA, CD74, HELLS, SPN, BLNK 0.011676 0.297758
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GO:0007010~cytoskeleton 
organization
LSP1, RHOJ, EPB4.1L1, TAGLN, GSN, FOXJ1, ELN, CNN2, HAUS8, CAP1, ANTXR1, 
RACGAP1, EHD2, DIAP3 0.012715 0.309683
GO:0015630~microtubule 
cytoskeleton
CKAP2, CDC6, KIF22, PRC1, KNTC1, CENPF, RACGAP1, CCNB1, KIF1A, MAD2L1, SPAG5, 
KIF20B, TUBB6, HAUS8, TUBA1A, KIF20A 0.047474 0.321235
GO:0046649~lymphocyte activation ICOSL, ITGAX, CD8A, CXCR4, SOX4, H2-DMA, CD74, HELLS, SPN, BLNK 0.013596 0.322345
GO:0045580~regulation of T cell 
differentiation CD83, FOXJ1, H2-AA, H2-DMA, CD74 0.014592 0.326889
GO:0043292~contractile fiber ANK2, ACTA2, ANKRD1, TPM1, MMP2, VCL 0.047268 0.329052
GO:0002520~immune system 
development ICOSL, CD8A, FOXJ1, CCR2, SOX4, CDK6, H2-DMA, LTB, HELLS, CD74, SPN, TIMP1, ADD1 0.014272 0.330477
GO:0042287~MHC protein binding H2-AA, H2-DMA, CD74 0.038646 0.342949
GO:0016641~oxidoreductase activity, 
acting on the CH-NH2 group of 
donors, oxygen as acceptor LOX, LOXL2, LOXL1 0.038646 0.342949
GO:0002449~lymphocyte mediated 
immunity IGHG1, ICOSL, CD8A, H2-AA, H2-DMA, CD74 0.017053 0.365689
GO:0005770~late endosome H2-AB1, CD63, H2-DMA, CD74 0.062507 0.382503
GO:0046332~SMAD binding COL3A1, COL1A2, COL5A2 0.046917 0.391371
GO:0005874~microtubule CKAP2, KIF22, KIF1A, PRC1, SPAG5, KIF20B, TUBB6, HAUS8, TUBA1A, KIF20A 0.062454 0.391766
GO:0006268~DNA unwinding during 
replication MCM2, MCM4, MCM6 0.018954 0.392174
GO:0042330~taxis LSP1, CCL22, CX3CR1, ROBO2, CX3CL1, CCL5, CXCL10 0.020852 0.406497
GO:0006935~chemotaxis LSP1, CCL22, CX3CR1, ROBO2, CX3CL1, CCL5, CXCL10 0.020852 0.406497
GO:0002684~positive regulation of 
immune system process IGHG1, CD83, ICOSL, FOXJ1, H2-AA, CACNB3, THBS1, H2-DMA, CD74, SPN 0.021186 0.406517
GO:0007626~locomotory behavior LSP1, MYO5A, CCL22, CX3CR1, ASTN1, ROBO2, CX3CL1, ATP1A2, CCL5, NRG1, CXCL10 0.020349 0.409022
GO:0016638~oxidoreductase activity, 
acting on the CH-NH2 group of donors LOX, LOXL2, LOXL1 0.051272 0.410147
GO:0043588~skin development COL1A1, ADAMTS2, LTB, COL5A2 0.020799 0.410746
GO:0008015~blood circulation ACE, CAV1, ANK2, ACTA2, ATP1A2, NRG1, TPM1 0.022578 0.41685
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GO:0003013~circulatory system 
process ACE, CAV1, ANK2, ACTA2, ATP1A2, NRG1, TPM1 0.022578 0.41685
GO:0032508~DNA duplex unwinding MCM2, MCM4, MCM6 0.022453 0.419955
GO:0051085~chaperone mediated 
protein folding requiring cofactor H2-DMB1, H2-DMA, CD74 0.022453 0.419955
GO:0060325~face morphogenesis COL1A1, MMP2, PLEKHA1 0.022453 0.419955
GO:0007517~muscle organ 
development CAV1, TAGLN, TNC, ELN, PDGFRB, FHL2, TAGLN2, NRG1, TPM1 0.023506 0.424911
GO:0051249~regulation of lymphocyte 
activation CD83, ICOSL, FOXJ1, H2-AA, CENPF, H2-DMA, CD74, SPN 0.024062 0.427657
GO:0051249~regulation of lymphocyte 
activation CD83, ICOSL, FOXJ1, H2-AA, CENPF, H2-DMA, CD74, SPN 0.024062 0.427657
GO:0051249~regulation of lymphocyte 
activation CD83, ICOSL, FOXJ1, H2-AA, CENPF, H2-DMA, CD74, SPN 0.024062 0.427657
GO:0032392~DNA geometric change MCM2, MCM4, MCM6 0.026194 0.427726
GO:0004950~chemokine receptor 
activity CXCR4, CCR2, CX3CR1 0.055766 0.428254
GO:0001501~skeletal system 
development
LGALS3, PDGFRB, MGP, FHL2, UBD, COL1A1, GPNMB, EIF2AK3, COL5A2, MMP2, BMP8B, 
PLEKHA1 0.02612 0.431222
GO:0045582~positive regulation of T 
cell differentiation CD83, H2-AA, H2-DMA, CD74 0.024691 0.431276
GO:0002250~adaptive immune 
response IGHG1, ICOSL, CD8A, H2-AA, H2-DMA, CD74 0.025135 0.432382
GO:0002460~adaptive immune 
response based on somatic 
recombination of immune receptors 
built from immunoglobulin superfamily 
domains IGHG1, ICOSL, CD8A, H2-AA, H2-DMA, CD74 0.025135 0.432382
GO:0051674~localization of cell PLAT, PVR, CCL22, CXCR4, FOXJ1, CD34, ST14, CX3CR1, ASTN1, CAP1, CX3CL1, NRG1 0.025515 0.432642
GO:0048870~cell motility PLAT, PVR, CCL22, CXCR4, FOXJ1, CD34, ST14, CX3CR1, ASTN1, CAP1, CX3CL1, NRG1 0.025515 0.432642
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GO:0045619~regulation of lymphocyte 
differentiation CD83, FOXJ1, H2-AA, H2-DMA, CD74 0.027339 0.43729
GO:0019956~chemokine binding CXCR4, CCR2, CX3CR1 0.060393 0.445704
GO:0045621~positive regulation of 
lymphocyte differentiation CD83, H2-AA, H2-DMA, CD74 0.028948 0.447502
GO:0043067~regulation of 
programmed cell death
IGHG1, STIL, CENPF, NR4A1, HSPA1B, CX3CL1, CD74, TIMP1, ANK2, BTG2, NUPR1, 
CX3CR1, TGM2, PHLDA3, LTB, EIF2AK3, FGF2, SPN, HELLS 0.02893 0.451647
GO:0004857~enzyme inhibitor activity SERPINB6B, COL6A3, SERPINE1, ANXA1, TIMP2, SERPINH1, PI15, TIMP1, ANXA2 0.063148 0.45183
GO:0006928~cell motion
PLAT, PVR, FOXJ1, ASTN1, CX3CL1, CCL22, CXCR4, CD34, ST14, CX3CR1, ROBO2, CAP1, 
NRG1, BOC 0.030551 0.452768
GO:0005544~calcium-dependent 
phospholipid binding ANXA1, ANXA5, ANXA2 0.065146 0.453657
GO:0010941~regulation of cell death
IGHG1, STIL, CENPF, NR4A1, HSPA1B, CX3CL1, CD74, TIMP1, ANK2, BTG2, NUPR1, 
CX3CR1, TGM2, PHLDA3, LTB, EIF2AK3, FGF2, SPN, HELLS 0.030252 0.453672
GO:0002443~leukocyte mediated 
immunity IGHG1, ICOSL, CD8A, H2-AA, H2-DMA, CD74 0.031253 0.456237
GO:0051084~'de novo' 
posttranslational protein folding H2-DMB1, H2-DMA, CD74 0.030168 0.457008
GO:0006458~'de novo' protein folding H2-DMB1, H2-DMA, CD74 0.030168 0.457008
GO:0060323~head morphogenesis COL1A1, MMP2, PLEKHA1 0.030168 0.457008
GO:0042802~identical protein binding S100A4, CLDN4, CD8A, GDF6, TRA2A, NR4A1, OLFML2A, CENPF, ROBO2, SDCBP2 0.068838 0.463993
GO:0002694~regulation of leukocyte 
activation CD83, ICOSL, FOXJ1, H2-AA, CENPF, H2-DMA, CD74, SPN 0.033034 0.470901
GO:0002694~regulation of leukocyte 
activation CD83, ICOSL, FOXJ1, H2-AA, CENPF, H2-DMA, CD74, SPN 0.033034 0.470901
GO:0002694~regulation of leukocyte 
activation CD83, ICOSL, FOXJ1, H2-AA, CENPF, H2-DMA, CD74, SPN 0.033034 0.470901
GO:0045061~thymic T cell selection H2-DMA, CD74, SPN 0.034364 0.476229
GO:0016064~immunoglobulin 
mediated immune response IGHG1, ICOSL, H2-AA, H2-DMA, CD74 0.035595 0.476341
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GO:0030334~regulation of cell 
migration LAMA2, CXCR4, CCR2, THBS1, VCL, CXCL10 0.035335 0.477779
GO:0050865~regulation of cell 
activation CD83, ICOSL, FOXJ1, H2-AA, CENPF, H2-DMA, CD74, SPN 0.035063 0.479123
GO:0050865~regulation of cell 
activation CD83, ICOSL, FOXJ1, H2-AA, CENPF, H2-DMA, CD74, SPN 0.035063 0.479123
GO:0050865~regulation of cell 
activation CD83, ICOSL, FOXJ1, H2-AA, CENPF, H2-DMA, CD74, SPN 0.035063 0.479123
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GO:0005624~membrane fraction
CYP2C54, CYP39A1, CYP3A13, H6PD, MET, SYTL1, 
SCNN1A, ITPR1, POR 2.11E-04 0.022304729
GO:0005792~microsome CYP2C54, CYP39A1, CYP3A13, H6PD, ITPR1, POR 2.59E-04 0.013787048
GO:0005626~insoluble fraction
CYP2C54, CYP39A1, CYP3A13, H6PD, MET, SYTL1, 
SCNN1A, ITPR1, POR 2.67E-04 0.009477745
GO:0042598~vesicular fraction CYP2C54, CYP39A1, CYP3A13, H6PD, ITPR1, POR 3.03E-04 0.008073594
GO:0000267~cell fraction
CYP2C54, CYP39A1, CYP3A13, H6PD, MET, SYTL1, 
SCNN1A, ITPR1, POR 6.01E-04 0.012790001
GO:0019898~extrinsic to membrane
CYP2C54, CYP39A1, CYP3A13, VPS37B, GFRA1, 
SYTL1, POR 0.00410082 0.070660948
GO:0009055~electron carrier activity CYP2C54, CYP39A1, CYP3A13, CYP4F13, POR 0.005549574 0.609563569
GO:0020037~heme binding CYP2C54, CYP39A1, CYP3A13, CYP4F13 0.014273209 0.703223612
GO:0046906~tetrapyrrole binding CYP2C54, CYP39A1, CYP3A13, CYP4F13 0.016194009 0.601373271
GO:0030003~cellular cation homeostasis SLC30A1, AQP11, PTH1R, ITPR1 0.016439244 0.999451799
GO:0005783~endoplasmic reticulum
CYP2C54, CYP39A1, CYP3A13, H6PD, AQP11, ITPR1, 
POR, ZFYVE1 0.018005829 0.242506251
GO:0007596~blood coagulation F12, F9, F7 0.025337307 0.997011118
GO:0050817~coagulation F12, F9, F7 0.025337307 0.997011118
GO:0007599~hemostasis F12, F9, F7 0.026013809 0.981315875
GO:0055080~cation homeostasis SLC30A1, AQP11, PTH1R, ITPR1 0.027065454 0.955283229
GO:0055114~oxidation reduction
ASPDH, CYP2C54, CYP39A1, CYP3A13, H6PD, 
CYP4F13, POR 0.030023208 0.936820279
GO:0046872~metal ion binding
COL18A1, ZBTB7A, CYP2C54, AHCY, CYP3A13, 
CYP4F13, TRIM41, F9, ZFP707, F7, ITPR1, POR, 
BRAP, PCDH1, CYP39A1, ZFP598, SLC30A1, 
SLC17A2, SCNN1A, NR1H4, ZFYVE1 0.032144496 0.748525103
GO:0005506~iron ion binding CYP2C54, CYP39A1, CYP3A13, CYP4F13, POR 0.032589721 0.673681585
Appendix table 4.6: Gene ontology terms significantly enriched in mRNA commonly upregulated in HFHS diet fed mice treated with curcumin 
and vitamin D3 liposomes
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GO:0043169~cation binding
COL18A1, ZBTB7A, CYP2C54, AHCY, CYP3A13, 
CYP4F13, TRIM41, F9, ZFP707, F7, ITPR1, POR, 
BRAP, PCDH1, CYP39A1, ZFP598, SLC30A1, 
SLC17A2, SCNN1A, NR1H4, ZFYVE1 0.035245749 0.636025962
GO:0050878~regulation of body fluid levels F12, F9, F7 0.039389198 0.951879107
GO:0043167~ion binding
COL18A1, ZBTB7A, CYP2C54, AHCY, CYP3A13, 
CYP4F13, TRIM41, F9, ZFP707, F7, ITPR1, POR, 
BRAP, PCDH1, CYP39A1, ZFP598, SLC30A1, 
SLC17A2, SCNN1A, NR1H4, ZFYVE1 0.039972748 0.626513805
mmu04610:Complement and coagulation cascades F12, F9, F7 0.022529712 0.579335881
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